Exploring The Role Of FGFR2c Misregulation In Syndromic Craniosynostosis by Lee, King Lam
  
EXPLORING THE ROLE OF 
FGFR2C MISREGULATION IN 
SYNDROMIC CRANIOSYNOSTOSIS 
 
A THESIS SUBMITTED IN FULFILMENT OF THE DOCTOR OF PHILOSOPHY 
DEGREE AT  
UNIVERSITY COLLEGE LONDON 
 
2018 
 
KING LAM LEE 
 
DEVELOPMENTAL BIOLOGY & CANCER PROGRAMME 
UCL GREAT ORMOND STREET INSTITUTE OF CHILD HEALTH 
UNIVERSITY COLLEGE LONDON 
 
 
 
 1 
I-Declaration 
 
I, King Lam Lee, confirm that the work presented here is my own. 
King Lam Lee performed the majority of experiments and conceived the project. Contributions 
from others are stated in this section otherwise. Emma Peskett (Pauws lab c.2013) performed 
RT-qPCR analysis on E12.5 R26RFgfr2cV5/+; βactinCRE/+, and immunohistochemistry on paraffin 
sections for the V5 epitope prior to the start of this project (Chapter 2). I was assisted by 
Charlotte Quinn (MSc 2017, Pauws lab) for quantitative analysis in Chapter 5A, and Sherine 
Pranata (BSc 2017, Pauws lab) for cartilage analysis in the Crouzon mouse model (Chapter 5B). 
RNAseq was performed in collaboration with UCL Genomics and genes ranked in ‘R’ console 
by John Apps (J.P Martinez-Barbera lab) prior to Gene Set Enrichment Analysis. RT-qPCR of 
candidate genes was performed by Somaya Taha (MSc 2017, Pauws lab) and reanalysed by 
King Lam Lee.  
  
 
 
______________________________________  
 2 
II-Acknowledgements 
This PhD took almost 4 years. I sit here on a chilly February afternoon contemplating 
on the people who made this endeavour possible. Looking back, it has been an incredible 
journey, a rollercoaster ride both on and off the pitch. I have met wonderful colleagues turning 
into friends along the way, and all of you have contributed immensely to my overall growth in 
one respect or another. Firstly, I would like to express my deepest gratitude to my supervisors 
Erwin Pauws and Philip Stanier for their continued support over the past few years. Both of you 
have watched me mature as a scientist and grown out of my natural milieu to drive this project. 
In addition, I want to thank Peter Munro and Matt Hayes at UCL IOO for laser captured 
microdissection, Mike Hubank, Tony Brooks and Mark Kristiansen at UCL Genomics for 
RNAseq, and Dale Moulding for microscopy assistance. Special credit also goes to my sponsors 
UCL and GOSHCC for making this research possible.  
It is not uncommon to experience a stalemate of scientific inspirations throughout this 
journey. This doctorate would not have been possible without the sustained support of friends 
and colleagues in the BDRC and GGM, who were always approachable in times of adversity. I 
want to specially thank Chloe Santos, who has been patient with me comes rain or shine. Phil 
and Gudrun’s lab (informally known as ‘Lunch Mob’): Emma Peskett, Dale Bryant, William 
Baird, Pambos Demetriou, Miho Ishida, Rimante Seselgyte, Melissa Riachi, Constance Maurer, 
Nita Solanky, Jess Buxton, Cristina Aleman-Charlet; and past members Lucas Alvizi, Susanne 
Stalman and Lydia Leon. All of you have given me incredible memories in and outside the lab, 
and I look forward to many more to come. I also had the pleasure to mentor nine students 
throughout my PhD, and I am very pleased to have witnessed all of you to excel in your own 
rights, and am grateful for your contributions to my project in one way or another-special 
credits to Rosanna Aiello, Charlotte Quinn, Sherine Pranata and Somaya Taha for your 
inconceivable efforts. Scott Haston and ‘Captain’ Leonidas Panousopoulos-you’ve managed to 
make life at ICH and beyond hilarious. I also owe my debt to my wonderful friends outside the 
lab and my undergraduate supervisor Clemens Kiecker, without your inspiration I wouldn’t 
 3 
have pursued a PhD. Last but not least, the greatest debt is owed to my family for their 
continued support through the many walks of life.  
I sit here concluding my thoughts as another chapter in my book draws to a close. I 
suppose this chapter was written to its full potential and is a memorable one. It is doubtless 
there will be challenges and fine performances along the way, and pursuing a PhD has certainly 
accomplished in strengthening my character and resilience. Finally, I would like to dedicate this 
thesis to those individuals who taught me, with specific regards to my mentors in academia and 
the teachers at school. To this end, I shall conclude with a principle from a great wartime Prime 
Minister:  
‘Success is not final, failure is not fatal:  
        it is the courage to continue that counts.’-Sir Winston Churchill.  
 
Until we meet again, 
Kevin K.L Lee. 
Sunday 11th February 2018.  
London, United Kingdom. 
 4 
III-Table of Contents 
 
I-Declaration ................................................................................................................................ 1 
II-Acknowledgements ................................................................................................................. 2 
III-Table of Contents .................................................................................................................. 4 
IV-List of Figures ........................................................................................................................ 8 
V-List of Appendices ................................................................................................................... 9 
VI-List of Abbreviations ........................................................................................................... 10 
VI.a-General abbreviations ........................................................................................................................ 10 
VI.b-Genes and protein abbreviations ........................................................................................................ 11 
VII-Abstract .............................................................................................................................. 12 
Chapter 1 
General Introduction ................................................................................................................ 13 
1.1-An overview of the mammalian skull ................................................................................ 14 
1.2-Embryonic origins of the head and coronal suture morphogenesis ............................... 16 
1.4-Molecular basis of FGF signalling ..................................................................................... 20 
1.4.1-Cytosolic signalling pathways of FGFR ........................................................................................... 21 
1.4.2-Kinetics of FGF signalling ................................................................................................................ 25 
1.4.2.1-Autophosphorylation domains of FGFRs .................................................................................. 25 
1.4.2.2-Intracellular response and dynamics of FGF signalling ........................................................... 28 
1.5-Modes of bone formation ................................................................................................... 31 
1.5.1-Endochondral ossification ................................................................................................................. 31 
1.5.1.1-Mesenchymal condensation ....................................................................................................... 34 
1.5.1.2-Chondrogenesis in the growth plate .......................................................................................... 35 
1.5.1.3-Hedgehog and PTHrP signalling: A major feedback loop for chondrocyte maturation ........... 38 
1.5.1.4-The role of FGF signalling in endochondral ossification.......................................................... 40 
1.5.1.5-Sox9 and Runx2: molecular switches for hypertrophic differentiation ..................................... 42 
1.5.2-Intramembranous ossification ........................................................................................................... 45 
1.5.2.1- Osteoblast maturation programme ........................................................................................... 49 
1.5.2.2-Effects of FGF signalling on osteoblast maturation programme .............................................. 50 
1.5.2.3-Cytosolic signalling cascades responsible for osteoblastogenesis ............................................ 52 
1.6-Human genetics of syndromic craniosynostosis and mouse models ............................... 56 
1.6.1-Craniosynostosis ............................................................................................................................... 56 
1.6.2-Human genetics of FGFRs and craniosynostosis .............................................................................. 59 
1.7-Mouse models for craniosynostosis ................................................................................... 63 
1.7.1-FGFR1 .......................................................................................................................................... 63 
1.7.2-FGFR2 .......................................................................................................................................... 64 
1.7.3-FGFR3 .......................................................................................................................................... 67 
1.7.4-FGF ligands and craniosynostosis ............................................................................................... 69 
1.7.5-Other mouse models with syndromic craniosynostosis .................................................................... 71 
1.7.5.1-Twist1, Msx2 .............................................................................................................................. 71 
1.7.5.2-Hedgehog related genes ............................................................................................................ 74 
1.7.5.3-Transforming growth factor beta (TGFβ) signalling misregulation.......................................... 75 
1.7.5.4-Other mouse models with craniosynostosis phenotype .............................................................. 76 
1.7.6-Evaluation of mouse models in the literature .................................................................................... 79 
1.8-Aim of project ..................................................................................................................... 83 
 5 
Chapter 2 
Materials and Methods ............................................................................................................. 84 
2.1-Animals ................................................................................................................................................ 85 
2.2- Genotype determination ...................................................................................................................... 89 
2.2.1-DNA extraction ............................................................................................................................. 89 
2.2.2-Genotype determination for Rosa26 or CRE ................................................................................ 89 
2.2.3-Genotyping for the Fgfr2cC342Y/+ knock in mutation ..................................................................... 91 
2.2.4-Genotyping for the KRasG12D/+ mice ............................................................................................. 92 
2.3-Culture systems .................................................................................................................................... 94 
2.3.1-Cells .............................................................................................................................................. 94 
2.3.2-Cell transfection ........................................................................................................................... 94 
2.3.3-Ex vivo calvarial explant cultures ................................................................................................ 94 
2.4-Quantitative RT-qPCR ......................................................................................................................... 95 
2.4.1-RNA extraction ............................................................................................................................. 95 
2.4.2-cDNA synthesis ............................................................................................................................. 95 
2.4.3-Quantitative RT-qPCR .................................................................................................................. 95 
2.5-Immunoblots ........................................................................................................................................ 97 
2.5.1-Protein extraction for whole embryos .......................................................................................... 97 
2.5.2- Protein extraction for cells .......................................................................................................... 98 
2.5.3-Transfer and antibody blotting ..................................................................................................... 98 
2.5.4-Re-blotting membranes ................................................................................................................. 98 
2.5.5-pERK/tERK immunoblots ............................................................................................................. 99 
2.6-Histology ............................................................................................................................................ 100 
2.6.1-Embryo embedding for frozen sections ....................................................................................... 100 
2.6.2-Paraffin embedding .................................................................................................................... 100 
2.6.3-Bone and cartilage histology ...................................................................................................... 100 
2.6.4-Wholemount alizarin red stain ................................................................................................... 100 
2.6.5-Wholemount alcian blue staining of calvaria ............................................................................. 101 
2.6.6-Cartilage histology (sections) ..................................................................................................... 101 
2.6.7-Alkaline phosphatase (ALP) assay ............................................................................................. 101 
2.6.8-Wholemount alizarin red stain ................................................................................................... 101 
2.6-In situ hybridisation (ISH) ................................................................................................................. 103 
2.6.1-Cloning the mV5 transgene for RNA in situ probe ..................................................................... 103 
2.6.2-In vitro transcription .................................................................................................................. 105 
2.6.3-mV5 wholemount ISH ................................................................................................................. 107 
2.6.4-In situ hybridisation on tissue sections ....................................................................................... 107 
2.7-Immunohistochemistry (IHC) ............................................................................................................ 109 
2.7.1-IHC for frozen sections ............................................................................................................... 109 
2.7.2-IHC on paraffin sections ................................................................................................................. 111 
2.8-Phenotypic analysis ............................................................................................................................ 113 
2.8.1-Gross analysis of phenotype ....................................................................................................... 113 
2.8.2-Morphometric analysis of the craniofacial skeleton ................................................................... 113 
2.8.3-Data transformation for littermates ............................................................................................ 115 
2.9-Statistical analysis .............................................................................................................................. 116 
2.10-Image acquisition ............................................................................................................................. 116 
2.11-Profiling the coronal suture .............................................................................................................. 116 
2.11.1-Histology for LCM .................................................................................................................... 116 
2.11.2-Performing laser capture microdissection ..................................................................................... 117 
2.11.3-RNA preparation and sequencing ................................................................................................. 117 
2.11.4-Expression analysis ....................................................................................................................... 117 
2.11.5-Gene set enrichment analysis (GSEA) .......................................................................................... 119 
Chapter 3 Results (Part I) 
Investigation of Fgfr2c expression levels in the Fgfr2c-V5 transgenic mouse ................... 120 
3.1-Introduction ...................................................................................................................... 121 
3.2-Results ................................................................................................................................ 122 
 6 
3.2.1-Evaluation of FGFR2c-V5 expression ............................................................................................ 122 
3.2.2-Strategies to determine conditional FGFR2c-V5 overexpression ................................................... 124 
3.2.3-Expression validation in R26RFgfr2cV5/+; Wnt1CRE/+ and R26RFgfr2cV5/+; Mesp1CRE/+ ......................... 124 
3.2.4-Expression validation in R26RFgfr2cV5/+; βactinCRE/+ ........................................................................ 126 
3.2.5-Visualizing the V5 epitope in vivo .................................................................................................. 127 
3.2.6-Use of reporter lines to indirectly show Fgfr2c-V5 overexpression ................................................ 130 
3.3-Discussion .......................................................................................................................... 132 
3.3.1-Expression validation in the mesoderm lineage .............................................................................. 132 
3.3.2-The V5 epitope ................................................................................................................................ 134 
Chapter 4 Results (Part II) 
Phenotypic analysis of the craniofacial skeleton in Fgfr2c overexpression mice .............. 136 
4.1-Introduction ...................................................................................................................... 137 
4.2-Results ................................................................................................................................ 138 
4.2.1-Fgfr2c overexpression causes growth restriction ............................................................................ 138 
4.2.2- Fgfr2c overexpression leads to frontal bone hypoplasia and patent suture .................................... 140 
4.2.3-Ubiquitous Fgfr2c overexpression does not result in coronal synostosis ....................................... 144 
4.3-Discussion .......................................................................................................................... 147 
4.3.1-Fgfr2c overexpression yields skeletal hypoplasia in the NCC lineage ........................................... 147 
4.3.2-Osteogenic potential in R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2cC342Y/+ .............................................. 150 
4.3.3-FGFR2c overexpression results in a cleft palate phenotype ........................................................... 152 
4.3.4-Ear malformation in R26RFgfr2cV5/+; βactinCRE/+ is an ectopic effect ................................................ 153 
4.3.5-Experimental considerations ........................................................................................................... 155 
4.3.6-Future directions ............................................................................................................................. 156 
Chapter 5 Results (Part III) 
Comparison of the FGFR2 signalling pathway in Fgfr2cC342Y/+ and  R26RFgfr2cV5/+; 
βactinCRE/+ mice ........................................................................................................................ 158 
5.1-Introduction ...................................................................................................................... 159 
5.2-Results ................................................................................................................................ 160 
5.2.1-FGFR2c overexpression and FGFR2c-C342Y mutation lead towards an overactive RAS-MAPK 
pathway in vivo and in vitro ..................................................................................................................... 160 
5.2.3-Expression of SPRY2, SPRY4, ETV5 in HEK293T cells ................................................................ 163 
5.2.4-No ectopic expression of FGFR2c signalling in E16.5 coronal sutures .......................................... 165 
5.3-Discussion .......................................................................................................................... 167 
5.3.1-Biochemical similarities between R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2cC342Y/+ .............................. 167 
5.3.2-Expression analysis of SPRY2, SPRY4 and ETV5 in vitro .............................................................. 168 
5.3.3-Similar expression patterns of FGFR2 signalling readouts in the coronal suture ........................... 169 
5.3.4-Future direction ............................................................................................................................... 170 
Chapter 6 Results (Part IV) 
Exploring RAS-MAPK pathway misregulation in vivo ....................................................... 172 
6.1-Introduction ...................................................................................................................... 173 
6.2-Results: Part A .................................................................................................................. 174 
6.2.1-Gross phenotype of R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ ........................................................... 174 
6.2.2-Introduction of the Fgfr2c overexpression allele into Fgfr2cC342Y/+ partially rescues the Crouzon 
phenotype ................................................................................................................................................. 177 
6.2.3-R26RFgfr2cV5/+; βactinCRE/+; Fgfr2cC342Y/+ yields hypoplasia of the calvarial bones.......................... 177 
6.2.4-Fgfr2c overexpression delays coronal suture morphogenesis in Fgfr2cC342Y/+ ............................... 181 
6.3-Results: Part B .................................................................................................................. 182 
6.3.1-Overactivation of RAS-MAPK pathway with oncogenic KRasG12D/+ induces severe skeletal 
hypoplasia with ectopic cartilage phenotype ............................................................................................ 182 
 7 
6.3.2-Ectopic cartilage phenotype is also abundant in Fgfr2c-C342Y embryos ....................................... 185 
6.4-Discussion .......................................................................................................................... 187 
6.4.1-Part A: Phenotypic considerations of R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+................................ 187 
6.4.2-Part B: Overactive RAS-MAPK pathway potentially leads to terminal differentiation defects ..... 189 
6.4.3- Emerging role of cartilage in craniosynostosis .............................................................................. 190 
6.4.4-Future directions ............................................................................................................................. 193 
6.5-A working model for FGFR2c and syndromic craniosynostosis .................................. 195 
Chapter 7 Results (Part V) 
Profiling the embryonic coronal suture ................................................................................ 198 
7.1-Introduction ...................................................................................................................... 199 
7.2-Results ................................................................................................................................ 200 
7.2.1-RNA was extracted from microdissected coronal sutures ............................................................... 200 
7.2.2-General quality of RNAseq from LCM samples ............................................................................. 201 
7.2.3-GSEA reveals multiple molecular signatures in the embryonic suture ........................................... 204 
7.2.4-Shortlisting candidate genes for expression validation ................................................................... 206 
7.2.5-RT-qPCR expression validation of candidate genes ....................................................................... 209 
7.2.6-Preliminary results of RNAseq expression validation .................................................................... 210 
7.2.6.1-The upregulated genes ............................................................................................................. 210 
7.2.6.2-The downregulated genes ........................................................................................................ 210 
7.3-Discussion .......................................................................................................................... 212 
7.3.1-Molecular events occurring in the embryonic suture ...................................................................... 212 
7.3.2-Validation of selected differentially expressed genes identified by RNAseq ................................. 214 
Upregulated genes: .............................................................................................................................. 214 
7.3.2.1-Papln (Papilin) ........................................................................................................................ 214 
7.3.2.2-Map3k6 .................................................................................................................................... 215 
7.3.2.3-Col9a1 ..................................................................................................................................... 216 
Downregulated genes: ......................................................................................................................... 217 
7.3.2.4-Pcyt1b ...................................................................................................................................... 217 
7.3.2.5-Pdgfb ....................................................................................................................................... 218 
7.3.2.6-Rsad2 ....................................................................................................................................... 220 
7.3.3-Justifications of using LCM to screen the embryonic suture .......................................................... 222 
7.3.4-Experimental limitations ................................................................................................................. 223 
7.3.5-Future Directions ............................................................................................................................ 225 
7.3.5.1-Functional analysis ................................................................................................................. 225 
7.3.5.2-Transcriptomic experiments .................................................................................................... 226 
Chapter 8 
General Discussion And Concluding Remarks .................................................................... 228 
8.1-Overall summary and scope of research in the wider community ..................................................... 229 
8.2-Concluding remarks ........................................................................................................................... 237 
Publications  ............................................................................................................................ 238 
Appendix .................................................................................................................................. 241 
References ................................................................................................................................ 259 
 
 8 
IV-List of Figures 
 
FIGURE 1: ANATOMY OF THE MAMMALIAN SKULL. .................................................................................................................. 15 
FIGURE 2: SUTURES OF THE CALVARIA. ..................................................................................................................................... 15 
FIGURE 3: SCHEMATIC SHOWING CNCCS IN THE DEVELOPING EMBRYO. ............................................................................ 18 
FIGURE 4: THE EMBRYONIC DERIVATIVES OF THE CALVARIA. ............................................................................................... 18 
FIGURE 5: EMBRYONIC DERIVATIVE OF THE CORONAL SUTURE. ........................................................................................... 19 
FIGURE 6: ALTERNATIVE SPLICING OF HUMAN AND MOUSE FGFR2 .................................................................................... 23 
FIGURE 7: FGF SIGNALLING PATHWAY. .................................................................................................................................... 24 
FIGURE 8: TYROSINE RESIDUES (RED CIRCLES) REQUIRED FOR RAS-MAPK, PI3K-AKT, STAT, PLCΓ-PKC 
ACTIVATION. ........................................................................................................................................................................ 27 
FIGURE 9: A SCHEMATIC SHOWING ENDOCHONDRAL OSSIFICATION. ................................................................................... 33 
FIGURE 10: MARKERS OF ENDOCHONDRAL OSSIFICATION IN THE GROWTH PLATE. ......................................................... 38 
FIGURE 11:PTHRP-IHH REGULATORY LOOP IN THE GROWTH PLATE. ............................................................................... 39 
FIGURE 12: MOLECULAR TRIGGERS FOR HYPERTROPHIC DIFFERENTIATION IN CHONDROCYTES. .................................. 44 
FIGURE 13-MINERALIZATION OF THE CALVARIA. ................................................................................................................... 46 
FIGURE 14: OVERVIEW OF FGF LIGAND-FGFR INTERACTION IN OSTEOGENESIS. ............................................................ 48 
FIGURE 15: OSTEOBLAST MATURATION PROGRAMME. .......................................................................................................... 50 
FIGURE 16: A SUMMARY OF FGFR2 SIGNALLING CASCADES REGULATING CELLULAR PROLIFERATION AND 
DIFFERENTIATION. .............................................................................................................................................................. 55 
FIGURE 17: PRESENTATION OF A PATIENT WITH CROUZON SYNDROME. ............................................................................ 57 
FIGURE 18: CRANIOSYNOSTOSIS AFFECTS SKULL DYSMORPHOLOGY. .................................................................................. 57 
FIGURE 19: DISTRACTION OSTEOGENESIS ON THE HUMAN CALVARIA ................................................................................. 58 
FIGURE 20: FREQUENCY AND DISTRIBUTION OF MUTATIONS IDENTIFIED ON THE FGFRS. ............................................. 60 
FIGURE 21: EXPRESSION OF FGFRS IN THE CORONAL SUTURE ............................................................................................ 61 
FIGURE 22: MOUSE MODEL FOR HUMAN CROUZON SYNDROME, FGFR2CC342Y/+. ............................................................... 62 
FIGURE 23: INTERBREEDING STRATEGY TO INTRODUCE MTMG ALLELE INTO THE FGFR2C OVEREXPRESSION MOUSE.
 ............................................................................................................................................................................................... 86 
FIGURE 24: INTRODUCTION OF THE FGFR2C OVEREXPRESSION ALLELE INTO FGFR2CC342Y/+. ........................................ 87 
FIGURE 25: STRATEGY FOR R26R RECOMBINANTS GENOTYPING. ....................................................................................... 90 
FIGURE 26: GENOTYPING STRATEGY OF KRASLSL-G12D/+ AND ITS RECOMBINANTS. ........................................................... 92 
FIGURE 27: PRIMER DESIGN AGAINST MV5 TRANSGENE. .................................................................................................... 104 
FIGURE 28: RESOLVING THE CORRECT MV5 BAND............................................................................................................... 104 
FIGURE 29: SEQUENCE ALIGNMENT OF AN FGFR2C-V5 CLONE CONTAINING THE MV5 INSERT. .................................. 105 
FIGURE 30: PLASMID MAP OF MV5 ......................................................................................................................................... 106 
FIGURE 31: PLASMID LINEARIZATION (TOP) AND IN VITRO TRANSCRIPTION OF MV5 PROBES USING APPROPRIATE 
ENZYMES (BOTTOM). U: UNCLEANED PROBES; C: CLEANED PROBES USING CHROMA SPIN COLUMNS. ........... 106 
FIGURE 32: FGFR2C OVEREXPRESSION DOES NOT HAVE AN EFFECT ON LIMB LENGTH AND IS USED AS AN ENDOGENOUS 
CONTROL FOR DATA TRANSFORMATION. ..................................................................................................................... 114 
FIGURE 33: PIPELINE FOR RNASEQ ANALYSIS. .................................................................................................................... 118 
FIGURE 34 EXPRESSION VALIDATION OF FGFR2C OVEREXPRESSION IN E12.5 R26RFGFR2CV5/+;ΒACTINCRE/+............. 123 
FIGURE 35: EXPRESSION VALIDATION OF FGFR2C IN THE E16.5 CALVARIA AND LIMB ................................................ 125 
FIGURE 36 EXPRESSION VALIDATION IN E16.5 R26RFGFR2CV5/+; ΒACTINCRE/+ CALVARIA. ............................................. 126 
FIGURE 37: V5 IHC ON FROZEN SECTIONS WITH IMAGES SHOWING AXIAL SECTIONS OF THE TELENCEPHALON (N>2 
FOR ALL CONDITIONS DESCRIBED). ............................................................................................................................... 128 
FIGURE 38: MV5 WHOLEMOUNT ISH ON E12.5 R26RFGFR2CV5/+; MESP1CRE/+ (N=1/6).............................................. 129 
FIGURE 39: REPORTER LINES TO SHOW CRE ACTIVITY IN THE E16.5 CORONAL SUTURE. ........................................... 131 
FIGURE 40: GROSS PHENOTYPE OF EMBRYOS WITH FGFR2C OVEREXPRESSION. ............................................................ 139 
FIGURE 41 CRANIOFACIAL PHENOTYPES OF FGFR2C OVEREXPRESSING MUTANTS AT E18.5. ..................................... 142 
FIGURE 42 CRANIOFACIAL BONES OF THE NCC LINEAGE DISPLAY HYPOPLASIA. ........................................................... 143 
FIGURE 43: ABSENCE OF CORONAL SYNOSTOSIS IN R26RFGFR2CV5/+; ΒACTINCRE/+ EX VIVO AFTER CULTURE. .............. 145 
FIGURE 44: COMPARISON OF OSTEOBLAST ACTIVITY IN THE CORONAL SUTURE. ............................................................ 146 
FIGURE 45: UPREGULATION OF PERK IN VIVO AND IN VITRO IN R26RFGFR2CV5/+; ΒACTINCRE/+ AND FGFR2CC342Y/+. .. 161 
FIGURE 46: EXPRESSION OF PERK IN THE OSTEOGENIC FRONT IS ALSO PRESENT IN R26RFGFR2CV5/+; ΒACTINCRE/+. 162 
FIGURE 47: EXPRESSION VALIDATION OF CELLS TRANSFECTED WITH EITHER IIIC-V5 OR C342Y-V5 PLASMIDS. . 164 
 9 
FIGURE 48: SPRY2, SPRY4 AND ETV5 EXPRESSION IN TRANSFECTED CELLS. .............................................................. 164 
FIGURE 49 NO ECTOPIC EXPRESSION OF FGFR2 SIGNALLING READOUTS IN VIVO. (A-C) ISH OF SPRY2; (D-F) SPRY4; 
(G-I) ETV5. ...................................................................................................................................................................... 166 
FIGURE 50 GROSS PHENOTYPE OF R26RFGFR2CV5/+; ΒACTINCRE/+; FGFR2CC342Y/+. ........................................................... 175 
FIGURE 51: POST HARVEST QUANTIFICATION OF R26RFGFR2CV5/+;ΒACTINCRE/+;FGFR2CC342Y/+. ................................... 176 
FIGURE 52: FGFR2C OVEREXPRESSION PARTIALLY RESCUES THE FGFR2CC342Y/+ PHENOTYPE. .................................... 179 
FIGURE 53: MORPHOMETRIC ANALYSIS OF THE CALVARIA. ................................................................................................ 180 
FIGURE 54: ATTENUATED OSTEOBLAST ACTIVITY IN R26RFGFR2CV5/+;ΒACTINCRE/+;FGFR2CC342Y/+ (N=3)................. 181 
FIGURE 55: SEVERE CRANIOFACIAL HYPOPLASIA IN KRASG12D/+; WNT1CRE/+ (N=6/6) AT E18.5. ........................... 184 
FIGURE 56; EXPANSION OF CALVARIAL CARTILAGE IN E16.5 FGFR2C-C342Y EMBRYOS. .......................................... 186 
FIGURE 57: A WORKING MODEL OF OSTEOGENESIS REGULATED BY FGFR2 AND CRANIOSYNOSTOSIS (TOP). ......... 197 
FIGURE 58: RNA IS EXTRACTED FROM LCM. ....................................................................................................................... 200 
FIGURE 59: PCA PLOT AND SEQUENCE ALIGNMENT TO REFERENCE GENOME OF LCM CAPTURED SAMPLES. ........... 202 
FIGURE 60: IN SILICO CONTROL OF LCM, SEQUENCED DATA WAS RUN AGAINST A FGF ENTITY LIST. ........................ 203 
FIGURE 61: ENRICHED GENES OF FGFR2CC342Y/+. ................................................................................................................. 205 
FIGURE 62: PIPELINE FOR EXPRESSION VALIDATION AND HEATMAP OF HIGHLY DIFFERENTIALLY EXPRESSED GENES.
 ............................................................................................................................................................................................ 207 
FIGURE 63: EXPRESSION VALIDATION OF CANDIDATE GENES AT E12.5 EMBRYOS. ....................................................... 211 
FIGURE 64: POTENTIAL APPROACH TO GENERATE ENDOGENOUS REPORTER MICE FOR FGFR2B (A) AND FGFR2C (B) 
LINEAGE TRACING. ........................................................................................................................................................... 235 
FIGURE 65: EXPRESSION OF THE H2B-EGFP-2A CONSTRUCT. ........................................................................................ 236 
 
V-List of Appendices 
 
APPENDIX 1: TRIZOL EXTRACTION .......................................................................................................................................... 242 
APPENDIX 2: IMMUNOBLOTS .................................................................................................................................................... 243 
APPENDIX 3: WHOLEMOUNT BONE AND CARTILAGE STAIN ................................................................................................ 244 
APPENDIX 4: ALP ASSAY .......................................................................................................................................................... 245 
APPENDIX 5: PLASMID LINEARIZATION AND IN VITRO TRANSCRIPTION ........................................................................... 246 
APPENDIX 6: WMISH ............................................................................................................................................................... 247 
APPENDIX 7: SECTION ISH ....................................................................................................................................................... 250 
APPENDIX 8: FROZEN SECTION IHC ....................................................................................................................................... 253 
APPENDIX 9: PARAFFIN SECTIONS IHC .................................................................................................................................. 255 
APPENDIX 10: PROTOCOL FOR GENERATING PRENATAL CALVARIAL OSTEOBLAST CULTURES. .................................... 256 
APPENDIX 11: ENRICHED GENE SETS IN FGFR2CC342Y/+ ...................................................................................................... 257 
 
 
 10 
VI-List of Abbreviations 
 
VI.a-General abbreviations 
 
AER Apical epidermal ridge  
    ALP Alkaline phoshatase 
    ATP Adenosine triphosphate 
    BCIP 5-bromo-4-chloro-3-indolyl phosphate 
   BSA Bovine serum albumin 
    cNCCs Cranial neural crest cells 
    DAPI 4',6-diamidino-2-phenylindole 
   DIG Digoxygenin 
    ECL Enzymatic chemiluminescence 
   ECM Extracellular matrix 
    Eks Elbow-knee synostoses 
    ELISA Enzyme-linked immunosorbent assay 
   EMT Epithelial mesenchymal transition 
   ES Enrichment score  
    EtOH Ethanol 
     FACS Fluorescence activated cell sorting  
   FDR  False discovery rate 
    FRET Forster resonance energy transfer 
   GCP Greig cephalopolyndactyly  
   GOF Gain of function 
    HCMV Human cytomegalovirus  
    HISS Heat inactivated sheep serum 
   HRP Horse radish peroxidase  
    HSCs Hemapoetic stem cells 
    HZ Hypertrophic zone 
    IFN Interferon 
     IgI Immunoglobulin like 
    IHC Immunohistochemistry 
    ISH  In situ hybridisation 
    LADD Lacrimo-auriculo-dento-digital 
   LOF Loss of function 
    MeOH Methanol 
     MPs Mesenchymal progenitors 
    MSCs Mesenchymal stem cells 
    MSS Multiple synostoses syndrome 
   NaOH Sodium hydroxide 
    NBT Nitro blue tetrazolium chloride 
   NCC Neural crest cells 
    NTMT Nacl; tris-hcl (hydrochloric acid); mgcl2 (magnesium chloride); 0.1% tween-20 
PBS Phosphate buffered saline 
    PCA Principal component analysis 
   PFA Paraformaldehyde 
    PTW Phosphate buffered saline-0.1% tween 
   PZ Proliferation zone 
    ROI Region of interest 
    RT Room temperature 
    RT-qPCR Real time quantitative polymerase chain reaction  
  RZ Resting zone 
    SADDAN Severe achondroplasia with developmental delay and acanthosis nigricans 
SSC Saline sodium citrate 
    TBST Tris buffered saline-tween-20  
   TK Tyrosine kinase 
    TSA Tyramide signal amplification  
   WT Wild type 
     ZPA Zone of polarising activity 
    
 
 11 
VI.b-Genes and protein abbreviations 
 
ADAM A disintegrin and metalloproteinase 
ADAMTS1 A Disintegrin And Metalloproteinase with Thrombospondin Type 1 motifs  
ASK1 Apoptosis signalling regulating kinase 1 
ASK2 Apoptosis signalling regulating kinase 2 
Atf4 Activating transcription factor 4 
bHLH Basic helix loop helix 
 BMP Bone morphogenetic protein 
CCT CTP: phosphocholine cytidydyltransferase  
CDK Cyclin dependent kinase 
 Col Collagen 
  CRKL CRK-Like protein 
 Dusp6 Dual specificity phosphatase 6 
Dusp6 Dual specificity phosphatase 6  
EGFR Epidermal growth factor receptor  
En-1 Engrailed1 
  ERF Ets domain-containing transcription factor  
ESRP Epithelial spicing regulatory protein  
ETS  E-twenty six 
 FBN Fibrillin 
  FGF Fibroblast growth factors 
 FGFR Fibroblast growth factors receptor 
FoxA Forkhead box A  
 FOXO Forkhead box O 
 FOXO1 Forkhead box protein 1 
 Frem1 Fras1 related extracellular related gene 1  
FRS2α Fibroblast growth factor substrate alpha 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
Gdf6 Growth differentiation factor 6  
Grb2 Grwoth factor receptor bound2 
HDAC Histone acetylase 
 HSPG Heparin sulphate proteoglycans  
Id Inhibitor of DNA binding protein 
Ihh  Indian hedgehog  
 Jag1  Jagged1 
  Map3k6 Mitogen activated protein kinase kinase kinase 6 
Mef2c Myocyte enhancer factor 2c 
Mesp1 Mesoderm posterior 1 
 Msx2  Msh homeobox 2 
 mV5 Mouse V5 
  Nell1 Nel-like type 1 molecule  
 NGF Nerve growth factor 
 Papln Papilin 
  Pcty1b Phosphate cytidylyltransferase 1, choline, beta 
Pdgf Platelet derived growth factor  
Pdgfr Platelet derived growth factor receptor 
PPR Pthrp Receptor 
 Ptch Patched 
  PTHrP Parathyroid hormone related peptide  
Rab23 Ras-related protein Rab23 
 Rsad2 Radical SAM domain containing 2  
Rsk2 Ribosomal times Kinase 
 RTK Receptor tyrosine kinase 
 Runx2 Runt related transcriptor factor 2 
Shp2 Src homology region 2 domain containing phosphatase 
SKI SKI proto-oncogene 
 Sos Son of sevenless 
 Sox9 Sry hmg box 9 
 Spry Sprouty 
  STAT Signal Transducer and Activator of Transcription 
Tcf12  Transcription factor 12 
 TGF  Transforming growth factor 
TGFBR Transforming growth factor beta receptor 
TNFα Tumour Necrosis Factor α 
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VII-Abstract 
 Craniosynostosis is a 
common feature of craniofacial birth defects, and is characterised by premature fusion of the cranial 
sutures in the developing calvarium. Pathogenic FGFR2 signalling is a major cause of syndromic 
craniosynostosis and is caused by activating mutations within the FGFR2 gene. In particular, 
mutations affecting the IIIc isoform (i.e. FGFR2c-C342Y) contribute to coronal synostosis, a 
common phenotype in human Crouzon syndrome. This study aims to address the downstream effects 
of misregulated FGFR2c signalling in vivo. Conditional overexpression of Fgfr2c (R26RFgfr2cV5/+; 
βactinCRE/+) results in craniofacial hypoplasia without coronal synostosis, which is in contrast to 
Fgfr2cC342Y/+, a well-studied mouse model for human Crouzon syndrome. Assessment of the coronal 
suture reveals that R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2cC342Y/+ have opposing phenotypes, where the 
former display insufficient osteoblast activity. However, biochemical examination of RAS-MAPK 
activity in embryonic sutures of Fgfr2cC342Y/+ and R26RFgfr2cV5/+; βactinCRE/+ demonstrates 
upregulated pERK expression. The opposing phenotypes seen between Fgfr2cC342Y/+ and 
R26RFgfr2cV5/+; βactinCRE/+ mice suggested the possibility that Fgfr2c overexpression on the 
Fgfr2cC342Y/+ (R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+) genotype may serve to ameliorate the 
Crouzon phenotype. This study reports that the Crouzon phenotype was only partly spared in 
R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ mice, together with a partial rescue of the coronal suture. The 
latter was due to delayed calvarial ossification as well as reduced osteoblast activity. Therefore, this 
study demonstrated that an intricate balance would be required for FGF signalling in order to correct 
calvarial bone and suture morphogenesis, and that increasing the expression of the wild-type 
FGFR2c isoform may be a viable method to prevent or delay craniosynostosis progression. In 
addition, this study has uncovered a novel role for cartilage in craniosynostosis development and has 
performed comparative expression-profiling (RNAseq) on the E16.5 coronal suture of Fgfr2cC342Y/+ 
and WTs to uncover novel genes potentially involved in syndromic craniosynostosis. Further 
elucidation of the highly complex FGFR2c signalling pathway remains to be deciphered in order to 
improve our understanding of normal craniofacial development and its related pathologies, while 
providing a framework for the innovation of novel therapeutic strategies. 
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Chapter 1 
General Introduction 
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1.1-An overview of the mammalian skull 
 
 The mammalian skull is a 
complex anatomical structure comprising of the neurocranium and viscerocranium. The 
framework of the skull offers protection and support as well as forming the basis for the face. 
The neurocranium ensheathes the brain whilst the viscerocranium supports functions such as 
those related to eating, breathing and hearing. The major bones of the neurocranium in the 
human include the frontal, parietal, occipital, sphenoid and temporal bones (Wilkie and Morriss-
Kay, 2001) (Figure 1 A). In the mouse, there is an additional interparietal bone located posterior 
to the parietal bone (Figure 1 B). In order to accommodate brain growth, the calvarium (skull 
vault) expands throughout infancy along the cranial sutures, which are channels of 
undifferentiated mesenchyme located between individual bones (Johnson and Wilkie, 2011). 
Figure 2 illustrates the sutures of the human calvaria.  
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Figure 1: Anatomy of the mammalian skull.  
(A) Illustration showing the major bones in the human; (B) and in murine animal. (A) is 
modified from Wilkie and Morris-Kay 2001. 
 
 
 
Figure 2: Sutures of the calvaria.  
(A) Diagram indicating the sutures of the calvarium; (B) Cross section illustration of a cranial 
suture.  
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1.2-Embryonic origins of the head and coronal suture morphogenesis  
 
Significant progress has been made to fate map the embryonic origins of the vertebrate 
head using a combination of classical embryology techniques (i.e. Carbocyanine Dye labelling) 
and mouse reporter lines (eg. Rosa26-LacZ) (Jiang et al., 2002, McBratney-Owen et al., 2008, 
Chai et al., 2000, Yoshida et al., 2008, Jiang et al., 2000, Serbedzija et al., 1992, Lumsden et al., 
1991). In particular, the availability of mouse reporters enabled lineage tracing of specific 
groups of cells at a spatial-temporal resolution that were previously limited with classical 
embryology techniques. The vertebrate skull is derived from two distinct germ layers with 
skeletogenic potential: the mesoderm and neural crest cells (NCC).  Specifically, NCCs located 
in cranial regions (cranial NCCs; cNCCs) contribute to a large majority of derivatives in the 
head- forming the basis for the orofacial, frontal-nasal prominence in the calvarium and the 
viscerocranium (‘chondrocranium’) (Chai et al., 2000, McBratney-Owen et al., 2008, Yoshida 
et al., 2008). In addition to this, cNCCs contribute towards cartilaginous elements of the skull: 
Transplantation of cNCCs into host mesoderm tissue is sufficient to ectopically induce cartilage 
in the avian embryo (Schneider, 1999, McBratney-Owen et al., 2008). cNCCs are organised into 
three migratory streams known as the trigeminal, hyoid and post-otic (Figure 3). The latter two 
streams are beyond the scope of this section (for a comprehensive review, see (Graham et al., 
2004)) but the trigeminal stream, arising from the midbrain and rhombomeres 1 and 2, is of 
significance as it gives rise to the viscerocranium and the orofacial prominence (Serbedzija et 
al., 1992, Lumsden et al., 1991, McBratney-Owen et al., 2008).  
Additionally, cNCCs rostral to the hindbrain-such as the mesencephalic and 
diencephalic NCCs, are also involved in neurocranium morphogenesis and frontonasal 
prominence (Lumsden et al., 1991, Yoshida et al., 2008). In combination with reporter lines in 
higher vertebrates, cell labelling using Wnt1CRE/+ specific for NCCs and Mesp1CRE/+ for the 
mesoderm, reveal that the calvaria is derived from two embryonic lineages (Yoshida et al., 
2008).  NCCs contribute to the frontal bone whilst the parietal bone is solely mesodermal 
(Figure 4). However, the interparietal bone is of dual embryonic origin. The frontal and parietal 
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bones are bisected by the coronal suture, juxtaposed at the neural crest-mesoderm interface. Due 
to the distinct embryonic origins of the calvaria, it can be perceived as an embryonic 
compartment whereby distinct cell populations are segregated and separated by a cell lineage 
restricted boundary (Kiecker and Lumsden, 2005). There is a suggestion that the coronal suture 
is derived from the mesoderm, since these cells appear to be derived from the paraxial 
mesoderm at E7.5 and are specified by Hedgehog signalling (Yoshida et al., 2008, Deckelbaum 
et al., 2012, Deckelbaum et al., 2005). Deckelbaum and colleagues (2012) demonstrated that 
cells forming the coronal suture express the homeodomain factor Engrailed-1 (En-1), a 
transcription factor involved in anterior-posterior patterning, and is responsible for the correct 
positioning of the coronal suture. These En-1 precursor cells migrate from the supraorbital 
region in a rostral-dorsal manner between E11.0-E17.5, forming a boundary with the cNCCs 
and mesodermal precursors (Figure 5) (Deckelbaum et al., 2012). As the coronal suture 
mesenchyme is flanked by the osteogenic fronts of the intramembranous bones, maintaining 
suture patency will therefore require tightly co-ordinated cross-talk between the osteogenic 
fronts and the suture mesenchyme to sustain cellular proliferation and differentiation.  
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Figure 3: Schematic showing cNCCs in the developing embryo.  
Rostral cNCCs include diencephalic and mesencephalic cNCCs (Yellow and purple 
respectively). Major cNCCs migratory streams of the rhombomeres include the Trigeminal 
(Blue), Hyoid (Pink), Post-Otic (Green) streams.  
 
 
Figure 4: The embryonic derivatives of the calvaria.  
The frontal bone (F) is derived from the NCCs while the parietal bone (P) is from the 
mesoderm. Adapted from Yoshida et al., 2008. 
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Figure 5: Embryonic derivative of the coronal suture.  
Coronal suture precursors (En+ cells) are Hedgehog responsive and are derived from the 
paraxial mesoderm at E7.5 as indicated by En1-R26-LacZ lineage tracing. These cells halt at the 
supraorbital region before migrating dorsally and apically to form the suture. Adapted from 
Deckelbaum et al., 2012. 
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1.4-Molecular basis of FGF signalling  
 
There are 23 distinct Fibroblast Growth Factors (FGF) which interact with 4 families of 
FGF receptors (FGFR) (FGFR1, FGFR2, FGFR3, FGFR4) (Ornitz and Itoh, 2015). FGFs are 
grouped by sequence homology and are structurally similar, where they have a conserved 
sequence of around 120 amino acids long. FGF ligands have different affinities towards the 
receptors and the interpretation of its signalling output and cellular response are highly 
complex. Affinity of FGF ligands towards its receptor is modulated by heparin/heparin sulphate 
proteoglycans binding to FGF ligands extracellularly (Eswarakumar et al., 2005).  Table 1 
summarises the receptor specificity of FGF ligands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: FGF ligand affinities.  
Data assembled from Ornitz and Itoh, 2015.
Subfamily FGF Cofactor Receptor Affinity 
FGF1 
FGF1 
H
ep
ar
in
 o
r 
H
ep
ar
in
 S
u
lp
h
at
e 
ALL FGFRs 
FGF2 FGFR1c, 3c > 2c, 1b, 4 
FGF4 
FGF4 
FGFR1c, 2c > 3c, 4 
FGF5 
FGF6 
FGF7 
FGF3 
FGFR2b > 1b 
FGF7 
FGF10 
FGF22 
FGF8 
FGF8 
FGFR3c > 4 > 2c >1c >3b 
FGF17 
FGF18 
FGF9 
FGF9 
FGFR3c > 2c > 1c, 3b > 4 
FGF16 
FGF20 
FGF15/19 
FGF15/19 
βKlotho 
FGFR1c, 2c, 3c, 4 
FGF21 FGFR1c, 3c 
FGF23 αKlotho FGFR1c, 3c, 4 
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FGFRs are receptor tyrosine kinases (RTKs) dimers consisting of an extracellular binding 
domain, transmembrane domain and a tyrosine protein kinase located intracellularly. The 
extracellular portion of the receptor consists of three immunoglobulin-like loops (IgI, DI-DIII) 
each possessing unique functions. In particular, the DII and DIII domains serve as the major 
ligand-binding site. The DIII loop determines the different isoforms of FGFRs and is therefore 
ligand specific. Alternative splicing of mRNA transcripts in the 3’ (C-terminal) half of DIII loop 
determines the expression of ‘IIIb’ and ‘IIIc’ isoforms, occurring solely in FGFR1, FGFR2 and 
FGFR3. The ‘IIIb’ and ‘IIIc’ isoforms are encoded by exons 8 and 9 respectively, whilst exon 7 
codes for the N-terminal of DIII (‘IIIa’) (Figure 6) (Eswarakumar et al., 2005). In addition, 
expression of the ‘IIIb’ and ‘IIIc’ isoforms are tissue specific: while the ‘IIIb’ isoform is 
expressed in epithelial tissue, the ‘IIIc’ isoform is mainly expressed in the mesenchyme (Orr-
Urtreger et al., 1993). Receptor activation usually involves FGF ligands expressed in the tissue 
complementary to its receptor establishing a paracrine loop between the epithelium and 
mesenchyme (Eswarakumar et al., 2005, Ornitz and Itoh, 2015). An example for this interaction 
can be found in the developing limb bud, between Fgfr2b (epithelial) and Fgf10 (mesenchymal) 
(Li et al., 2007). One of the key regulatory elements for FGFR2 splice forms lies in intron 8, 
located in the intragenic region between exons 8 and 9 of FGFR2 (Warzecha et al., 2010). 
Alternative splicing of IIIb and IIIc isoforms is effected by Epithelial Splicing Regulatory 
Protein (ESRP) 1 and ESRP2, which were originally identified in a high throughput cDNA 
screen (Warzecha et al., 2010). Both variants of ESRPs were enriched in epithelial cell lines 
(e.g. PNT2) with high endogenous expression of Fgfr2b. ESRPs coordinate alternative splicing 
of FGFR2 primarily towards the IIIb isoform, overexpression of ESRPs in mesenchymal cell 
lines that result in a splice switch from IIIc to IIIb (Warzecha et al., 2010). These splice 
switches have important implications in development, where they help to control the temporal 
ligand-mediated response of the tissue (Warzecha et al., 2010).  
1.4.1-Cytosolic signalling pathways of FGFR 
FGFR signal transduction is mediated through three major pathways: RAS-MAPK, 
PI3K-AKT and PLCγ-PKC pathways (Figure 7). Upon ligand binding, the receptor dimerises 
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and is autophosphorylated, leading to the recruitment and coupling of the anchor protein FRS2α 
(Fibroblast Growth Factor Substrate) at the receptor. FRS2 is required for FGFR signal 
transduction, as FRS2α null embryos exhibit embryonic lethality at E7.5 (Hadari et al., 2001).  
It is responsible for assembling a multiprotein complex consisting of docking and effector 
proteins which transduce signals to downstream kinases leading to transcriptional activation: 
Formation of the Grb2-Sos (Growth factor receptor bound 2-Son of Sevenless) complex is 
common to activate both RAS-MAPK and PI3K-AKT pathways. In addition to these, FGFR can 
also convey their signals via PLCγ-PKC pathway through a series of calcium signalling 
intermediates (Eswarakumar et al., 2005, Ornitz and Itoh, 2015). FGF signalling can be 
negatively regulated at multiple levels of the cascade. For example, Sprouty (Spry) family 
proteins regulate both the sensitivity of RAS-MAPK pathway and PI3K-AKT pathway through 
inhibition of Grb2. Downstream of the cascade, MAPK can be inactivated by Dusp6 (Dual 
Specificity Phosphatase 6). The most common transcriptional targets for FGF signalling 
pathway include ETS (E-Twenty Six; RAS-MAPK pathway), FOXO1 (Forkhead box protein 1; 
P13K-AKT pathway) and STAT (Signal Transducer and Activator of Transcription; PLCγ-PKC 
pathway), each playing a handful of roles (Ornitz and Itoh, 2015). In the RAS-MAPK pathway, 
ETS expression leads to transcriptional activation of downstream genes associated with FGF 
signalling whilst in the P13K-AKT pathway, FOXO1 inhibition has anti-apoptotic effect. 
Expression of STAT by the PLCγ-PKC pathway activates target gene expression in the STAT 
pathway (Ornitz and Itoh, 2015). Collectively, cellular response towards FGF target gene 
expression is associated with controlling proliferation, differentiation, survival and migration 
(Ornitz and Itoh, 2015). 
 Activation of FGF signalling also drives signal transduction via non-canonical 
cascades. STAT1, STAT3 and STAT5 can directly bind to the receptor and translocate to the 
nucleus to initiate gene expression. In regards to cellular function, STAT proteins play an 
important role in FGFR3 signalling to modulate cellular proliferation via expression of cell 
cycle inhibitor p21 (Sahni et al., 1999). Other pathways that FGFRs influence include p38, Src 
and Jnk albeit the mechanisms are less well characterised (Brewer et al., 2015).  Interestingly, a 
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novel signalling mechanism has been implicated for FGF signalling whereby the receptor and 
ligand are co-translocated to the nucleus after receptor internalisation (Maher, 1996, Reilly et 
al., 2004). This process has been mainly studied in FGFR1 and is shown to be clathrin 
dependent endocytosis (Reilly et al., 2004). This nuclear translocation mechanism is also 
reported in FGFR2 and FGFR3 (Zhou et al., 2015a, May et al., 2016). Upon reaching the 
nucleus, the complex is imported into the nucleus interior via the cargo protein importin β 
(Reilly and Maher, 2001). The consequence of FGFR1 nuclear localisation is believed to be 
related to regulation of cell proliferation, for which it facilitates expression of c-Jun and cyclin 
D1 (Reilly and Maher, 2001). From a clinical perspective, mis-translocation is implicated in 
cellular transformation in cancers (Coleman et al., 2014, May et al., 2016). The signals that 
initiate nuclear entry remain elusive, but the signal peptide is believed to be within the 
transmembrane domain of the receptor (Myers et al., 2003). 
 
 
 
Figure 6: Alternative splicing of human and mouse FGFR2  
Exons 8 and 9 encode for the posterior portion of the D3 Ig loop, and produce the two FGFR2 
isoforms. FGFR2b is produced from alternative splicing of exon 8, and FGFR2c from exon 9 
respectively. Exon 7 is common to both isoforms and accounts for the anterior portion (IIIa) of 
the D3 loop. TM: transmembrane domain, RTK: (receptor) tyrosine kinase domain.   
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Figure 7: FGF signalling pathway.  
Activation of FGFRs activates the PI3K-AKT (Green), RAS-MAPK (Blue) and PLCγ-PKC 
(Yellow) pathways. The respective colour of each target gene corresponds to the pathway. 
Image courtesy and modified from: Erwin Pauws.   
 
 
 
 25 
1.4.2-Kinetics of FGF signalling  
1.4.2.1-Autophosphorylation domains of FGFRs  
FGFRs dimerize and induce trans-phosphorylation of the tyrosine kinase (TK) domain 
upon ligand binding. The first phase of phosphorylation involves the Y653 tyrosine residue, 
followed by Y583, Y463, Y766 and Y785 in the second phase. The last phase of 
phosphorylation requires activation of Y654 (Ornitz and Itoh, 2015). This sequential 
phosphorylation of tyrosine residues leads to amplification of tyrosine kinase activity by a factor 
of 500-1000 fold (Ornitz and Itoh, 2015). In addition to signal amplification, phosphorylation of 
distinct tyrosine residues results in recruitment of binding proteins required for downstream 
signalling transduction via RAS-MAPK, PI3K-AKT and PLCγ-PKC cascades (Figure 8) 
(Ornitz and Itoh, 2015). RAS-MAPK and PI3K-AKT activation requires the FGFR kinase 
FRS2α phosphorylation, which is constantly bound to the juxtamembrane of FGFR (Ornitz and 
Itoh, 2015). Upon receptor activation, FRS2α is activated by CRKL (CRK-Like protein) that is 
bound to Y463 (Figure 8; 1). Phosphorylated FRS2α consequently recruits Grb2 to the receptor 
to initiate downstream signal transuction (Figure 8; 2) (Ornitz and Itoh, 2015). The Y766 
residue is required for the activation of the PLCγ-PKC pathway, whilst a docking site is present 
on Y677 for STAT proteins respectively. (Ornitz and Itoh, 2015) Therefore, differential 
activation of these tyrosine residues will result in diverse cellular response. This is elegantly 
shown in vivo where introduction of a point mutations in the transmembrane domain (L424A 
and R426A; Fgfr2CLR allele) prevented FRS2α recruitment and abolished both RAS-MAPK and 
PI3K-AKT signalling (Eswarakumar et al., 2006). Furthermore, introduction of the Fgfr2-CLR 
allele into the Crouzon mouse model (Fgfr2cC342Y/+) resulted in a rescue of craniofacial 
malformations implicating the role of RAS-MAPK and/or PI3K-AKT in its pathogenesis 
(Eswarakumar et al., 2006). Similar examples can be drawn in FGFR1 hypomorphs, where 
targeting of the Y766 site in Fgfr1 gene led to defects of the axial skeleton due to abrogation of 
PLCγ-PKC signalling (Partanen et al., 1998). Therefore, targeting specific tyrosine residues 
downstream of receptors enable the elucidation of cascades contributing to a pathogenic 
phenotype. Similar work was performed in PDGFRα, whereby a series of autophosphorylation 
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mutants were generated by knockin technologies in order to understand activation of 
downstream cascades (Klinghoffer et al., 2002). One allele targeted Y731/Y742 residue that 
prevented activation of PI3K; whilst another targeted the Y572/Y574 residues that prevented 
recuitment of Src, a cytoplasmic tyrosine kinase (Klinghoffer et al., 2002). Although substantial 
efforts were made to understand the signal transduction, little is known about the consequences 
within an in vivo context. Differential activation of the TK domain is responsible to translate 
effects caused by ligand/independent receptor activation (next section). Signal transduction by 
receptor tyrosine kinases (RTKs) could either drive an additive or differential cellular response. 
For example, a cumulative response can be hypothesised when disrupting multiple tyrosine 
residues that lead to a similar, but subtle phenotypic spectrum (i.e. binding sites to FRS2 and 
PLCγ) (Brewer et al., 2015, Partanen et al., 1998). In contrast, differential cellular response is 
hypothesized when a receptor is able to drive two distinct cellular responses. This is evident in 
endochondral ossification where activation of FGFR3 can inhibit chondrocyte proliferation via 
STAT and hypertrophic differentiation is prevented by RAS-MAPK signalling (Li et al., 1999, 
Murakami et al., 2004). The mechanism for such differences, despite conserved RTK domains 
across FGFRs, is not well understood (Ornitz and Itoh, 2015). However, it is likely to be related 
on how the receptor perceives the signal, which in turn influences receptor activation (discussed 
in the next section 1.4.2.2).  
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Figure 8: Tyrosine residues (red circles) required for RAS-MAPK, PI3K-AKT, STAT, 
PLCγ-PKC activation.  
RAS-MAPK and PI3K-AKT: FRS2α is constantly bound to the juxtamembrane of FGFR. Upon 
receptor activation, FRS2α is activated by CRKL (CRK-Like protein) that is bound to Y463 (1). 
Phosphorylated FRS2α consequently recruits Grb2 to the receptor to initiate downstream signal 
transuction (2); STAT pathway activation requires Y677 phosphorylation and recruitment of 
PLCγ requires Y766 respectively. TM: transmembrane domain; TK: tyrosine kinase.  
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1.4.2.2-Intracellular response and dynamics of FGF signalling 
 
Despite multiple ligands having affinities towards a given FGFR, it is possible that the 
nature of their signal transduction mechanisms is different. This is particularly important to 
address how signals are conveyed from the extracellular domain of the receptor to influence 
RTK activation. Receptor activation can be either ligand dependent or independent, which gives 
distinct signalling output and downstream interpretation. An example for the former instance 
can be drawn in the role of FGF7 and FGF10 in branching morphogenesis of the lung 
(Francavilla et al., 2013). Despite having affinities for FGFR2b, application of FGF7 in ex vivo 
lung cultures led to formation of cysts in contrast to that of FGF10, which promoted branching 
of the lung (Francavilla et al., 2013). This phenotypic consequence is due to receptor activation 
by FGF7 that led to cellular proliferation whilst FGF10 stimulated a migration response. On a 
molecular level, FGF10 facilitates activation of Y734 domain in the RTK that is the main driver 
causing these differences in cellular response. Specific activation of the Y734 tyrosine residue is 
responsible for promoting receptor recycling to the cell surface after endocytosis and 
concommitant downstream augmentation of PI3K-AKT signalling. However, binding of FGF7 
to FGFR2b results in the opposite response where the receptor is degraded in the endosomes 
after endocytosis, which is independent of Y734 phosphorylation (Francavilla et al., 2013). This 
differential response caused by receptor trafficking ultimately determine amplitude and 
temporal dynamics of signal transduction. Here, application of FGF10 can be perceived as 
possessing a sustained response to receptor activation, whereby the signal elicited by FGF7 
binding is transient due to increased receptor degradation (Francavilla et al., 2013). Altered 
trafficking dynamics were also reported in receptors independent of ligand activation. For 
example, a variant of the Crouzon mutation (C278F) has increased retention from the membrane 
due to increased ubiquitination by the E3 ubiquitin ligase Cbl (Hatch et al., 2006). The 
mechanisms causing aberrant receptor turnovers mutant FGFRs are yet to be investigated in 
detail even though a substantial cohort of craniofacial syndromes being caused by aberrant FGF 
signalling. Despite substantial efforts having been made to dissecting the pathway responsible 
for proliferation and differentiation (Ornitz and Marie, 2015, Marie, 2012), the mechanisms 
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controlling signalling dynamics concerning individual mutations on FGFRs still remain unclear. 
A particular focus could be to investigate signals and regulators required for protein sorting 
immediately after receptor activation. For example, cytoplasmic TKs such as Src, which is 
recruited to FRS2 immediately after FGFR activation, helps to internalise the receptor 
(Sandilands et al., 2007, Kaabeche et al., 2004). Of note, a comprehensive review on the effects 
of known TRK receptor trafficking has been published elsewhere (Miaczynska, 2013). 
Understanding the full picture for receptor trafficking will provide a critical insight to how 
signals are modulated and the subsequent effect on the transduction cascades.     
How does two FGF ligands elicit a dissimilar response on the same receptor? This 
could relate to the FGF ligand affinities to co-factors such as Heparin Sulphate Proteoglycans 
(HSPGs). HSPGs are cell surface and extracelluar matrix (ECM) proteins that consists of a core 
protein, to which heparin sulphate glycosaminoglycan chains are attached (Lin, 2004). Core 
proteins of HSPG includes syndecan, perlecan, glypican and agrin. These can be anchored to the 
transmembrane (e.g. syndecan), localised on the cell surface (e.g. glypican) or diffusible in the 
ECM (e.g. perlecan or agrin) (Lin, 2004). FGFRs have a binding site for HSPG in the IglII loop 
to increase affinity of FGFs towards its receptor (Lin, 2004). HSPGs can modulate the 
morphogenic nature of FGFs that results in changing the binding affinity to receptors. FGF10 
and FGF7 have different affinity towards HSPGs, and mutating a binding site (R187V) for 
HSPG on FGF10 mimicked the cellular events normally caused by FGF7 through FGFR2b 
signalling during branching morphogenesis. Together with Francavilla et al (2013), these results 
explain the role of HSPG in modulating the ligand’s association with the receptor, which 
consequently elicit differential activation of the RTK domain and cellular response 
(Makarenkova et al., 2009). Other co-factors acting on the FGF signalling pathway include two 
Klotho family members, αKlotho and βKlotho, which act as binding partners for endocrine 
FGFs in place of HSPGs (Kuro-o, 2008). FGF15/19, FGF21 and FGF23 have low affinity 
towards HSPGs to that of paracine FGF ligands which allow the ligands to diffuse more freely 
across the ECM (Kuro-o, 2008). Indeed, disruption to endocrine FGFs is associated with a 
number of metabolic diseases. For example, FGF15 and FGF19 are secreted from intestines 
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modulate bile synthesis from the liver (Inagaki et al., 2005). Other modes of signalling include 
intracellular FGFs, comprising of the FGF11 family (FGF11, FGF12, FGF13 and FGF14). 
Little is known about their roles, but they are not known to bind to FGFRs (Olsen et al., 2003). 
However, they may assist on post-translational modifications and interaction with cytoskeleton 
(Wu et al., 2012).   
Genetic ablation or gain of function (GOF) approaches to critical mediators of FGF 
signalling have provided substantial insights into the nature of downstream signalling. 
Therefore, it is widely accepted that the interactions between FGF ligands and FGFRs can 
function individually or in combination (See section; Mouse models). The latter is particularly 
notable since it is widely thought that FGF signals are conveyed through FGFR homodimers. 
However, additional research have provided insights into FGFRs that are capable of forming 
heterodimers. These studies include i) FGFR2 is able to transphosphorylate cells expressing a 
dominant negative form of FGFR (Bellot et al., 1991); ii) Overexpression of truncated FGFR1, 
lacking the cytoplasmic domain, is able to sequester activation of FGFR2-3 upon ligand binding 
(Ueno et al., 1992); iii) Recently, heterodimer interactions within FGFRs were confirmed via 
Forster Resonance Energy Transfer (FRET) (Del Piccolo et al., 2017). Here, the C-terminal 
domains of the FGFR1-3 were replaced with a respective fluorescent tag (e.g. mCherry). FGFR 
heterodimers were confirmed by FRET when a strong heterogenous signal was detected in 
proximity to each other. In the same study, the authors also investigated the effects of GOF 
mutations affecting FGFR3 (i.e. A391E and G380R) and found that they can also stabilise 
FGFR1 and FGFR2 (Del Piccolo et al., 2017). It is unknown as to the role of heterodimers in 
controlling the dynamics FGF signalling. A speculation could be to help increase the diversity 
for FGF signalling response. Similarities can be drawn in Platelet Derived Growth Factor 
(PDGF) signalling, where the α and β isoforms of Platelet Derived Growth Factor Receptor 
(PDGFR) are interchangable (Klinghoffer et al., 2001). However, downstream RTK signalling 
is likely to be conserved, whereby displacing the extracellular domain for one another (i.e. α to 
β and β to α) led to a largely redundant phenotype in PDGFRs (Klinghoffer et al., 2001). 
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In summary, to understand the kinetics of FGF signalling a multitude of factors must be 
considered ranging from the cell surface to intracellular signal transduction. Questions must be 
asked as to the immediate consequences after receptor activation that could influence 
subsequent signal transduction. This section has given examples on how phosphorylation of 
specific tyrosine residues can influence specific cascade activation and receptor turnovers. The 
complex interactions at the level of the receptor will therefore determine the outcome of the 
amplitude, and temporal dynamics of signal transmission.  
1.5-Modes of bone formation 
1.5.1-Endochondral ossification 
Endochondral bones form from gradual displacement of cartilage template to bone. An 
intricate balance of chondrocyte specification, proliferation, differentiation and maturation are 
key to this process (Yeung Tsang et al., 2014). Chondrocytes lay down a series of ECM proteins 
as they mature, laying the foundation of the immature bone (Dreier et al., 2008, Kapyla et al., 
2004). Deviation from normal chondrogenesis results in skeletal dysplasia and long bone 
defects ranging in phenotypic severity, which could be progressive or resulting in perinatal 
lethality (Yeung Tsang et al., 2014). Endochondral ossification can be summarized into three 
main processes: mesenchymal condensation (around E11.5), chondrocyte maturation (E13.5), 
primary (E15.5) and secondary ossification centre formation (P7) (Kozhemyakina et al., 2015). 
This is illustrated in Figure 9. Briefly, Mesenchymal stem cells (MSCs) cluster together to form 
osteo-chondroprogenitors which are bi-potential in nature (Barna and Niswander, 2007, 
Karuppaiah et al., 2016, Day et al., 2005). These cells are restricted in fate and adopt either an 
osteogenic or chondrogenic lineage to form osteoblasts and chondrocytes respectively (Day et 
al., 2005). Committed chondroprogenitors subsequently differentiate into chondrocytes that 
proliferate, matures and undergo cellular hypertrophy (Day et al., 2005). This series of events 
consequentially lead to the formation of the cartilage template ensheathed by the perichondrium 
(Colnot et al., 2004). The perichondrium is involved in formation of the bone collar, for which 
cells differentiate into osteoblasts to give rise to the future periosteum (Colnot et al., 2004). 
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During this time, primary ossification commences through vascular invasion of the periosteum, 
allowing blood vessels to penetrate into the calcifying cartilage (Colnot et al., 2004). 
Simultaneously, vascular invasion allows bone remodelling to occur, for which blood vessels 
carry cells (i.e. osteoclast and chondroclasts) involving in this process (Yeung Tsang et al., 
2014). The consequent remodelling of the cartilage template allows osteoblasts to lay down 
calcified matrix allowing osteogenesis to occur, aiding the formation of the trabecular bone 
(Colnot et al., 2004). Gradually, the cartilage template is split into two ends by the calcified 
matrix, forming the epiphysis (Colnot et al., 2004).  
The growth plate is absolutely essential for endochondral ossification as it controls the 
progressive events of chondrocyte proliferation, differentiation and maturation (Dreier et al., 
2008, Dy et al., 2012). This enables the correct formation of the cartilage template required for 
the bone cellular architecture. The growth plate possesses a hierarchal structure and consists of 
four zones: Resting zone (RZ) consists of round chondrocytes that serves as a progenitor pool 
for proliferation and differentiation. In the proliferation zone (PZ), the rounded chondrocytes are 
flattened, reorganized and aligned into columns that are important for longitudinal growth 
(Kozhemyakina et al., 2015, Yeung Tsang et al., 2014). These cells continue to divide in 
columns. In the pre-hypertrophic zone, the cells begin to undergo hypertrophic differentiation 
through cell cycle exits (Beier et al., 2001, Beier et al., 1999). Finally, in the hypertrophic zone 
(HZ), pre-hypertrophic chondrocytes terminally differentiate and greatly increases in size 
(Colnot et al., 2004, Vortkamp et al., 1996). The lowermost boundary of the HZ is gradually 
calcified and replaced by bone (Colnot et al., 2004). 
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Figure 9: A schematic showing endochondral ossification.  
Mesenchymal condensation occurs (blue cells) at E11.5 in the limb bud. MSCs differentiate into 
chondrocytes (red) at E13.5, and are surrounded by the perichondrium (white lining). As 
endochondral ossification progresses, the bone is separated by the osteoid, where 
vascularization (red lines) commences at roughly E15.5. This subsequently leads to formation 
of the primary ossification centre where chondrocytes are gradually displaced into bone. 
Gradually, the cartilage template is split into two ends by the calcified matrix (open circles), 
forming the epiphysis. The growth plate is essential for endochondral ossification as it controls 
the progressive events of chondrocyte proliferation, differentiation and maturation. Lastly, a 
secondary ossification centre forms at roughly P7, displacing the residual chondrocytes in the 
growth plate. Assembled from (Kozhemyakina et al., 2015).   
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1.5.1.1-Mesenchymal condensation 
The first stage of endochondral condensation requires mesenchymal progenitors cells to 
be differentiated towards a chondrocytic lineage, which occurs around E11.5 (Kozhemyakina et 
al., 2015). The initiation of this process is highly dependent on transforming growth factor β 
(TGFβ) signalling (Barna and Niswander, 2007, Lim et al., 2015). The TGFβ superfamily 
comprises of bone morphogenic protein (BMP) and TGFβ, which bind to their receptor 
complexes to activate SMAD transcriptional cofactors. BMP signals are tranduced via SMAD1, 
SMAD5 and SMAD8 whilst TGFβ signals are conveyed through SMAD2 and SMAD3. These 
SMAD cofactors are classified as ‘R-SMADS’ (receptor activated SMADs), referring to the 
direct release from the receptor complex upon signalling activation. R-SMADs subsequently 
form heterodimers with SMAD4, which translocates to the nucleus to initiate downsteam gene 
expression (Derynck and Zhang, 2003). In a live imaging study conducted by Barna and 
Niswander (2007), BMP signalling was shown to be required for cellular compaction of 
mesenchymal condensates (Barna and Niswander, 2007). Failure to form this condensate, due to 
genetic  ablation of both Bmp2 and Bmp4 in the mesenchyme, resulted in ulna and posterior 
digital malformation (Bandyopadhyay et al., 2006). BMP2 and BMP4 signals are likely to be 
conveyed through SMAD4 as its loss of function (LOF) led to loss of cellular condensates 
(Benazet et al., 2012). However, a largely normal phenotype is yielded should either one copy 
of Bmp2 or Bmp4 is available, implicating ligand redundancy. BMP signalling is critical to 
induce chondrocyte specification as Smad4-/- led to a reduction of Sox9 (Sry HMG Box 9) and 
Collagen (Col) 2 protein expression (Benazet et al., 2012).  
Sox9 is the single most important transcription factor required for chondrogenesis, and 
its ablation leads to complete loss of cartilage elements (Bi et al., 1999, Akiyama et al., 2002). 
Lineage tracing of Sox9 reveals it is expressed in the condensing mesenchyme and all cartilage 
primordia (Bi et al., 1999). In humans, LOF mutation to SOX9 is associated with campomelic 
dysplasia, and is phenotypically described as hypoplasia of all endochondral elements (Foster et 
al., 1994). Chondrocytes express a multitude of collagens as they mature: Immature 
chondrocytes are characterized by high abundance of Col2a1 and Col9a1 expression together 
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with a series of matrix proteoglycans (Gomez-Picos and Eames, 2015, de Crombrugghe et al., 
2001). In particular, deposition of these proteins by immature chondrocyte lays the foundation 
of the developing cartilage, whilst mature chondrocytes re-models the cartilage ECM and 
subsequently mineralizing it (Gomez-Picos and Eames, 2015). Sox9 is critical to drive the 
downstream expression of Col2a1 and Col9a1 and is therefore, important to drive the correct 
formation of cartilage primordia (Zhou et al., 1998). From a clinical point of view, skeletal 
dysplasia is caused by disruption to cartilage and bone development. There are approximately 
400 skeletal dysplasias identified so far, which can be either a GOF or LOF, and are commonly 
associated with dwarfism and embryonic lethality (Yeung Tsang et al., 2014). Therefore, the 
correct formation of cartilage is critical for normal bone development, particularly being reliant 
on the intricate balance of chondrogenesis at the growth plate. 
1.5.1.2-Chondrogenesis in the growth plate 
Chondrocytes continue to mature, becoming hypertrophic and ultimately form the basis 
of the cartilage template as mesenchymal condensation progresses. This highly coordinated 
temporal-spatial control of chondrogenesis essentially forms the basis of the growth plate. The 
growth plate can be loosely defined as chondrocytes in their different stages of maturation, and 
is characterized by an array of markers expressed in the different zones (Figure 10) 
(Kozhemyakina et al., 2015). In addition to the master regulator for chondrocyte differentiation, 
Sox9 is important to sustain chondrocyte identity (Bi et al., 1999, Akiyama et al., 2002). Sox9 is 
upstream of Sox5 and Sox6 (Akiyama et al., 2002), and the trio coordinate chondrocyte 
specification through regulation of genes that define its function such as Col2a1 (Smits et al., 
2004, Smits et al., 2001, Lefebvre et al., 2001). The importance of Col2a1 has been highlighted 
in a mouse model in which its conditional inactivation led to the loss of the growth plate (Li et 
al., 1995). As Col2a1 defines immature and mature chondrocytes across the growth plate, its 
ablation led to insufficient chondrocytes being amplified and resulted in truncation of the axial 
skeleton (Li et al., 1995). Control of the cell cycle is critical to progress onto subsequent stages 
of the maturation process. Whether the cell decides to continue proliferating or exit the cell 
cycle for events such as differentiation, lies with G1 phase of the cell cycle (Beier et al., 1999). 
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Progression in the cell cycle requires cyclin dependent kinase (CDKs), which is partnered with 
specific cyclin proteins to elicit target gene expression for cell cycle response and DNA 
replication. Chondrocytes express all of the D-type cyclins (D1, D2 and D3), which are 
involved in facilitating cellular proliferation (Beier et al., 1999). A comprehensive review on 
cell cycle mediators in chondrocytes is described elsewhere (Beier et al., 1999). However, in 
vivo literature on the role of cyclin in bone development is limited. Nonetheless, the growth 
plate of mice lacking cyclin D1 is considerably smaller, in particular to the proliferation zone 
(Beier et al., 2001). It is understood that cyclin D1 integrates signals from multiple pathways 
such as Parathyroid Hormone Related Peptide (PTHrP) and Hedgehog (Indian hedgehog, Ihh) 
(Beier et al., 2001, Long et al., 2001), linking their roles in controlling cellular proliferation. It is 
well understood that paracrine factors such as FGFs and IHH are expressed at the outer edges of 
the bone i.e. perichondrium/periosteum, to facilitate endochondral growth and chondrocyte 
survival (Figure 10) (Kozhemyakina et al., 2015). The next section will focus on the main 
pathways that facilitate chondrocyte proliferation and differentiation. 
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Figure 10: Markers of endochondral ossification in the growth plate. 
(A) is a schematic of the epiphyseal bone showing the expression of FGF ligands (red), PTHrP 
(purple) and FGFR2 (blue) in the perichondrium; (B) is an enlargement of the growth plate 
showing the expression of chondrocyte markers along different zones. Notice that respective 
ligands and receptors are expressed in complementary domains to facilitate paracrine loop (e.g. 
Ihh in hypertrophic zone and its receptor Ptch in proliferation zone). Data assembled from 
(Kozhemyakina et al., 2015)  
 
1.5.1.3-Hedgehog and PTHrP signalling: A major feedback loop for chondrocyte 
maturation 
 
Hedgehog and PTHrP signalling form a complex regulatory feedback loop controlling 
the rate of chondrocyte proliferation and differentiation (Yeung Tsang et al., 2014). In general, 
the ligand and receptor are expressed in zones complementary to each other with little overlap. 
For example, IHH is expressed in mature chondrocytes, located in the prehypertrophic and 
early-hypertrophic chondrocytes (Figure 10) (Iwasaki et al., 1997). IHH ligands are secreted and 
conveyed through the Patched (Ptch) receptor expressed in mature chondrocytes (Mak et al., 
2008). These signals are conveyed through Gli proteins, which are expressed prominently 
throughout the growth plate, juxtaposing IHH expression (Koziel et al., 2005). Meanwhile, 
PTHrP is expressed in the perichondral chondrocytes, whilst its receptor (PTHrP Receptor; 
PPR) is expressed in the proliferating and prehypertrophic zones (Figure 10) (Iwasaki et al., 
1997). The IHH-PTHrP paracrine loop is graphically illustrated in Figure 11: IHH is secreted 
from the hypertrophic zone and induces the expression of Pthrp in the perichondrium 
(Vortkamp et al., 1996), which maintains the expression of PTHrP, a negative regulator of 
chondrocyte differentiation. In response, PTHrP feeds back to Ihh expressing chondrocytes in 
the hypertrophic zone, preventing the differentiation of proliferating chondrocytes to pre-
hypertrophic chondrocytes (Vortkamp et al., 1996). Therefore, this tightly regulated paracrine 
loop is important to i) maintain the correct balance of chondrocytes entering hypertrophy, and 
ultimately determining the ossification rate and ii) to ensure correct formation of the bone 
architecture. Indeed, disruption to downstream elements of the Hedgehog or PTHrP cascade, 
has consequences on the cellular architecture of the growth plate. For example, overexpression 
of IHH has resulted in the ectopic expansion of cartilage in the growth plate due to insufficient 
chondrocytes going into hypertrophy. In contrast, ablation of PTHrP led to an enlarged 
 39 
hypertrophic zone due to an overabundance of cells going into hypertrophy (Kobayashi et al., 
2005). It is believed Gli3 is the main transducer of IHH signalling (Koziel et al., 2005). A 
characteristic of Ihh-/- is premature chondrocyte differentiation and expansion of the 
hypertrophic zone (See Figure 11), and genetic ablation of Gli3 partially restores chondrocyte 
proliferation and reverses excessive chondrocyte hypertrophy (Koziel et al., 2005).  
 
 
Figure 11 :PTHrP-IHH regulatory loop in the growth plate.  
(1) Chondrocytes in the perichondrium secretes PTHrP and acts on PTHrP-Receptors (PPR) in 
the pre-hypertrophic zone. PTHrP maintains chondrocyte proliferation and represses/delays 
expression of Ihh. This prevents hypertrophic differentiation of chondrocytes. PTHrP is likely to 
suppress Ihh expression in a dose dependent manner; (2) IHH is secreted from the pre-
hypertrophic zone and binds to Ptch receptors in perichondrial chondrocytes to maintain the 
expression of PTHrP. As this process in Hedgehog dependent, the signals are conveyed through 
Gli proteins; (3) IHH secreted from the pre-hypertrophic chondrocytes also act on the 
proliferation zone to maintain the amount of chondrocytes entering hypertrophy. (4) As the 
bone elongates, PTHrP repression decreases linearly resulting in the upregulation of Ihh leading 
towards hypertrophic differentiation (Col10). This highly intricate loop is important to regulate 
the size of growth plate and correct formation of the bone architecture. Furthermore, the growth 
plate provides a robust model to study organogenesis due to the presence of intricate feedback 
loops. Assembled from (Vortkamp et al., 1996).    
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1.5.1.4-The role of FGF signalling in endochondral ossification 
FGFR3 is the principal mediator for endochondral growth in the long bone (Deng et al., 
1996). Expression of Fgfr3 commences after mesenchymal condensation, situated in the core of 
the mesenchyme (Ornitz and Marie, 2015). Fgfr1 is expressed when the epiphyseal plates are 
formed, and when chondrocytes further mature (Ornitz and Marie, 2015). Both Fgfr1 and Fgfr3 
have distinctive expression pattern where the former is mainly expressed in pre-hypertrophic 
and hypertrophic chondrocytes, the latter is expressed in proliferating chondrocytes (RZ and 
PZ) (Figure 10) (Kozhemyakina et al., 2015). The distinctive expression pattern directly infers 
their roles in growth plate, as Fgfr1 seeks to maintain the survival of hypertrophic chondrocytes, 
whilst Fgfr3 in proliferation and differentiation. Indeed, disruption of FGFR3 function (GOF 
mutation) in humans is associated with long bone defects such as achondroplasia and 
thanatophoric dysplasia, which are closely examined in mouse models (discussed in detail in 
Section 1.7.3). FGFR3 is a negative regulator of bone formation and as such, GOF-FGFR3 is 
commonly associated with dwarfism (Li et al., 1999). Interestingly, it is believed the 
undergrowth phenotype is conveyed through STAT, as FGFR3 activation is associated with 
increased STAT1, STAT5a and STAT5b expression and cell cycle repressors (p21, p18 and 
p19) (Li et al., 1999). Conversely, removal of Fgfr3-/- is associated with bone overgrowth (Deng 
et al., 1996). This is associated with expansion of the PZ in the growth plate and therefore, 
resulted in the amplification of chondrocytes (Deng et al., 1996). This loss of FGFR3 is 
complemented with the increase of Hedgehog genes such as Ihh and Ptch implying excessive 
chondrocytes undergoing hypertrophy and that FGFR3 is upstream of Hedgehog signalling 
(Chen et al., 2001, Iwata et al., 2000, Ornitz and Marie, 2015, Zhou et al., 2015b). Moreover, it 
has recently been shown that GOF mutation of FGFR3 (Y367C) has a direct consequence on 
cilia length, the primary location for Hedgehog signalling (Martin et al., 2018). FGF ligands are 
expressed in the perichondrium and diffuse into the growth plate to facilitate growth (Ornitz and 
Marie, 2015). The major binding partner for FGFR3 is likely to be FGF18, as the growth plate 
histology of Fgf18-/- yielded a similar cellular consequence to Fgfr3-/- (Ohbayashi et al., 2002, 
Deng et al., 1996). This included increased chondrocyte proliferation together with upregulation 
of Hedgehog signalling (Ihh and Ptch) during early development (around E15.5) (Ohbayashi et 
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al., 2002, Liu et al., 2002). However, in contrast to Fgfr3-/-, Fgf18-/- mice display delays in 
ossification in both endochondral and intramembranous bones (Ohbayashi et al., 2002). In 
particular to the former, this observation suggests FGF18 expressed in the perichondrium may 
act on hypertrophic chondrocytes expressing FGFR1 in the HZ (Liu et al., 2002). It is believed 
that FGFR3 plays dual roles in maintaining chondrocyte proliferation and initiation of 
hypertrophy (Murakami et al., 2004, Sahni et al., 1999). This is related to the nature of growth 
factor signalling itself whereby activation of FGFRs initiate signal transduction through 
multiple cascades (Ornitz and Itoh, 2015). In particular, activation of FGFR3 led to 
phosphorylation of STAT1, which repressed proliferation of chondrocytes in vitro (Sahni et al., 
1999, Li et al., 1999). Moreover, overactivation of the RAS-MAPK pathway through MEK1 
reversed skeletal overgrowth phenotype in Fgfr3 nulls (Fgfr3-/-; Col2a1 (MEK1)) through 
restoration of chondrocyte proliferation (Murakami et al., 2004). Altogether, results obtained by 
Murakami et al (2004) suggest activation of FGFR3 is important to maintain the pool of 
chondrocyte undergoing proliferation and hypertrophic differentiation that is critical for 
subsequent ossification process in the PZ and HZ.   
Historically, FGF2 was the first ligand identified in the growth plates (Ornitz and 
Marie, 2015). However, conditional deletion of FGF ligands does not appear to impact 
significantly on bone development likely due to compensatory effects of FGFs, such as 
conditional ablation of Fgf2-/- or Fgf9-/- resulted in a redundant phenotype (Montero et al., 2000, 
Colvin et al., 2001a, Colvin et al., 2001b). Despite FGFR2 being a positive regulator of bone 
formation, it appears to facilitate osteoblast differentiation. For example, the Crouzon mutation 
(C342Y) affects the mesenchymal (IIIc) variant of FGFR2 and has enhanced expression of 
osteogenic markers such as Runx2 and Osteopontin without significant consequence on limb 
development (Eswarakumar et al., 2004). This is similar to isoform specific knockout of Fgfr2c 
(Fgfr2c-/-), which led to delays in ossification due to a reduction of chondrocytes in the PZ 
(Eswarakumar et al., 2002). Despite FGFR2 functioning as a positive regulator of bone 
formation, its role is far more significant during the early stages of limb development. FGFR2 is 
expressed in both the apical epidermal ridge (AER) and the condensing mesenchyme of the 
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limb bud, and is confined to the periosteum during the late stages of embryogenesis (Delezoide 
et al., 1998). Further elucidation of its role came from isoform specific knockouts, and reveals 
that the epithelial IIIb isoform is required for limb bud outgrowth (De Moerlooze et al., 2000, 
Revest et al., 2001). These Fgfr2b-/- display a complete loss of limb structures (De Moerlooze et 
al., 2000, Revest et al., 2001). In situ hybridization also reveals a complete loss of transcripts 
expressed in the AER such as Fgf8, and Shh in the zone of polarizing activity (ZPA) (Revest et 
al., 2001). Furthermore, it is understood that the early stages of limb bud initiation requires 
FGF10 (mesenchyme) signalling to FGFR2b in the AER, which subsequently induces epithelial 
FGF8 signalling back to FGFR1c to establish the paracrine axis (Ornitz and Marie, 2015).  In 
contrast, conditional inactivation of Fgfr2cflox/- in the mesenchyme using Dermo1CRE/+ only 
yielded minor shortening of long bones (Yu et al., 2003). These results imply FGFR2b plays 
critical roles in patterning the limb, and that FGFR2c is less critical in this process. Whilst the 
role of FGFR2c in the early limb bud remains elusive, it can be said that FGFR2c is a 
determinant of longitudinal bone length and ossification rates through controlling osteoblast 
differentiation.  
1.5.1.5-Sox9 and Runx2: molecular switches for hypertrophic differentiation 
The HZ expresses a multitude of markers including Runx2, Ihh, Col10a1, Osteopontin 
and Mmp13 matrix metalloprotease. In particular to Runx2, it is the master regulator of 
osteoblast differentiation and its LOF (Runx2-/-) results in the loss of calcified bone (Komori et 
al., 1997). Expression of Runx2 is required for hypertrophic differentiation and Runx2-/- have 
smaller HZ and impaired Col10a1 expression (Kim et al., 1999). Importantly, the inverse 
relationship between Sox9 and Runx2 determine fate transition from chondrocytes into 
osteoblasts (Dy et al., 2012, Zhou et al., 2006). Moreover, Sox9 directly interacts with the 
Runx2 promoter and suppresses its expression in a dose dependent manner (Zhou et al., 2006). 
Overexpression of Sox9 under the control of the osteoblast promoter Col1a1, is therefore able to 
prevent osteoblastogenesis, leading towards decreased bone mass (Zhou et al., 2006). In 
addition to its role as a master regulator for chondrocyte differentiation, it is also important to 
maintain chondrocyte identity throughout the maturation process. Along with Myocyte 
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Enhancer Factor 2c (Mef2c), Sox9 can also directly facilitate expression of Col10a1 to drive 
hypertrophic differentiation (Dy et al., 2012). Sox9 is a target of multiple pathways that is 
subjected to potentiation (FGFs, BMP/TGFβ, Hedgehog) and repression (Wnt) (Kozhemyakina 
et al., 2015). As a consequence, this allows Sox9 to maintain its expression in chondrocytes, and 
to enable correct transition between different phases of maturation. As Sox9 is a master 
regulator for chondrocyte specification and to maintain its identity, it could be said that the 
intricate spatial-temporal control of Sox9 determines the fate of cartilage and bone formation (Bi 
et al., 1999). Therefore, depletion of Sox9 expression spells the end of chondrocyte fate. In 
addition to Sox9, Forkhead box A (FOXA) transcription factors also play a part in facilitating 
hypertrophic differentiation (Ionescu et al., 2012). The binding site for FoxA2 factors was first 
characterized through identification of regulatory elements upstream of the chicken Collagen X 
(Ionescu et al., 2012). Augmentation of FoxA2 has been shown to potentiate expression of 
hypertrophic marker genes Col10a1 and Mmp13 in vitro. Together with LOF to Foxa3, 
disruption to Foxa2 (Foxa3-/-; Foxa2flox/-; Col2a1CRE/+) has been shown to delay hypertrophic 
differentiation. FoxA2 possess a similar binding site to Sox9, which could imply either 
competition or displacement with Sox9 during hypertrophic differentiation (Ionescu et al., 
2012).     
This section has discussed major pathways that trigger transition into hypertrophic 
differentiation in the growth plate (PTHrP, IHH and FGFR3), however, epigenetic factors may 
also facilitate this transition. It is well understood that histone modifications are critical to 
modulate gene expression by changing chromatin structure (Bannister and Kouzarides, 2011). 
In particular, transcriptional activity is repressed through tightening chromatin structure, which 
is performed through histone deacetylases (HDACs) (Bannister and Kouzarides, 2011). 
Hypertrophic differentiation is conveyed through HDAC4, downstream of PTHrP signalling 
(Vega et al., 2004, Correa et al., 2010). In fact, Hdac4-/- resulted in ectopic expression of Ihh 
and expansion of the HZ (Vega et al., 2004). Despite increased chondrocytes entering 
hypertrophy, these cells were not able to switch to an osteogenic fate. This is due to Runx2 
being directly repressed by HDAC4 in a dose dependent manner (Vega et al., 2004).  
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In summary, there are multiple triggers that drive hypertrophic differentiation. This is 
summarized in Figure 12 below. Ultimately, the entry into the hypertrophic programme requires 
downregulation of Sox9, which suppresses expression of Runx2 linearly and it’s downstream 
targets that are required for hypertrophic differentiation (Zhou et al., 2006). As Sox9 integrates 
with multiple pathways, the intricate signalling balance upstream of Sox9 is required for smooth 
transition into hypertrophic chondrocytes.  
  
 
Figure 12: Molecular triggers for hypertrophic differentiation in chondrocytes.  
Chondrocyte identity is dependent on the expression of Sox9 (blue wedge). Here, high Sox9 
expression is required to maintain chondrocyte identity and it represses Runx2 expression in a 
dose dependent manner. Sox9 expression is upregulated (green) by Hedgehog signalling (Hh), 
FGF, and BMP/TGFβ signalling and therefore, maintaining chondrocyte proliferation and 
identity. The transition to hypertrophic chondrocytes requires activated Wnt signalling, which 
represses (red) Sox9 and promote Runx2 expression. Other transcription factors promoting this 
transition include FoxA2/A3 where it is important to upregulate hypertrophic gene expression. 
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1.5.2-Intramembranous ossification  
The calvarium is an intramembranous bone that is formed by condensation and 
mineralization of the craniofacial mesenchyme (Teven et al., 2014). This is in contrast to 
endochondral ossification where the bone is gradually displaced from a cartilaginous template 
(section 1.5.1) (Ornitz and Marie, 2015). Calvarial osteogenesis begins at around E13.5, 
osteoblast precursors express Runx2, a member of the Runt transcription factor family (Peskett 
et al., 2017). Runx2 is a critical master regulator for osteoblast differentiation and its loss leads 
to significant skeletal hypoplasia, dwarfism and defects to the gross skeletal system (Komori et 
al., 1997). Mineralisation of the calvaria occurs at around E16.5 and progresses in a ventral to 
dorsal direction, a fully ossified calvaria can be perceived by E18.5 (Iseki et al., 1997) (Figure 
13).  
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Figure 13-Mineralization of the calvaria.  
Calvarial osteogenesis begins at E15 in a ventral to dorsal direction. Bone mineralization occurs 
at E16, as indicated by Alizarin Red staining on the left panel. Modified from Iseki et al., 1997.  
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Calvarial osteoblasts are derived from two distinct embryonic lineages, the mesoderm 
and NC (Yoshida et al., 2008, Quarto et al., 2010). Differentiated osteoblasts lay down the 
osteoid matrix of the calvarium during this process, consisting mainly of Col1 (Teven et al., 
2014). This deposition of osteoid matrix extends outwards from the ossification centre. The 
outer edges of the bones develop into wedged shaped groups of cells that form the osteogenic 
front, which extend into the adjacent mesenchyme to recruit cells and advance the growth of 
cranial bones. The cranial suture is defined by the limits of the cranial bones coming into 
proximity with each other, bisected by a sea of undifferentiated mesenchyme. Cranial sutures 
remain unossified and patent during normal development, whilst new bones are formed at the 
osteogenic fronts. The suture mesenchyme needs to remain undifferentiated to maintain suture 
patency (reviewed in: (Teven et al., 2014). Generally speaking, osteoblast differentiation 
requires high levels of FGF signalling that is reflective of bone formation (Iseki et al., 1997, 
Iseki et al., 1999). Therefore, active FGF signalling is found along the bones and most active at 
the osteogenic fronts, whilst the suture mesenchyme has low levels of FGF signalling (Rice et 
al., 2000).   
FGFs and FGFRs are differentially expressed in the cranial sutures (Hajihosseini and 
Heath, 2002). FGFs are mainly expressed in the mesenchyme, the surrounding dura and 
pericranial mesenchyme (Rice et al., 2000). The ligands common in both sagittal and coronal 
suture include Fgf2, Fgf9 and Fgf18 between E15-E17 (Hajihosseini and Heath, 2002, Kim et 
al., 1998, Rice et al., 2000, Deckelbaum et al., 2005). FGF18 in particular appears to be a major 
ligand regulating cranial bone development, as conditional knockout resulted in delays to 
ossification and coronal morphogenesis (Ohbayashi et al., 2002). Furthermore, Fgf18 is 
expressed strongly in the osteogenic fronts of the frontal and parietal bones, potentially involved 
in commitment of progenitor cells towards an osteoblast lineage (Hajihosseini and Heath, 
2002). FGF18 has a high affinity to the IIIc isoform of FGFRs and is likely to be a binding 
partner of FGFR1c and FGFR2c in differentiating osteoblasts (Ornitz and Itoh, 2015, Rice et al., 
2000).  
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Fgfr1, Fgfr2 and Fgfr3 are co-expressed in osteoprogenitors and differentiating 
osteoblasts of the cranial bones between E15-E17 (Figure 14) (Rice et al., 2000, Iseki et al., 
1999). In addition to osteoprogenitors, Fgfr3 is mainly expressed in the underlying dura mater 
and calvarial cartilage (Delezoide et al., 1998, Rice et al., 2000, Iseki et al., 1999). Despite the 
expression of Fgfr3 in the cranial bones, it does not appear to play major roles in craniofacial 
development. This is due to LOF since Fgfr3-/- resulted in a redundant phenotype (Deng et al., 
1996). Furthermore, evidence from the human genetics and mouse models generated by knock 
in technologies, point towards the importance of craniofacial development in FGFR1 and 
FGFR2 signalling. This is discussed in detail in section 1.7, together with mouse models that 
contribute towards the understanding of craniofacial syndromes. 
 
Figure 14: Overview of FGF ligand-FGFR interaction in osteogenesis.  
High FGF signalling is required for MSC (blue circles) commitment into an osteoblast lineage. 
Cells in the osteogenic front are osteoprogenitors (pre-mature osteoblasts, orange circles), and 
progress through a series of maturation steps to become osteoblasts (red circles) and osteocytes 
(brown circles) that is FGF signalling dependent. Cranial sutures express a series of FGFs. 
FGF2 and FGF9 are used in this illustration as they are common to both sagittal and coronal 
sutures. Both of these ligands are expressed prominently in the suture mesenchyme, dura mater 
and pericranial mesenchyme. Consequently, these ligands diffuse to the cranial bones (arrows), 
binding to osteoprogenitors and maturing osteoblasts expressing FGFR1, FGFR2 and of an 
extent FGFR3. This highly coordinated maturation process is required to generate the correct 
amount of osteoblasts for bone formation.  
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1.5.2.1- Osteoblast maturation programme 
Runx2 expression is directly downstream of FGFR2 (Miraoui et al., 2009), and a series 
of skeletal dysplasia and craniofacial syndromes are directly related to aberrations to FGF 
signalling (Ornitz and Itoh, 2015). Osteoblasts are derived from MSCs during intramembranous 
ossification. Figure 15 highlights the main transcription factors responsible for osteoblast 
differentiation and maturation. FGF signalling is upstream of all these process (Ornitz and 
Marie, 2015). In order for MSCs to differentiate into the osteoblast lineage, a combination of 
transcription factors is required. Runx2 is fundamental for osteoblast differentiation as Runx2 
deletion results in a complete loss of skeletal elements (Komori et al., 1997). Maintaining a 
balance of Runx2 expression is therefore crucial to normal skeletogenesis. Osterix is directly 
downstream from Runx2 and is also required for osteoblast differentiation (Takarada et al., 
2016). Osteoblasts progress through multiple stages of maturation process, and mature 
osteoblasts express different markers to those immature precursors. For example, committed 
osteoblasts express Osteopontin, Alkaline Phosphatase (ALP), Osteocalcin and Col1α1, 
important for bone mineralisation process (Hirakawa et al., 1994, Malaval et al., 1994, Iseki et 
al., 1997). These proteins provide the groundwork for subsequent bone mineralisation through 
calcium phosphate deposition, and are directly driven by Osterix expression (Nakashima et al., 
2002). Mature osteoblasts demarcate the bone lining and can undergo apoptosis to help bone 
remodelling, while a cohort of osteoblasts can further mature into osteocytes, mainly situated in 
the bone matrix and marked by the expression of Sclerostin and Activating Transcription Factor 
4 (Atf4) (Long, 2012). These cells constitute around 95% of mature bone, forming an intricate 
network with osteoblasts subject for bone remodelling (Long, 2012).  
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Figure 15: Osteoblast maturation programme.  
MSCs are characterised by the expression of Twist1, Prx1 and Sca1. Commitment of MSCs 
require the master regulator Runx2, and is concomitantly expressed with Osterix (Osx) in early 
osteoblasts. As the osteoblast matures, it starts to express mineralizing factors such as 
Osteopontin, Collagens, and Alkaline Phosphatase (ALP). Here, the osteoblasts can undergo 
inactivation or apoptosis, or aid remodelling through differentiation into osteocytes, 
characterised by the expression of Osteocalcin, Sclerostin and Atf4. Depending on the stage of 
the maturation process, FGF/FGFR2 signalling is responsible for proliferation, differentiation 
and apoptosis. 
 
1.5.2.2-Effects of FGF signalling on osteoblast maturation programme 
FGF signalling plays a wide range of roles concerning cellular proliferation, 
differentiation, survival and apoptosis (Ornitz and Itoh, 2015). Generally speaking, it has a 
stimulatory effect on osteoblasts and bone formation. Exposure to FGF signalling is able to 
commit MSCs into the osteogenic lineage through expression of Runx2 (Miraoui et al., 2009, 
Valta et al., 2006). As GOF mutations in FGFRs are associated with increased osteogenesis (e.g 
Fgfr2cC342Y/+; See mouse models in section 1.7) (Eswarakumar et al., 2004), it is possible that a 
proportion of patients with craniofacial syndromes may be associated with mis-specification of 
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MSCs towards an osteogenic lineage. However, as yet the contribution of these embryonic 
lineages towards pathogenesis remains elusive. This section will comment on in vitro data that 
have contributed to the understanding of osteoblast biology.  
The effect of FGF signalling is complex and is dependent on a multitude of factors that 
modulate spatial-temporal dynamics. The overall effect of FGF signalling is linked to the stage 
of maturation in osteoblasts. For example, differentiation is increased in osteoblasts of Fgfr1-/-, 
whereas both proliferation and differentiation is delayed in osteoprogenitors (Jacob et al., 2006). 
However, prolonged exposure of FGF2 and FGF9 to mature calvarial osteoblasts attenuated 
osteoblast differentiation and mineralization (Fakhry et al., 2005). These alterations in cellular 
response may be related to changes to receptor expression. For example, differentiating 
osteoblasts having higher levels of Fgfr1 expression to that of osteoprogenitors, which are 
dominated by Fgfr2 expression (Iseki et al., 1999). The changes in FGFR expression therefore 
yield distinct cellular consequences in response to endogenous ligands during the maturation 
process. The biochemical changes that alter FGF signalling dynamics can also change 
temporally. For example, Fgfr2b transcript levels are significantly higher in the frontal bone of 
adult mice compared to that of embryonic stages, which could determine the overall sensitivity 
of the receptor towards FGF ligands (Quarto et al., 2009). The combination of FGF ligands 
expressed in vivo will also drive the cellular response. FGF2 and FGF18 are example of ligands 
required for osteoblast maturation and are also present in the developing suture (Rice et al., 
2000, Ohbayashi et al., 2002, Montero et al., 2000). For instance, deficiency in Fgf2 (Fgf2-/-) is 
related to osteopenia due to reduced osteoblastogenesis and bone mineralization (Montero et al., 
2000). Similarly, Fgf18-/- resulted in delayed suture closure and calvarial ossification 
(Ohbayashi et al., 2002). These FGFs also play an important role in MSC commitment towards 
an osteoblast lineage in culture (Byun et al., 2014). Altogether, these results suggest FGF 
signalling is essential for specification, growth and maintenance of osteoblasts.  
In addition to regulating cellular proiferation and differentiation, FGF signalling is also 
responsible to facilitate apoptosis. This event is stage dependent, as exposure to FGF1 in 
immature calvarial osteoblasts resulted in proliferation to that of late osteoblasts which 
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facilitated apoptosis (Mansukhani et al., 2000). Similar observations were reported in 
osteoblasts in the presence of GOF mutations (i.e. S252W) (Mansukhani et al., 2000). In vivo 
analysis revealed that the amount of cells undergoing programmed cell death is progressive over 
late gestational to early postnatal development (Rice et al., 1999). This is particularly interesting 
in deciphering the mechanics for suture closure. For example, GOF mutations such as FGFR2-
C342Y are known to have premature cellular proliferation and differentiation in the coronal 
suture. However, it is likely that apoptosis plays an integral part in suture abolishment in latter 
stages of embryogenesis (Eswarakumar et al., 2004, Rice et al., 1999).  
1.5.2.3-Cytosolic signalling cascades responsible for osteoblastogenesis 
Signals are conveyed from the membrane via the RAS-MAPK, PI3K-AKT and PLCγ-
PKC cascades in the FGF signalling pathway (Ornitz and Itoh, 2015). Figure 16 summarizes the 
roles of these cascades in osteoblastogenesis. Activation of these pathways individually or in 
combination yields distinctive cellular responses. Therefore, due to the complexity of RTK 
signal transduction, in vitro studies have focused on dissecting the biochemical cascades 
responsible for osteoblastogenesis. Treatment of FGF2 and FGF4 can faciliate cellular 
proliferation in osteoblast progenitors via the RAS-MAPK and PI3K-AKT pathways (Choi et 
al., 2008). Activation of RAS-MAPK pathway alone is also sufficient to induce osteoblast 
differentiation through FGFR2 via Runx2 expression (Suzuki et al., 2012, Shukla et al., 2007, 
Miraoui et al., 2009). Indeed, ectopic osteoblast activity caused by an overactive FGFR2 
pathway (e.g. FGFR2-S252W) can be reversed through ERK or p38 inhibition (Suzuki et al., 
2012). In addition to understanding craniofacial development, the nature of GOF mutations 
affecting FGFRs helps to dissect the complex aetiology of growth factor signalling. For 
example, ectopic osteogenesis caused by the S252W mutation can cause transactivation of 
Runx2 via the PLCγ-PLC cascade in MSCs and osteoblasts (Miraoui et al., 2009, Kim et al., 
2003a). Exposure to FGF signalling also result in the concommitant activation of the PI3K-
AKT cascade. The role of PI3K-AKT may aid cellular proliferation through survival, as 
pharmacological inhibition of AKT is sufficient to increase apoptosis (Raucci et al., 2008, Tran 
et al., 2003). In the absence of AKT, Forkhead Box O (FOXO) transcription factors facilitate 
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expression of pro-apoptotic genes (e.g. Caspase 9) (Tran et al., 2003). Furthermore, constitutive 
activation of AKT in early osteoblasts is sufficient to force differentation via expression of 
Osterix (Raucci et al., 2008). This observation is consistent in the presence of a FGFR2-C342Y 
mutation (Raucci et al., 2008). The ectopic differentiation of osteoblasts, due to augmentation of 
PI3K-AKT pathway has been found to be beneficial in healing of fractured endochondral and 
membrous bones (Burgers et al., 2013). It is also possible that the PI3K-AKT signalling 
pathway modulates the sensitivity of FGF signalling. In calvarial osteoblasts, augmentation of 
pAKT through knockdown of PTEN, a negative regulator of the AKT pathway, led to 
upregulation of Fgf18 and downregulation of the RAS-MAPK feedback antagonist Spry2 
(Guntur et al., 2011). This observation is consistent with that of ectopic expression of osteoblast 
markers in vitro, which implies positive reinforcement of FGF signalling under pathogenic 
conditions (Guntur et al., 2011). FGF signalling is also able to facilitate crosstalks with multiple 
growth factor signalling pathways such as Epidermal Growth Factor (EGF) and PDGF to 
control osteogenesis (Miraoui et al., 2010a). Osteoblasts carrying mutant FGFR2-S252W has 
upregulated expression of EGFR and PDGFRα. This event is mediated by Cbl, as activated 
Spry2 interacts with ubiquitin ligase Cbl to prevent degradation of EGFR and PDGFRα. 
Furthermore, pharmacological inhibition of either EGFR or PDGFR is sufficient to reverse 
ectopic osteoblast differentiation normally caused by the S252W mutation. This cellular 
response is conveyed through the PLCγ-PKC pathway (Miraoui et al., 2010a). Similarly, 
expression of the Src family Lyn and Fyn, is shown to have negative effect on osteoblast 
differentiation (Kaabeche et al., 2004). Src family proteins are known to transduce signals 
directly from active RTKs (Schwartzberg, 1998). Constituative active FGFR2 causes increased 
ubiquitination and degradation of FGFR2 that resulted in premature osteoblast differentiation 
(Kaabeche et al., 2004). Ultimately, these studies highlight the aberrant crosstalks and 
downstream feedback loops in changing the dynamics of FGF signalling and osteoblast 
differentiation. Furthermore, It appears that the importance of positive feedback loops, such as 
those involved with PDGFR and EGFR, puts compensatory effect into context. In the above 
example, the upregulation of both PDGFR and EGFR could be a compensatory response to 
downregulation of the FGFRs in order to achieve the same cellular response (i.e. 
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differentiation). In addition to crosstalk with growth factor signalling pathways, FGF signalling 
is also sufficient to induce a positive effect on osteoblast differentiation with Wnt signalling. 
FGF2 is upstream of canonical Wnt signalling, and that endogenous FGF2 is able to supress 
degradation of βcatenin to facilitate osteogenic gene expression (Fei et al., 2011, Raucci et al., 
2008). Similar applies to BMP/TGFβ signalling, where osteoblast differentiation is potentiated 
in the presence of FGF2/FGF9 (Fakhry et al., 2005). Ultimately, these results indicate that FGF 
signalling has a positive effect to potentiate bone formation, but more importantly, functioning 
upstream as the main regulator controlling osteoblastogenesis. Other modulators of bone 
formation include Twist1, which acts as a negative regulator (Bialek et al., 2004). On a clinical 
level, haploinsufficiency of Twist1 is associated with complex craniosynostosis in Saethre-
Chotzen syndrome (Howard et al., 1997). Knockdown of Twist1 is implicated in premature 
osteoblast differentiation (Miraoui et al., 2010b). This is due to Twist1 haploinsufficiency 
resulting in the upregulation of PI3K-AKT pathway, which is responsible for driving the 
expression of osteogenic markers (Guenou et al., 2006). PI3K-AKT cascade misregulation is 
caused by an attenuation of PI3K tagged for degradation by Cbl (Guenou et al., 2006). 
Accordingly, Twist1 is involved in promoting stemness and survival of MSCs and osteoblasts 
(Miraoui et al., 2010b, Yousfi et al., 2001). Twist1 has the ability to dampen cell death by 
suppressing the p53 apoptotic pathway (Maestro et al., 1999). Expression of tumor suppressor 
genes such as p19-ARF are reduced in the presence of Twist1 (Maestro et al., 1999). 
Furthermore, Twist1 is able to prevent cell death mediated by Caspase-3 and Tumour Necrosis 
Factor α (TNFα) (Maestro et al., 1999, Yousfi et al., 2002). In particular, it has been 
demonstrated that Twist1 can bind to Tnfα promoters to modulate its expression (Sosic et al., 
2003). Twist1 is likely to form a negative regulatory loop with FGFR2 (Guenou et al., 2005). 
Indeed, it is able to directly interact with the Fgfr2 promoter, and that calvarial osteoblasts 
obtained from Saethre Chotzen patients have decreased expression of Fgfr2 in vitro (Guenou et 
al., 2005). Furthermore, Twist1+/- mice have ectopic expression of Fgfr2 normally absent from 
the suture mesenchyme, implying it is a negative regulator of FGFR2 signalling (Rice et al., 
2000). The role of Twist1 in vivo is further examined in section 1.7.5 from in vivo data, but it is 
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likely that premature suture closure is associated with excessive osteoblastogenesis from the 
suture mesenchyme.   
 
 
Figure 16: A summary of FGFR2 signalling cascades regulating cellular proliferation and 
differentiation. 
FGFR2 activation leads to potentiation of RAS-MAPK, PI3K-AKT and PLCγ-PKC cascades. In 
general, RAS-MAPK induces cellular proliferation and differentiation, whilst PI3K-AKT and 
PLCγ-PKC drives differentiation. Runx2 is downstream of both RAS-MAPK and PLCγ-PKC 
cascades, responsible drive expression of osteogenic genes (Alp, Col1a1 and Osteocalcin (OC)). 
It should be noted that cellular differentiation caused by PI3K-AKT cascade is independent of 
Runx2. Adapted from: (Marie, 2012) 
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1.6-Human genetics of syndromic craniosynostosis and mouse models 
 
1.6.1-Craniosynostosis 
 
Craniosynostosis is a common feature of craniofacial birth defects, with a prevalence of 
1:2500 births (Cohen and Krelborg, 1992). It is characterized by premature fusion of calvarial 
bones and could occur along multiple cranial sutures. Around 30% of craniosynostosis occurs 
within a characterised craniofacial syndrome (‘syndromic craniosynostosis’) with a genetic 
cause, whilst the majority of non-syndromic cases have a de novo cause (‘non syndromic 
craniosynostosis’) (Johnson and Wilkie, 2011). The molecular basis for craniosynostosis is 
complex: A dominant mutation within one of the FGFR 1, 2 and 3 genes are common to 
syndromic craniosynostosis, while intra-uterine constraint is the likely cause to the latter 
(Muenke et al., 1997, Muenke et al., 1994, Reardon et al., 1994, Johnson and Wilkie, 2011). 
The phenotypic consequence of craniosynostosis is skull distortion with secondary sensory-
neurological deficits through an increase of intracranial pressure (Figure 18) (Derderian and 
Seaward, 2012). Typically, FGFR mutations are responsible for the ‘Crouzonoid’ phenotype 
comprising of complex craniosynostosis, midfacial hypoplasia, strabismus and brachycephaly 
(Figure 17). Figure 18 summarizes the skull distortions observed in humans according to the 
type of suture fusion. As a result of craniosynostosis, symptoms include optic atrophy, blindness 
and hearing deficits (Derderian and Seaward, 2012). There is currently no pharmacological 
treatment for craniosynostosis, with repeating surgical modalities the primary option to 
accommodate normal brain growth by correcting skull dysmorphology and reducing intracranial 
pressure, a procedure known as craniectomy (Johnson and Wilkie, 2011). Specifically, surgical 
interventions aim to re-open the suture (‘distraction osteogenesis’) with calvarial remodelling 
(Park and Yoon, 2012). Figure 19 illustrates the surgical modalities used to remodel the 
calvaria.   
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Figure 17: Presentation of a patient with Crouzon syndrome.  
(A) Frontal view, (B) lateral view, (C) Cephalogram and (D) CT-scan. Notable phenotypes 
include midfacial hypoplasia, strabismus, brachycephaly. Modified from (Lee et al., 2012). 
   
 
Figure 18: Craniosynostosis affects skull dysmorphology.  
Red arrows indicate the direction of growth. Jagged line illustrates location of fused suture. 
 58 
 
Figure 19: Distraction osteogenesis on the human calvaria  
 (A) to reopen the coronal suture, (B) sagittal suture, (C) lambdoid suture and (D) unilateral 
coronal suture. Adapted from Park and Yoon, 2012.
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1.6.2-Human genetics of FGFRs and craniosynostosis 
Historically, mutation to MSX2 (Msh homeobox 2) gene was first to be identified 
associated with syndromic craniosynotosis, eliciting a clinical phenotype known as ‘Boston-
type craniosynostosis’ (Jabs et al., 1993). Mutations on FGFRs were later identified. Perhaps the 
most common gene involved in syndromic craniosynostosis is the FGFR (Wilkie, 2005). The 
most notable characteristics of craniofacial dysmorphology is the ‘Crouzonoid phenotype’ with 
coronal synostosis being the most common type of suture fusion (Wilkie and Morriss-Kay, 
2001). In general, mutations affecting FGFRs are activating (‘gain-of-function’; GOF), allowing 
it to be constitutively active e.g. C342Y (Wilkie, 2005). Moreover, they have an autosomal 
dominant inheritance pattern (Wilkie, 2005). A generalisation is that the craniofacial spectrum 
elicited by FGFRs signalling misregulation depends on the tissue specificity and allelic 
mutations along the receptor gene (Wilkie, 2005) (Figure 20). Table 2 summarises all the 
clinical outcomes affected by common FGFR mutations. Interestingly, allelic mutations 
affecting the linker region (S252, P253, C278 and C342) accounts for 80% of all 
craniosynostosis. In fact, an interesting observation illustrated by Wilkie (2005) is that identical 
substitutions across FGFR paralogues are conserved at equivalent positions along the gene. For 
example, amino acid changes to linker regions of the receptors such as, proline to arginine 
(Pro250Arg), gives rise to Pfeiffer (FGFR1), Muenke (FGFR1) and Apert (FGFR2) syndromes 
(Figure 20), with coronal synostosis being a common phenotype of mutant FGFR1-FGFR3 
(Wilkie, 2005). FGFR1-FGFR3 is expressed along the edges of the calvarial bones with FGFR2 
predominantly in the osteogenic front (Figure 21) (Johnson et al., 2000, Iseki et al., 1999). 
However, the spatial localisation of the splice forms is not well characterised due to its high 
sequence homology and instead, it is mainly through isoform specific knockouts in mouse 
models that their functions have been delineated. Undeniably, mouse models offer a significant 
platform to study human disease progression, and generating models carrying knock in 
mutations can help to address questions concerning the phenotypic diversity caused by various 
mutations. To date, a large cohort of craniofacial research is focussed on the genomic landscape, 
but little delineates the biochemical and transcriptomic events that influence cellular activity in 
vivo. In order to advance translation, it is critical to address the aberrant mechanisms that lead 
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toward craniofacial abnormalities. An example of such a model is the Fgfr2cC342Y/+ mouse 
model for human Crouzon syndrome that is used throughout this project (Figure 22) 
(Eswarakumar et al., 2004).  
 
 
Figure 20: Frequency and distribution of mutations identified on the FGFRs.  
Note the frequency of FGFR mutations are located in the linker region (IgIIIa, IgIIIc), in 
particular to FGFR1 and FGFR2. FGFR3 mutations have a strong prevalence in the 
transmembrane domain. Adapted from Wilkie 2005. 
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Figure 21: Expression of FGFRs in the coronal suture  
Note the predominance of Fgfr2 in the osteogenic front of the embryonic suture. F: Frontal bone, P: Parietal bone, b: brain, s: skin. Adapted from Johnson et al., 
2000. 
Gene Mutations/location Clinical syndrome Key clinical features 
FGFR1 
Widespread (haploinsufficiency) Kallmann syndrome Anosmia, hypogonadotrophic hypogonadism 
P252R (100%) Pfeiffer syndrome (mild) Craniosynostosis, cutaneous syndactyly 
N330I, Y374C, C381R Osteoglophonic dysplasia Short stature, craniosynostosis, bone demineralisation 
FGFR2 
S252W (66%), P253R (32%) Apert syndrome Craniosynostosis, crouzonoid faciesa, bony syndactyly 
IgIIIc (71%), IgIIIa (23%), TK, IgI 
Crouzon/Pfeiffer/Jackson–Weiss/Antley–
Bixler syndromes 
Craniosynostosis, crouzonoid facies, graded severity of limb 
anomalies (nil, broad first digits, elbow fusion) 
Y375C (>85%), S372C Beare Stevenson syndrome Severe craniosynostosis, cutis gyrata 
FGFR3 
P250R (>99%) Muenke syndrome Coronal craniosynostosis, clinically not diagnostic 
HCH: N540K (42%). ACH: G380R 
(99%). TDI: R248C (56%), Y373C 
(22%), stop codon (12%). TDII: K650E 
(100%). SADDAN: K650M (100%) 
Hypochondroplasia/achondroplasia 
/SADDAN/thanatophoric dysplasia I and II 
(TDI, TDII) 
Short-limbed bone dysplasia of graded severity from mild short 
stature to neonatal lethality; acanthosis nigricans in severely 
affected survivors; craniosynostosis in TDII and some TDI 
A391E (100%) Crouzon syndrome with acanthosis nigricans Craniosynostosis, crouzonoid facies, acanthosis nigricans 
R621H New syndrome 
Sensorineural hearing loss, camptodactyly, tall stature, 
kyphoscoliosis, microcephaly, developmental delay 
Table 2: Summary of mutation affecting FGFRs and its clinical outcome. SADDAN:  Severe achondroplasia with developmental delay and acanthosis 
nigricans. 
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Figure 22: Mouse model for human Crouzon syndrome, Fgfr2cC342Y/+.  
Brachycephaly, midfacial hypoplasia and coronal synostosis (*) is a phenotypic hallmark for 
both patient and mouse model. Image courtesy: Erwin Pauws.
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1.7-Mouse models for craniosynostosis 
 
Mouse models associated with craniosynostosis and bone diseases are compiled in 
Table 3 and Table 4. 
1.7.1-FGFR1 
Mutations in FGFR1 are hallmarks for Kallman, Jackson-Weiss and Pfeiffer syndromes 
(Ornitz and Itoh, 2015). In addition to the common craniofacial abnormalities, severe Pfeiffer 
syndrome patients exhibit limb and digit abnormalities (Muenke et al., 1994). Specifically, these 
patients have varying degrees of syndactyly, finger truncation, broad digits and short limbs 
(Muenke et al., 1994). The P252R substitution responsible for Pfeiffer syndrome was originally 
identified in the early 1990s, affecting exon 5 of FGFR1, common to both splice forms 
(Muenke et al., 1994). The mutation was eventually reproduced in the mouse genome, creating a 
model for Pfeiffer syndrome (Fgfr1P250R/+) with bi-coronal craniosynostosis along with 
enhanced expression of osteogenic genes (Zhou et al., 2000). Additionally, these mice have 
increased cell proliferation at P5 in the sutures. On the other hand, loss of function mutations 
(e.g. G237S, P722H, N724K) to this receptor is more associated with hormone dysregulation 
than with skeletal defects, and is related to Kallman syndrome (Pitteloud et al., 2006). Fgfr1 is 
expressed prominently in the distal limb bud between E8.5-E12.5, and is required for its correct 
initiation and outgrowth (Verheyden et al., 2005, Li et al., 2005). Conditional inactivation of 
Fgfr1-/- in the limb bud mesenchyme (TCre/+) do result in long bone and digital defects during 
later stages of development, similar to those in Pfeiffer patients (Verheyden et al., 2005, Li et 
al., 2005). Therefore, the differential phenotype elicited by LOF mutations in humans and 
knockout mice suggest dosage sensitivity of FGFR1 signalling.    
Complete removal of FGFR1 signalling leads to embryonic lethality and is seen 
comprehensive throughout the literature (Deng et al., 1994, Yamaguchi et al., 1994). Multiple 
strategies have been adopted to ameliorate this problem, including generation of hypomorphs by 
reducing the expression of full length FGFR1, mutating binding sites for Frs2 on Fgfr1, or 
preventing Trk autophosphorylation (Partanen et al., 1998). Additionally, Partanen and 
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colleagues (1998) have achieved isoform specific knockout to exons 8 (IIIb) and 9 (IIIc) by 
inserting a stop codon into these exons. Fgfr1b appears to be the major player in axial skeleton 
development, as Fgfr1b-/- display vertebrate column truncations and limb abnormalities, despite 
the craniofacial skeleton remains largely normal (De Moerlooze et al., 2000). Thus, the lack of 
craniofacial phenotype exhibited by FGFR1 LOF implies its role in craniofacial development is 
minor. Fgfr1c knockout is embryonic lethal suggesting the importance of the mesenchymal 
isoform in embryogenesis (Partanen et al., 1998).  
1.7.2-FGFR2 
 
FGFR2 is a positive regulator for osteoblast differentiation and manipulating this 
signalling pathway has adverse consequences to osteoblast differentiation. It is well 
characterised that Runx2, the master regulator for osteoblast differentiation, is downstream of 
FGFR2 signalling (Miraoui et al., 2009). Therefore, a substantial proportion of clinical 
syndromes and bone diseases have been related to FGFR2 misregulation. The role of FGFR2 in 
osteogenesis was characterised using knockout models. Several groups have generated Fgfr2 
knockout lines with similar phenotypes, yielding a series of gastrulation, placental and 
osteogenesis defects (Yu et al., 2003, Arman et al., 1998, Arman et al., 1999, Xu et al., 1998). 
The first FGFR2 knock out was generated by targeted disruption to the kinase domain of the 
receptor, preventing autophosphorylation (Arman et al., 1998). Other Fgfr2 knockouts followed, 
by disrupting immunoglobulin loops along the receptor gene (Xu et al., 1998). Xu et al., (1998) 
generated a knockout by removing exons encoding the IgIII loop responsible for ligand 
specificity. Despite homozygous lethality at E10.5, this study was the first to provide insights 
into the role of FGFR2 in limb development as these mutants fail to develop limb buds, owing 
to a loss of paracrine signalling responsible for tissue outgrowth (Xu et al., 1998). It was later 
discovered through Fgfr2b-/- that the IIIb isoform is critical for limb outgrowth, as these mice 
have a complete loss of the appendicular skeleton (De Moerlooze et al., 2000, Revest et al., 
2001). Fgf10 is a likely candidate for limb outgrowth as Fgf10-/- mice exhibit striking 
similarities to Fgfr2b-/- mice (Sekine et al., 1999, Min et al., 1998). Similarly, Fgfr2c-/- mice 
show this isoform is required for normal craniofacial development (Eswarakumar et al., 2002). 
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Others have also generated conditional Fgfr2 knockouts to study tissue specific effects: 
Conditional knockout in the mesenchyme using Dermo1Cre/+ leads to defects in both axial and 
craniofacial skeleton (Yu et al., 2003). Specifically, these mice have decreased bone density, 
truncated femur owing to insufficient chondrocyte and osteoblast proliferation, brachycephaly 
and dwarfism (Yu et al., 2003).  
A large cohort of characterised craniofacial syndromes are commonly associated with 
FGFR2 germline mutations (Figure 20) (Wilkie, 2005). GOF mutations in the FGFR2 gene are 
characteristic of Apert, Crouzon, and Beare-Stevenson syndromes (Wilkie, 2005). FGFR2 
signalling is a key player in craniofacial development. Crouzon syndrome is caused most 
commonly by a substitution mutation in FGFR2c (FGFR2c-C342Y; at the DIII Ig loop) and is 
autosomal dominant (Reardon et al., 1994). The substitution of a cysteine to a tyrosine residue 
results in the stabilization of intermolecular disulphide bonds at the receptor extracellular 
domains, leading to constitutive activation (Eswarakumar et al., 2005). The phenotypes 
affecting the IIIc isoform in Crouzon syndrome are mainly craniofacial, whilst those in Apert 
syndrome have additional limb phenotypes such as truncation and syndactyly, as the mutation 
(e.g. FGFR2-S252W) affects both FGFR2 splice variants (Johnson and Wilkie, 2011). Mouse 
models are available for the most common FGFR2 craniofacial syndromes:  Fgfr2cC342Y/+ 
(Crouzon), Fgfr2cW290R/+ (Crouzon) and Fgfr2S250W/+ (Apert), Fgfr2S252W/+ (Apert) (Wang et al., 
2005b, Eswarakumar et al., 2004, Mai et al., 2010, Chen et al., 2003). A common characteristic 
in these models are shortened midface, brachycephaly and coronal suture obliteration, which 
mimicks the human disease phenotype. On a cellular level, these mutations affect FGFR2 
function by altering osteoblast proliferation, differentiation and apoptosis in the suture. 
Eswaraskumar et al 2004 reported an early increase (around E13.5) in cellular activity at the 
osteogenic front that is responsible for suture obliteration in Fgfr2cC342Y/+ (Eswarakumar et al., 
2004). On the other hand, Chen et al., 2003 reported increased apoptosis is a key player for 
coronal synostosis development in a separate mouse model for Apert syndrome (Fgfr2S250W) 
(Chen et al., 2003).  
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It is not well understood how a separate allelic mutation also affecting the transmembrane 
domain of FGFR2 gives rise to Beare-Stevenson syndrome (Fgfr2Y394C/+) (Wang et al., 2012). 
Similar to the C342Y mutation, FGFR2-Y394C stabilises intermolecular bonds of unpaired 
cysteine residues leading towards constitutive activation. However, despite some craniofacial 
similarities, Beare-Stevenson patients have additional skin abnormalities including cutis gyrate 
(thickened scalp) and acanthosis nigricans (hyper pigmentation) (Wang et al., 2012). A mouse 
model has also been generated to study this mutation (Fgfr2Y394C/+), but the pathogenic origins 
of the cutaneous phenotype remains unclear (Wang et al., 2012). Increasing gene dosage also 
allows the identification of novel phenotypes in animal models. For example, a detailed analysis 
of Fgfr2cC342Y/C342Y identified exencephaly, overt cleft of the secondary palate and a series of 
segmentation defects along the axial skeleton (Peskett et al., 2017). 
Due to a common craniofacial phenotype elicited in animal models for syndromic 
synostosis, they provide a robust platform to test novel therapeutic approaches and evaluate the 
safety of treatment. For instance, Shukla et al., 2007 attempted to rescue the coronal suture 
through knockdown of the RAS-MAPK pathway with short-hairpin RNA (shRNA) and ERK 
inhibitor (U0126) in the Apert mouse model. Despite rescuing the suture, longitudinal 
monitoring of these mice revealed a series of growth restrictions and unknown causes of death 
post-treatment (Shukla et al., 2007). Indeed, the activating nature of FGFR2 has led to the 
assumption that attenuation of downstream signalling is sufficient to rescue craniofacial 
malformations (Shukla et al., 2007, Pfaff et al., 2016). Several studies were able to demonstrate 
this in vivo: Firstly, craniofacial morphology was rescued when a mutant Frs2α allele was 
introduced onto the Fgfr2cC342Y/+ mouse, which prevented activation of the downstream RAS-
MAPK pathway (Eswarakumar et al., 2006). Secondly, systematic ERK knockdown using 
shRNA was also sufficient to rescue craniosynostosis in Fgfr2S252W/+ (Shukla et al., 2007). 
However, the view of dampening the signal may well be over-simplistic given the complexity of 
pathogenic FGFR2 signalling. Snyder-Warwick et al 2010 examined the nature of FGF 
signalling output in the palates of the Crouzon mouse model (Snyder-Warwick et al., 2010). The 
authors have found Spry2, Spry4, Etv5 and Dusp6, all direct targets of FGF signalling, to be 
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downregulated across multiple developmental stages (Snyder-Warwick et al., 2010). On the 
cellular level, these embryos had reduced cellular proliferation that was the cause of palatal 
shelf elevation delays. Moreover, isoform specific knockout of Fgfr2c (Fgfr2c-/-) is sufficient to 
phenocopy that of Fgfr2cC342Y/+ with apparent coronal synostosis (Eswarakumar et al., 2002). 
The paradoxical nature of FGFR2c signalling remains to be elucidated, but it is accepted that an 
intricate balance of signalling activity is required for normal development. 
1.7.3-FGFR3 
 
FGFR3 is a negative regulator for bone formation (Deng et al., 1996). Several groups 
have successfully created multiple FGFR3 knockout lines with different targeting methods, all 
showing consistent bone overgrowth phenotypes (Deng et al., 1996, Colvin et al., 1996, 
Eswarakumar and Schlessinger, 2007). The most notable characteristic is that these mice have a 
larger appearance as a consequence of ectopic chondrogenesis (Deng et al., 1996, Colvin et al., 
1996). Despite this, their bones have increased porosity, likely due to a reduction in bone 
mineralisation. Further development of isoform specific knockouts revealed that the Fgfr3c 
isoform is responsible for this hyperplastic phenotype (Eswarakumar and Schlessinger, 2007). 
Interestingly, a hyperactive FGFR3 pathway leads to opposite effects where GOF mutations in 
FGFR3 were associated with short-limbed dwarfism caused by skeletal dysplasias such as 
achondroplasia and thanatophoric dysplasia (Rousseau et al., 1994, Shiang et al., 1994, Bellus et 
al., 1995). The missense mutation for achondroplasia was originally identified as glycine to 
arginine substitution (FGFR3-G380R) within the transmembrane domain of FGFR3 (Shiang et 
al., 1994, Bellus et al., 1995). This mutation decreases receptor trafficking from the membrane, 
resulting in increased levels of phosphorylation during exposures to FGF ligands and signalling 
activation (Monsonego-Ornan et al., 2000). Histological analysis reveals a saturation of FGFR3 
at mutant mouse growth plates, coincided with fewer chondrocytes in growth plates and 
hypertrophic zones (Monsonego-Ornan et al., 2000, Segev et al., 2000). Several mouse models 
have been made for achondroplasia such as Fgfr3G374R/+ and Fgfr3G369C/+ using knock in 
approaches to the transmembrane domain (Wang et al., 1999, Chen et al., 1999). Others 
integrated the human FGFR3-G380R cDNA into the mouse genome, phenocopying the human 
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disease (Segev et al., 2000, Lee et al., 2017). In addition to the dwarfism phenotype, these mice 
also display brachycephaly and brain distortion (Wang et al., 1999). Thanatophoric dysplasia is 
the most severe form of dwarfism (Tavormina et al., 1995). The genetic differences that 
separate achondroplasia and thanatophoric dysplasia lies within receptor activation. Mutations 
that result in achondroplasia are caused by ligand dependent receptor overactivation, whilst 
mutant FGFR3 variants for thanatophoric dysplasia are constitutively active (Ornitz and Itoh, 
2015). Mutations responsible for thanatophoric dysplasia stabilise intramolecular bonds of 
FGFR3 at either the transmembrane domain (Fgfr3S365C/+) or the ligand specific domain 
(Fgfr3Y367C/+) (Chen et al., 2001, Pannier et al., 2009, Ornitz and Itoh, 2015). In humans, a 
further mutation affecting the TK domain i.e. FGFR3-K650E was identified, but a mouse model 
is not yet available for this, perhaps owing to the potency of mutations affecting the kinase 
domain (Ornitz and Itoh, 2015). There have been reports linking craniosynostosis to 
achondroplasia and thanatophoric dysplasia in the literature; however, these links are not well 
established. For example, thanatophoric dysplasia patients exhibit a cloverleaf skull, suggestive 
of severe craniosynostosis (Tavormina et al., 1995), a separate mutation for achondroplasia-
FGFR3-A391E, is identified in Beare-Stevenson patients (Meyers et al., 1995) and similarly in 
the mouse, an isolated study reports coronal synostosis in Fgfr3G380R/+ (Lee et al., 2017).  
The P250R mutation is the most common mutation identified in the three FGFR 
paralogues (Wilkie, 2005). Muenke syndrome is a consequence of FGFR3-P250R mutation, 
where unilateral or bicoronal synostosis is an apparent characteristic (Muenke et al., 1994). The 
P250R mutation affects both FGFR3 isoforms, which increases affinity for FGF ligands 
(Muenke et al., 1994, Wu et al., 2009). A knock-in of this mutation in the mouse recapitulated 
Muenke syndrome (Fgfr3P244R/+) (Twigg et al., 2009). However, the craniosynostosis phenotype 
was incompletely penetrant due to background differences between mouse strains. Despite the 
variability observed in the general craniofacial skeleton, it was nevertheless a consistent mouse 
model for studying inner ear development (Mansour et al., 2009, Mansour et al., 2013). Muenke 
individuals were reported to have poor sensory reception towards the low end of the auditory 
spectrum (Mansour et al., 2009). Analysis of the Fgfr3P244R/+ mouse identified multiple 
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disruptions to the cochlear duct cytoarchitecture with alterations to the overall balance of 
support cells, with bias towards Dieter cell fate differentiation (Mansour et al., 2013, Mansour 
et al., 2009). This change of fate was largely due to the mutation causing the receptor losing 
ligand specificity, allowing ligands to bind promiscuously to both Fgfr3b and Fgfr3c isoforms 
(Mansour et al., 2013). Genetic rescue of the ear phenotype can be achieved by reducing a copy 
of Fgf10, a ligand specific to both isoforms, in compound mutants (Fgfr3P244R/+; Fgf10+/-) 
(Mansour et al., 2013). Perhaps this study offers perspectives into the reason why 
craniosynostosis does not develop in the Muenke mouse: it could be a consequence of the 
precise ligands available in the coronal suture which are required to induce the phenotype, and 
may explain the inconsistencies observed in the original study.      
1.7.4-FGF ligands and craniosynostosis 
 
The embryonic coronal sutures express a repertoire of FGF ligands (Hajihosseini and 
Heath, 2002). However, it is not known how FGF ligands coordinate craniofacial development 
or regulate suture patency. The difficulty largely stems from FGF ligands having multiple 
affinities toward their receptors (Table 1) (Zhang et al., 2006). Therefore, abrogation of FGF 
genes in vivo is likely to result in a redundant phenotype (Zhang et al., 2006, Barak et al., 2012, 
Wright and Mansour, 2003). In light of this, determining whether a phenotype is a consequence 
from a single FGF ligand or a combination working synergistically remains a challenge. The 
FGF ligand is abundant during development and any genetic perturbation will most likely result 
in defects to organogenesis. One of the main purposes of FGF signalling in development is to 
mediate cross talks between the mesenchyme and epithelium (Ornitz and Itoh, 2015). The most 
common FGF ligands involved in this process include epithelial expressed FGF9 and FGF10 in 
the mesenchyme, each signalling reciprocally to their tissue specific FGFR isoforms (Ornitz and 
Itoh, 2015). An example of tissue specific interaction is in the developing limb bud, instituting a 
positive feedback loop for its outgrowth (Li et al., 2007, Revest et al., 2001). Thus, disrupting 
the tight coordination genetically results in a series of skeletal dysplasias in the axial skeleton, 
largely affecting bone mass, densities and stunted growth (De Moerlooze et al., 2000, Revest et 
al., 2001, Eswarakumar et al., 2002, Eswarakumar et al., 2004). In addition to genetic 
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approaches, surgical bead implantations soaked in known FGF ligands have been fundamental 
to understanding osteogenesis in vivo (Iseki et al., 1999). Explicitly, this classical embryology 
approach is well characterised to investigate the impact of specific ligands on the calvaria e.g. 
FGF2, to probe for ectopic osteogenesis (Iseki et al., 1999). All the FGF ligands are expressed 
in the coronal suture with the exception of FGF3 and FGF4 (Hajihosseini and Heath, 2002). 
There has not been a report of syndromic craniosynostosis associated with ligand function other 
than FGF9 to date (Harada et al., 2009). However, mutations to FGF3, FGF8 and FGF10 are 
sufficient to cause craniofacial malformations, but the mechanisms responsible for their 
pathogenesis lie beyond the scope of this section (Ornitz and Itoh, 2015).  
Multiple synostoses syndrome (MSS) is characterised by multiple fusion of synovial 
joints in the axial skeleton (Wu et al., 2009). It is autosomal dominant and is caused by a 
missense mutation in FGF9 (FGF9-S99N) (Wu et al., 2009). A phenotype closely resembling 
MSS in the mouse, with fusion in the elbow and knee, has been reported upon substitution of 
arginine-143 to threonine (Fgf9N143T/+) (Harada et al., 2009). In addition to elbow-knee 
synostoses (EKS), these mice exhibit coronal synostosis. The consequence of the mutation has 
led to a loss-of-function to FGF9 binding to heparin, affecting overall FGFR signalling potency. 
This protein interaction impairment resulted in hyper diffusibility of the ligand in the 
extracellular matrix, encroaching into the joint and suture mesenchyme to induce synostosis. 
Additionally, mouse mutants carrying the missense mutation have ectopic expression of 
multiple osteoblast precursor markers such as Runx2 and Osteopontin in the coronal suture 
mesenchyme at E16.5 (Harada et al., 2009). FGF9 has high affinity towards the IIIc isoforms, in 
particular to FGFR3c (Zhang et al., 2006). Thus, coronal synostosis for Muenke syndrome is 
indirectly linked to FGF9, as the mutation affecting Muenke syndrome (FGFR3-P250R) is a 
consequence of FGFR3c having high affinities towards FGF9 (Harada et al., 2009, Muenke et 
al., 1997).  
Due to the promiscuity of ligand-receptor interaction, it is possible that ectopic 
expression of FGF ligands can also drive tissue specific phenotypes provided the receptors are 
expressed in the right tissue. In this scenario, Carlton and colleagues successfully phenocopied 
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the Crouzon mouse model (Fgfr2cC342Y/+) by disrupting the intergenic regions of Fgf3 and Fgf4, 
normally absent from the wild-type (WT) suture, with midfacial hypoplasia, brachycephaly and 
bi-coronal synostosis (Carlton et al., 1998). Phenotypic redundancy is a consequence of ligand 
compensation. For example, in respect to FGF9, a fully penetrant urogenital tract defect is only 
observed when both Fgf9 and Fgf20 are knocked out (Barak et al., 2012). This is similar during 
cardiovascular morphogenesis, with partial penetrance when single deletions to Fgf3 and Fgf10 
occurred at one time (Urness et al., 2011).  
In summary, the marginal nature of syndromic craniosynostosis related to FGF ligands 
is likely associated with ligand redundancies, especially when the coronal suture expresses 20 of 
the 22 FGF ligands. The spatial-temporal dynamics of FGF signalling, along with the diversity 
of FGF ligands functioning synergistically, will therefore make biological data difficult to 
interpret. As biological signals are conveyed through the receptors, targeting FGFRs yield more 
substantial phenotypes to that observed in ligands while giving direct interpretation to its 
function. 
1.7.5-Other mouse models with syndromic craniosynostosis 
 
1.7.5.1-Twist1, Msx2 
The Twist family genes encode two basic-helix-loop-helix (bHLH) transcription 
factors: Twist1 and Twist2 (also known as Dermo1) (Qin et al., 2012). Originally, Twist1 was 
demonstrated to be required for neural tube morphogenesis whilst Twist2, involved in regulating 
cytokine gene expression (Chen and Behringer, 1995, Sosic et al., 2003). Twist1 plays a variety 
of roles in mesoderm development focussing mainly in mesenchymal tissue and is expressed in 
the cranial mesenchyme (Bildsoe et al., 2013). Twist1 is expressed prominently in the suture 
mesenchyme and its inactivation in mice results in coronal synostosis (Behr et al., 2011a, 
Carver et al., 2002). This is due to Twist1 functions as a negative regulator of bone formation 
where it prevents osteoblast differentiation through Runx2 inhibition (Bialek et al., 2004). 
Runx2 deficient mice display delayed osteogenic activity in vivo, but introducing a copy of 
Twist1 null allele into Runx2+/- (Runx2+/-; Twist1+/-) was sufficient to spare a hypoplastic 
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phenotype (Bialek et al., 2004, Komori et al., 1997). Conversely, in vitro analysis of Twist1 
knockdown revealed decreased Runx2 expression with increased apoptosis (Yousfi et al., 2001, 
Maestro et al., 1999). Additionally, mutant Twist1 drives increased expression of FGFR2 in 
vitro and in vivo, perhaps as a compensatory effect, to upregulate the sensitivity of FGF 
signalling for cellular survival (Miraoui et al., 2010b, Connerney et al., 2008). In regards to 
disease pathogenesis, autosomal inheritance of mutations in TWIST1 is representative of 
Saethre-Chotzen syndrome and is a LOF mutation (Howard et al., 1997, el Ghouzzi et al., 
1997). Saethre-Chotzen patients display complex suture abolishment most notably coronal, 
posterior frontal and lambdoid sutures with digit duplication (el Ghouzzi et al., 1997, Howard et 
al., 1997). The first Twist1 mutant was described in 1995 to study cranial neural tube closure, 
with deletions in the protein-coding region of the gene by substituting exon 1 with a neo-
cassette (Chen and Behringer, 1995). However, these Twist1 homozygotes were embryonic 
lethal at E11.5 due to an open neural tube. Twist1+/- mice were viable with partial penetrance of 
limb and craniofacial phenotypes that replicated human disease according to the to genetic 
background of the animals (Bourgeois et al., 1998). In addition to Twist1 being a negative 
regulator for osteogenesis, it also functions to inhibit chondrocyte differentiation. Twist1+/- 
demonstrates enhanced chondrocytic activity in the coronal suture mesenchyme with 
upregulation of chondrocyte markers such as Sox9, Collagen II and Collagen X, but its 
significance is currently elusive (Behr et al., 2011a). Contact inhibition also appears to play 
important roles in mediating Saethre-Chotzen syndrome, as both the Notch ligand Jagged1 
(Jag1) and the ephrin receptor-EphA4 are downstream of Twist1. Conditional knockout of either 
Jag1 or EphA4 on a Twist1+/- background augments the craniosynostosis phenotype, whilst 
removal of either Jag1 or EphA4 is not sufficient to derive this pathogenesis (Ting et al., 2009, 
Yen et al., 2010). Both these studies stress the importance of contact inhibition in controlling 
osteoblast differentiation in the mesenchyme, conditional removal of which leads to mis-
specification, and loss of positional information in specifying the suture boundary. Additionally, 
LOF mutations in JAG1 in humans is linked to Alagille syndrome, bridging the pathogenesis 
with Saethre-Chotzen syndrome (Yen et al., 2010). bHLH proteins plays a plethora of roles in 
development and functions in hetero/homo-dimers (Massari and Murre, 2000). bHLH proteins 
 73 
are classified by its tissue distribution, ability to dimerize and DNA binding specificities. Class I 
bHLH proteins are known as ‘E proteins’ and are abundant in multiple tissue types to that of 
Class II e.g. Twist, that has restricted expression domains. Both Class I and Class II HLH 
proteins contain the basic domain and is therefore DNA binding to that of the Class III factors. 
Examples of Class III proteins include Id (Inhibitor of DNA binding), which facilitates 
dimerization with E proteins and perturb formation of heterodimer formation between ClassI/II 
proteins (Massari and Murre, 2000). The degree of Twist1 syndromic craniosynostosis is related 
to their binding partners and the dimers they form. For example, a severe craniosynostosis 
phenotype is caused by a frameshift in Tcf12 in a Twist1 background (EIIaCRE/+; Tcf12flox/-; 
Twist1+/-) (Sharma et al., 2013). Transcription factor 12 (Tcf12) is an E protein, and the inability 
to form the Twist1-Tcf12 heterodimer results in a severe phenotype. The same scenario occurs 
to LOF of bHLH inhibitors Id1 and Id3 under a Twist1 heterozygous background, with the 
former showing greater penetrance (Id1+/-; Twist1+/-) (Connerney et al., 2008).        
Mutations in MSX2 are associated with Boston type craniosynostosis (Jabs et al., 1993). 
Substitution of a histidine to a proline at position 148 on the MSX2 protein increases binding 
affinity towards the DNA (Ma et al., 1996). Msx2 is expressed in the sagittal and lambdoid 
sutures of the mouse, and its overexpression-either WT or through a GOF mutation-Msx2P7H/+, 
leads to narrowing of the sagittal suture and abnormal bone overgrowth, particularly to the 
parietal bone (Liu et al., 1995). In contrast, MSX2 haploinsufficiency in humans leads to ectopic 
calvarial foramen and delayed suture closure, due to the loss of binding affinity to target DNA 
(Wilkie et al., 2000). Similar observation is reported upon knockout of Msx1 and Msx2 in vivo 
(Roybal et al., 2010).  The ectopic foramen was not a consequence of embryonic patterning 
defect but rather, a mitotic decrease in the bone, likely from the ossification centre (Roybal et 
al., 2010, Ishii et al., 2003). Msx2 and Twist1 interact to coordinate cellular proliferation and 
differentiation: Firstly, haploinsufficiency of both genes lead to ectopic frontal foramen 
formation and secondly, knockout of both alleles result in increased phenotypic severity (Ishii et 
al., 2003). Analysis of embryos between E12.5 and E14.5 revealed the pathogenesis is mainly a 
reduction of osteoblast differentiation beginning at E12.5. It is interesting to note that the 
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transcripts of these genes do not display the same expression pattern embryonically, but lead to 
the same phenotypic outcome. Therefore, this suggests these transcription factors may work 
synergistically as a co-factor to derive the same phenotype at the protein level (Ishii et al., 
2003).  
1.7.5.2-Hedgehog related genes 
 
Gli3 is associated with Greig cephalopolysyndactyly (GCP). GCP is an autosomal 
dominant disorder affecting both limb and craniofacial development, and is associated with Gli3 
LOF (Hui and Joyner, 1993). The most notable characteristics include supernumeric fingers 
(polydactyly), macrocephly and a broad forehead. Additional phenotype includes lambdoid 
synostosis (Rice et al., 2010). Gli3 is primarily a repressor of Hedgehog signalling, which its 
LOF exacerbates, resulting in GCP. Specifically, GCP is caused by deletions to 7p13 on the 
human chromosome, and is also mapped to the same region in the mouse genome (Hui and 
Joyner, 1993). Johnson (1967) developed the first mouse model ‘Xtra Toes’, Gli3Xt-J/Xt-J (Xt-J), 
carrying an intragenic deletion of Gli3 (Johnson, 1967, Hui and Joyner, 1993).   
Augmented Hedgehog signalling is related to Carpenter syndrome, through LOF to 
RAB23 (Ras-related protein Rab23)- a separate negative regulator of Hedgehog signalling 
preventing signalling transduction through Gli2 repression (Jenkins et al., 2007, Eggenschwiler 
et al., 2006). Carpenter syndrome patients display complex synostosis, but Rab23-/- mice do not 
recapitulate this phenotype and is lethal embryonically (Eggenschwiler et al., 2001). Thus, the 
Gli3Xt-J/Xt-J was used to study Hedgehog misregulation in craniosynostosis instead (Rice et al., 
2010). Further analysis of Gli3Xt-J/Xt-J reveals ectopic osteoblast differentiation in the lambdoid 
sutures, which leads to early suture abolishment. Lambdoid synostosis can be rescued however, 
through augmentation of FGF signalling, which upregulates expression of Twist1 (Rice et al., 
2010, Rice et al., 2000). Interestingly, missense mutations to human MEGF8 (multiple EGF like 
domain 8), a single pass membrane protein, phenocopies those observed in Carpenter syndrome 
(Twigg et al., 2012). Additional features include left-right asymmetry and cardiac defects, 
which was also reported in a mouse mutant generated as a result of a large-scale mutagenesis 
screen (Megf8C193R/+) (Zhang et al., 2009, Aune et al., 2008). However, craniofacial or skeletal 
 75 
defects were not analysed in this paper. It is unclear to the role of Megf8 during development, 
but the close resemblance between MEGF8 and Carpenter syndrome suggests the mechanism 
responsible is highly similar. A speculation as such could affect early development, and given 
by the abnormalities in left right-asymmetry, it is likely to affect both Nodal and Hedgehog 
signalling. In particular to the latter, it has been shown recently that Megf8 dampens Hedgehog 
signalling in the primary cilia that could explain the phenotypic similarities to Carpenter 
syndrome caused by RAB23 mutation (Pusapati et al., 2018).  
1.7.5.3-Transforming growth factor beta (TGFβ) signalling misregulation 
 
TGFβ signalling misregulation is associated with Marfan syndrome, a rare disorder 
occurring between 1:5,000 individuals (Judge and Dietz, 2005). Marfan syndrome is a complex 
disease affecting multiple systems. It is associated with craniofacial and skeletal 
dysmorphology, cardiovascular abnormalities, tissue fibrosis, ocular, and mental deficits (Judge 
and Dietz, 2005). Loeys-Dietz disease and Shprintzen-Goldberg syndrome, have a varying 
phenotypic spectrum of the described ‘Marfanoid phenotype’ (MacCarrick et al., 2014, 
Carmignac et al., 2012, Loeys et al., 2005, Judge and Dietz, 2005). In particular, patients with 
Marfanoid phenotype and craniosynostosis are commonly referred to as ‘Shprintzen-Goldberg 
syndrome’. Missense mutations in the extracellular matrix protein Fibrillin 1 (FBN1) was first 
identified to be associated with Marfan syndrome, and has been implicated in craniosynostosis 
(Dietz et al., 1991, Sood et al., 1996). However, multiple knock-ins were generated in the 
mouse without craniosynostosis together with phenotypic variations between mouse strains in 
visceral organ systems (Carta et al., 2006, Judge et al., 2004, Ng et al., 2004, Pereira et al., 
1999). LOF to the TGFβ signalling repressor- SKI (SKI proto-oncogene) was later identified, 
linking craniosynostosis in Shprintzen-Goldberg to TGFβ signalling (Doyle et al., 2012, 
Carmignac et al., 2012). Mutations in the genes encoding the transforming growth factor beta 
receptors (TGFBR), TGFBR1 and TGFBR2 are associated with Loeys-Dietz disease (Loeys et 
al., 2005). Loeys-Dietz patients typically have cardio-ventricular and outflow tract 
abnormalities, cleft palate, hypertelorism and occasionally craniosynostosis (Loeys et al., 2005). 
Substitution mutation in TGFBR1 and TGFBR2 augment TGF signalling activity, given by 
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increase of pSMAD readout, and is therefore a GOF mutation (Loeys et al., 2005). 
Craniosynostosis can be a phenotype of mutations in either of the receptors, and several mouse 
models have been generated to mimic this syndrome with varying degrees of phenotypic 
severity (i.e. Tgfbr1M318R/+ and Tgfbr2G357W/+) (Gallo et al., 2014). In particular, Tgfbr1M318R/+ has 
partial coronal synostosis with additional kyphosis in the thoracic region (Gallo et al., 2014).  
1.7.5.4-Other mouse models with craniosynostosis phenotype  
 
The previous section described mouse models that have a strong correlation to 
syndromic craniosynostosis. There are also mouse mutants that possess craniosynostosis but do 
not fall within a categorised syndrome or bone disease. Substantial cohorts of these mutants are 
related to growth factor signalling misregulation (See below). Further to Fgfr2C342Y/+, isoform 
specific knockouts such as Fgfr2b-/- and Fgfr2c-/- also display craniosynostosis phenotype 
(Eswarakumar et al., 2002, De Moerlooze et al., 2000). In particular, Fgfr2c-/- mutants harbour 
coronal synostosis that phenocopies the Fgfr2cC342Y/+ (Eswarakumar et al., 2002). The main 
difference between both models lies within the disease progression, where the latter possesses 
the accelerated phenotype during early embryogenesis (Eswarakumar et al., 2002, Eswarakumar 
et al., 2004). Fgfr2b-/- displays a subtle form of craniosynostosis, with fusion of the parietal and 
squamous temporal bones (De Moerlooze et al., 2000). It is established that a hallmark of 
craniosynostosis is the upregulation of the RAS-MAPK pathway (Shukla et al., 2007). Indeed, 
knockout of (Dusp6-/-) a negative regulator of ERK, results in coronal synostosis (Li et al., 
2007). Similarly, LOF mutations to Ets2 repressor factor (ERF) is also implicated in compound 
craniosynostosis affecting the coronal and sagittal sutures (Twigg et al., 2013). ERF is 
responsible for the export of active ERK from the nucleus to attenuate its transcriptional 
activation activities, and conditional knockout of ERF (ERFΔ/-) recapitulates its phenotype 
(Twigg et al., 2013).   
Although not commonly associated with craniosynostosis, Platelet derived growth 
factor (PDGF) signalling has also been related to craniofacial malformations and coronal 
synostosis (He and Soriano, 2017, Moenning et al., 2009, Soriano, 1997). This is most likely 
due to the conserved nature of growth factor signalling downstream of the receptor. Signalling 
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misregulation in an isoform of the platelet derived growth factor receptor (PDGFR)-PDGFRα, 
is implicated in midline defects and a split face (Pdgfrα-/-) (Soriano, 1997). Moreover, οver-
activation of PDGFRα (PdgfrαD842V/+) drives ectopic chondrogenesis that elicits coronal and 
lambdoid synostosis through the P13K-AKT cascade (He and Soriano, 2017). A similar 
phenotype is replicated in a transgenic over-expression model located at the Rosa26 locus 
(R26RPdgfrα-D842V/+) (Moenning et al., 2009).  
In addition to growth factors, Wnt/β-catenin signalling is also a key player in regulating 
osteoblast proliferation and differentiation, whereby potentiation of signalling favours these 
conditions (Yu et al., 2005). In the absence of signalling activation, β-catenin is prevented from 
being translocated to the nucleus through degradation. Therefore, Wnt signalling modulators are 
critical to modulate signalling sensitivity: Axin serves as a scaffold for formation of a β-catenin 
degradation complex, and its degradation is therefore Axin dependent (Logan and Nusse, 2004). 
Augmentation of Wnt signalling by Axin2-/- results in coronal and interfrontal synostosis (Yu et 
al., 2005). Similarly, overexpression of a osteoinductive protein, Nel-like type 1 molecule 
(Nell1) elicits posterior frontal suture craniosynostosis, along with the partial closure of sagittal 
and coronal sutures (Zhang et al., 2002). NELL1 was originally isolated from samples obtained 
from unilateral (non-syndromic) coronal synostosis patients, and is expressed in the 
mesenchyme and osteogenic fronts (Ting et al., 1999). NELL1 expression is upregulated in 
sutures undergoing premature fusion, and is believed to augment Wnt/ β-catenin signalling, 
through interactions with β-integrins in osteoblasts (Ting et al., 1999, James et al., 2015).  
Other mutants reported in the literature include the following: Growth differentiation 
factor 6 (Gdf6) is a secreted morphogen associated with the BMP signalling pathway (Ducy and 
Karsenty, 2000). Mutants lacking both alleles of Gdf6 (Gdf6-/-) display coronal synostosis and 
appendicular skeleton abnormalities, with fusion of the tarsals and carpals (Settle et al., 2003). 
Runx2 is indispensable for osteoblast differentiation, and overexpression of Runx2 in the 
mesenchyme, driven under the endogenous promoter Prx1 (Prx1-Runx2), elicits multiple 
synostosis, inclusive of multiple joint fusions in the appendicular skeleton (Maeno et al., 2011). 
Metopic suture synostosis is caused by LOF mutations to Fras1 related extracellular related 
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gene 1 (FREM1), and is a cause of trigonocephaly in humans (Vissers et al., 2011). Frem1 
encodes a protein secreted by mesenchymal cells that aids extracellular matrix remodelling 
(Smyth et al., 2004). In the mouse, Frem1 is expressed along the periphery of the frontal bone, 
immediately adjacent to the interfrontal suture (metopic eqivalent) (Vissers et al., 2011). The 
orginal mouse model generated-Frem1Bat/+ is a hypomorph, with the mutation mapped through 
ENU mutagenesis (Smyth et al., 2004). The mouse harbours a substitution mutation (T>C) 
which causes exon skipping to occur during transcription (Smyth et al., 2004). A knockout is 
also available, Frem1qbrick/+, which includes exon 2 deletion (Kiyozumi et al., 2006, Vissers et 
al., 2011). Both mouse models harbour interfrontal synostosis, with the latter mutant possessing 
a stronger phenotype (Vissers et al., 2011).  
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1.7.6-Evaluation of mouse models in the literature 
 Mouse models have been central to study 
human diseases. Together with lineage tracing reporters, the phenotypes caused by knock in 
mutations have been critical to understand the pathways required for craniofacial development. 
Furthermore, mouse models provide a platform to test novel therapeutic strategies and 
management techniques (Wang et al., 2015, Perlyn et al., 2006, Maruyama et al., 2016). 
However, it is well discussed in the murine research community that significant discrepancies in 
expected phenotypes may be the result of genetic differences between species, genetic 
redundancies and sensitivities. An example of this can be seen for RAB23 mutation responsible 
for human Carpenter syndrome (Eggenschwiler et al., 2001, Jenkins et al., 2007). LOF of the 
mammalian homologue of RAB23, results in exencephaly and early embryonic lethality 
(Eggenschwiler et al., 2001). Other examples include Ets domain-containing transcription factor 
(ERF), where craniosynostosis is only observed in a mouse model harbouring a conditional 
allele (ErfΔ/-) in contrast to that of a deletion (Erfdl1/-) (Twigg et al., 2013, Papadaki et al., 2007). 
The difference in phenotype is due to the conditional allele having a greater efficiency in 
abrogating Erf gene expression (Twigg et al., 2013). Similar can be said of those mouse models 
related to Marfan syndrome that do not recapitulate a craniofacial phenotype (Gallo et al., 2014, 
Judge et al., 2004, Ng et al., 2004, Pereira et al., 1999).  
The ability to generate gene knockout models has been pivotal in our understanding of 
gene function, and this in turn is dependent upon successful and accurate targeting of the 
specific allele of interest. Therefore, it makes sense that the overall design of a targeting vector 
is vital to reproducibly produce a consistant phenotype. However, there are instances in the 
literature where a wide phenotypic spectrum can be produced. Examples of this can be seen in 
the Fgfr2 knockouts, as the receptor protein has multiple functionalities (Molotkov et al., 2017, 
Yu et al., 2003). A common strategy to generate an Fgfr2 knockout is through the removal of 
the ligand-binding domain (exons 8-9, IgI loop3). However, this mutant did not result in the 
complete removal of the FGFR2, but yielded a truncated, albeit non functional, receptor instead. 
On the other hand, removal of exon 5, common to both Fgfr2b and Fgfr2c isoforms, did not 
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lead to the expression of a truncated receptor (Yu et al., 2003, Molotkov et al., 2017). In fact, 
there are slight phenotypic differences too between the knockouts, with the latter Fgfr2c 
knockout appearing less severe (Yu et al., 2003, Molotkov et al., 2017). Targeting constructs 
recombined between intragenic regions also have an effect on gene expression. Here, removal 
of exon 9 encoding Fgfr2c is able to cause a splice switch that results in ectopic Fgfr2b 
expression (Hajihosseini et al., 2001). LoxP sites were inserted in Fgfr2 intergenic regions of 
exons 8-10, and conditional removal of the loxP sites through recombination could have 
increased susceptibility to alternative splicing alterations (Hajihosseini et al., 2001). The 
upregulation of Fgfr2b subsequently shifted the phenotype from a Crouzon spectrum to that of 
Apert (Hajihosseini et al., 2001). Nonetheless, the successful targeting of specific genes has 
been vital to determine gene function contributing towards human disease. 
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Mouse models for characterised syndromes and developmental bone diseases 
  
Gene 
Mutation/Insertion/recombina
nts  Bone disease/Syndrome Synostosis Model Reference  
Fgf9 N143T EKS/MSS 
Coronal 
LOF Harada et al 2009 
Fgf3 Intragenic retroviral insertion 
mutagenesis Crouzon phenocopy Overexpression Carlton et al 1998 Fgf4 
Fgfr1 
P250R 
Pfeiffer Coronal, interfrontal, sagittal  
GOF 
Zhou et al 2000 
Fgfr2 C342Y Crouzon 
Coronal 
Eswarakumar et al 2004  
  W290R Crouzon   
  S252W 
Apert Coronal, sagittal, lambdoid 
Wang et al 2005 
  S250W Chen et al 2003 
  Y394C Beare-Stevenson 
Coronal 
Wang et al 2012 
Fgfr3 P244R Muenke Twigg et al 2009 
  G374R 
Achondroplasia 
N/A 
Wang et al 1999 
  G369C Chen et al 1999 
  G380R Segev et al 2000 
  S365C 
Thanatophoric dysplasia 
Lee et al 2017 
  Y367C Pannier et al 2009 
Twist1  Gene trap, Twist1+/- 
Saethre-Chotzen Coronal, sagittal, lambdoid LOF 
Chen and Behringer 1995 
Behr et al 2011 
Id1 Id1+/-; Twist1+/- 
Connerney et al 2008  Id3 Id3+/-; Twist1+/- 
Msx2 Timp1-P7H 
Boston-type craniosynostosis Coronal, sagittal, lambdoid 
GOF 
Lin et al 1995 
  CMV-P7H 
  CMV-WT Overexpression 
Jag1 Gene trap, Jag1+/- 
Alagille 
No phenotype LOF 
Yen et al 2010   
Jag1+/-; Twist1+/-; Mesp1CRE/+ 
Coronal, sagittal, lambdoid LOF 
Gli3 
Intragenic deletion, Gli3Xt-J/Xt-J 
Greig 
cephalopolysyndactyly/Carpent
er Syndrome Lambdoid LOF 
Hui and Joyner 1993 
  Rice et al 2010 
Tgfbr1 M318R Loeys-Dietz disease  Coronal  GOF Gallo et al., 2014 
Table 3: Mouse models for characterised syndromes and developmental bone diseases. 
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Table 4: Mouse models with craniosynostosis but do not fall within a characterised syndrome
Gene Mutation/Insertion/recombinant Synostosis Model Reference  
Fgfr2c Exon 9 STOP, Fgfr2c-/- 
Coronal 
LOF 
Eswarakumar et al 2002 
  Exon 9 flox, Fgfr2cΔ/+ Hajihosseini et al 2001 
Fgfr2b Exon 8 STOP, Fgfr2b-/- Squamous temporal-parietal De Moerlooze et al 2000 
Nell1 WT (CMV*) Coronal, sagittal, posterior frontal Overexpression Zhang et al 2002 
Axin2 Gene trap, Axin2-/- Coronal, Interfrontal 
LOF 
Yu et al 1995 
Dusp6  Exon3 STOP, Dusp6+/-  
Coronal 
Li et al 2007   Dusp6-/- 
Gdf6 Gene trap, Gdf-/- Settle et al 2003 
Pdgfrα D846V (R26*) Coronal, interfrontal  Overexpression Moenning et al 2009 
  PdgfrαD842V/+; Meox2CRE/+ Coronal 
GOF He and Soriano 2017   PdgfrαD842V/+; Mesp1CRE/+ Coronal, lambdoid 
EphA4 EphA4-/- 
Coronal LOF Ting et al 2009   Twist1+/-; EphA4+/- 
Runx2 Prx1-Runx2 Pan-synostosis Overexpression Maeno et al 2011 
Erf Exon 2+3 deletion, Erf-/-  
No phenotype 
LOF 
Papadaki et al 2007 
  Erf flox, ErfΔ/+ 
Twigg et al 2013   Erf flox, ErfΔ/- Coronal, sagittal, lambdoid 
Frem1 Frameshift (T>C) at intron 25, Frem1bat/+ 
Posterior frontal  
Hypomorph Smyth et al 2004 
  Exon 2 deletion, Frem1QBrick/+ LOF Vissers et al 2011 
 
*=Promoter 
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1.8-Aim of project 
 
Despite the large cohort of studies where mutations were identified to contribute towards 
craniofacial birth defects, questions remain as to the developmental and molecular events that 
contribute to syndromic craniosynostosis. This PhD project therefore provides a comprehensive 
and comparative analysis of a novel transgenic mouse model generated in the Pauws lab 
(R26RFgfr2cV5/Fgfr2cV5) with that of the more widely studied Fgfr2cC342Y/+. The following objectives 
for this PhD were: 
i) To identify the embryonic lineage sensitive to Fgfr2c signalling in the craniofacial 
skeleton.  
ii) To examine the nature of Fgfr2c signalling misregulation at the protein and RNA 
level.  
iii) To explore the phenotypic impact of Fgfr2c overexpression on Fgfr2cC342Y/+ 
(R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+). 
iv) To investigate the consequences of over-activating the downstream cascade 
commonly associated with syndromic craniosynostosis (RAS-MAPK), using an 
oncogenic mouse model (KRasLSL-G12D/+).  
v) To identify novel genes contributing to syndromic craniosynostosis using 
transcriptomic profiling.    
The overall aim is to generate a detailed understanding of the molecular events that occur 
during normal and abnormal suture morphogenesis, which ultimately lead to the identification 
of novel therapeutic opportunities aimed at reducing recurrent surgeries for syndromic 
craniosynostosis.
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Chapter 2 
Materials and Methods 
 
 
 85 
 
2.1-Animals 
 
All the animals used in this thesis are summarized in Table 5. Generation of the Fgfr2c 
overexpression mouse (R26RFgfr2cV5/Fgfr2cV5): To target the Rosa26 genomic locus 
(Gt(ROSA26)tm1Sor), Fgfr2c-V5 construct was inserted 3’ to a targeting vector carrying the loxP-
PGK-neo-tPa-loxP cassette (Soriano, 1999). The V5 epitope tagged to the Fgfr2c is unique to 
transgene expression and differentiates transgenic from endogenous FGFR2c protein 
expression. Following selection, the construct was linearised and injected into embryonic stem 
cells using standard procedures at UCL Transgenic Services. The founders (CD1) were 
maintained as homozygotes (R26RFgfr2cV5/Fgfr2cV5).  
βactinCRE/+ was previously described in Sakai et al., 1997 (Sakai and Miyazaki, 1997). 
CRE recombinase is driven under the control of the βactin promoter to generate ubiquitous 
expression. Mesp1CRE/+ was previously described in Saga et al., 1999 (Saga et al., 1999). CRE 
recombinase is driven under the control of Mesoderm posterior 1 (Mesp1) promoter to elicit 
conditonal expression in the mesoderm. Wnt1CRE/+; R26RYFP/+ was previously described in 
Freem et al., 2010 (Freem et al., 2010). CRE recombinase is driven under the control of the 
Wnt1 promoter to generate conditional expression in the NCC lineage. Wnt1CRE/+ mice were 
crossed with R26RYFP/YFP reporter to generate Wnt1CRE/+; R26RYFP/+ offspring. Cells positive with 
the CRE allele will also express the reporter protein, thus labeling cells from the NCCs lineage. 
Wnt1CRE/+; R26RYFP/+. Wnt1CRE/+; R26RYFP/+animals were bred with WT to lineage trace cells 
from NCC lineage in the calvaria. R26RmTmG/mTmG  was previously described in (Muzumdar et al., 
2007). This reporter line was chosen to show CRE activity in the sutures in Chapter 3. The 
mTmG allele was crossed with R26RFgfr2cV5/Fgfr2cV5 to generate a double conditional mouse that 
overexpresses both mTmG and Fgfr2cV5 (R26RFgfr2cV5/mTmG) upon conditional overexpression. 
The breeding strategy is shown in Figure 23.  
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Figure 23: Interbreeding strategy to introduce mTmG allele into the Fgfr2c 
overexpression mouse. 
R26RmTmG/mTmG were crossed with R26RFgfr2cV5/Fgfr2cV5 to produce R26RFgfr2cV5/+; R26RmTmG/+. The 
F1 recombinants were subsequently bred with conditional CRE lines to drive Fgfr2c-V5 
overexpression and reporter activity. A total of 8 genotypes were expected from the F2 
recombinants. This was a method attempted to indirectly show the expression of FGFR2c-V5 
when IHC failed to address the localization of the transgenic protein in the calvaria. Red box is 
indicates the desired genotype but however, due to the nature of trans-heterozygotes, only  the 
genotype with CRE reporter activity was selected (dotted box). 
   
 
Fgfr2cC342Y/+ was previously described in Eswarakumar et al., 2004, with the colony re-
derived through the EMMA (European Mouse Mutant Archive) consortium. Fgfr2cC342Y/+ was 
crossed with CD1-WT to derive Fgfr2cC342Y/+ embryos. KRasLSL-G12D/+ was previously described 
in Tuveson et al., 2004 (Tuveson et al., 2004). KRasLSL-G12D/+ was paired with a Wnt1CRE/+ to 
conditionally over-activate mutant KRas-G12D in the NCC lineage. R26RFgfr2cV5/Fgfr2cV5 allele 
was introduced into the Fgfr2cC342Y/+ to generate a double mutant; all littermates were genotyped 
for both Fgfr2cC342Y/+ and Fgfr2c-V5 allele (R26RFgfr2cV5/+; Fgfr2cC342Y/+) prior to any 
experimental proceedings. Fgfr2cC342Y/+; R26RFgfr2cV5/+ was subsequently crossed with 
βactinCRE/+ to generate ubiquitous overexpression (R26RFgfr2cV5/+; βactinCRE/+;Fgfr2cC342Y/+), with 
embryos harvested at E18.5. The breeding strategy is illustrated in Figure 24. R26RFgfr2cV5/+; 
Fgfr2cC342Y/+; βactinCRE/+ is to be presented with an underline 
(R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+) from here on to aid visual clarity.  
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Figure 24: Introduction of the Fgfr2c overexpression allele into Fgfr2cC342Y/+.  
R26RFgfr2cV5/Fgfr2cV5 was crossed with Fgfr2cC342Y/+ to generate R26RFgfr2cV5/+; Fgfr2cC342Y/+. These 
F1 recombinants were subsequently matched with βactin
CRE/+. A total of 8 genotypes were 
expected from the cross, and the desired recombinant carries all three alleles in R26RFgfr2cV5/+; 
βactinCRE/+;Fgfr2cC342Y/+ (Red) 
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Mouse Lines Strain Description References MGI 
βactinCRE/+ 
Mixed 
CD1 
Ubiquitous 
expression 
Sakai et al., 
1997 (Biochem 
Biophys Res 
Commun) 1919410 
Wnt1CRE/+; 
R26RYFP/+ 
C57BL/6 
NCCs specific 
expression with 
eYFP reporter allele  
Danielian et al., 
1998 (Curr. 
Biol) 
2386570 
Mesp1CRE/+ 
Mixed 
CD1 
Core mesoderm 
specific expression 
Saga et al., 
1999 
(Development) 2176467 
R26RFgfr2cV5/Fgfr2cV5 
Fgfr2cV5 
overexpression 
under Rosa26 
transgene 
This lab 
6150825 
R26RmTmG/mTmG C57BL/6 
Dual reporter 
mouse. Expresses 
eGFP post excision 
and tdTomato prior 
to recombination  
Muzumdar et 
al., 2007 
(Genesis) 
3716464 
R26RFgfr2cV5/mTmG 
Mixed 
CD1 
Dual reporter mouse 
with Fgfr2cV5 allele 
This lab 
N/A 
Fgfr2cC342Y/+ 
Mouse model for 
human Crouzon 
syndrome  
Eswarakumar et 
al., 2004 
(PNAS) 3053095 
WT 
Wild type on a CD1 
background  
Charles River 
Laboratories N/A 
KRasLSL-G12D/+ C57BL/6 
Conditional 
oncogenic KRas-
G12D with Lox-
STOP-Lox (LSL) 
minigene cassette  
Tuveson et al., 
2004 (Cancer 
Cell) 
2429948 
R26RFgfr2cV5/+; 
Fgfr2cC342Y/+ 
Mixed 
CD1 
Mouse model for 
human Crouzon 
syndrome carrying 
the Fgfr2cV5 flox 
transgene 
This lab 
N/A 
Table 5: Mouse lines used in this thesis. 
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2.2- Genotype determination 
2.2.1-DNA extraction 
A biopsy sample was obtained from recombinants for genotyping. A cocktail of lysis 
buffer1 and Proteinase K (Roche) was applied to the samples and incubated for 1 hour 30 mins 
at 55 oC, followed by 10 mins incubation at 85oC to inactivate the enzyme. An equal proportion 
of isopropanol was added to the lysate to precipitate the DNA, followed by a brief wash in 70% 
EtOH. The lysate was air dried thoroughly and reconstituted in 20-50µl H2O.  
2.2.2-Genotype determination for Rosa26 or CRE  
 
Genotyping primers span the Rosa26 short arm to determine the presence of the 
R26RFgfr2cV5/Fgfr2cV5 floxed allele (Figure 25 A). To determine Fgfr2c-V5 overexpression 
recombinants, mice carrying the Fgfr2c-V5 floxed allele were crossed with respective CRE 
recombinase animals (βactinCRE/+; Wnt1CRE/+ or Mesp1CRE/+) and analysed at desired embryonic 
stages as required per experiment. Littermates were genotyped for CRE and LoxP excision on 
the transgene, where the primers span the Rosa26 short arm and 5’ of the Fgfr2c-V5 transgene. 
The expected amplicon for the Fgfr2c-V5 overexpressing recombinants was 0.64kb for the 
excised transgene (Figure 25 B) and 0.50kb for CRE recombinase (Figure 25 C). Table 6 and 
Table 7 describe the primers and PCR parameters used to determine respective genotypes of the 
mouse lines driven under the Rosa26 promoter respectively.  
 
                                                     
1 100mM Tris-HCL pH 8.5, 5mM EDTA, 0.2% SDS, 200mM NaCl 
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Figure 25: Strategy for R26R recombinants genotyping.  
Primers specific for the recombinants span the Rosa26 short homology arm and the excision 
junction between the LoxP site and Fgfr2c-V5. Expected amplicon: 0.5kb (CRE); 0.64kb 
(R26R-FGFR2cV5).  
 
Primers Sequence Amplicon 
CRE (Forward) accctgatcctggcaatttcgg 
0.5kb CRE (Reverse) gatgcaacgagtgatgaggttc 
R26R-FGFR2cV5 (Common 
Forward) 
aaagtcgctctgagttgttat 
0.64kb R26R-FGFR2cV5 (Reverse) tgaggataccactttagaaccaga 
R26R-FGFR2cV5 (flox) (Reverse) ggttgaggacaaactcttcgc 0.31kb 
R26R-mTmG (Forward) ctctgctgcctcctggcttct  
0.25kb R26R-mTmG (Reverse) cgaggcggatcacaagcaata 
R26R-YFP (Forward) aaagtcgctctgagttgttat 
0.32kb R26R-YFP (Reverse) aagaccgcgaagagtttgtc 
Table 6 Genotyping primers for Rosa26 or CRE  
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PCR Steps CRE R26R-Fgfr2cV5 
R26R-
mTmG R26R-YFP 
Initial denaturation 94oC, 2mins  94oC, 5mins  
Denaturation  94oC, 30 secs  94oC, 30secs  94oC, 20secs  94oC, 30secs  
Annealing  63oC, 45secs 60oC, 30secs 58oC, 25secs 60oC, 30secs 
Extension 72oC, 45 secs 72oC, 40secs 72oC, 45secs 72oC, 40secs 
Final Extension 72oC, 5mins 
Total Cycles 29 37 32 37 
Table 7: PCR parameters for Rosa26 and CRE primers 
 
2.2.3-Genotyping for the Fgfr2cC342Y/+ knock in mutation 
A set of primers amplifies the WT Fgfr2 fragment (Table 8). Table 9 denotes PCR 
cycling parameters for the Fgfr2 primer pairs. The C342Y mutation inserts a restriction site on 
the Fgfr2 construct for RSAI enzyme (Eswarakumar et al., 2004). Therefore, a further 
enzymatic digest using RsaI (New England Biolabs) is required to determine the mutation in 
Fgfr2. The PCR products were subsequently incubated at 37oC, 1 hour before enzymatic 
denaturation at 85oC. Two bands were expected for CD1-WT (373bp/136bp) and three for 
heterozygotes (311/136/62bp).  
Primers Sequence Amplicon 
Fgfr2 (Forward) cggtgtctcttcgtgtctctc 
 
550bp (WT) 
370bp/136bp (WT + RsaI) 
311bp/136bp/62bp (Het + RsaI) 
311bp/62bp (HOM+ RsaI) 
Fgfr2 (Reverse) gaggggtcatttggaacattt  
Table 8: Fgfr2 genotyping primers and expected amplicon after RSAI digestion to determine knock in 
mutation. 
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Step FGFR2-C342Y 
Initial denaturation 95oC, 2mins  
Denaturation  95 oC, 2mins 30 secs 
Annealing  60 oC, 20s (-1oC/cycle) 
Extension 72 oC, 1min 
Final Extension 72oC, 5mins 
Total Cycles 15 
Table 9: PCR cycling parameters for Fgfr2 primers. 
 
2.2.4-Genotyping for the KRasG12D/+ mice 
The genotyping strategy for KRasLSL-G12D/+ is illustrated below (Figure 26) (Table 10 and 
Table 11). The KRas-LSL-G12D is conferred by a transcriptional termination stop element 
(loxP-STOP-loxP) upstream of the oncogenic KRas (*), characterized by a substitution mutation 
from GGT to GAT in exon 1.   
 
Figure 26: Genotyping strategy of KRasLSL-G12D/+ and its recombinants.  
Common primers (1+2) flank the exons and intragenic regions, whilst primer 3 is specific for 
stop element (*) G12D mutation.    
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Step KRas 
Initial denaturation 95oC, 2mins  
Denaturation  95oC, 30secs  
Annealing  61oC, 30secs 
Extension 72oC, 45secs 
Final Extension 72oC, 5mins 
Total Cycles 34 
Table 11: PCR cycling parameters for KRas. 
 
Primers Sequence Amplicon 
KRas 1 (Common Forward) gtctttccccagcacagtgc WT: 622bp 
G12D: 650bp KRas 2 (Common Reverse) ctcttgcctacgccaccagctc 
KRas 3 (Flox) agctagccaccatggcttgagtaagtctgca LSL: 500bp 
Table 10: Genotyping primers for KRas. 
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2.3-Culture systems 
2.3.1-Cells 
 
HEK293T (immortalized human embryonic kidney cells) were cultured in Dulbecco 
Minimum Essential Medium (DMEM) alpha culture medium (Gibco) supplemented 
with 10% Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin.  
2.3.2-Cell transfection 
Cells were transfected with plasmids carrying the FGFR2c-V5 construct (pFgfr2c-V5), 
Fgfr2cC342Y/+ (pFgfr2c-C342Y-V5) or control pcDNA in 6 well plates when they have 
reached 50% confluence. A cocktail of 100µl Optimem culture medium (Gibco), 1ul FuGENE 
transfection reagent (Promega) and 1ug of DNA was added to each well prior to 48 hours 
incubation at 37°C, 5% CO2. Success of cellular transfection was determined by the V5 epitope 
on the Fgfr2 plasmids. 
2.3.3-Ex vivo calvarial explant cultures 
Embryos were harvested at E17.5 and dissected in PBS. The calvaria was dissected 
from the skin and brain and cultured in Dulbecco’s Modified Eagle Medium (DMEM, Sigma) 
supplemented with 10% Fetal Bovine Serum (FBS, Sigma) and 5% Penicillin-Streptomycin. 
The medium was refreshed every other day and cultured for 2 weeks at 37oC, 5% CO2. Calvaria 
were fixed in 70% ethanol and processed for 0.01% Alizarin Red stain upon experimental 
completion.   
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2.4-Quantitative RT-qPCR 
2.4.1-RNA extraction  
RNA was extracted using the Trizol method (Invitrogen). E12.5 whole embryos, E16.5 
calvaria, or HEK293T cells were homogenized in 1ml Trizol and incubated at room temperature 
(RT) for 5mins, prior to phase separation with chloroform (Sigma). The aqueous phase was 
isolated in a new tube, and RNA precipitated in 500ul of isopropanol. The samples were 
centrifuged to pellet the RNA, with the supernatant discarded. The RNA was washed in 70% 
Ethanol (EtOH) and re-pelleted. EtOH was subsequently removed with the RNA allowed to air-
dry, and resuspended in RNAse free water (Sigma) in appropriate volumes (around 100ul). A 
full protocol is found in Appendix 1. 
2.4.2-cDNA synthesis 
cDNA was synthesized using the QuantiTect Reverse Transcription Kit (Qiagen) 
according to the manufacturer’s protocol. cDNA synthesis was performed at 2ug with all the 
reagents doubled linearly. Briefly, genomic DNA was eliminated from the RNA extraction 
process using the supplied ‘gDNA wipeout buffer’. The cocktail was incubated at 42oC for 2 
mins before resting on ice. The RNA was subsequently incorporated with the reverse 
transcription reaction cocktail consisting of reverse transcriptase, primers and reaction buffer. 
Reverse transcription was performed at 42oC for 15 mins and at 95oC for 3 mins to inactivate 
the enzyme. The cDNA was diluted 1:2 to reach a final concentration of 1ug for RT-qPCR.       
2.4.3-Quantitative RT-qPCR 
Expression analysis was performed using Taqman assays (Applied Biosystems). RT-
qPCR was achieved using the 7500 Fast Real Time PCR System (Applied Biosystems) or 
StepOne Real-Time PCR System (Applied Biosystems) on a 96-well plate at 1ug. The reaction 
was set up at 12ul per well (Table 12), with a minimum of three technical replicates per 
genotype, with Rn18 chosen as the reference gene. Table 13 illustrates all the assays used for the 
RT-qPCR. The collected dataset was analysed and exported into the 7500 Fast Real-Time and 
StepOne PCR Software (Applied Biosystems). Amplification efficiencies were checked in 
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target genes and controls prior to data analysis using the ΔΔCt method normalized to the 
controls.  
 
RT-qPCR reaction (/well) Volume (µl) 
TaqMan Fast Universal Master 
Mix (Applied Biosystems) 
6 
Assay 0.6 
cDNA (1ug) 1 
H2O 4.4 
Total 12 
Table 12: RT-qPCR reaction 
 
 
Reference 
Genes 
Company Assay ID Specie 
Fgfr2c 
Applied Biosystems 
Mm01269938_m1 Mouse 
Fgfr2b Mm01275520_m1 Mouse  
Rn18 Mm03928990_g1 Mouse  
SPRY2 Hs01921749_s1 Human 
SPRY4 Hs01935412_s1 Human 
ETV5 Hs00927557_m1 Human 
Rn18 Mm03928990_g1 Mouse  
Col9a1 Mm00483836_m1 Mouse  
Map3k6 Mm00522235_m1 Mouse 
Pcyt1b Mm00616920_m1 Mouse 
Papln Mm01307240_m1 Mouse 
Pdgfb Mm00440677_m1 Mouse 
Rsad2 Mm00491265_m1 Mouse 
Table 13: RT-qPCR assays
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2.5-Immunoblots  
 
All the stock reagents required for immunoblotting can be found in Appendix 2. 
 
2.5.1-Protein extraction for whole embryos 
 
E12.5 embryos were dissected under ice cold PBS and homogenized in RIPA buffer2 
with MINI complete protease inhibitor cocktail (Sigma) and centrifuged to obtain protein 
lysates. Protein concentration was determined using Bradford reagent (Biorad) and 
spectrophotometry. Protein lysates were prepared at 30ug in a cocktail of 4x Lamelli buffer 
(Biorad) and dithiothrethiol, and were denatured at >80oC for 8 mins. Samples were 
immediately stored in -20oC until required.  
                                                     
2 150mM NaCl, 1% Triton X-100 (Fisher), 0.5% sodium deoxycholate (Sigma), 0.1% SDS (Sigma), 50mM Tris-pH 
8.0 (Fisher) 
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2.5.2- Protein extraction for cells 
 
Cells were washed in ice cold PBS and harvested on ice. Cells were resuspended in a 
specialized lysis buffer3 optimized for cells and lysed by pipetting. Cell lysates were harvested 
by centrifugation and aqueous phase isolated. Protein concentration was determined using 
Bradford reagent (Biorad) and spectrophotometry. Protein lysates were prepared at 10ug in a 
cocktail of 4x Lamelli buffer (Biorad) and Dithiothrethiol, and were denatured at >80oC for 8 
mins. Samples were immediately stored in -20oC until required.  
2.5.3-Transfer and antibody blotting 
V5 immunoblot: Lysates were resolved in 10% gel at 130V in Tris/Glycine/SDS 
Running Buffer (Biorad). Gels were transferred using a semi-dry cell, Trans Blot Turbo 
Transblot Transfer System (Biorad) onto prepacked PVDF membranes optimized for the system 
(Transblot Turbo Mini PVDF Transfer Packs; Biorad). Blots were washed in 0.1% Tris buffered 
saline with 0.1% Tween (TBST) before blocking in 5% Milk-TBST for 2 hours at RT. Anti-V5 
antibody was incubated at 1:1000 overnight at 4oC in 1% Milk-TBST (Table 14 and Table 15). 
Following washes in 0.1% TBST the following day, blots were incubated with appropriate anti-
specie horseradish peroxidase (HRP) secondary antibodies (1:3000) for 1 hour. Membranes 
were washed thoroughly in TBST and developed using Enzymatic Chemiluminescence (ECL) 
reagents (General Electric).       
2.5.4-Re-blotting membranes 
Immunoblots can be stripped of its antibodies and reblotted with a subsequent antibody 
of interest, such as Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) loading control 
(Millipore). Blots were washed in H2O prior to antibody stripping with 0.2M Sodium hydroxide 
(NaOH) at 37oC. Membranes were blocked in 5% Milk-TBST, and re-blotted with GAPDH 
1:5000 in 1% Milk-TBST overnight at 4oC. Secondary HRP antibodies were applied the 
following day at 1:3000 and subsequently redeveloped, with all blotting procedures maintained 
as described above.  
                                                     
3 50mM pH7.6 Tris-Base; 150mM NaCl, 1% Triton X-100, 0.02% Sodium Azide, 1mM MINI protease inhibitor 
(Roche), 1mM sodium orthovanadate, 25mM sodium fluoride 
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2.5.5-pERK/tERK immunoblots 
V5 immunoblots were stripped of its antibodies and reblotted with the subsequent 
antibody of interest (Table 15). Blots were washed in H2O prior to antibody stripping with 0.2M 
sodium hydroxide (NaOH) at 37oC. Membranes were blocked in 5% BSA-TBST, and re-blotted 
with pERK (1:2000, Cell Signalling Techologies), in 1% BSA-TBST overnight at 4oC. 
Secondary HRP antibodies were applied the following day at 1:3000 and redeveloped as above. 
The strip and re-blot cycle is performed two more times, such that tERK (1:2000; Cell 
Signalling Technologies) and GAPDH (1:10,000; Millipore) can be applied.  
 
Primary 
Antibodies  
Concentration 
Host and 
Class 
Company Cat. No. 
Secondary 
Antibody 
(1:3000) 
Company 
Host and 
Class 
αV5 1.1000 Mouse 
Monoclonal 
IgG 
Invitrogen R960-25 
αMouse 
HRP 
Dako 
Rabbit 
Polyclonal 
IgG αGAPDH 1.5000 Millipore MAB374 
Table 14: Immunoblot conditions for E12.5 whole embryos 
 
Antibodies Company  Catalogue No. 
Host 
specie  
Primary 
concentrations  
Secondary 
antibody 
(1:3000) 
αV5 Invitrogen R960-25 
Mouse   
1.1000 anti-mouse 
HRP  αGAPDH Millipore MAB374 1.10000 
α-pERK Cell Signalling 
Technologies 
D13.14.4E XP 
Rabbit  1.2000 
anti-rabbit 
HRP  α-tERK 9102 
Table 15: Immunoblot conditions for cells 
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2.6-Histology 
2.6.1-Embryo embedding for frozen sections 
Embryos were harvested at E16.5 or E18.5 with the heads removed from the axial 
skeleton. Heads were mounted on a cork disc, embedded in OCT compound (VWR) on the 
axial plane, and snap frozen using the dry ice isopentane (VWR) method. Heads were stored in -
80oC until required for cryosectioning. Cryosections were cut between 15-20um on the Model 
OTF Cryostat (Bright), with sections mounted on Superfrost Plus slides (VWR). 
2.6.2-Paraffin embedding 
E16.5 embryo heads were skinned and fixed in 4% Paraformaldehyde (PFA) or 10% 
formalin overnight before graded dehydration in EtOH. Embryos were cleared in analytical 
grade xylene (Fisher) before paraffin wax displacement in a 60oC oven. The samples were 
embedded and sectioned on a microtome (Leica) between 8-10um on the axial plane. 
2.6.3-Bone and cartilage histology  
 
E18.5 embryos were skinned and eviscerated after phenotypic analysis. Embryos were 
dehydrated in 75% EtOH overnight at 4oC and stained with 0.01% alcian blue (Sigma) working 
reagent4 overnight, room temperature (RT).  Embryos were washed in 75% EtOH for a further 
24 hours and cleared in 1% potassium hydroxide (Fisher) (KOH) the following day. After 
sufficient clearing, 0.01% alizarin red working solution 5  was added to the embryos. The 
embryos were processed overnight and washed in 1% KOH the following day. Samples were 
transferred to a graded glycerol (Sigma) gradient and were eventually stored in 80% Glycerol. 
The wholemount protocol can be found in Appendix 3. 
2.6.4-Wholemount alizarin red stain 
 
Calvarial explants were fixed in 70% EtOH overnight at 4oC before transferring to 1% 
KOH. After sufficient clearing to remove residual tissue surrounding the calvaria, 0.01% 
alizarin red working solution (0.01% Alizarin Red-1% KOH) was added to the calvaria and 
                                                     
4 0.01% Alcian blue (Sigma); 20% acetic acid; 80% of 75% EtOH 
5 0.01% Alizarin red (Sigma)-1% KOH 
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stained overnight. This was followed by subsequent washes in 1% KOH prior to graded 
glycerol in preparation to storage. Stained calvaria is stored in 80% Glycerol-H2O. 
2.6.5-Wholemount alcian blue staining of calvaria 
E18.5 embryos were skinned and eviscerated. Embryos were dehydrated in 75% EtOH 
overnight at 4oC and stained with alcian blue working reagent6 overnight-RT.  Embryos were 
washed in 75% EtOH for a further 24 hours and cleared in 1% KOH (Fisher) the following day. 
The embryos were processed overnight and washed in 1% KOH the following day. The 
embryos were eventually processed for graded glycerol-H2O (Sigma) equilibration after 
sufficient washes in 1% KOH. The calvaria was eventually dissected for in 80% Glycerol-H2O.    
2.6.6-Cartilage histology (sections) 
 
E16.5 embryo heads were paraffin embedded as previously described in section 2.6.2 
and cut on the coronal plane between 10-12um on the microtome (Leica). Sections were 
dewaxed in Histoclear (National Diagnostics) and redehydrated in graded EtOH. Sections were 
processed for 0.01% alcian blue working reagent6 and counter-stained using 1% Nuclear Fast 
Red (Sigma) to visualise the nucleus. Sections were dehydrated in graded EtOH and mounted in 
DPX. 
2.6.7-Alkaline phosphatase (ALP) assay  
Cryosectioned embryos were thawed and immediately fixed in 4% PFA before 
permeablised in 0.1% TBST. Samples were equilibrated in NTMT before developing in NBT-
BCIP-NTMT solution7. To allow even developing times, all samples were processed at once. 
Developed samples were counterstained with 1% nuclear fast red (Sigma) and mounted in 
Mowiol mounting media (Sigma) (Appendix 4). 
2.6.8-Wholemount alizarin red stain 
Calvarial explants were fixed in 70% EtOH overnight at 4oC before transferring to 1% 
KOH. After sufficient clearing to remove residual tissue surrounding the calvaria, 0.01% 
alizarin red working solution (0.01% Alizarin Red-1% KOH) was added to the calvaria and 
                                                     
6 0.01% alcian blue (Sigma); 20% acetic acid; 80% of 75% EtOH 
7 NBT: 4.5ul/ml, BCIP: 3.5ul/ml, NTMT 
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stained overnight. This was followed by subsequent washes in 1% KOH prior to graded 
glycerol in preparation to storage. Stained calvaria is stored in 80% Glycerol-H2O. 
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2.6-In situ hybridisation (ISH) 
2.6.1-Cloning the mV5 transgene for RNA in situ probe 
Transgenic mouse V5 (mV5) was cloned in the Pauws lab. Primers spanning a unique 
portion of the V5 transgene were designed using Primer 3 plus software 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi), and validated using in 
silico PCR software (http://rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr) (Figure 27). DNA was 
extracted from R26RFgfr2cV5/Fgfr2cV5 ear biopsies to use as the template DNA for PCR 
amplification. Primers were obtained from Sigma and amplified with standard PCR protocol 
(expected amplicon: 155bp). The PCR product derived from ear biopsies yielded two bands 
close to the band of interest (Figure 28 A). To determine the correct band, a second PCR 
reaction was set up against a plasmid (pcDNA3) already carrying Fgfr2cV5 in the lab (Figure 28 
B). Subsequently, the specific band was extracted using the Gel Extraction Kit (Qiagen), and 
was cloned into the pGEMT-Easy Vector (Promega) according to the manufacturers’ protocol. 
The cloned plasmids were transformed into XL1-Blue competent cells (Agilent) and starting 
cultures amplified in SOC medium (Thermo). The cultures were spread onto ampicillin agar 
plates for selection. A total of 6 colonies were picked and processed for MINI overnight 
inoculation containing Luria Broth and ampicillin (1:1000 dilution). Plasmids were extracted 
using the QIAprep Spin MINIprep kit (Qiagen) according to the manufacturer’s protocol the 
following day. An additional diagnostic digest was performed with EcoRI (Promega) to 
visualize the insert. However, the insert was not detected in the gel, and a diagnostic PCR using 
the mV5 primers were implemented to confirm the presence of the insert (Figure 28 C). 
Extracted plasmids were sent for sequencing at Barclay House (UCL), and the sequence aligned 
using BLAST (NIH) to determine the success of the cloning and direction of the insert (Figure 
29). Meanwhile, Plasmid DNA containing the V5 insert was processed for an overnight MIDI 
inoculation, and extracted using the QIAprep MIDIprep kit (Qiagen) according to the 
manufacturer’s protocol the following day. The same controls were applied to the MIDIprep 
plasmids as for the MINI using enzyme and PCR reactions for quality assurance.  
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Figure 27: Primer design against mV5 transgene.  
mV5 primers spanning unique portion of Rosa26 transgene with V5 epitope. The expected 
amplicon is 155bp. 
 
 
Figure 28: Resolving the correct mV5 band.  
(A) Multiple bands yielded in the ear biopsies of R26RFgfr2cV5/Fgfr2cV5 (HOM); (B) A second PCR 
was set up against a plasmid vector (pcDNA3) already carrying Fgfr2c-V5 to determine the 
correct band. (C) No dropout was detected in any of the clones, and PCR was adopted to 
amplify the insert using mV5 primers. Note that clone 3 did not carry the insert. 
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Figure 29: Sequence alignment of an Fgfr2c-V5 clone containing the mV5 insert. 
The output here is a screenshot from BLAST (NCBI). 
 
2.6.2-In vitro transcription 
mV5 plasmid was linearized with either Sal1 or NCO1 enzyme (Promega) to generate 
the respective sense and antisense RNA probes. PCR Cleanup Kit (Qiagen) was utilized to 
remove restriction enzymes prior to in vitro transcription according to the manufacturer’s 
protocol. Figure 30 illustrates the plasmid map. mV5 probes were transcribed at 37oC in a 
cocktail of Digoxigenin (DIG) (Roche) with T7 RNA polymerase for sense, and SP6 for 
antisense probes respectively. DNAse1 (Roche) treatment was applied to the transcription 
cocktail to remove any plasmid DNA, and passed through a Chroma Spin Column (Clontech) to 
clean the products according to the manufacturer’s protocol. RNA probes were quantified by gel 
electrophoresis (Figure 31) and concentrations determined by Nanodrop (Thermo). Specific 
protocols for plasmid linearization and in vitro transcription can be found in Appendix 5.
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Figure 30: Plasmid map of mV5  
Plasmid map is shown with the enzymes required for diagnostic digest, linearization and in vitro 
transcription. 
 
Figure 31: Plasmid linearization (Top) and in vitro transcription of mV5 probes using 
appropriate enzymes (Bottom). U: uncleaned probes; C: Cleaned probes using Chroma Spin 
Columns. 
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2.6.3-mV5 wholemount ISH  
E12.5 whole embryos were harvested and fixed in 4% Paraformaldehyde (PFA) 
overnight prior to graded dehydration in methanol (MeOH). Embryos were bleached in 6% 
H2O2-MeOH before serial rehydration. Embryos were washed in phosphate buffered saline 
(PBS)-0.1% Tween (Sigma) (PTW), and treated with 1:1000 Proteinase K in PTW to 
permeabilise embryos for roughly 30 minutes. Post-fix8 was applied to stop the Proteinase K 
activity before further washes in PTW. Subsequently, embryos were equilibrated in 
hybridisation buffer9 before sense or antisense mV5 probes hybridisation. Sox9 antisense probe 
(Lovell Badge group), were used as a positive control for experiment. Hybridisation was 
attempted at 65oC and 70oC for these probes. Following hybridisation, embryos were washed in 
Solution 1 10  and Solution 2 11  at respective hybridization temperatures and washed in Tris 
buffered saline- 1% Tween-20 (TBST). Hybridised probes were detected with alkaline 
phosphatase-coupled Anti-DIG antibodies (1:2000, Roche), and was incubated overnight in 5% 
Heat Inactivated Sheep Serum (HISS) in TBST at 4oC. Post antibody washes were performed in 
TBST, before transferring to NTMT12 for probe development. For detection of DIG probes, a 
cocktail of BCIP (5-Bromo-4-chloro-3-indolyl phosphate, Sigma) and NBT (Nitro Blue 
Tetrazolium Chloride, Sigma) was applied in alkaline phosphatase buffer NTMT. Subsequently, 
specimens were washed briefly in PTW before storage in 4% PFA. The full protocol and stock 
reagent are available in Appendix 6. 
2.6.4-In situ hybridisation on tissue sections 
 
For paraffin sections, sections were dewaxed in Histoclear (National Diagnostics) and 
rehydrated in graded EtOH, while frozen sections were immediately rehydrated in DEPC-H2O. 
Briefly, sections were fixed in 4% PFA and permeabilised in Proteinase K solution at 10 mg/ml. 
Proteinase K reaction was stopped by fixing in 4% PFA, and subsequent electrostatic attractions 
neutralised in a cocktail of 0.1M Triethaloamine solution with acetic anhydride prior to further 
                                                     
8 0.1% Gluteraldehyde (Sigma) in 4% PFA 
9 50% Formamide, 5x Saline Sodium Citrate (SSC) pH4.5, 1%SDS, 50ug/ml yeast tRNA, 50ug/ml heparin 
10 50% Formamide, 5x SSC, 1% SDS and DEPC-H2O 
11 as Solution 1, but with 2x SSC 
12 pH9.5, 5M NaCl; 1M Tris-HCl (Hydrochloric Acid); 1M MgCl2 (Magnesium Chloride); 0.1% Tween-20 
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washes in DEPC-PBS. Tissue sections were dehydrated in graded ethanol and left to air dry 
prior to hybridisation process. Digoxigenin (DIG) RNA ISH was achieved at 300ng/ml probes 
in hybridisation mix13  with DIG antisense RNA probes overnight at 65oC in a humidified 
chamber. The plasmids used to synthesise Spry2, Spry4 and Etv5 ISH probes were a gift from 
the Basson Lab. Post hybridisation washes were performed in a temperature-controlled water 
bath at 65C and washed in a series of formamide and graded SSC14 solutions (2x and 0.2x 
SSC). The sections were subsequently washed in Buffer 115 and blocked in 10% HISS, and 
incubated with anti-DIG antibody (1:2000, Roche) in 1% HISS overnight at 4C. Sections were 
developed in NBT/BCIP the following day in a cocktail of Buffer 216 and 10% Polyvinylacetate. 
The slides were allowed to develop in the dark at room temperature until sufficient signal was 
visualized. Developed slides were mounted in Mowiol mounting media. Protocol is available in 
Appendix 7. 
 
                                                     
13 Formamide, 5M NaCl, 1M Tris pH 8.5, 0.5M EDTA pH 8, Denharts solution, RNase inhibitor, tRNA 
14 NaCl, sodium citrate, adjusted to pH 7.0. See appendix 8 for details 
15 1M Tris-HCl pH7.6, 5M NaCl, H2O. See appendix 8 for details 
16 1M Tris pH9.5, 5M NaCl, 2M MgCl2. See appendix 8 for details 
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2.7-Immunohistochemistry (IHC) 
2.7.1-IHC for frozen sections 
2.7.1.1-Detection of V5 epitope and YFP: Cryosections were thawed at RT in a 
humidified chamber and rehydrated in PBS before fixation in 4% PFA. Sections may proceed to 
antigen retrieval at 110oC, 2 mins in 10mM pH6.5 Sodium citrate buffer17 in a decloaking 
chamber (Biocare Medical) at 110oC-2 mins after brief washes in PBS to remove the fixative. 
Sections were then permeabilised in 0.1% PBST and non specific binding quenched in blocking 
buffer18 and 10% HISS prior to incubation of αV5 primaries (between 1:100-1:500) in working 
antibody solution (blocking buffer + 1% HISS) overnight at 4oC. YFP was detected using an 
antibody specific for GFP (Invitrogen) at a concentration of 1:500. After several washes in 0.1% 
PBST, appropriate anti specie biotinylated (Dako), or Alexa Fluor-488 (Life Technologies) 
conjugated secondary antibodies were incubated for 1 hour RT in working antibody solution. 
Samples incubated with biotinylated secondary antibodies were subject to streptavidin-555 
conjugate amplification (1:500, Life Technologies), and 0.1% Sudan black-70% EtOH 
incubation to reduce auto-fluorescence if necessary. Further washes in 0.1% PBST was 
performed to remove excess secondary antibodies before counterstaining nuclei in 4, 6-
diamidino-2-phenylindole (DAPI; Life Technologies) at a concentration of 1:10,000 in PBS. 
Sections were subsequently washed in PBS and coverslipped in Mowiol mounting media. Table 
16 and Table 17 summarise the conditions for IHC on frozen sections, and a full protocol is 
available in Appendix 8. 
                                                     
 17 10mM Sodium Citrate, 0.05% Tween-20, adjusted to pH6.5 with HCl 
18 0.1% PBST, 0.15% Glycine and 2mg/ml BSA 
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Antibodies Company  
Catalogue 
No. 
Host 
specie  
Primary 
concentrations  
Secondary, anti specie 
IgG 
Streptavidin 555 
amplification 
Anti-V5 Tag  Invitrogen  R960-25 Mouse 
1.100 
1.250 (Biotinated) 1.500 
1.250 
1.500 
Anti-V5 Tag-ChIP Grade  Abcam  ab9116 Rabbit 
1.100 1.500 (Biotinated) 
1.500 1.250 1.250 (Biotinated) 
Anti-Fibronectin  Abcam  ab23750 Rabbit 
1.100 
1.250 (Biotinated) 1.500 
1.250 
1.500 
Anti-GFP tag Invitrogen A-11120 Mouse 1.500 1.250 (Alexa Fluor-488) N/A 
Table 16: V5 IHC for frozen sections 
Antibodies Company  
Catalogue 
No. 
Host 
specie  
Primary 
concentrations  
Secondary, anti specie-
biotinayted IgG 
Streptavidin 555 
amplification 
Anti-V5 Tag Invitrogen  R960-25 Mouse 
1.500 1.500 1.500 Anti-Fibronectin Abcam  ab23750 Rabbit 
Table 17: V5 IHC for frozen sections with antigen retrieval (10mM Sodium Citrate Buffer, pH 6.5) at 110oC, 2mins  
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2.7.2-IHC on paraffin sections 
 
2.7.2.1-Detection of V5 epitope: Paraffin sections were dewaxed in Histoclear 
(National Diagnostics) before graded EtOH rehydration. Antigen retrieval was executed in a 
decloaking chamber (BioCare Medical) at 110oC for 2 mins in 10mM Sodium Citrate pH6.5 
buffer or Declere solution (Sigma). Sections were permeabilised in 0.1% PBST and blocked in 
10% sheep serum (Sigma) and blocking buffer. αV5 antibody (CST or Invitrogen) were tested 
at multiple concentrations, and incubated overnight in 1% HISS and blocking buffer Table 18. 
Appropriate secondary antibodies were incubated for an hour the following day. A goat-anti-
mouse Alexa Fluor-488 secondary (Life Technologies, 1:500) was used to detect V5 directly 
without amplification, whilst a goat-anti-rabbit biotinylated antibody was used to boost V5 
signal (1:250, Dako). Signals were subsequently amplified using Streptavidin 555 (1:500, Life 
Technologies) conjugates that recognize biotin. Sections were washed several times in 0.1% 
PBST, and stained for DAPI (1:10,000, Thermo Fisher) in PBS before coverslipped in Mowiol 
mounting medium (Sigma). Conditions are summaried in Table 18, and a full protocol is 
available in Appendix 9. 
 
 
 
Antibodies Company  Cat. 
Host 
specie  
Antigen 
Retrieval  Primary  
2o anti specie 
IgG Amplification Notes 
αV5 Tag  Invitrogen   R960-25 Mouse Declere 
1.500 
1.500, Alexa 
Fluor-488 N/A 
 Emma 
Peskett
, 
c.2013 1.2000 
 
αV5 Tag  
Cell 
Signalling 
Technologies D3H8Q Rabbit 
10mM 
Sodium 
Citrate 
pH6.5 
1.100 1.250, anti-
rabbit 
biotinayed 
IgG 
1.500 
(Steptavidin 
555)   1.250 
Table 18: V5 IHC on paraffin sections 
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2.7.2.2-pERK and osteopontin IHC 
Paraffin sections were dewaxed in Histoclear (National Diagnostics) before graded 
EtOH rehydration. Antigen retrieval was executed in a decloaking chamber (BioCare Medical) 
at 110oC for 10 minutes in 10mM Sodium Citrate pH6.5 buffer. Sections were permeabilised in 
0.1% PBST and blocked in 10% sheep serum (Sigma) and blocking buffer19. Primary antibodies 
were incubated on the sections overnight in 1% sheep serum (Sigma) and blocking buffer. 
pERK (rabbit mIgG, Cell Signalling Technologies) was used at 1:250 and anti-osteopontin 
(Mouse mIgG, Developmental Studies Hybridoma Bank) at 1:200, and appropriate secondary 
antibodies were incubated for an hour the following day. Goat-anti-mouse Alexa Fluor 488 
secondary antibodies were used against osteopontin and whilst biotin goat-anti-rabbit secondary 
antibodies (Dako) were used against pERK. The pERK signals were amplified using 
Streptavidin 555 conjugates (Life Technologies) at 1:500. 0.1% Sudan black was applied onto 
tissue sections for 5 minutes to quench any autofluorescence, and rinsed briefly in PBST to 
relieve any excess staining. Lastly, tissue sections were stained in DAPI (Thermo Fisher) at 
1:10,000 in PBS before coverslipped in Mowiol mounting medium (Sigma) (Appendix 9). 
Table 19 illustrates conditions required of pERK/osteopontin IHC.    
 
 
 
                                                     
19 0.15% Glycine, 2mg/ml BSA (Bovine Serum Albumin) in 0.1% PBST 
Antibodies Company  Cat. 
Host 
specie  
Antigen 
Retrieval  
Primary 
concentrations  
Secondary, 
anti specie 
IgG Amplification 
Anti-pERK 
Cell 
Signalling 
Technologies 
D13.14.4
E XP Rabbit 
10mM Sodium 
Citrate pH6.5 at 
110oC, 2mins 
1.250 
1.250, anti-
rabbit 
biotinayed 
IgG 
1.500 
Steptavidin 555 
Anti-
Osteopontin DSHB  
MPIIIB1
0 (1) Mouse 1.200 
1.200, Alexa 
Fluor-488 N/A 
Table 19: pERK/Osteopontin IHC conditions 
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2.8-Phenotypic analysis 
 
2.8.1-Gross analysis of phenotype 
Embryos harvested at E18.5 and were weighed on a fine balance. An electronic caliper 
(Fisher) was used to measure the crown-rump length and head length of the embryo. Data were 
subsequently transformed and processed for statistical analysis.   
2.8.2-Morphometric analysis of the craniofacial skeleton 
E18.5 calvaria stained with bone and cartilage stain were subjected to ‘Region of 
Interest’ (ROI) analysis using FIJI software (NIH). The craniofacial skeleton was dissected for 
the frontal, parietal and nasal bones in 80%-glycerol and flat mounted onto frosted slides 
(Fisher). Images were taken for surface area measurements of frontal, parietal and nasal bones 
using FIJI. Two measurements were made from both hemispheres of the bone, and the results 
were expressed as an average value. The quantification was performed blind without knowledge 
of the embryo’s genotype beforehand in order to eliminate any bias. The mandibles were also 
quantified in the same manner with the length measured instead. As embryo sizes vary between 
litters, data normalisation was necessary to reduce signal to noise ratio and allow comparisons 
between litters to occur. Quantified data were normalized to an endogenous structure that was 
not affected by FGFR2c signalling, and the length of the appendicular skeleton was chosen for 
this purpose (Figure 32 A & B) (Eswarakumar et al., 2002, Eswarakumar et al., 2004). 
Measurements were taken from both forelimbs, measured from the scapula to the wrist. The 
results were expressed as the average length acquired from both limbs. The result indicates that 
Fgfr2c overexpression has no influence on limb length (p=0.271; control: n=9; R26RFgfr2cV5/+; 
βactinCRE/+: n=4), and was therefore chosen as the endogenous control for data transformation of 
litters (See section 3.2.9). The results were subsequently processed for statistical analysis. 
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Figure 32: Fgfr2c overexpression does not have an effect on limb length and is used as an 
endogenous control for data transformation. 
(A) Images of the mouse forelimb; (B) Graph showing the average forelimb length measured 
from the scapula to the wrist (p=0.271; Control: n=9; R26RFgfr2cV5/+; βactinCRE/+: n=4). Statistics: 
Student’s t-test with Welch’s correction. Error bars depict SEM. Scale bar: 2mm.   
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2.8.3-Data transformation for littermates 
 
1) Find sample mean (x̅) 
-Let m1 and m2 be raw measurements 
 
m1 + m2
2
= x̅ 
2) Find population (n) mean of littermate (Lμ) 
 
∑ x̅
n
= Lμ 
3) To minimize sample variability between littermates, normalize littermates against 
a constant (i.e average limb length) 
 
i) Find normalization factor (L.nf) against average limb length  
-Let Average limb length constant be 16.9162 
-Let L.nf be normalization factor  
 
16.9162
Lμ
= L. nf 
ii) Normalize the mean measurements (x̅) of each littermate to average limb 
length (L.nf) to obtain transformed data (Tx̅)  
 
x̅ x L. nf = Tx̅ 
 
4) Find relative percentage change in respect to controls 
 
i) Find total average of controls across all littermates (ConTμ), given by the sum 
of all control samples (ConTx̅) to population (n) 
 
∑ Con.Tx̅ 
n
 = Con. Tμ 
ii) Compare mutant samples (Mut. Tx̅) relative to total average of control group 
(Con. Tμ). Overall change in mutants is expressed as a relative percentage to 
Con.Tμ 
    
   [ 
Mut. x̅
Con. Tμ
]  x 100 = relative change (%) 
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2.9-Statistical analysis 
 
SPSS Statistics 22 (IBM) software was used as the primary statistical package for data 
analysis. First, the data was tested for normality using Shapiro-Wilk test to determine the use of 
parametric or non-parametric tests. Independent samples t-test (‘Student’s t test’) with Welch’s 
correction (parametric) or Mann Whitney U (non-parametric) tests were used to compare the 
difference of means between the control and mutant groups where appropriate. One-way 
ANOVA with Tukey posthoc or non-parametric Kruskal Wallis with Dunn-Bonferroni posthoc 
test was adopted for analysis of three or more groups. A p-value of <0.05 was considered 
significant. The analysed data were plotted using Prism 6.0 software (GraphPad).   
2.10-Image acquisition 
Images concerning phenotype or embryology were acquired on the Zeiss Steni SV6 
Stereoscope mounted with a camera (Leica DFC 490). For sections, fluorescent images were 
captured on the Leica DM1000 microscope mounted with a camera (Photometrics CoolSnap 
CF). Brightfield images were acquired on the Zeiss Axioplan 2 microscope attached with a 
camera (Zeiss Axiocam HRc).   
2.11-Profiling the coronal suture 
 
2.11.1-Histology for LCM 
E16.5 CD1-WT and Fgfr2cC342Y/+ embryo heads were embedded in OCT Compound 
(VWR) and snap frozen using -80oC isopentane method. The heads were sectioned at 20µm 
along the axial plane using a cryostat (Bright), and mounted on Arcturus PEN membrane glass 
slides (Life Technologies). Sections were dried and stored at -80oC until required.  Mounted 
sections were subjected to 1% Alizarin Red/0.06% Fast Green (Sigma) to visualise the coronal 
suture. Sections were rehydrated and stained in 1% alizarin red for 5 mins and washed in H2O. 
The sections were subsequently counterstained with 0.06% fast green until sufficient prior to 
further washes in H2O to remove excess staining. Finally, sections were dehydrated in graded 
EtOH and stored in -80oC until use. 
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2.11.2-Performing laser capture microdissection 
 
Coronal sutures were microdissected on the PALM-Axiovert 200M Microscope (Zeiss). 
The ROI of the coronal suture is defined by the appositional growth limits of the frontal and 
parietal bones. The ROI is selected manually on the PALMRobo software (Zeiss), which 
defines the laser path of the LCM. Bilateral coronal sutures from the same embryo were 
captured along the dorsal-ventral profile down to the level of the eye. Samples were collected 
using Adhesive Cap 500 collection tubes (Zeiss). Subsequently, 200µl of lysis buffer RLT 
(Qiagen) was added to the samples immediately after collection, and stored at -80oC until RNA 
extraction.  
2.11.3-RNA preparation and sequencing 
RNA was extracted using the RNeasy micro-kit (Qiagen) according to the 
manufacturer’s protocol. Sample quality was determined with the 2200 Tapestation (Agilent). 
RNA samples were amplified, and cDNA library constructed using the Clonetech SMART-Seq 
v4 Ultra Low Input RNA Kit (Takara) in accordance to the manufacturer’s protocol. The cDNA 
libraries were sequenced paired end at a depth of 30 millions reads per sample on the Illumina 
NextSeq 500 platform. A total of three biological replicates per genotype within the same litter 
(CD-1 WT and Fgfr2cC342Y/+) were sequenced. The sequenced data (FASTQ files) were aligned 
using TopHat and Cufflink software to generate Binary Alignment Map (BAM) files for 
subsequent analysis on Strand NGS softwre. Alignments were visualised on the BaseSpace 
platform (Illumina). All procedures were carried out at UCL Genomics with the exception of 
RNA extraction and data interpretation on BaseSpace. 
2.11.4-Expression analysis  
 
Figure 33 is a diagrammatic representation of the RNAseq pipeline. BAM files were 
uploaded and analysed on the Strand NGS software. Samples were categorised for their 
genotype, with a cut off threshold of 10 folds applied for differential expression analysis based 
on the DeSeq2 algorithm. Additional filters were applied to ensure alignment quality against the 
reference genome: Reads must have both mates present such that it improves mapping to a 
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precise region. Any reads that were not paired, too far apart, missing, translocated, 
misorientated or unaligned were excluded from the analysis. To select the genes for expression 
validation, read counts must be consistent across all three biological replicates to ensure 
accuracy. A subsequent PubMed search was conducted to determine its role and relevance to 
craniofacial development. A total of six genes were selected for expression validation. On a 
separate analysis, BAM files were run against a FGF entity list (Table 20) serving as an in silico 
experimental control, and data prepared for Gene Set Enrichment Analysis (GSEA). The entity 
list was assembled from multiple FGF signalling readouts described in (Ornitz and Itoh, 2015). 
 
 
 
Figure 33: Pipeline for RNAseq analysis. 
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Gene 
Symbol ENSEMBL 
 
Gene Symbol ENSEMBL 
Stat1 ENSMUSG00000026104 
 
Fgf18 ENSMUSG00000057967 
Fgf7 ENSMUSG00000027208 
 
Fgf11 ENSMUSG00000042826 
Fgf2 ENSMUSG00000037225 
 
Stat5a ENSMUSG00000004043 
Spry1 ENSMUSG00000037211 
 
Stat3 ENSMUSG00000004040 
Foxo1 ENSMUSG00000044167 
 
Etv4 ENSMUSG00000017724 
Fgf5 ENSMUSG00000029337 
 
Fgf10 ENSMUSG00000021732 
Fgf6 ENSMUSG00000000183 
 
Fgf9 ENSMUSG00000021974 
Fgf23 ENSMUSG00000000182 
 
Fgf17 ENSMUSG00000022101 
Fgf21 ENSMUSG00000030827 
 
Spry2 ENSMUSG00000022114 
Fgfr2 ENSMUSG00000030849 
 
Fgf14 ENSMUSG00000025551 
Fgf3 ENSMUSG00000031074 
 
Etv5 ENSMUSG00000013089 
Fgf4 ENSMUSG00000050917 
 
Fgf12 ENSMUSG00000022523 
Fgf15 ENSMUSG00000031073 
 
Tsc2 ENSMUSG00000002496 
Fgf20 ENSMUSG00000031603 
 
Spry4 ENSMUSG00000024427 
Fgf22 ENSMUSG00000020327 
 
Fgf1 ENSMUSG00000036585 
Dusp6 ENSMUSG00000019960 
 
Fgf8 ENSMUSG00000025219 
   
Fgf13 ENSMUSG00000031137 
   
Fgf16 ENSMUSG00000031230 
Table 20: FGF entity list 
 
2.11.5-Gene set enrichment analysis (GSEA) 
 
The initial output of the RNAseq dataset from Illumina was processed for GSEA to 
determine the molecular signature in Fgfr2cC342Y/+. Genes were pre-ranked in ‘R’ statistic 
programme based on Wald’s test statistic with the help of Dr John Apps (UCL). The ranked 
genes were subsequently uploaded onto the GSEA software 
(http://software.broadinstitute.org/gsea/index.jsp), and ran against the hallmark gene set 
database on MSigDB. Gene sets must be at least 75% confident, through their False Discovery 
Rate (FDR, q<0.25), and display 95% (p<0.05) confidence for their enrichment.   
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Chapter 3 
Results (Part I) 
Investigation of Fgfr2c 
expression levels in the 
Fgfr2c-V5 transgenic mouse
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3.1-Introduction 
 
The aim of the Fgfr2c overexpression model (R26RFgfr2cV5/Fgfr2cV5) is to perturb molecular 
events downstream of FGFR2c. This section gives an introduction to the Fgfr2c overexpression 
transgenic mouse, and the approaches adopted to confirm its overexpression in specific tissue 
types. Expression validation is critical to show that the overexpression allele is functional both 
at the RNA and protein level. The following methods have been employed to demonstrate this: 
i) Use of real time quantitative polymerase chain reaction (RT-qPCR) to investigate 
the expression of Fgfr2c. 
ii) Detection of the V5 epitope using immunoblots, immunohistochemistry (IHC) and 
in situ hybridisation (ISH), unique to the transgenic FGFR2c-V5 protein.  
iii) Use of transgenic reporter mice to detect CRE recombinase activity in vivo. 
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3.2-Results 
 
3.2.1-Evaluation of FGFR2c-V5 expression  
 
To investigate the impact of FGFR2c signalling in the craniofacial skeleton, the Pauws 
laboratory generated a transgenic mouse that conditionally overexpresses the WT form of 
Fgfr2c (R26RFgfr2cV5/Fgfr2cV5) in collaboration with the UCL Transgenic Service. RT-qPCR was 
used to confirm the relative expression of Fgfr2c in the overexpressing recombinants (Figure 34 
A). Figure 34 A shows an upregulation of FGFR2c expression by 1.8 folds in whole E12.5 
embryos overexpressing Fgfr2c ubiquitously (n=3) (courtesy: Emma Peskett). In addition to 
RT-qPCR, the overall purpose of the V5 epitope is to tag conditional FGFR2c overexpression at 
the protein level, in order to distinguish the transgenic receptor protein from endogenous 
FGFR2c in the embryo (Figure 34 B). A indicates the expression of the V5 tag in E12.5 
R26RFgfr2cV5/+; βactinCRE/+ wholemount embryos (n=3). 
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Figure 34 Expression validation of Fgfr2c overexpression in E12.5 R26RFgfr2cV5/+; βactinCRE/+ 
RT-qPCR of Fgfr2c, there is roughly a 1.8 folds of transcript upregulation; (B) Immunoblot of the V5 epitope. Control is R26RFgfr2cV5/+; Error bars: SEM; RT-qPCR 
courtesy: Emma Peskett. 
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3.2.2-Strategies to determine conditional FGFR2c-V5 overexpression 
 
R26RFgfr2cV5/Fgfr2cV5 was crossed with the following CRE lines to delineate the role of 
FGFR2c in craniofacial development: βactinCRE/+ (ubiquitous), Wnt1CRE/+ (NCCs), Mesp1CRE/+ 
(mesoderm). Therefore, it is crucial to demonstrate the correct embryonic compartment 
expresses transgenic Fgfr2c-V5. As the calvaria derives from the NCC and mesoderm, 
conditional overexpression is expected in the frontal bone (NCC, R26RFgfr2cV5/+; Wnt1CRE/+) and 
parietal bone (mesoderm, R26RFgfr2cV5/+; Mesp1CRE/+). In regards to the R26RFgfr2cV5/+; 
βactinCRE/+, overexpression is expected in both lineage derivatives. E16.5 was chosen as the 
ideal stage to perform this experiment, due to the earliest morphological appearance of the 
calvaria.  
3.2.3-Expression validation in R26RFgfr2cV5/+; Wnt1CRE/+ and R26RFgfr2cV5/+; 
Mesp1CRE/+ 
 
There was an increase of Fgfr2c transcripts in the frontal bone upon conditional 
overexpression using the Wnt1CRE/+ (R26RFgfr2cV5/+; Wnt1CRE/+) (A). Fgfr2c transcript was 
upregulated by 2.07 fold (p=0.0203; n=4) relative to the controls (R26RFgfr2cV5/+), whilst no 
difference was detected in the parietal bone and the limb negative control (Figure 35 A & B). 
Next, expression validation was attempted for conditional overexpression in the mesoderm 
(R26RFgfr2cV5/+; Mesp1CRE/+) (Figure 35 C & D). Surprisingly, there was a significant increase of 
Fgfr2c transcripts in the frontal bone (p=0.0245; n=4) by 0.73 folds relative to the controls 
(Figure 35 C), but not in the parietal bone in these mutants. Despite the fact that the limb is a 
derivative of mesoderm, RT-qPCR analysis indicated that limb Fgfr2c transcripts did not differ 
at E16.5 between R26RFgfr2cV5/+; Mesp1CRE/+ and controls (Figure 35 D) (Loebel et al., 2012).  
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Figure 35: Expression validation of Fgfr2c in the E16.5 calvaria and limb 
(A) Significant increase of Fgfr2c transcript in the frontal bone of R26RFgfr2cV5/+; Wnt1CRE/+ and 
(B) no changes in transcript levels in the limb. (C) Significant increase of the Fgfr2c transcript 
was detected in the frontal bone of R26RFgfr2cV5/+; Mesp1CRE/+ and (D) no changes in expression 
in the limb. Statistics: Student’s t-test with Welch’s correction. Error bars: SEM.
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3.2.4-Expression validation in R26RFgfr2cV5/+; βactinCRE/+ 
 
The lack of overexpression observed in R26RFgfr2cV5/+; Mesp1CRE/+ prompted the need to 
investigate the mesoderm lineage further. R26RFgfr2cV5/+; βactinCRE/+ was selected as a control for 
this purpose to elucidate whether there are any transcript upregulation in the mesoderm (Figure 
36). In particular, Fgfr2c overexpression is to be expected in both frontal and parietal bones. 
Unexpectedly, the same trend is observed in R26RFgfr2cV5/+; βactinCRE/+ to that of R26RFgfr2cV5/+; 
Mesp1CRE/+: there was no difference in transcript levels observed in the parietal bone, but only in 
the frontal bone of 1.48 folds (n=3) (Figure 36 A). Statistical test was not performed owing to 
an error during the planning of the experiment. Instead of processing the samples individually 
for RNA extraction, the samples were pooled together based on their lineage derivatives in a 
single tube. RT-qPCR analysis was also performed in the limb, where there was a significant 
upregulation of Fgfr2c transcripts in the limb by 1.96 folds (p=0.05; n=2) (Figure 36 B).  
 
 
Figure 36 Expression validation in E16.5 R26RFgfr2cV5/+; βactinCRE/+ calvaria. 
(A) No differences in Fgfr2c transcripts in the parietal bone of R26RFgfr2cV5/+; βactinCRE/+; (B) 
Significant increase of Fgfr2c transcript in the limb of R26RFgfr2cV5/+; βactinCRE/+. Statistics: 
Student’s t-test with Welch’s correction. Note: no statistical analysis was performed in (A).   
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3.2.5-Visualizing the V5 epitope in vivo 
 
Visualising the V5 epitope was integral to understanding the spatial localization of cells 
expressing transgenic FGFR2c. Table 16 and Table 17 summarise the IHC conditions 
performed on frozen sections of controls and R26RFgfr2cV5/+; βactinCRE/+ (n > 2) for each 
condition described). This study, along with a previous member of the Pauws lab (Emma 
Peskett c.2013), also attempted IHC on paraffin sections (Data not shown). Conditions were as 
described in Table 18 for paraffin sections. Unfortunately, the V5 epitope was not detected over 
the course of this study in R26RFgfr2cV5/+; βactinCRE/+. The results obtained were either non-
specific or lacking positive signal (Figure 37). Panel A shows IHC performed on frozen sections 
with varying concentrations of the V5 antibody. All conditions were performed in adjunct with 
a control antibody against fibronectin, where specific signals for blood vessels in the 
telencephalon were detected in all conditions attempted (Figure 37 B). Antigen retrieval with 
10mM sodium citrate buffer was also attempted, but yielded the same results as without 
unmasking for the V5 antibody (Figure 37 C). ISH was subsequently attempted to detect the V5 
epitope, with a unique portion of the mV5 transgene cloned into the pGEM-T vector (Figure 
30). The mV5 in situ probe was tested in embryos where conditional expression can be 
distinguished from background staining. For this reason, ISH was attempted in E12.5 
R26RFgfr2cV5/+; Mesp1CRE/+. This experiment was only partially successful, with 1 out of 6 
embryos yielding positive hybridization in the limb bud under the conditions attempted (Figure 
38; arrow). Due to the difficulty to optimize the in situ probe, ISH was not continued.  
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Figure 37: V5 IHC on frozen sections with images showing axial sections of the telencephalon (n>2 for all conditions described). 
(A) αV5 IHC performed at multiple concentrations (1:100-1:500), note the lack of specific staining in these sections; (B) All conditions were carried out with a 
positive (αFibronectin) and a negative control (Secondary antibodies only), this panel is a representative from this cohort of attempts; (C) αV5 performed with 
0.01M sodium citrate antigen retrieval buffer. Scale bar: 200um.   
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Figure 38: mV5 wholemount ISH on E12.5 R26RFgfr2cV5/+; Mesp1CRE/+ (n=1/6). 
Arrow denotes an embryo with positive hybridization of mV5 in situ probe in the limb (arrow) 
(1/6). Sox9 is adopted as an experimental control, showing positive staining in the somites and 
limbs. 
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3.2.6-Use of reporter lines to indirectly show Fgfr2c-V5 overexpression  
 
This experiment sets out to address two aims: Firstly, to show Fgfr2c overexpression 
indirectly through reporter activity and secondly, to demonstrate that the CRE lines were not 
compromised due to the results obtained thus far. Yoshida and colleagues have previously 
lineage traced the calvaria, providing a reference control for this study (Yoshida et al., 2008). 
R26RmTmG/mTmG   was introduced into the R26RFgfr2cV5/Fgfr2cV5 (R26RFgfr2cV5/mTmG) in an attempt to 
visualize the Fgfr2c-V5 expressing cells (Figure 23). The mTmG reporter was previously 
described in Muzumdar et al 2007, consisting of a R26R-loxP-tdTomato-tPA-loxP-eGFP 
construct with the ability to generate mosaic expression upon recombination. Unfortunately, it 
was difficult to collect sufficient embryos owing to the low expectancy of Mandelian ratio (1:8) 
obtained from the resultant genotypes. Eventually, a heterozygous reporter allele recombined 
with a respective CRE (i.e R26RmTmG/+; CRE/+) was chosen instead (Figure 39). Control 
embryos (R26RmTmG/+) did not display any evidence for recombination and tdTomato was 
expressed globally across tissue as expected (Figure 39 A-D). Consistent with previous 
literature, reporter activity for R26RmTmG/+; Mesp1CRE/+ was only detected in the parietal bone 
(n=2) (Figure 39 I-L), whilst R26RmTmG/+; βactinCRE/+ was in both frontal and parietal bones 
(n=2) (Figure 39 E-H). Due to the presence of the Rosa26-YFP reporter allele already present in 
the Wnt1CRE/+; R26RYFP/+, interbreeding with the R26RmTmG/mTmG was not necessary. Wnt1CRE/+; 
R26RYFP/+ was eventually crossed with WT to visualize YFP reporter in embryos. As expected, 
cells positive for the Wnt1CRE/+ and YFP was only detected in the frontal bone (n=3) (Figure 39 
M-P). 
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Figure 39: Reporter lines to show CRE activity in the E16.5 coronal suture. 
(A-D) Control embryos (R26RmTmG/+) did not show any evidence of CRE recombination and 
tdTomato is expressed throughout the cranial bones; (E-H) Complete recombination is present 
in R26RmTmG/+; βactinCRE/+ and eGFP is expressed throughout the cranial bones; (I-L) Cells 
derived from the mesoderm only expresses eGFP in the parietal bone of R26RmTmG/+; 
Mesp1CRE/+. (M-P) Cells derived from the NCC lineage only express YFP in Wnt1CRE/+; 
R26RYFP/+ mice; Coronal sutures are shown on the axial plane; Single channels are displayed in 
false colour; f: Frontal bone, p: Parietal Bone; Scale bar: 200um. 
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3.3-Discussion 
 
This section deals with experiments to investigate and confirm expression of the 
Fgfr2c-V5 in the embryo. However, this task faced multiple challenges that encompass the 
conditional overexpression in specific lineages, in particular to the mesoderm (discussed 
below), and the localization of the V5 epitope in vivo. The significance of the latter aim is of 
specific importance, as the spatial localization of the V5 epitope directly corresponds to the cells 
that express transgenic FGFR2c-V5. Due to the difficulties in visualizing the V5 epitope, an 
alternative strategy was to detect RNA expression using an antisense ISH probe designed 
against a unique portion of the transgene containing the V5 sequence. This was partially 
successful as conditional expression was observed in the R26RFgfr2cV5/+; Mesp1CRE/+. 
Subsequently, reporter mice were used to indirectly infer the localization of overexpressing cells 
in vivo, and to confirm that there was no compromise to the CRE lines used in this study. Given 
these issues, the following discussion will focus on the potential shortcomings as well as 
detailing the techniques that could be adopted to address the problems.   
3.3.1-Expression validation in the mesoderm lineage 
 
 An interesting 
observation was the lack of Fgfr2c transcript upregulation in the parietal bone for R26RFgfr2cV5/+; 
Mesp1CRE/+ and R26RFgfr2cV5/+; βactinCRE/+. The effects observed in the mesoderm are likely due 
to the nature of the Rosa26 transgene acting on specific tissue types. It is characterised that the 
transgene does not elicit uniform expression across all tissue types, given by the fluorescent 
intensity of reporter proteins (Tchorz et al., 2012, Kisseberth et al., 1999, Mao et al., 1999). This 
is reflective of the low Fgfr2c RNA expression in the parietal bone upon conditional expression. 
It is unknown as to the mechanism contributing to this molecular event, but it could either 
suggest i) attenuated transgene expression in or ii) augmented RNA degradation in the parietal 
bone tissue. As we shall see, the lack of Fgfr2c overexpression in the parietal bone may have an 
impact on the phenotype yielded in the phenotypic experiments later in this study (See Chapter 
3, Results part II).  
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 To determine the 
molecular discrepancy of the mesoderm, limb tissue was adopted as a control to demonstrate 
Fgfr2c overexpression. However, Fgfr2c transcript levels remain similar to controls in 
R26RFgfr2cV5/+; Mesp1CRE/+. Mesp1 is an early cranial mesoderm marker, able to give rise to 
multiple progenitors within the lineage (Chan et al., 2013, Gopalakrishnan et al., 2015, 
Lescroart et al., 2010). It has been shown that Mesp1 activity, which is detectable in the early 
limb bud, is absent by E17.5 (Gopalakrishnan et al., 2015, Saga et al., 2000). In this regard, 
expression validation should be carried out at the appropriate embryonic stage. Cellular 
heterogeneity may also contribute to temper with late stage expression validation in the limb 
tissue, as muscle tissue express multiple markers (Gopalakrishnan et al., 2015, Chan et al., 
2013). Therefore, the expression of Mesp1 is restricted to a specific cell type (i.e. satellite cells) 
(Chan et al., 2013), making it difficult to distinguish positive results from the bulk tissue mass. 
The Mesp1 limb results contrasts that of R26RFgfr2cV5/+; βactinCRE/+, where Fgfr2c expression is 
expected in every cell. The heterogeneity of the tissue is also related to the abundance of Fgfr2c 
transcripts observed in the frontal bone of R26RFgfr2cV5/+; Mesp1CRE/+. This could be explained by 
the prominence of mesodermal progenitors derived from the paraxial mesoderm lining the 
periphery of the frontal bone by E18.5 (Deckelbaum et al., 2012). As Mesp1 is sufficient to give 
rise to the paraxial mesoderm, the intermixing of cells in the frontal bone would have led to a 
false positive for Fgfr2c overexpression in this tissue.  
Two possible methods to tackle these issues include: 
i) Use fluorescence activated cell sorting (FACS) to enrich for the specific cells of interest 
within the dissected tissue sample. This could be achieved through the use of antibodies such as 
αV5 or αCRE. The results could then be expressed as a total number of cells positive for the 
antigen of interest within the tissue, backed up with expression data from any primary cultures 
generated. 
ii) Expression validation was performed at a late stage for Mesp1CRE/+ recombinants. Future 
experiments could attempt to isolate structures from an earlier embryonic stage. A potential 
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tissue to perform this experiment would be the developing heart, as the endocardium and 
myocardium strongly express Mesp1 (Saga et al., 2000) 
 
3.3.2-The V5 epitope 
 
An advantage of the V5 epitope is the small size as the polypeptide is 14 amino acids 
long. The V5 is tagged at the C-terminal of the transgenic FGFR2c, and the minimal size of the 
tag reduces potential interference with protein function, whilst still serving as a robust marker 
for transgenic protein expression. However, the V5 epitope was not easily visualized by IHC 
methods. The difficulties to detect the epitope may be due to a very specific protocol being 
required for the antibody. Few other studies that have reported successful visualizion of the V5 
in vivo are likely due to ectopic or particularly high levels of expression levels of the tag. For 
example, one study used a viral vector to drive expression in the mouse hippocampus (Verbeeck 
et al., 2012). In this respect, expression levels are likely to exceed those of the Rosa26 locus. 
The widely available Rosa26 construct (Gt(Rosa26)tm1Sor) achieves moderate levels of transgene 
expression (Mao et al., 1999). As mentioned previously, it is speculated that the Rosa26 
transgene elicits broad, albeit not uniform reporter activity across different tissue (Kisseberth et 
al., 1999, Mao et al., 1999). Several groups have criticized the construct over the moderate 
levels of expression, and have substituted the endogenous promoter for one that exacerbates 
transgene expression (e.g. pCAGG) to accelerate phenotypic severity (Nyabi et al., 2009, 
Tchorz et al., 2012). The ‘moderate’ expression can be reflected in immunoblots in this study, 
as the V5 epitope was only detected between 30-50ug of R26RFgfr2cV5/+; βactinCRE/+ lysates. 
Therefore, it is likely to pose greater difficulties to detect the protein using IHC methods and as 
shown in Figure 37, yielded negative results even in the presence of streptavidin signal 
amplification. Despite the fact that reporter lines were used to indirectly show the transgene 
expression, there are tools that could help with detecting the epitope. For example, undertaking 
Tyramide Signal Amplification (TSA) in IHC provides significant signal amplification for 
proteins with low expression. Other considerations such as placement of the epitope, could also 
affect the overall function of the protein (Park et al., 2015). Placement of the tag should be away 
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from any functional domains. In this study, V5 is tagged towards the C-terminal of FGFR2c, 
adjacent to the catalytic domain of the terminal, which could be disadvantages to the overall 
catalytic function of the receptor. Any potential disruptions to the receptor could be determined 
by immunobloting, such as appreciating the phosphorylation of Frs2α, or the catalytic domains 
of FGFR2c-V5. The mV5 ISH probe was initially tested on R26RFgfr2cV5/+; Mesp1CRE/+ 
wholemounts, with expression expected in the mesoderm e.g. limb. Despite partial success, the 
majority of attempts appeared to yield non-specific binding, which was potentially due to the 
small size of the probe, being under 200bp long. Ideally, an ISH probe should be greater the 
500bp to increase hybridization specificity. Due to the lack of success with the wholemount 
ISH, section ISH with the mV5 was not carried out.  
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Chapter 4 
Results (Part II) 
Phenotypic analysis of the 
craniofacial skeleton in Fgfr2c 
overexpression mice 
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4.1-Introduction 
 
To analyse the complexity of FGFR2c signalling in craniofacial development, the 
Pauws lab generated a novel transgenic mouse model (R26RFgfr2cV5/Fgfr2cV5). The craniofacial 
skeleton was thoroughly examined using a series of morphometric analyses as described in this 
section. By using a conditional receptor overexpression approach, lineage sensitivities to 
FGFR2c signalling can be identified. A large proportion of the craniofacial skeleton is derived 
from the NCCs and mesoderm (Jiang et al., 2002). Firstly, a constitutively active βactinCRE/+ 
was crossed with R26RFgfr2cV5/Fgfr2cV5 to identify the regions sensitive to FGFR2c signalling. 
Secondly, Mesp1CRE/+ and Wnt1CRE were adapted as lineage specific controls for the 
R26RFgfr2cV5/Fgfr2cV5. The latter CRE lines were important as they serve to identify ectopic 
expression of Fgfr2c-V5 generated by the βactinCRE/+. 
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4.2-Results 
 
4.2.1-Fgfr2c overexpression causes growth restriction 
 
R26RFgfr2cV5/Fgfr2cV5 were crossed with either βactinCRE/+ (Ubiquitous), Wnt1CRE/+  (NCC) 
or Mesp1CRE/+ (Mesoderm) to induce conditional overexpression of Fgfr2c (Figure 40 A). 
R26RFgfr2cV5/+; βactinCRE/+ embryos were examined at E18.5 for their size (head length and crown 
rump length-‘CRL’) and weight (Figure 40 B-E). Results were expressed as an average 
percentage change (Av.Δ %) relative to controls (R26RFgfr2cV5/+). Ubiquitous Fgfr2c 
overexpression (n=9) led to a significant reduction in the head length (Av.Δ 7.19%; p<0.0001; 
t(17.78)=7.74) (Figure 30 D), CRL (Av.Δ 4.83%; p=0.0018; t(13.23)=3.90) (Figure 30 C) and 
weight (Av.Δ12.26%; p=0.0001; t(22.16)=5.39) (Figure 30 E) to the controls (n=17). 
R26RFgfr2cV5/+; βactinCRE/+ embryos also display a fully penetrant microtia in the outer ear 
(n=6/6) (Figure 40 B; arrow). The calvaria are derived from the NCC and mesoderm (Yoshida 
et al., 2008). R26RFgfr2cV5/Fgfr2cV5 were subsequently crossed with Wnt1CRE/+ or Mesp1CRE/+ with 
their phenotypes corroborated with R26RFgfr2cV5/+; βactinCRE/+ to identify any ectopic effects 
generated by the ubiquitous CRE line. R26RFgfr2cV5/+; Wnt1CRE/+ embryos (n=6) yielded 
significant decrease in weight (Av.Δ6.72%; p=0.0028; t(9.23)=4.05) (Figure 30 E) while head 
length (Figure 30 D) and CRL were not significantly reduced (Figure 30 C). Moreover, ears 
were normal in R26RFgfr2cV5/+; Wnt1CRE/+. No significant reduction was seen in embryos upon 
Fgfr2c overexpression in the mesoderm using Mesp1CRE/+ (R26RFgfr2cV5/+; Mesp1CRE/+) (n=9) to 
the controls (n=4) (Figure 40 B-D). Altogether, ubiquitous and conditional Fgfr2c 
overexpression in the NCC lineage causes skeletal hypoplasia with overall stunted growth.  
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Figure 40: Gross phenotype of embryos with Fgfr2c overexpression. 
(A) Schematic of R26RFgfr2cV5/Fgfr2cV5 breeding schematic; (B) Microtia (n=6/6) (Arrow) observed in E18.5 R26RFgfr2cV5/+; βactinCRE/+ and not R26RFgfr2cV5/+; Wnt1CRE/+ 
and R26RFgfr2cV5/+; Mesp1CRE/+. Inserts are magnified images of the external ear; (C) Significant reduction in body length of R26RFgfr2cV5/+; βactinCRE/+ (p<0.0018; 
n=9); (D) Significant reduction in head length in R26RFgfr2cV5/+; βactinCRE/+ (p<0.0001; n=9); (E) Significant reduction in weight in R26RFgfr2cV5/+; βactinCRE/+ 
(p<0.0001, n=9) and R26RFgfr2cV5/+; Wnt1CRE/+ (p<0.0028, n=6). Statistics: Student’s t-test with Welch’s correction. Error bars depict SEM. Scale bar: 5mm. 
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4.2.2- Fgfr2c overexpression leads to frontal bone hypoplasia and patent 
suture  
 
Craniofacial structures were assessed at E18.5 and quantified for the surface area and 
length for mandibles. Figure 41 is a panel showing the craniofacial skeleton, and areas affected 
in the Fgfr2c overexpression mutants are highlighted in arrows and asterisks (Figure 41). 
Quantitative data were expressed as an average percentage change in the mutants relative to the 
controls (R26RFgfr2cV5/+) normalized to 100% (Av.Δ %) (Figure 42). Frontal bones of 
R26RFgfr2cV5/+; βactinCRE/+ were significantly smaller (Av.Δ11.4%; p<0.0001; t(22.98)=6.99; 
n=9) (Figure 41 E green arrow; Figure 42 A) along with other NCC derivatives such as nasal 
bones (Av.Δ12.90%; p<0.0001; t(22.06)=7.91; n=10) (Figure 41 D open arrow; Figure 42 C) 
and mandibles (Av.Δ5.77%; p<0.0001; t(20.64)=7.30; n=9) (Figure 41 D black arrow; Figure 
42 D). No significant reduction was observed in the mesoderm derived parietal bone (Figure 42 
B). Moreover, these mutants had notable hypoplasia of the tympanic ring in the middle ear 
(Figure 41 F orange arrow; n=9/10), overt cleft palate (Figure 41 F, asterisk; n=4/10) and a 
wider interfrontal suture (Figure 41 E line; n=9/9). Similarly, R26RFgfr2cV5/+; Wnt1CRE/+ embryos 
followed a similar trend with significant decreases in NCC derivatives: Frontal bone 
(Av.Δ9.12%; p=0.0131; t(6.89)=3.32; n=6) (Figure 41 H, green arrow; Figure 42 B), nasal 
bones (Av.Δ7.91%; p=0.0024; t(9.077)=4.17; n=6) (Figure 41 G, open arrow; Figure 42 C); 
and mandibles (Av.Δ3.71%) (p=0.0007; t(9.96)=4.82; n=6) (Figure 41 G black arrow; Figure 
42 D). Moreover, the clefting phenotype was heterogeneous in its severity: 1 out of 6 embryos 
exhibit an overt cleft (Figure 41 I, asterisk) whilst 3 out of 6 display palatal shelf hypoplasia 
(data not shown). No middle ear defects were present in this cohort of embryos (n=0/3). In 
R26RFgfr2cV5/+; Mesp1CRE/+, calvarial bone size appeared unchanged (Figure 41 K; Figure 42 D) 
and no defects were present in the ear or the palate (n=0/9) (Figure 41 L). In summary, Fgfr2c 
overexpression causes skeletal hypoplasia.  
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Figure 41 Craniofacial phenotypes of Fgfr2c overexpressing mutants at E18.5. 
Wholemount bone and cartilage histology of (A-C) Controls (R26RFgfr2cV5/+); (D-F) 
R26RFgfr2cV5/+; βactinCRE/+; (G-I) R26RFgfr2cV5/+; Wnt1CRE/+; (J-L) R26RFgfr2cV5/+; Mesp1CRE/+; 
R26RFgfr2cV5/+; βactinCRE/+ display smaller in frontal bones (E, green arrow; n=9), nasal bones (D, 
, open arrow; n=6) and mandibles (D, black arrow; n=9). Tympanic ring hypoplasia (F, orange 
arrow; n=9/10), wider frontal suture (E, line; n=9/9) and overt cleft palate (F, *; n=4/10) were 
also present; R26RFgfr2cV5/+; Wnt1CRE/+ (G-I) also exhibit smaller frontal bones (H, green arrow; 
n=6), nasal bones (G, open arrow; n=6) and mandibles (G, black arrow; n=6). Clefting 
phenotype is heterogenous (I, *; Overt: 1/5, palatal shelf hypoplasia: 3/5). No obvious 
phenotypic differences were observed in R26RFgfr2cV5/+; Mesp1CRE/+ (J-L; n=9). f=Frontal bone, 
p=Parietal bone; Scale bar: 1mm. 
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Figure 42 Craniofacial bones of the NCC lineage display hypoplasia. 
(A) R26RFgfr2cV5/+; βactinCRE/+ (p<0.0001; n=9) and R26RFgfr2cV5/+; Wnt1CRE/+ (p<0.0131; n=6) shows significant insufficienies of the frontal bone; (B) No phenotypic 
differences in the parietal were observed across all genotypes; (C) Significant reduction in size of the nasal bone in R26RFgfr2cV5/+; βactinCRE/+ (p<0.0001; n=9) and 
R26RFgfr2cV5/+; Wnt1CRE/+ (p<0.0024; n=6); (D) Significant reduction in the mandibles of R26RFgfr2cV5/+; βactinCRE/+ (p<0.0001; n=9) and R26RFgfr2cV5/+; Wnt1CRE/+ 
(p<0.0007; n=6). Data was normalized to the limb endogenous control and expressed as an average percentage change (%). Statistics: Student’s t-test with Welch’s 
correction; Error bars: SEM; Δ: Difference of means in respect to the control group. 
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4.2.3-Ubiquitous Fgfr2c overexpression does not result in coronal synostosis 
 
Coronal synostosis is a hallmark of Crouzon-Pfeiffer syndrome and can be observed in 
the Fgfr2cC342Y/+ mouse model as well as the Fgfr2c knockout (Eswarakumar et al., 2004, 
Eswarakumar et al., 2002). Strikingly, none of the aforementioned embryos with Fgfr2c 
overexpression show signs of coronal synostosis. While subtle changes in the Fgfr2cC342Y/+ 
coronal suture morphology are visible from E17.5, full fusion of frontal and parietal bones is not 
visible until three weeks after birth (Eswarakumar et al., 2004). Due to the presence of a cleft 
palate in R26RFgfr2cV5/+; βactinCRE/+ embryos, mice do not survive after birth, making it 
impossible to assess the postnatal synostosis phenotype. Ex vivo explant cultures were adopted 
to overcome this problem (Figure 43). Previous explant cultures in our lab showed that evidence 
for coronal synostosis could be achieved after one week of culture in Fgfr2cC342Y/+ E17.5 
calvaria. In R26RFgfr2cV5/+; βactinCRE/+ calvaria, coronal synostosis was not observed, while 
Fgfr2cC342Y/+ calvaria appears to be undergoing fusion compared to that of the control (n=7) and 
R26RFgfr2cV5/+; βactinCRE/+ (n=6) at T15 (Figure 43; Arrow). Upon culture within this time 
window, there was no evidence for coronal synostosis in R26RFgfr2cV5/+; βactinCRE/+ after 15 days 
of culture. Additionally, the effect of FGFR2 perturbation on osteoblast maturation at a pre-
synostosis embryonic stage (E16.5) was examined by analysing alkaline phosphatase (ALP) 
activity (Figure 44). Fgfr2cC342Y/+ sutures display increased suture overlap and ectopic ALP in 
the sutural mesenchyme (n=3) (Figure 44; arrow), whilst ALP activity in R26RFgfr2cV5/+; 
βactinCRE/+ appear less, and the frontal and parietal bones are spaced normally that resemble 
controls (n=3) (Figure 44; asterisk). This data implies that FGFR2c overexpression does not 
cause coronal craniosynostosis and does not mimic FGFR2 activation in the Fgfr2cC342Y/+ suture. 
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Figure 43: Absence of coronal synostosis in R26RFgfr2cV5/+; βactinCRE/+ ex vivo after culture. 
Suture overgrowth had increased after 15 days of culture. Fgfr2cC342Y/+ was used as a control for the assay to demonstrate the synostosis process, where suture fusion 
was apparent (arrowhead, insert). Insert is a magnified image of the representative coronal suture in the respective explants (*). Scale bar: 1mm. 
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Figure 44: Comparison of osteoblast activity in the coronal suture. 
Note the increased overgrowth in the osteogenic fronts of Fgfr2cC342Y/+ and ectopic expression of ALP in the suture mesenchyme (arrow). Notice the extension of the 
osteogenic fronts in R26RFgfr2cV5/+; βactinCRE/+appears underdeveloped to that of Fgfr2cC342Y/+ (*). N=3 analyzed for each genotype; F: Frontal Bone; P: Parietal bone; 
Insert is a magnified crop of the suture; Scale bar: 200um. 
 
 147 
4.3-Discussion 
 
FGFR2c signalling misregulation was examined through Fgfr2c overexpression and 
compared that to Fgfr2cC342Y/+. This section reports global Fgfr2c overexpression yielded 
craniofacial hypoplasia, microtia along with a clefting phenotype. Strikingly, this cohort of 
mutants did not develop coronal synostosis as opposed to Fgfr2cC342Y/+ and Fgfr2c-/- 
(Eswarakumar et al., 2004, Eswarakumar et al., 2002). Furthermore, growth restriction is a 
hallmark phenotype in the overexpression model. However, analysis of the appendicular 
skeleton (i.e. the limb, Figure 32) in R26RFgfr2cV5/+; βactinCRE/+, rules out intrauterine constriction 
as the probable cause for global growth restriction.    
 
4.3.1-Fgfr2c overexpression yields skeletal hypoplasia in the NCC lineage  
 
This study reports craniofacial hypoplasia of the NCs lineage upon conditional Fgfr2c 
overexpression. A previous morphometric analysis of the adult Fgfr2cC342Y reports smaller 
frontal and nasal bones, accompanied by a short anterior cranial base (Liu et al., 2013). 
Diminished calvarial bone volume was also reported in other mouse models for syndromic 
craniosynostosis most notably in Fgfr2S252W/+ and Fgfr3P244R/+ (Muenke syndrome) (Twigg et al., 
2009, Chen et al., 2003). This is consistent with our finding that hypoplasia of NC-derived 
bones is present in E18.5 R26RFgfr2cV5/+; βactinCRE/+ mice. However, Fgfr2cC342Y/+ embryos at 
E18.5 do not show similar signs of hypoplasia at this stage (See Figure 53). The nature of the 
C342Y mutation itself plays different roles in both early and late stages of development (Liu et 
al., 2013, Mansukhani et al., 2000). The C342Y mutation favours early osteoblast commitment 
but however during late stages of gestation, it inhibits bone mineralisation and facilitates 
cellular apoptosis (Liu et al., 2013, Mansukhani et al., 2000, Rice et al., 1999). Any phenotypic 
effects of remodelling in the frontal bone by the C342Y mutation will be too early to be 
perceived at this stage. Overall, the similarities observed between both mouse models suggest 
shortening of the frontal bone is a contributor to mid-facial hypoplasia. Despite similarities 
observed in the frontal bone of Fgfr2cC342Y/+ and R26RFgfr2cV5/+; βactinCRE/+, it is likely that the 
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derived phenotype is mechanistically different: R26RFgfr2cV5/+; βactinCRE/+ implies frontal 
hypoplasia is a result of early embryonic defect whereby in Fgfr2cC342Y/+ is a progressive 
disorder, as the phenotype elicited is only reported postnatally, suggesting bone remodelling 
could be the main player contributing to hypoplasia (Hatch et al., 2006, Eswarakumar et al., 
2004, Liu et al., 2013).   
The changes to the frontal bone architecture provide insights into coronal synostosis 
and NCC misregulation. NCs dominate the head mesenchyme during early embryogenesis, and 
require constant re-positioning with cells derived from the mesoderm to compartmentalise the 
calvaria (Yoshida et al., 2008, Jiang et al., 2000). As such, loss of cellular polarity in NCs has 
been reported to drive craniosynostosis via the ectopic expansion of the frontal bone (Tabler et 
al., 2016, Tabler et al., 2013, Merrill et al., 2006). Others have also investigated the skeletogenic 
potentials of NCCs, where it has greater response to FGF signalling and osteogenic potentials 
compared to the mesoderm derived osteoblasts (Li et al., 2010, Yu et al., 2005). Additionally, in 
humans, a set of genes involved in NCCs specification such as SNAI1 and ZIC2 have been 
identified to be involved in craniosynostosis, but their relationship with FGF signalling is less 
understood (Twigg et al., 2015, Twigg and Wilkie, 1999). Interestingly, SNAI1 is not required 
for NCC specification in the mouse, as SnaI1 conditional knockout only yielded defects to left-
right asymmetry (Murray and Gridley, 2006). In contrast, Zic2-/- yielded significant loss of pre- 
and post- migratory NCCs, and led to a reduction of NCCs populating the head mesenchyme at 
E9 (Elms et al., 2003). Zic2 is downstream of FGF8, as their expression patterns overlap in the 
midline of the telencephalon, and FGF8 overexpression can expand the expression domain of 
Zic2 (Okada et al., 2008). Similarly, whole genome sequencing in humans uncovered a GOF 
mutation in human ZIC1 as a novel player involved in coronal synostosis (Twigg et al., 2015). 
In Xenopus, Zic1 and Pax3 act synergistically in the surface ectoderm to commit cells towards a 
NCC fate. Co-injection of Zic1 and Pax3 mRNA into Xenopus animal caps lead to ectopic 
expression of NCC markers such as Foxd3 and Slug (Sato et al., 2005). The function of Pax3 
and Zic1 appear to integrate NCC inducing signals from multiple signalling pathways: FGFs 
functions upstream of Pax3 and Zic1 as an NCC inducer along with a low BMP and Wnt signal 
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(Sato et al., 2005, Mayor et al., 1997, LaBonne and Bronner-Fraser, 1998). These findings 
imply correct patterning of the head mesenchyme is essential for correct craniofacial 
development. As NCCs play substantial roles in craniofacial development, it is therefore not 
surprising when the elicited phenotype is a consequence of NCCs mis-specification by 
perturbed FGF signalling.  
3.3.2-Role of the mesoderm in craniosynostosis 
The lack of a coronal synostosis phenotype in R26RFgfr2cV5/+; βactinCRE/+ suggests that 
the mechanisms contributing towards disease pathogenesis are different to that of Fgfr2cC342Y/+. 
There is a speculation that there is insufficient ligand present endogenously to drive 
craniosynostosis. Coronal synostosis of Fgfr2cC342Y/+ stems from the mesoderm, and is a 
consequence of enhanced cellular activity during the early stages of suture morphogenesis, as 
this is apparent to the increased appositional growth and hyperplasia of the parietal bone (See 
Figure 53) (Eswarakumar et al., 2004). Furthermore, the enhanced ALP expression mimics 
those in the Apert mouse model (Fgfr2P253R/+), with increased overlap from the parietal bone 
(Wang et al., 2010). Interestingly, coronal synostosis is only sufficient to be developed in the 
mesoderm of a conditional mouse model for Apert syndrome (Fgfr2S252W/+; Mesp1CRE/+) 
(Holmes and Basilico, 2012, Holmes et al., 2009). Similar to the mechanisms of Fgfr2cC342Y/+, 
suture abolishment in the Apert mouse model is primarily a consequence of increased cellular 
apoptosis in the osteogenic fronts and suture mesenchyme during late gestation stages (Holmes 
and Basilico, 2012, Deckelbaum et al., 2012, Rice et al., 1999). However, the lack of parietal 
bone phenotype in R26RFgfr2cV5/+; βactinCRE/+ could hinder suture pathogenesis. Firstly, a 
possible explanation is the limited ligand availability in the mesoderm during early 
embryogenesis in vivo, and may require a higher response to FGF signalling to stimulate the 
osteogenic programme (Behr et al., 2010, Quarto et al., 2009). Secondly, the lack of a parietal 
bone phenotype in R26RFgfr2cV5/+; βactinCRE/+ could be due to the efficiency of transgene, where 
transcript upregulation was absent from the parietal bone (Figure 35 and Figure 36). 
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4.3.2-Osteogenic potential in R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2cC342Y/+   
Osteoblasts derived from both NCC lineage and mesoderm have different osteogenic 
potentials, where the former demonstrates greater sensitivity for osteoblast differentiation 
(Quarto et al., 2010, Liu et al., 2013). The difference is due to the molecular profile of these 
osteoblasts and their endogenous expression of Fgfr2c (Quarto et al., 2009). The frontal bone 
display higher endogenous expression of Fgfr2c during late gestation (E17.5), explaining 
greater sensitivities toward FGF ligands (Quarto et al., 2009). This would ultimately determine 
the threshold for osteoblast differentiation between the tissue types in respect to the endogenous 
FGF ligands available in vivo (Quarto et al., 2010, Hajihosseini and Heath, 2002). The parietal 
bone is known to have attenuated expression of Fgfr2c and its ligands to that of the frontal bone 
and therefore, the osteogenic potential is lessened relative to that of the frontal bone (Behr et al., 
2010). Another point to consider is that receptor overexpression and Fgfr2cC342Y/+ are 
functionally distinct as the former is ligand dependent, and ligand will act as a limiting factor 
for receptor activation.  
The dissimilar ALP activity in R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2cC342Y/+ observed at 
E16.5 signifies the ossification process between both mouse models is functionally distinct. In 
line with previous report, suture overgrowth was identified in Fgfr2cC342Y/+ and this chapter 
further reports ectopic ALP activity in the mesenchyme (Eswarakumar et al., 2004). The ectopic 
expression of ALP in the mesenchyme echoes those in the Apert mouse model (Fgfr2P253R/+), in 
parallel with increased osteoblast commitment in the osteogenic fronts (Wang et al., 2010). 
These reports suggest a common characteristic in GOF mutations, where these mutations drive 
ectopic osteoblast differentiation to aid premature suture closure. R26RFgfr2cV5/+; βactinCRE/+ 
displays insufficient osteoblast activity in the coronal suture at E16.5, implying insufficient 
osteoblastogenesis. FGFR2 signalling is a mitogenic factor and is involved in osteoblast 
maturation, the phenotype observed in R26RFgfr2cV5/+; βactinCRE/+ suggests delays to this program 
(Ornitz and Itoh, 2015). The master regulator for osteoblast differentiation- Runx2, is well 
characterised to be downstream of the FGF signalling pathway, and it would be ideal to 
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investigate whether there are aberrations to osteoblast commitment in these sutures, along with 
markers for early and late osteoblasts (Xiao et al., 2000, Miraoui et al., 2009).  
It should be noted that WT-FGFR2 overexpression and FGFR2-C342Y are functionally 
distinct as the former is ligand dependent, and receptor activation will depend on the 
concentration of ligand available endogenously. Thus, these receptors are mechanistically 
different, and would drive distinctive signalling interpretations and characteristic phenotypes 
(Miraoui et al., 2009). For instance, Miraoui et al., 2009 reports that PLCγ-PKC is a major 
effector of osteoblast differentiation in mutant FGFR2-S252W to that of the WT, where the 
latter signals through RAS-MAPK cascade. Here, ectopic osteoblast differentiation was only 
rescued through the knockdown of the PLC-PKC pathway in cells carrying the mutant receptor 
(Miraoui et al., 2009). Given by the data reported in vitro, the functional basis of the receptor is 
distinct from one another, where mutations affecting the receptor drive preferential bias towards 
an effector cascade. Of note, mutant FGFR2 has greater stimulatory effect for osteoblast 
commitment and mineralization than receptor overexpression, where the latter express latent 
cellular activity (Miraoui et al., 2009).  
Maintaining a correct balance of osteoblast proliferation-differentiation is critical for 
suture patency. R26RFgfr2cV5/+; βactinCRE/+ display similarities with the Fgfr2c-/- in the coronal 
suture through decreased appositional growth (Eswarakumar et al., 2002). Specifically, 
R26RFgfr2cV5/+; βactinCRE/+ have decreased osteoblast commitment in the coronal suture, whereas 
Fgfr2c-/- has decreased cell proliferation and bone formation in the suture (Eswarakumar et al., 
2002). However, R26RFgfr2cV5/+; βactinCRE/+ do not develop coronal synostosis that is in contrast 
to Fgfr2cC342Y/+ and Fgfr2c-/- (Eswarakumar et al., 2004, Eswarakumar et al., 2002). It is likely 
that the overall signalling disruption by receptor overexpression is less extreme than that of 
complete signalling removal (Fgfr2c-/-), and that of a constitutively active receptor 
(Fgfr2cC342Y/+). This is reflected by the subtlety of the phenotype under ubiquitous receptor 
overexpression. As mentioned, a speculation that causes the suture undergrowth between 
R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2c-/- could lie within aberrations to osteoblast differentiation 
and maturation program (Yu et al., 2003). Ultimately, there will be less osteoblast generated for 
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bone formation resulting in underdevelopment of the suture. In contrast, sustained expression of 
C342Y mutation is likely to result in an amplification of osteoblasts prior to late stage apoptosis 
that augment pre-mature suture closure in the osteogenic front (Eswarakumar et al., 2004, 
Holmes and Basilico, 2012, Holmes et al., 2009, Liu et al., 2013). The master regulator for 
osteoblast differentiation- Runx2, is well characterised to be downstream of the FGF signalling 
pathway, and future efforts should aim to delineate osteoblast commitment in the sutures at 
multiple stages (Xiao et al., 2000, Miraoui et al., 2009). 
Overall, the ALP data presented in this chapter provides a comparative analysis of 
osteoblast activity in the coronal suture between mouse models with coronal synostosis. The 
results presented are in line with previous literature, whereby receptor overexpression and 
FGFR2c-C342Y possess distinct signalling characteristics.  
4.3.3-FGFR2c overexpression results in a cleft palate phenotype 
 
Murine palatogenesis commences at E11.5 and is complete by E17.5. Morphogenesis of 
the murine palate occurs in three major morphogenic events concerning i) vertical outgrowth ii) 
shelf elevation iii) fusion (Bush and Jiang, 2012). The palate derives from the orofacial 
prominence, and initial shelf outgrowth occurs after the fusion of maxillary process and medial 
nasal processes. Of note, the facial prominence is predominantly populated by NCCs (Chai et 
al., 2000). During this time, the primary and secondary palates are formed as a result of paired 
outgrowth alongside the tongue. Palatal shelf elevation occurs between E14.5-E15.5 towards the 
midline, with fusion occurring along the seam after elevation (Bush and Jiang, 2012). Cleft 
palate is common pedigree to FGFR-related craniofacial syndromes, and a handful of genes 
have been implicated in syndromic cleft palate inclusive of FGFR2 (Stanier and Pauws, 2012, 
Bush and Jiang, 2012). However, the prevalence of cleft palate in human Crouzon syndrome is 
less than that in Apert patients, which may be owed to the mutation affecting both isoforms in 
the latter (Stanier and Pauws, 2012). Palatogenesis is a tightly regulated process of epithelial 
and mesenchymal interactions involving FGFR2: However, FGFR2b appears to be the major 
player involved in palatal shelf elevation as conditional knockout of this isoform or its 
corresponding ligand, Fgf10, led to an overt cleft. Fgfr2b expression is restricted to the 
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epithelium of the palatal shelf, whilst Fgf10 is confined to the mesenchyme. Cellular analysis of 
the palatal shelf also shed light on the nature of proliferative activity. Fgfr2b-/- has greater 
impact on decreasing proliferative activity in the epithelium than the mesenchyme (Rice et al., 
2004).  
The overt cleft phenotype in both R26RFgfr2cV5/+; βactinCRE/+ and R26RFgfr2cV5/+; Wnt1CRE/+ 
were not fully penetrant: 40% (4/10) of R26RFgfr2cV5/+; βactinCRE/+ embryos display an overt cleft 
whilst 20% (1/5) for R26RFgfr2cV5/+; Wnt1CRE/+. The partial penetrance may boil down to a 
multitude of factors. FGF ligands have multiple affinities towards specific isoforms (Zhang et 
al., 2006). Therefore, ectopic expression of the receptors may have interacted with endogenous 
ligands in the tissue, especially in the case of βactinCRE/+, the receptor would be expressed in the 
epithelium. Lineage tracing using the R26RmTmG/+; Wnt1CRE/+ indicates that the palatal shelf 
mesenchyme is derived from NCCs (Nik et al., 2016). The low penetrance of R26RFgfr2cV5/+; 
Wnt1CRE/+ indicates that the mesenchyme may play secondary roles in elevation to that of the 
epithelium, an expected location of Fgfr2b expression. Moreover, any phenotypic consequences 
elicited by receptor overexpression will be determined by the availability of FGF ligands in the 
tissue. Altogether, the low penetrance of overt cleft in Fgfr2c overexpression suggests that the 
IIIc isoform is less critical than that of the IIIb in shelf elevation. This is evident in the lack of 
phenotype in Fgfr2c-/-, which corresponded to the endogenous removal of the receptor in vivo 
(Eswarakumar et al., 2002). However, it is unclear as to the mechanism that leads towards a 
palatal phenotype in Fgfr2cC342Y/C342Y homozygote, but the similarities with R26RFgfr2cV5/+; 
βactinCRE/+ is perhaps a consequence of insufficient cells generated for shelf elevation (Peskett et 
al., 2017, Snyder-Warwick et al., 2010).     
4.3.4-Ear malformation in R26RFgfr2cV5/+; βactinCRE/+ is an ectopic effect  
 
There are no reports of external ear defects related to human Crouzon syndrome or in 
Fgfr2cC342Y/+. However, isolated cases were reported in humans, such as a mutation responsible 
for Jackson-Weiss syndrome (FGFR2-C342R), which results in hearing loss and ear canal 
hypoplasia (Park et al., 1995). This study describes R26RFgfr2cV5/+; βactinCRE/+ embryos have 
microtia with hypoplasia of the tympanic ring.  
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Interestingly, the microtia phenotype is reflective of lacrimo-auriculo-dento-digital (LADD) 
syndrome (Rohmann et al., 2006). The biochemical basis for LADD syndrome remains unclear, 
but appears to be related to FGF signalling via haploinsufficiencies of FGFR2, FGFR3 and 
FGF10 (Rohmann et al., 2006). In reference to FGFR2, a number of mutations identified in 
LADD syndrome affect the intracellular kinase domain of the receptor (Rohmann et al., 2006). 
Experimentally, mutant FGF10 has reduced binding affinity for FGFR2b and was increasingly 
susceptible to proteolytic degradation compared to WT-FGF10 (Shams et al., 2007).  
However, the external ear phenotype observed in the R26RFgfr2cV5/+; βactinCRE/+ is a likely 
consequence of ectopic expression of FGFR2c in the presence of ligands with high affinities for 
FGFR2b. The lack of ear external phenotype observed in mouse models of Fgfr2c suggests this 
(Eswarakumar et al., 2002, Eswarakumar et al., 2004). Moreover, Fgfr2b-/- leads to inner ear 
dysgenesis, owing to mispatterning of the otic vesicle (De Moerlooze et al., 2000, Pirvola et al., 
2000). Specific features affected by the IIIb knockout include hypoplastic otic vesicle, with 
dysmorphology of the cochlea and vestibular apparatus during late gestation. Furthermore, 
cochleovestibular neurons fail to form and under development of the sensory epithelium 
(Pirvola et al., 2000). Despite no obvious visible defect in the R26RFgfr2cV5/+; βactinCRE/+ cochlea 
during whole mount skeleton stains, functional aberrations to the inner ear cannot be ruled out 
given the prominent role of FGFs in ear development. Of note, a clear hypoplastic tympanic 
ring was seen in the R26RFgfr2cV5/+; βactinCRE/+ that phenocopies to that of Fgfr2c-/- at E18.5, 
implying a role for FGFR2c in ossification of the auditory bulla (Eswarakumar et al., 2002).    
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4.3.5-Experimental considerations  
 
Perhaps the most difficult aspect of the phenotypic analysis surrounds the subtlety of 
the phenotype. This is likely due to the phenotype being dependent on the presence of the 
endogenous ligand. On the quantitative front, post harvest analysis of E18.5 embryos was 
performed with an electronic caliper, which may not be able to detect any minute phenotypic 
changes. It was noted for R26RFgfr2cV5/+; Wnt1CRE/+ that there was no significant decrease of 
embryo lengths. In particular, head size reduction was only observed using FIJI software that 
provided sufficient resolution for analysis. The stunted growth restriction in R26RFgfr2cV5/+; 
βactinCRE/+ also promoted the investigation into whether this was a secondary defect of 
intrauterine constriction. The limb was previously reported to be independent of alterations to 
FGFR2c signalling in Fgfr2cC342Y/+ (Eswarakumar et al., 2002, Eswarakumar et al., 2004). This 
serves as an internal control to investigate global growth restriction. It was determined in Figure 
32 that there was no difference between appendage skeleton length in the mutants, ruling out the 
possibility of intrauterine constraints. However, it is also ideal to perform phenotypic analysis 
of placentas in adjunct to limb length in the future. Moreover, due to the lack of phenotypic 
variations in the limb, it serves a robust constant for data transformation during the 
morphometric analysis.  
Evidence for craniosynostosis development ex vivo can be observed after 15 days in 
culture previously in this lab. It should be noted that calvarial explant cultures were not as 
robust as in vitro cultures. An example of this can be seen in Fgfr2cC342Y/+ where a complete 
fusion of the suture was not observed. Therefore, Fgfr2cC342Y/+ was cultured alongside 
R26RFgfr2cV5/+; βactinCRE/+ calvaria where possible to serve as an experimental control. Two 
factors can account for the overall calvarial growth in i) the extent of the bone overlap and ii) 
the pH indicator in the culture media. Should the calvaria grow over time, the extent of the 
overlap would be more substantial than that before culture. In the latter case, the media turns 
yellow to indicate metabolic activity. A second strategy that could be used to bypass the 
perilethality in R26RFgfr2cV5/+; βactinCRE/+ is a tamoxifen inducible CRE line. Ideally, tamoxifen 
would be administered after palatal closure at around E15.5 to induce Fgfr2c overexpression. 
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This is a plausible strategy to overcome the perilethality but ultimately, it depends on whether 
the research question is aimed at addressing suture formation or its patency. In the latter 
circumstance, along with the progressive nature of craniosynostosis, then using a tamoxifen 
inducible CRE line is desirable. However, suture formation commences between E12.5-E13.5 
and using an inducible CRE would not address questions concerning early embryogenesis in 
this experiment (Iseki et al., 1997, Deckelbaum et al., 2012).  
4.3.6-Future directions 
 
For the duration of this project, efforts were focused upon the frontal and parietal bones 
of the calvaria. The next stage of the morphometric analysis should be migrated onto micro-CT 
and compare the phenotype to that of Fgfr2cC342Y/+. Data obtained from micro-CT will have 
sufficient resolution to perform further analysis that concerns volume and bone density. The 
latter case is of particular interest as osteoblasts derived from the NCCs and mesoderm differs 
in their mineralisation potentials (Senarath-Yapa et al., 2013). Therefore, it would be 
informative to appreciate the overall porosity of R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2cC342Y/+ to 
compare the ossification ratios. In regards to the calvarial explants, it would be interesting to 
observe whether craniosynostosis can be induced through FGF bead implants at the suture, 
given the increased number of receptors present through overexpression. This overall 
experiment would be sufficient to show that there is insufficient ligand present to drive suture 
closure in R26RFgfr2cV5/+; βactinCRE/+.     
Abnormal cellular activity is a consequence of signalling misregulation. A handful of 
studies examined the cellular proliferation directly in the coronal sutures of mouse models for 
syndromic craniosynostosis (Eswarakumar et al., 2004, Wang et al., 2005b, Holmes and 
Basilico, 2012). It is important to note that proliferative assays label cells at multiple stages of 
the cell cycle: markers such as Ki67 are abundant throughout the cell cycle, whereas BrdU only 
labels the S-phase (Iatropoulos and Williams, 1996). Future studies should aim to perform co-
labelling of markers to fully clarify the ratio of cells undergoing proliferation and 
differentiation. For example, Ki67/EdU co-labelling can be used to understand the ratio of cells 
exiting the cell cycle for osteoblast differentiation in the suture, with an aim to address whether 
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there are aberrations to terminal differentiation (Haston et al., 2017). Therefore, the overall aim 
of this experiment is to improve clarity for cellular proliferation, and to fully determine whether 
is any disruption to the overall osteoblast differentiation program.  
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Chapter 5 
Results (Part III) 
Comparison of the FGFR2 
signalling pathway in Fgfr2cC342Y/+ 
and  
R26RFgfr2cV5/+; βactinCRE/+ mice 
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5.1-Introduction 
 
R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2cC342Y/+ result in distinct phenotypes. It is well 
known that constitutive active FGFR2 leads to upregulation of the RAS-MAPK pathway, and 
that pERK serves as a readout for FGF signalling misregulation (Pfaff et al., 2016). Inspection 
of the RAS-MAPK cascade is mainly performed using immunoblots, with the spatial 
localization of pERK expressing cells remaining unclear in vivo. A single study shows the 
expression of pERK in the coronal suture but without sufficient clarity (Deckelbaum et al., 
2005). In the current study, the phospho-epitope was found to be preserved in vivo, and pERK 
signal was amplified with streptavidin conjugates. Furthermore, this chapter demonstrates 
pERK is co-expressed in osteoblasts marked by the expression osteopontin. As FGFR2 plays 
multiple roles in proliferation, differentiation and survival, visualizing pERK activity allows the 
inference of biochemical activity during suture morphogenesis. Further to this, this study 
examined the expression of multiple FGFR2 RAS-MAPK target genes (Spry2, Spry4, Etv5) 
using ISH and RT-qPCR. 
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5.2-Results 
 
5.2.1-FGFR2c overexpression and FGFR2c-C342Y mutation lead towards 
an overactive RAS-MAPK pathway in vivo and in vitro 
 
To assess whether Fgfr2c overexpression leads to a similar activation of the RAS-
MAPK pathway, the levels of pERK was investigated in vivo and in vitro. In this respect, 
expression of pERK was visualised in E16.5 coronal sutures using immunohistochemistry, at a 
stage where the sutures were morphologically similar (Control: n=4; Fgfr2cC342Y/+: n=4; 
R26RFgfr2cV5/+; βactinCRE/+: n=3) (Figure 45). pERK is expressed all along the perimeter of the 
frontal and parietal bones and upon closer inspection, cells positive for pERK co-express 
osteopontin, indicative of mature osteoblasts (Figure 45 A). Interestingly, both mutants show an 
increase of pERK expression as compared to controls (Figure 45 A). Both Fgfr2cC342Y/+ and 
R26RFgfr2cV5/+; βactinCRE/+ mutants display increased pERK expression at the osteogenic fronts of 
the bones flanking the suture (compare Figure 45 A and Figure 45). pERK activity was also 
modelled in vitro using HEK293Ts (n=4 independent transfections) (Figure 45 B). pERK 1 and 
2 were activated upon transfection of pFGFR2cV5 (‘IIIc-V5’) (encoding the wild-type 
FGFR2-IIIc isoform) and pFGFR2c-C342Y-V5 (‘C342Y-V5’) (encoding the mutated receptor) 
relative to mock transfected cells. Further, there was an increase of ERK1 and ERK2 
phosphorylation in both instances. Quantification of the blots using densitometry reveals 
significant upregulation of pERK in both FGFR2cV5 transfected conditions (Figure 45 C). 
Specifically, there was significantly more pERK activity in the C342Y-V5 (p<0.0001) and IIIc-
V5 (p=0.0101) transfected cells relative to the pcDNA control cells as expected from the 
Western blot results. Cells transfected with C342Y-V5 has an increased pERK output by 8.1 
units than that of WT-V5 transfected group (p=0.0005) likely due to the constitutive activation 
of the mutant receptor. 
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Figure 45: Upregulation of pERK in vivo and in vitro in R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2cC342Y/+. 
(A) pERK (red) coincides with the expression of osteopontin along the periphery of the bone and the osteogenic front at E16.5, marking mature osteoblasts. Both 
R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2cC342Y/+ have upregulated pERK (red) in vivo as compared to controls. The invagination in Fgfr2cC342Y/+ was an artefact of tissue 
processing (B) Western blot to demonstrate upregulation of pERK upon cellular transfection of pFgfr2IIIc-V5 (IIIc-V5) and pFgfr2c-C342Y-V5 (C342Y-V5) 
plasmids in HEK293Ts. (C) Relative pERK:tERK ratio quantified by densitometry of transfected HEK293T cells. F: Frontal Bone; P: Parietal Bone; White arrow 
marks the location of the coronal suture; Insert is a magnified cropped of the coronal suture; Statistics: Oneway ANOVA with Tukey’s posthoc. Error bars: SEM. 
Scale Bar: 200um.   
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Figure 46: Expression of pERK in the osteogenic front is also present in R26RFgfr2cV5/+; βactinCRE/+. 
pERK expression is also detected in the osteogenic fronts of control and R26RFgfr2cV5/+; βactinCRE/+. White arrowhead depicts the location of the coronal suture. F: 
Frontal bone; P: Parietal bone. Scale bar: 200um.
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5.2.3-Expression of SPRY2, SPRY4, ETV5 in HEK293T cells 
In addition to relative biochemical activity, HEK293T cells were transfected with IIIc-
V5 and C342Y-V5 to model the downstream activity of FGF signalling in vitro, and to compare 
the differences between receptor overexpression and the C342Y mutation. In general, there was 
an increase of readout transcript upon cellular transfection of IIIc-V5 and C342Y-V5 plasmids 
into HEK293Ts (n=4). Expression of FGFR2c was confirmed using assays for the Fgfr2c gene 
and a negative control of Fgfr2b (Figure 47). The raw data for the transfected plates are 
represented in Figure 47. There was a significant increase between pcDNA and C342Y-V5 
transfected conditions in both SPRY4 (Oneway ANOVA: F(2,9)=9.85, p=0.005; Tukey’s: 
p=0.004) and ETV5 (Oneway ANOVA: F(2,9)=9.197, p=0.007; Tukey’s: p=0.005) expression 
(Figure 48 B and C). Expression was increased by an average of 37.8 units for SPRY4 and 64.0 
units for ETV5 respectively (Figure 48 B and C). Transcript increase lies close to statistical 
significance pcDNA and IIIc-V5 conditions (SPRY4: Tukey’s: p=0.076; ETV5: Tukey’s: 
p=0.084) (Figure 48 B and C). No differences were detected between the IIIc-V5 and C342Y-
V5 transfected groups for all readout assays. In regards to SPRY2, there were no expression 
changes between all transfected conditions (Figure 48 A). Moreover, the average RQ value was 
low upon all conditions suggesting the absence of SPRY2 regulation in HEK293T cells. 
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Figure 47: Expression validation of cells transfected with either IIIc-V5 or C342Y-V5 
plasmids. 
There is a marked increase of Fgfr2c (IIIc) transcripts but not Fgfr2b (IIIb), confirming the 
success of the transfection. 
 
 
 
Figure 48: SPRY2, SPRY4 and ETV5 expression in transfected cells. 
(A) Low RQ values between all transfected conditions suggest the absence of SPRY2 regulation 
in HEK293Ts; (B) Significant increase in SPRY4 transcript between C342Y-V5 and pcDNA 
conditions (p=0.004; n=4); (C) Significant increase in ETV5 transcript between C342Y-V5 and 
pcDNA conditions (p=0.005; n=4). Statistics: Oneway ANOVA with Tukey’s posthoc test. 
Error bars depict SEM. 
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5.2.4-No ectopic expression of FGFR2c signalling in E16.5 coronal sutures  
Next, ISH was performed in sections to determine the expression of FGFR2 signalling 
target genes in vivo at E16.5 (Figure 49). Spry2 (A-C), Spry4 (D-F) and Etv5 (G-I) are direct 
transcription targets of FGFR2c signalling and the RAS-MAPK cascade (Snyder-Warwick et 
al., 2010, Ornitz and Itoh, 2015). Due to the difficulty of preserving suture integrity in frozen 
sections, several biological replicates were performed using paraffin wax (Figure 49 C & F). 
Spry2, Spry4 and Etv5 were expressed along the frontal and parietal bones without any ectopic 
activity detected in the coronal suture of both R26RFgfr2cV5/+; βactinCRE/+ (Spry2: n=3; Spry4: 
n=3; Etv5: n=5) and Fgfr2cC342Y/+ (Spry2: n=4; Spry4: n=3; Etv5: n=3) to the controls (Spry2: 
n=5; Spry4: n=4; Etv5: n=3). Additionally, Spry2 and Spry4 expression were also detected in 
the epidermis of the skin. While both models show an activated RAS-MAPK pathway in the 
suture, the fact that only Fgfr2cC342Y/+ activation results in craniosynostosis suggest that 
FGFR2c overexpression cascade activation is functionally distinct to that of the mutant 
receptor.
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Figure 49 No ectopic expression of FGFR2 signalling readouts in vivo. (A-C) ISH of Spry2; 
(D-F) Spry4; (G-I) Etv5. 
Inserts are high-resolution crop outs of the coronal suture (*). ISH was performed in paraffin 
sections in (C) and (F). F: Frontal bone, P: Parietal bone. Scale bar: 200um.
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5.3-Discussion 
 
5.3.1-Biochemical similarities between R26RFgfr2cV5/+; βactinCRE/+ and 
Fgfr2cC342Y/+ 
 
FGFR2 signalling activation plays multiple roles in cellular proliferation, 
differentiation, and apoptosis (Miraoui et al., 2009, Mansukhani et al., 2000). The master 
regulator for osteoblast differentiation- Runx2, is well characterised to be downstream of the 
FGF signalling pathway (Xiao et al., 2000, Miraoui et al., 2009), and that exposures to FGF 
ligands are sufficient to drive osteoblast gene expression (Iseki et al., 1997, Miraoui et al., 2009, 
Xiao et al., 2000, Kim et al., 2003a). Interestingly, pERK cellular expression was not solely 
confined to the osteogenic front, but also along the outer edges of the bone. In general, both 
R26RFgfr2cV5/+; βactinCRE/+ and Fgfr2cC342Y/+ exhibited upregulated pERK readouts. A plausible 
explanation for the phenotypic differences observed in this study, albeit with similarities in 
RAS-MAPK signalling properties, is that activating mutations to FGFR2 elicit dissimilar 
cascade activation to that of WT-FGFR2 (Kim et al., 2003a, Miraoui et al., 2009). Miraoui et 
al., 2009 compared the differences in cascade activation and concluded that Apert-FGFR2-
S252W transactivates the PLCγ-PKC pathway to drive ectopic osteoblast differentiation, 
whereas WT-FGFR2 predominantly signals through the RAS-MAPK in MSCs (Miraoui et al., 
2009). Eventually, this misregulation by mutant FGFR2 drives elevated matrix mineralisation 
and ALP activity (Miraoui et al., 2009). Other growth factor pathways such as PDGFR also 
behave similarly, where increasing levels of PDGFR signalling is sufficient to drive ectopic 
osteogenesis and complex craniosynostosis via PLCγ-PKC pathway in vivo (Moenning et al., 
2009). The skeletal hypoplasia, coronal suture patency and increased porosity observed in 
R26RFgfr2cV5/+; βactinCRE/+ suggests delayed osteoblast maturation, but it is unknown how Fgfr2c 
overexpression interrupts this harmony. As FGFR2 is critical for cell-renewal, one speculation 
is shifting the balance from osteoblast differentiation to proliferation in early development. This 
hypothesis is supported by in vitro cultures of MSCs, as exposure to FGF2 promotes stemness 
in the presence of osteoblast differentiation media (Baddoo et al., 2003).  
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The upregulated pERK in R26RFgfr2cV5/+; βactinCRE/+ can also be explained by sensitization of 
signalling activity due to the over abundance of FGFR2c. In this respect, the ratio between 
receptor to endogenous FGF ligand is greatly bolstered. An example of signalling sensitization 
can be linked to pain and nociception, as glutamate receptors are upregulated to enable neurons 
to be hyperexcitable (Harris et al., 1996). This can be tested in vitro, by comparing the ratios 
between ligands tagged with radioisotope to surface receptors. Given the nature that ectopic 
osteogenesis can be achieved through constant exposure of FGF ligands in vitro and in vivo, the 
lack of coronal synostosis in R26RFgfr2cV5/+; βactinCRE/+ is likely to be insufficient ligand present 
endogenously to drive the osteogenic program (Iseki et al., 1997, Sarkar et al., 2001). This 
property can be related to the decreased appositional growth and osteoblast activity observed in 
the sutures of R26RFgfr2cV5/+; βactinCRE/+ (Figure 44).    
5.3.2-Expression analysis of SPRY2, SPRY4 and ETV5 in vitro  
 
Spry2, Spry4 and Etv5 were previously described as direct readouts of the RAS-MAPK 
pathway (Snyder-Warwick et al., 2010, Pratilas et al., 2009). There are four Sprouty proteins 
identified in both mouse and humans, acting to suppress RTK signalling at multiple levels 
(Ornitz and Itoh, 2015). SPRY2 protein suppresses FGF signalling early on in the cascade 
through Grb2-Sos intervention, to prevent recruitment of FRS2, whilst SPRY4 acts downstream 
to inhibit Raf activation (Hanafusa et al., 2002, Sasaki et al., 2003). Together with ETV4, ETV5 
constitute to the Erm family of proteins responsible for downstream FGFR2 gene expression 
(Firnberg and Neubuser, 2002, Chotteau-Lelievre et al., 2001). As these are driven directly by 
FGF signalling, they would provide a good marker for potential downstream signalling 
aberrations.  
Cellular transfection of HEK293Ts was adopted to model the overall downstream 
activity of the RAS-MAPK pathway. Interestingly, cellular transfection did not affect SPRY2 
expression, suggesting it is not directly downstream of FGFR2c signalling in this cell line. 
However, SPRY4 and ETV5 did display transcript changes post transfection, indicating the 
presence of SPRY4 and ETV5 in HEK293Ts. The lack of statistical significance between 
pcDNA and IIIc-V5 conditions is related to the nature of the statistical test. The low sample 
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population and unequal variance (Levene’s test, p=0.056 for SPRY4 and p=0.064 for ETV5) 
between test groups would have influenced the outcome of Oneway ANOVA and Tukey’s post 
hoc tests leading towards Type II error (‘False negative’) (e.g. pcDNA and IIIc-V5 conditions). 
Overall, the outcome of this experiment is a proof of concept that increased downstream readout 
activity is corresponded with Fgfr2c overexpression and those carrying GOF mutations i.e. 
Fgfr2cC342Y/+.   
5.3.3-Similar expression patterns of FGFR2 signalling readouts in the 
coronal suture 
 
FGF signalling readouts were not ectopically expressed in either Fgfr2cC342Y/+ and 
R26RFgfr2cV5/+; βactinCRE/+. On the one hand, ISH is a qualitative assay and may not provide 
sufficient resolution to detect subtle changes at transcript levels. However, this experiment did 
provide information to show that FGF signalling is confined within a specific spatial domain, 
along the membranous bones and the osteogenic front. This is expected as the expression of 
readouts coincides with periosteoblasts-cells known to be expressing Fgfr2 (Deckelbaum et al., 
2005, Johnson et al., 2000). However, owing to the nature of ubiquitous overexpression and the 
morphogenic nature of FGFs, ectopic expression is to be expected in the R26RFgfr2cV5/+; 
βactinCRE/+ suture mesenchyme. The lack of misexpression in these overexpressing mutants 
suggests FGFs act locally, perhaps confined to the osteogenic front, as opposed to long-range 
cues within the suture to govern osteogenesis. For example, Fgf18 and Fgf20 transcripts are 
detected in the osteogenic fronts of the coronal suture, coinciding with those genes involved in 
FGFR2 signalling, pointing towards potential autocrine interactions (Hajihosseini and Heath, 
2002, Ornitz and Itoh, 2015).  
As a high concentration of FGFs is required for osteogenesis and bone mineralisation, 
the spatial confinement of FGF signalling suggests craniosynostosis is a result of ectopic bone 
formation from the osteogenic fronts (Sarkar et al., 2001). The abundance of FGFs from the 
leading edge of the osteogenic front would have recruited additional MSCs from the suture 
mesenchyme to differentiate into this lineage. Therefore, the overall pool of MSCs in the 
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mesenchyme would be depleted over the course of development leading to premature suture 
abolishment.  
5.3.4-Future direction 
In vitro: A substantial number of experiments in this project are in vivo orientated. 
However, future work should be focused on in vitro assays as they offer a robust platform to 
dissect out molecular and cellular events. For instance, the expression analysis experiment using 
HEK293T cells is a proof of concept that qualitative (ISH) data can be backed up with 
quantitative approaches. HEK293T cells are however, immortalized and therefore not the 
optimal cell line to perform expression analysis, despite its advantage in modelling biochemical 
cascades. Therefore, using a more suited cell line such as MC3T3s, or through the generation of 
primary cultures from the calvaria of Fgfr2cC342Y/+ and R26RFgfr2cV5/+; βactinCRE/+, would help to 
ensure the relevance of future in vitro experiments. There is a protocol available to generate 
primary cultures from the calvaria (Appendix 10), which involves treating the tissue with a 
series of protease. However, the protocol does not account for lineage specific osteoblasts, and 
methods must minimize lineage mixing as they have different osteogenic potentials (Senarath-
Yapa et al., 2013, Quarto et al., 2010). This could be achieved by using flow cytometry against 
relevant markers specific to lineage specific osteoblasts. Future experiments could include the 
molecular basis for osteoblast differentiation and maturation. This is achieved by performing 
expression analysis on markers such as Runx2 and Osterix, or those involved in late stage 
differentiation such as Sclerostin or Osteocalcin. Next, cells from primary cultures could be 
assessed for the rate of ossification, which can be achieved through ALP and alizarin red assays. 
In vivo: The in vivo experiments should aim to backup findings from the in vitro 
environment, and seek to understand the cellular events in the suture. For instance, these 
experiments would be accomplished by IHC, and should focus on the differences of osteoblast 
commitment and maturation between the mouse models. Moreover, it would be important to 
demonstrate the co-expression of FGFR2c and pERK in the suture, which shows the 
contribution of FGFR2c in suture morphogenesis. However, this was not achieved owing to the 
lack of a robust FGFR2c antibody. One of the feedback regulators not investigated in this study 
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is Dusp6, a direct inhibitor of activated ERK. Coronal synostosis is a hallmark of Dusp6-/-, 
implying signalling augmentation in this pathology (Li et al., 2007). In particular, there is no 
literature that presents the activity of Dusp6 in the suture. As negative feedback occurs at the 
protein level, it would be crucial to compare the active Dusp6 (p-Dusp6) expression in both 
mouse models.  
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Chapter 6 
Results (Part IV) 
Exploring RAS-MAPK 
pathway misregulation in vivo
 173 
6.1-Introduction 
 
The results of this chapter are divided into two sections: 
 Part A explores the impact of ubiquitous Fgfr2c overexpression on Fgfr2cC342Y/+. This is 
because as Fgfr2c overexpression does not cause coronal synostosis, this experiment 
questions whether the addition of this allele to the Fgfr2cC342Y/+ would modify the 
craniofacial phenotype.  
 Part B focuses on over-activation of the RAS-MAPK pathway using the KRasLSL-G12D/+ 
(Tuveson et al., 2004). The aim of oncogenic KRas is to examine the role of RAS-
MAPK signalling in craniofacial development by minimizing cross talks at the level of 
the receptor.  
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6.2-Results: Part A  
6.2.1-Gross phenotype of R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ 
To assess the impact of the overexpression allele on Fgfr2cC342Y/+, a double mutant 
carrying both the Fgfr2c-C342Y and Fgfr2c overexpression allele was generated 
(R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+). The most apparent external anomaly resulting from 
Fgfr2c overexpression alone was microtia (Figure 50; arrow). This was exacerbated in double 
mutants where anotia was present in 90% of mice (Figure 50; dotted box) (n=10/11). External 
ear development was normal in Fgfr2cC324Y/+ mutants (n=15). As expected, R26RFgfr2cV5/+; 
βactinCRE/+ (n=11) displayed shortened head length to controls (Oneway ANOVA with Tukey’s 
post-hoc test: p=0.018; Δ3.43) (Figure 51A). This significant decrease was also present in 
R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ embryos (n=8; p=0.001; Δ5.24). Head length remained 
normal in Fgfr2cC342Y/+ (n=10) in respect to the controls, but were significantly larger than that 
of R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ (p<0.001; Δ6.50). Embryos carrying the 
overexpression allele were significantly lighter in weight: R26RFgfr2cV5/+;βactinCRE/+; 
Fgfr2cC342Y/+ displayed significant weight attenuation in respect to the controls (p=0.009; 
Δ10.14) and Fgfr2cC342Y/+ (p=0.009; Δ10.14) (Figure 51 C). As expected, R26RFgfr2cV5/+; 
βactinCRE/+ displayed significant reduction in weight to the control group (p=0.001; Δ9.86), in 
addition to Fgfr2cC342Y/+ (p=0.028; Δ8.10). No significant difference was observed in crown-
rump length between all genotypes (Figure 51 B). 
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Figure 50 Gross phenotype of R26RFgfr2cV5/+; βactinCRE/+;Fgfr2cC342Y/+. 
R26RFgfr2cV5/+; βactinCRE/+;Fgfr2cC342Y/+ embryos displays anotia (dotted box) compared to anotia seen in R26RFgfr2cV5/+; βactinCRE/+. Inserts are cropped images of the 
external ear. Scale bar: 5mm. 
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  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51: Post harvest quantification of R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+.  
(A) The head length of R26RFgfr2cV5/+; βactinCRE/+; Fgfr2cC342Y/+ were significantly smaller than 
that of Fgfr2cC342Y/+ and control groups (*); (B) CRL was unchanged in R26RFgfr2cV5/+; 
βactinCRE/+; Fgfr2cC342Y/+ relative to the controls; (C) R26RFgfr2cV5/+; βactinCRE/+; Fgfr2cC342Y/+ 
were significantly lighter than the controls (*) and Fgfr2cC342Y/+. Statistics: Oneway ANOVA 
with Tukey’s posthoc test. Error bars depict SEM; Δ: Difference of means between the 
genotypes. 
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6.2.2-Introduction of the Fgfr2c overexpression allele into Fgfr2cC342Y/+ 
partially rescues the Crouzon phenotype 
 
As FGFR2c overexpression does not cause suture synostosis, the question remains 
whether the addition of this allele to the Fgfr2cC342Y/+ mice would change the craniofacial 
phenotype. To assess the impact of the overexpression allele on Fgfr2cC342Y/+, morphometric 
analysis on the calvaria was carried out as previously described in Section 2.8. Examination of 
the craniofacial skeleton reveal partial rescue of the Crouzon phenotype (Figure 52): An 
enlarged interfrontal wormian bone is characteristic of Fgfr2cC342Y/+ (n=6/7) (Figure 52 E 
arrowhead), and these were generally smaller in R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ (n=4/5), 
combined with an enlarged widening of the posterior interfrontal suture (Figure 52; E and H 
line). However, an overt palate and tympanic hypoplasia were still present in these mutants 
(n=7/7 analysed) (Figure 52 F and I; arrowhead and * respectively).  
6.2.3-R26RFgfr2cV5/+; βactinCRE/+; Fgfr2cC342Y/+ yields hypoplasia of the 
calvarial bones  
 
Morphometric analyses of calvarial bones show that 
R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ frontal bones were smaller than that of the control 
(Δ11.86; p<0.001; Control: n=8, R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+: n=6) (Figure 53 A). 
Significant size reduction was also present when R26RFgfr2cV5/+; βactinCRE/+ frontal bones were 
compared to Fgfr2cC342Y/+ (Δ9.19%; p=0.001; n=6). Also, there was a significant decrease in 
frontal bone size between both R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ (Δ14.80%; p<0.001; n=6) 
when compared with Fgfr2cC342Y/+ (n=10). Morphometric analysis of the parietal bones indicates 
significant increase in the parietal bone of Fgfr2cC342Y/+ (n=10) as compared to all other 
genotypes (Control: Δ6.54%, p=0.001, n=8; R26RFgfr2cV5/+; βactinCRE/+: Δ6.08%, p=0.006, n=6; 
R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+: Δ5.44%, p=0.016, n=6) (Figure 53 B). Other derivatives 
of the NCC lineage were also analysed such as the nasal bone and mandible (Figure 53 C and 
D). The nasal bone were smaller in the R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ (Δ18.38%; 
p=0.033; n=3) to that of Fgfr2cC342Y/+ (n=5) (Figure 53 C). Inspection of the mandible revealed 
that embryos carrying the Fgfr2c overexpression allele exhibit micronagthia: 
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R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ (n=7) has smaller mandibles when compared to that of 
the control (Δ9.50%; p<0.001) and Fgfr2cC342Y/+ groups (Δ7.34%; p=0.013; n=9) (Figure 53 D). 
The same applies to R26RFgfr2cV5/+; βactinCRE/+ when compared to the control group (Δ4.75%; 
p=0.002; n=11). Altogether, these results suggest the overexpression allele has exerted influence 
over Fgfr2cC342Y/+, with potential rescue of the parietal bone. 
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Figure 52: Fgfr2c overexpression partially rescues the Fgfr2cC342Y/+ phenotype.  
Control embryos are illustrated in (A-C); Fgfr2cC342Y/+ (D-F) and R26RFgfr2cV5/+; βactinCRE/+;Fgfr2cC342Y/+ (G-I); The wormian bone in R26RFgfr2cV5/+; 
βactinCRE/+;Fgfr2cC342Y/+ appears comparatively smaller than in Fgfr2cC342Y/+ mice (n=4/5; compare E and H arrowhead), and a wider frontal posterior interfrontal 
suture (compare E and H line). Other features include severe tympanic ring hypoplasia (I, arrow) and cleft palate (I, *); Scale bar 1mm. 
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Figure 53: Morphometric analysis of the calvaria.  
(A) R26RFgfr2cV5/+; βactinCRE/+;Fgfr2cC342Y/+ has frontal bone hypoplasia, and is significantly smaller than of the control groups (*) and Fgfr2cC342Y/+; (B) Fgfr2cC342Y/+ 
display parietal bone hyperplasia across all groups compared; (C) Comparatively smaller nasal bone in R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ in respect to 
Fgfr2cC342Y/+; (D) Micronagthia in embryos carrying the Fgfr2c overexpression transgene. Asterisk (*) is statistical significance between the control and 
R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ groups; Statistics: Oneway ANOVA with Tukey’s posthoc test for (A) and (B); Kruskal Wallis test with Dunn’s posthoc for 
(C) and (D). Error bars depict SEM; Δ: Difference of means between the genotypes. 
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6.2.4-Fgfr2c overexpression delays coronal suture morphogenesis in 
Fgfr2cC342Y/+ 
 
Due to the morphometric differences observed, ALP was used to determine osteoblast 
activity and suture morphology. The coronal sutures of R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+  
were inspected to determine its phenotypic severity in respect to Fgfr2cC342Y/+ at E18.5 (Figure 
54). The increased overlap observed in Fgfr2cC342Y/+ sutures was ameliorated in the presence of 
the Fgfr2c overexpression allele (Figure 54; compare * to arrowhead) (Control: n=2; 
Fgfr2cC342Y/+: n=2; R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+: n=3). However, it is important to note 
that suture abolishment remains a likely consequence as boundaries between the membranous 
bones and suture mesenchyme was less distinctive to that of a control in 
R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+. Altogether, these results suggest the overexpression 
allele is possible to delay calvarial ossification in the presence of Fgfr2cC342Y/+ allele.         
 
 
 
Figure 54: Attenuated osteoblast activity in R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ (n=3).  
Note the dissimilar morphologies in this cohort of mutants, with undergrowth of the osteogenic 
front being a major characteristic (arrowhead). Asterisk indicates the overlapping region in 
Fgfr2cC342Y/+. F: Frontal bone P: Parietal bone; ALP: Alkaline phosphatase; Scale bar: 200um.   
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6.3-Results: Part B  
6.3.1-Overactivation of RAS-MAPK pathway with oncogenic KRasG12D/+ 
induces severe skeletal hypoplasia with ectopic cartilage phenotype  
 
Results from R26RFgfr2cV5/+; βactinCRE/+ indicates structures derived from NCC were 
sensitive to FGF signalling (Chapter 2, Results Part II). Activation of FGFRs leads to 
downstream RAS-MAPK, PI3K-AKT and PLCγ-PKC signal transduction (Ornitz and Itoh, 
2015). Oncogenic KRasLSL-G12D/+ was adopted to over-activate the RAS-MAPK pathway to 
minimise cross talks at the level of the receptor, and to determine its role in craniofacial 
development. Embryos were collected and analysed at E18.5 (Figure 55). Over-activation of 
KRasG12D/+ in the NCC lineage (KRasG12D/+; Wnt1CRE/+) led to brachycephaly (Figure 55 K; 
white arrow) with micrognathia (Figure 55 L, orange arrows; n=6/6). These KRasG12D/+; 
Wnt1CRE/+ embryos feature severe craniofacial hypoplasia with ectopic cartilage in the calvaria 
(Figure 55 N; Alcian blue only). Specifically, a cartilage boundary underlies the frontal bone 
adjacent to the coronal suture (Figure 55 M and N, ii), and bridges the suture on the ventral 
aspects (Figure 55 M; *). Additionally, calcified bone was absent in the NCC domain of the 
interparietal bone (Figure 55 M; i), while midline enlargement of sagittal and interfrontal 
sutures were apparent (Figure 55 M; line). A characteristic of KRasG12D/+; Wnt1CRE/+ embryos 
was the prominence of cartilage underlying the frontal bone, normally absent at this stage 
(Figure 55 M and N; iii). The chondrocranium of KRasG12D/+; Wnt1CRE/+ were also severely 
perturbed (Figure 55 O): Hypoplasia of the tympanic ring (Figure 55 O; bottom panel black 
arrow) was similar to that observed in R26RFgfr2cV5/+; βactinCRE/+ despite the outer ear appearing 
normal. Disruptions to the palate were evident too (Figure 55 O; red box), with the palatal 
shelves appearing jagged and porous suggesting severe hypoplasia, in addition to the adjacent 
membranous bone-lamina obturans. Posterior to this, the basisphenoid and hyoid bones (Figure 
55 O; bottom panel white arrow) also appearing hypoplastic, and the pterygoid plate appearance 
was analogous to a secondary, but smaller palatal shelf. A cleft in the maxilla was also 
presented anterior of the palate, owing to the lack of palatal process of the incisive bone. On the 
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contrary, no obvious defects were noted in KRasG12D/+; Mesp1CRE/+ mouse at E18.5 (n=2) 
(Figure 55 F-J). 
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Figure 55: Severe craniofacial hypoplasia in KRasG12D/+; Wnt1CRE/+ (n=6/6) at E18.5.  
(A-E) Control embryos; (F-J) KRasG12D/+; Mesp1CRE/+ embryos, no apparent phenotype was seen 
(n=0/2) at E18.5; (K-O) KRasG12D/+; Wnt1CRE/+ embryos, brachycephaly (K, white arrow), 
micrognathia (L, orange arrow) were noted. The calvaria is presented with an ectopic cartilage 
phenotype, with expansion of cartilage in the interparietal bone (panel M, designated as ‘i’), 
widening of the midline (line on panel M, sagittal and interfrontal sutures), a cartilage boundary 
lies adjacent to the edge of the frontal bone (M and N, ii), with cartilage bisecting the ventral 
aspects of the coronal suture (N, *), and ectopic frontal cartilage (M and N iii). The 
chondrocranium is also severely disrupted, with tympanic ring (panel O; black arrow) and hyoid 
(panel O; white arrow) hypoplasia and a series of palatal defects (see text). Scale bar: 3mm for 
all except ‘alcian blue only’ panels where it is 1mm. 
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6.3.2-Ectopic cartilage phenotype is also abundant in Fgfr2c-C342Y embryos 
 
Membranous bone ossification does not require a cartilaginous template, with 
mesenchymal condensation playing a major role in calvarial osteogenesis. Previously, this lab 
reported the failure to form an intact coronal suture in Fgfr2cC342Y/C342Y embryos at E15.5, along 
with a fusion of the frontal and parietal bone ossification centres (Peskett et al., 2017). Owing to 
the excessive cartilage phenotype observed in KRasG12D/+; Wnt1CRE/+ embryos, there is 
likelihood similar phenotypic consequence occurs in Fgfr2c-C342Y embryos in the event of 
RAS-MAPK signalling misregulation. Fgfr2cC342Y/+ and Fgfr2cC342Y/C342Y embryos were 
examined for cartilage using wholemount skeleton staining at E16.5. Upon examination of the 
phenotype, there was an overabundance of cartilage in both Fgfr2cC342Y/+ (n=4) and homozygous 
embryos (n=3), with the latter showcasing an exacerbated phenotypic spectrum (Figure 56 A; 
*). Specifically, the parietal and frontal cartilage failed to retreat in both cases. Coronal sections 
of embryos stained with 0.01% alcian blue indicate increased thickness of cartilage underlying 
the calvaria in Fgfr2c-C342Y (Figure 56 B; arrowhead). 
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Figure 56; Expansion of calvarial cartilage in E16.5 Fgfr2c-C342Y embryos. 
(A) Wholemount 0.01% alcian blue stain of the calvaria showing excess cartilage in the calvaria. Note in Fgfr2cC342Y/C342Y, the suture is completely abolished (*); 
(B) Coronal sections of Fgfr2c-C342Y embryos showing increased thickness of calvarial cartilage (arrowheads). Dotted boxes depict magnified region of 
interest; Arrows mark the location of the coronal suture. P: Parietal bone, F: Frontal bone; Scale bar: 1mm, magnified panels are 0.5mm. 
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6.4-Discussion 
 
6.4.1-Part A: Phenotypic considerations of 
R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+ 
 
The paradox of FGFR2c signalling was first implicated in Fgfr2c-/-, whereby removal of 
signalling through the IIIc isoform was sufficient to drive a phenotype similar to that of 
Fgfr2cC342Y/+ with craniosynostosis (Eswarakumar et al., 2002, Eswarakumar et al., 2004). The 
difference being Fgfr2cC342Y/+ display an early increase in cellular activity (E14.5) to that of 
Fgfr2c-/-, whereby attenuated signalling delayed calvarial ossification resulting in a ‘late onset 
craniosynostosis’ phenotype (Eswarakumar et al., 2004, Eswarakumar et al., 2002). The 
consequences of premature cellular activity of Fgfr2cC342Y/+ were observed by E16.5 due to the 
sutural overgrowth in both frontal and parietal bones (Eswarakumar et al., 2004).  
Augmentation of RAS-MAPK signalling is sufficient to derive a coronal synostosis 
phenotype in the craniofacial skeleton (Eswarakumar et al., 2004, Pfaff et al., 2016, Li et al., 
2007). It is accepted that phenotypic rescue of craniofacial malformations could be achieved at 
the level of the receptor such as uncoupling Frs2, but complexities remain as Trk signalling 
activates a plethora of cascades (Eswarakumar et al., 2006, Ornitz and Itoh, 2015). Targeted 
knockdown of ERK was sufficient to spare the coronal suture in Fgfr2S252W/+, possibly through 
alleviating cellular proliferation required for the early synostosis onset (Shukla et al., 2007). 
Ultimately, the aim is to ameliorate Crouzon phenotype through FGFR2c signalling attenuation. 
Despite the phenotypic similarities between Fgfr2cC342Y/+ and Fgfr2c-/-, the downstream 
signalling responsible for the paradox remains elusive. This dilemma was originally reported in 
the palatal shelves of Fgfr2cC342Y/C342Y that there was reduced RAS-MAPK output at the 
transcriptomic level, which led to decreased cellular proliferation and delayed shelf elevation 
(Snyder-Warwick et al., 2010). To compare our findings to previous studies, the coronal suture 
was used as a model to question this paradox. 
Previous studies attempted to elucidate the paradoxical nature of FGFR2 signalling, 
where the perception of a GOF mutation on the receptor leads to signalling attenuation (Snyder-
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Warwick et al., 2010, Pfaff et al., 2016, Bagheri-Fam et al., 2015). Specifically, two studies 
attempted to ameliorate phenotypes caused by the C342Y allele, by introducing the C342Y 
allele into the Fgfr2c-/- (Pfaff et al., 2016, Bagheri-Fam et al., 2015). Surprisingly, Pfaff et al., 
2016 observed an exacerbated craniofacial spectrum of Fgfr2cC342Y/+, while Bagheri-Fam et al., 
2015 did not rescue gonadal sex reversal, normally caused by Fgfr2cC342Y/C342Y in compound 
heterozygotes (Fgfr2cC342Y/-). Drawing results from this study, the question should not be 
restricted to the extent of downstream signalling amplitude, but as to which pathway the 
mutation transactivates at the level of the receptor.  
This section concludes Fgfr2c overexpression was sufficient to delay ossification, with 
a successful rescue of the Wormian bone and parietal bone sparing. Furthermore, this was also 
reflective in the widening of the interfrontal suture similar to that observed R26RFgfr2cV5/+; 
βactinCRE/+, owing to frontal bone reduction, and attenuated ALP activity in the suture. 
Interestingly, R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+  spared the parietal bone, which was 
significantly smaller than that of Fgfr2cC342Y/+. Altogether, the delayed ossification in 
R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+  suggests the overexpression allele have delayed ectopic 
osteoblast differentiation, possibly through the RAS-MAPK pathway (Miraoui et al., 2009). As 
FGFR2 is critical for cell-renewal, one speculation for this rescue is shifting the balance from 
osteoblast differentiation to proliferation through ‘scavenging activity’ of endogenous FGF 
ligands by excess FGFR2c (Baddoo et al., 2003). Altogether, the delayed ossification in 
R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+  suggests Fgfr2c overexpression have reduced premature 
osteoblast commitment normally caused by the C342Y allele (Eswarakumar et al., 2004, Peskett 
et al., 2017).  Interestingly, the penetrance of the cleft palate phenotype increased to 100% 
(n=7/7) in R26RFgfr2cV5/+;βactinCRE/+;Fgfr2cC342Y/+  to those observed in R26RFgfr2cV5/+; βactinCRE/+  
(40%) in Chapter 2. This indicates that the combination of the constitutively active receptor in 
with Fgfr2c overexpression exacerbates the cleft phenotype, resembling close similarities to 
Fgfr2cC342Y homozygotes (Peskett et al., 2017). However, it is also important to consider the 
extent of the Fgfr2c overexpression on the phenotype of R26RFgfr2cV5/+; βactinCRE/+; 
Fgfr2cC342Y/+. The main question is to address whether the alleles genetically interact, or those 
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perceived is the consequence of a combined phenotype between both alleles. For example, the 
tympanic ring phenotype could be the sole consequence of the Fgfr2c overexpression allele 
alone.  
6.4.2-Part B: Overactive RAS-MAPK pathway potentially leads to terminal 
differentiation defects 
 
Consequently, the oncogenic KRasLSL-G12D/+ was used to examine the role of RAS-
MAPK pathway in craniofacial development (Tuveson et al., 2004). The KRasLSL-G12D/+ model 
minimises cross talk at the level of the receptor and overactivates the RAS-MAPK pathway. 
Similar to the results obtained from R26RFgfr2cV5/+; βactinCRE/+, NCCs show greater susceptibility 
to changes in signalling to the mesoderm. As expected, KRasG12D/+; Wnt1CRE/+ yielded severe 
craniofacial hypoplasia, as mutant KRas increases clonogenic potentials while reducing terminal 
differentiation into daughter lineages (Tuveson et al., 2004, Haston et al., 2017).  
It is widely accepted that FGFs are strong potentiators of ERKs and it is therefore 
important to characterise the roles of cascade effectors. A comprehensive review was published 
recently highlighting the strategies to delineate NC development using mouse models that target 
RAS-MAPK (and PI3K-AKT) cascade effectors (Dinsmore and Soriano, 2018). NCs are highly 
susceptible to ERK1 and ERK2 signalling manipulation, embryos with ERK1 deletion are 
viable, but knockout of the latter contributes to lethality at implantation (Saba-El-Leil et al., 
2003, Mazzucchelli et al., 2002). Interestingly, ERKs are functionally redundant as embryonic 
lethality of ERK2 can be rescued through the introduction of the ERK1 transgene (Fremin et al., 
2015). Newbern et al., 2008 determined that ERK2 acts as the dominant isoform in craniofacial 
development. Specifically, ERK2 knockout in the NC lineage resulted in NC defects that were 
associated with mandibles truncation, cleft palate, loss of tongue and cardiac outflow tract 
abnormalities (Newbern et al., 2008). Generally speaking, augmentation of RAS-MAPK 
signalling promotes NCC proliferation and differentiation is a consequence of pathway 
suppression (Dinsmore and Soriano, 2018). This cellular consequence is comparable to 
embryonic stem cells maintaining pluripotency (Yamanaka et al., 2010). In the murine palate, it 
is understood that proliferation of palatal mesenchyme cells are driven by activated ERK 
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through the exposure to FGFs in culture, and that its inhibition led to downregulation of 
‘stemness’ genes (Vasudevan et al., 2015). In the same study, genetic ablation of Fgfr1 (Fgfr1-/-) 
led to ectopic osteoblast differentiation in the palatal shelves in vivo suggesting ERK as a 
negative regulator for differentiation (Vasudevan et al., 2015). Other examples were also 
presented in a separate conditional knockout of Erk2 (Parada et al., 2015). Here, Parada et al., 
2015 reported a compromise in terminal differentiation of osteoblasts in the developing 
mandibles. Erk2-/-; Wnt1CRE/+ embryos display a loss of osteoblast differentiation markers 
(Osterix and Col1a1) between E13.5-E14.5, which consequently led to micronagthia due to 
insufficient bone mineralisation (Parada et al., 2015). Multiple osteoblast differentiation defects 
were also perceived with regards to upstream (e.g. Src homology region 2 domain containing 
phosphatase, Shp2) and downstream effectors (e.g. Ribosomal S6 Kinase 2, RSK2) of ERK 
(Nakamura et al., 2009a, Nakamura et al., 2009b, Yang et al., 2004). For example, Shp2-/-; 
Wnt1CRE/+ embryos display a complete absence of NC craniofacial bones, and that RSK2-/- has 
delayed bone mineralisation, which implies active RAS-MAPK signalling is required for 
osteogenesis (Nakamura et al., 2009a, Yang et al., 2004). Furthermore, brachycephaly and 
delayed interfrontal suture closure are consequences of consitutively active Shp2 caused by a 
knockin mutation (Q79R) in the NCC lineage (Nakamura et al., 2009b). Here, sustained ERK 
activation led to reduced osteoblast commitment, which could be reversed through 
pharmacological inhibition of ERK (Nakamura et al., 2009b). Overall, RAS-MAPK signalling 
is essential to maintain the correct balance of osteoblast proliferation and differentiation for 
normal bone formation. Genetic knockins of mutations into pathway effectors provided 
headway into insights to the complexity of growth factor signalling. The use of oncogenic KRas 
G12D presented in this section has achieved this aim for craniofacial development, and the data 
suggests hyperactive RAS-MAPK pathway perturbs the terminal differentiation programme that 
is more extreme to that of FGFR2c overexpression.  
6.4.3- Emerging role of cartilage in craniosynostosis  
 
Calvarial cartilage coincides with membranous bones during embryonic development, 
and the underlying anlagen gradually recedes and is absent by postnatal day 10 in the mouse 
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(Holmbeck et al., 1999). Ectopic cartilage is associated with craniosynostosis, albeit its role is 
less understood, the cartilage anlagen persist beneath the suture mesenchyme (Holmes and 
Basilico, 2012, Maruyama et al., 2010, Wang et al., 2005b, He and Soriano, 2017, Holmbeck et 
al., 1999). The striking cartilage phenotype obtained from our KRasG12D/+; Wnt1CRE/+ 
phenocopies that reported in a recent study with PDGFRα signalling misregulation (He and 
Soriano, 2017). He and Soriano 2017 used a mouse model that conditionally over-activates 
PDGFRα signalling driven under an endogenous promoter (PdgfrD842V/+), and yielded distinct 
cartilage phenotypes in the mesoderm and NCC lineage upon conditional activation (He and 
Soriano, 2017). In particular, these authors demonstrated that the cartilage is specified through 
the P13K-AKT pathway, and that excess chondrocytes invades the mesenchyme and 
transdifferentiates into osteoblasts (He and Soriano, 2017). The results yielded from the 
KRasG12D/+; Wnt1CRE/+  embryos adhere to this data, as the G12D mutation is able to mediate 
cross talk with the P13K-AKT pathway (Tuveson et al., 2004). Additionally, loss of PTEN-a 
negative regulator of P13K-AKT pathway accelerates tumorigenesis in the presence of the 
KRasG12D/+ allele (Hill et al., 2010). PDGFR is not commonly associated with craniosynostosis 
however, this study and a previous report from the lab reveal Fgfr2cC342Y/+ display ectopic 
cartilage phenotype (Peskett et al., 2017). In this study, Fgfr2cC342Y/C342Y has exacerbated 
cartilage. Cartilage is not usually required for calvarial development as conditional knockout of 
the chondrocyte marker Sox9 does not have effects on membranous bones, raising questions 
about its involvement (Akiyama et al., 2002). However, several evidence have shown 
misregulation to FGF signalling led to ectopic chondrogenesis:  It is established that long-term 
exposure of FGF ligand is sufficient to commit NCCs to a chondrocytic lineage, through the 
expression of Sox9 (Bagheri-Fam et al., 2017, Chen et al., 2014, Sarkar et al., 2001). Similarly, 
forced expression of Fgf9 in the cranial mesenchyme is sufficient to transform the calvarial 
mesenchyme into cartilage during embryogenesis (Govindarajan and Overbeek, 2006). In the 
adult mice, double knockout of Fgfr1 and Fgfr2 disrupts remodeling in the long bone owing to 
depressed chondrocyte proliferation (Karuppaiah et al., 2016). 
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As the underlying cartilage bridges the mesenchyme beneath the sutures under 
pathogenic conditions, it could be involved in stabilising the surrounding tissue. This 
assumption can be related to the initial phases of fracture healing as cartilage enables fissures to 
be bridged in the bone tissue, and Sox9+ cells residing in the periosteum plays a critical role for 
this regenerative process (Einhorn and Gerstenfeld, 2015, He et al., 2017). Further, chondrocyte 
markers such as Col2a1 are upregulated in the mesenchyme prior to suture closure (Behr et al., 
2011a). Other syndromic mouse models for craniosynostosis also display ectopic cartilage such 
as Fgfr2S252W/+ and Twist1+/- albeit its role remains elusive, with a strikingly similar cartilage 
phenotype resting beneath the suture mesenchyme (Holmes et al., 2009, Behr et al., 2011a).  
The role of cartilage appears to play critical roles in suture closure. This study also 
describes differential expression of chondrocyte markers in the embryonic suture through a 
transcriptomic screen (See Chapter 7). The abnormal expression of chondrocytic genes in the 
mesenchyme suggests ectopic bone could be generated through chondrocytes in the suture, 
potentially through an endochondral manner: Yang et al., 2004 demonstrated that osteoblasts 
could be derived from hypertrophic chondrocytes expressing Col10a1 during endochondral 
ossification. Here, the authors identified osteoblast were derivatives of chondrocytes expressing 
Col10a1 and in addition; these osteoblasts contributed to bone repair upon grafting into a 
fractured bone (Yang et al., 2014). This transition in fate contradicts the dogma that osteoblasts 
and chondrocytes have a fundamentally distinct lineage. In particular to Saethre-Chotzen 
syndrome, Twist1 is sufficient to suppress chondrocyte gene expression. Due to the presence of 
Twist1 in the suture mesenchyme, Saethre-Chotzen syndrome could be a consequence of 
transdifferentiation of chondrocytes into osteoblasts (Reinhold et al., 2006). Moreover, the 
differentiation capacity of the calvarial mesenchyme appears to be bi-potential, based on the 
balance between transcription factors responsible for bone and cartilage (Aberg et al., 2005). 
For example, a positive regulator for osteoblast differentiation- Msx2, suppresses expression of 
chondrocyte genes such as Sox9 (Semba et al., 2000). Therefore, it would be interesting to 
elucidate whether there are hypertrophic chondrocytes expressed in the mesenchyme that could 
result in ectopic bone formation.   
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6.4.4-Future directions 
 
The lack of obvious phenotype obtained in KRasG12D/+; Mesp1CRE/+ could be explained 
by the phenotypic onset: For example, He and Soriano only observed craniosynostosis in adults 
of PdgfrGOF/+; Mesp1CRE/+ mice (He and Soriano, 2017). Future work should therefore aim to let 
the KRasG12D/+; Mesp1CRE/+ litter down and allow them to develop the phenotype postnatally. 
The use of oncogenic mouse models provides a powerful tool to dissect the complexities of 
growth factor signalling in development. The KRas protein remains upstream of the RAS-
MAPK cascade, it has potentials to crosstalk with PI3K-AKT pathway. To overcome this 
problem, there is an oncogenic BRaf mouse model available (BRafLSL-V600E/+) in the literature 
further downstream of the RAS-MAPK pathway (Dankort et al., 2007). However, the BRaf-
V600E mutation is more potent than that of the KRas-G12D (Dankort et al., 2007, Tuveson et 
al., 2004). A cause of concern revolves around early embryonic lethality, and is advisable to 
select CRE lines that can bypass gastrulation defects (e.g. inducible CRE). Nonetheless, the 
systematic use of oncogenic mouse models allows the pathway to be isolated at multiple levels. 
Should there be a high correlation to that pathway, the phenotypes obtained should remain 
consistent across all levels of signalling. Future studies will also need to address the mechanics 
of cascade activation of FGFRs in vivo. There have been attempts in the past to elucidate this by 
mutating binding sites on the catalytic domains of PDGFRs in the mouse (Klinghoffer et al., 
2002, Klinghoffer et al., 2001, Fantauzzo and Soriano, 2016). As generating a mouse mutant for 
individual binding domain is time consuming, technologies such as CRISPR-CAS9 will no 
doubt assist on this endeavour.  
Perhaps the most striking finding from this section was the cartilage phenotypes 
observed in KRasG12D/+; Wnt1CRE/+ and Fgfr2cC342Y/+. The question remains as to understanding 
the role of pathogenic FGFR2c signalling in chondrocyte specification. The initial approach to 
this problem is to determine whether there is a misexpression of chondrocytic markers between 
Fgfr2cC342Y/+ and R26RFgfr2cV5/+; βactinCRE/+. For example, this is achieved through analysis of 
chondrocyte markers such as Sox9 during the initial stages of suture morphogenesis: 
Preliminary data in this lab shows Sox9 is ectopically expressed beneath the suture primordia in 
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Fgfr2cC342Y/+ and Fgfr2cC342Y/C342Y by E14.5 (data not shown). Similarly, primary cultures from 
Fgfr2cC342Y/+ and R26RFgfr2cV5/+; βactinCRE/+ is to be generated from the cranial mesenchyme, and 
compare the chondrocytic potentials of both mouse models, which could be important to explain 
the phenotypic differences of the coronal suture. If ectopic cartilage plays substantial roles in 
craniosynostosis, efforts should attempt to halt the chondrogenic progression. As a proof of 
concept experiment, in vivo ablation of cells in the chondrocytic lineage is to be targeted in the 
calvaria through expression of Dipheria toxin (R26RDTA/+). This could be achieved through the 
introduction of the DTA allele into Fgfr2cC342Y/+, and using a Col2a1 CRE to target the cells 
(Sakagami et al., 2017). Other approaches could involve local application of beads soaked with 
inhibitors that halt chondrocyte proliferation, or disrupting the extracellular matrix to abrogate 
growth (Otsuki et al., 2010). Bone Morphogenetic Protein (BMP) signalling has been described 
as a co-partner to FGF signalling to regulate chondrocyte proliferation, and inhibitors of this 
pathway could also be explored (Retting et al., 2009). Another interesting subject discussed was 
the potentials of chondrocytes to fracture healing. Mechanistically, there are similarities that 
could be learnt between craniosynostosis and bone repair. To elucidate this, injury sites could be 
created in the calvaria of WT mice, and chondrocytes could be transplanted into chasms to 
determine its healing potential. Lastly, hypertrophic chondrocytes remain to be determined in 
the suture mesenchyme. This could be achieved by performing expression analysis of the suture 
and corresponded with appropriate protein expression in vivo using antibodies. 
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6.5-A working model for FGFR2c and syndromic craniosynostosis 
Figure 57 illustrates a potential working model for FGFR2c osteogenesis and 
syndromic craniosynostosis. The model amalgamates all the phenotypic and biochemical data 
together to derive a working model, which points towards defects in regulating the balance 
between proliferation and differentiation. In general, RAS-MAPK signalling governs the 
cloning potentials of MSCs, whilst PI3K-AKT and PLCγ-PKC cascades dictate cellular 
commitment towards osteogenic lineage (Miraoui et al., 2009, He and Soriano, 2017, 
Vasudevan et al., 2015). It should be assumed under WT conditions, a status quo is maintained 
between these pathways and a shift in pathway activation is expected under pathological 
conditions.  
Coronal synostosis in Fgfr2cC342Y/+ is caused by hyper-proliferation and differentiation 
during early embryogenesis (Eswarakumar et al., 2004). This is supported by ectopic activation 
of pERK and ALP activity in the coronal suture in this study. However, in vitro evidence 
implies ectopic osteogenesis in mutant FGFR2 (such as FGFR2-S252W) are mechanistically 
different to WT-FGFR2, where cellular differentiation is caused by abnormal activation of the 
PLCγ-PKC cascade (Miraoui et al., 2009). In this respect, the C342Y mutation could have 
potentially augmented activation of both RAS-MAPK and PLCγ-PKC cascades to drive 
premature suture closure. FGF signalling is sufficient to drive cellular proliferation through 
ERK activation (Yamanaka et al., 2010, Vasudevan et al., 2015). The hypoplasia phenotype 
observed in R26RFgfr2cV5/+; βactinCRE/+ implies insufficient osteoblast commitment for correct 
bone formation. This is supported by an overactive pERK readout and reduced ALP activity in 
the coronal suture in this study, and reaffirmed by the KRasG12D/+; Wnt1CRE/+ data in Figure 55 
that is known to cause terminal differentiaton defects (Tuveson et al., 2004, Haston et al., 2017). 
Therefore, sustained ERK activation in R26RFgfr2cV5/+; βactinCRE/+ resulted in a greater number of 
cells involved in proliferation that resulted in osteogenic delays and a patent suture. As coronal 
synostosis is potentially an ectopic differentiation defect in Fgfr2cC342Y/+, introduction of the 
overexpression allele into Fgfr2cC342Y/+ is likely to have delayed differentiation normally caused 
by the C342Y mutation by restoring proliferation. 
 196 
The same model can also be used to explain craniosynostosis phenotypes observed in 
Fgfr2c-/- and Fgfr2cC342Y/- (Pfaff et al., 2016, Eswarakumar et al., 2002). A characteristic of 
Fgfr2c-/- is delayed osteogenesis and suture abolishment, which is explained by insufficient 
osteoblast generated for bone formation (Eswarakumar et al., 2002). A potential mechanism for 
coronal synostosis in the Fgfr2c-/- is linked to cellular survival. Loss of the IIIc isoform would 
have attenuated ERK signalling that is critical for cell renewal and furthermore, it is understood 
that ERK suppression is sufficient to promote cellular differentiation (Vasudevan et al., 2015). 
As a result, the onset of a synostosis phenotype is slower than that of the Fgfr2cC342Y/+ 
counterpart. Finally, Fgfr2cC342Y/- has exacerbated phenotypic spectrum to that of 
Fgfr2cC342Y/C342Y. A notable characteristic of this compound mutant is severe skeletal hypoplasia, 
which could be attributed to ectopic differentiation without sufficient amplification of the 
progenitor pool. 
Therefore, using this model to explain the FGFR2c signalling paradox, it is potentially a 
result of altering the balance of cascade activation immediately downstream of FGFR2c. 
Disrupting the harmony of cascade activation would ultimately draw pronounced effects on 
cellular proliferation and differentiation that drive perturbed osteogenesis. As discussed 
previously, this model proposes the pathogenesis for coronal synostosis is mechanistically 
different between Fgfr2cC342Y/+ and Fgfr2c-/- despite yielding the same phenotypic outcome. As 
these mouse models were generated by knockin technology, the phenotypic similarties are 
dependent on the localisation of the ‘IIIc’ isoform. Collectively, this study has successfully 
elucidated the mystery behind the signalling paradox and that it should not be judged on the 
signalling amplitude alone but rather, the shift in cascade activation. 
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Figure 57: A working model of osteogenesis regulated by FGFR2 and craniosynostosis 
(Top).  
Bottom: Using the same model to explain the phenotypes obtained in Fgfr2c-/- and Fgfr2cC342Y/+. 
RAS-MAPK governs cellular proliferation (red arrows and blue box) whilst commitment is 
P13K-AKT/PLC-PKC pathways (Green box). Shifting this intricate balance disrupts overall 
integrity, and therefore yielding a series of craniofacial phenotypes associated with perturbed 
osteoblast differentiation. 
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Chapter 7 
Results (Part V) 
Profiling the embryonic coronal 
suture 
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7.1-Introduction 
 
Laser captured microdissection (LCM) was chosen as a method to obtain samples from 
the embryonic coronal suture. This section highlights results obtained from transcriptomic 
profiling of the E16.5 Fgfr2cC342Y/+ coronal suture, with an aim to identify genes misregulated 
by FGFR2c during the start of suture closure. E16.5 was chosen as the ideal embryonic stage 
because the morphological appearance of the coronal sutures is similar between Fgfr2cC342Y/+ 
and WT. Only Fgfr2cC342Y/+ was profiled, due to the animal as the accepted model for coronal 
synostosis. 
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7.2-Results 
 
7.2.1-RNA was extracted from microdissected coronal sutures  
 
To assemble samples for RNAseq, LCM was used to microdissect embryonic coronal 
sutures of E16.5 CD-1 WT and Fgfr2cC342Y/+. E16.5 was chosen as the desired developmental 
stage for RNAseq owing to the morphological similarities between WT and Fgfr2cC342Y/+. 
Figure 58 A shows the coronal suture before and after microdissection using LCM. A triplicate 
(n=3) of WTs and Fgfr2cC342Y/+ embryos from the same litter were microdissected along the 
dorsal-ventral profile of the bilateral coronal suture. Roughly 50-70 sections from the same 
embryo were captured into the collection adhesive caps. Figure 58 B is a representative of RNA 
quality extracted from captured samples after Tapestation analysis. The peaks denote ribosomal 
subunits 18s and 28s in the electropherogram, confirming the presence of RNA.  
 
Figure 58: RNA is extracted from LCM. 
(A) E16.5 coronal suture before and after capture; (B) Representative electropherogram 
denoting the presence of RNA. The small twin peaks denotes ribosomal subunits. F: Frontal 
bone, P: Parietal Bone. Arrows show the location of the coronal suture.   
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7.2.2-General quality of RNAseq from LCM samples 
The general quality of RNAseq data was first examined on BaseSpace prior to further 
analysis (Figure 59). BaseSpace analysis revealed strong transcript alignment in the 3’ region of 
the genome during the sequencing process of the captured samples (Figure 59 B). This was 
indicative RNA degradation and was expected for LCM.  
Principal Component Analysis (PCA) plot enables the stringency between biological 
replicates to be examined (Figure 59 A). Should the samples display similar expression profile, 
samples of the same genotype should cluster in proximity to each other. In regards to 
Fgfr2cC342Y/+ samples, they were grouped together on the PC1 axis. However, on the PC2 axis, 
one of the samples was dispersed from the group. The WT replicates were strongly dispersed, 
and no obvious cluster was identified for this genotype. However, two of the WTs were closer 
together along the PC1 axis (Figure 59 A). Furthermore, sequence alignment shows one of the 
samples-WT5 (UCLGNS1172-wt5); possess uniform coverage across the genome, indicative of 
a dissimilar expression profile to the rest of the samples (Figure 59 B).  
An entity list designated to FGF signalling was created to determine the extent of 
signalling misregulation in Fgfr2cC342Y/+, and to serve as an in silico control (Figure 60). Due to 
the variable nature of samples acquired by LCM, a cut off value of 1.5 fold was set to ensure 
subtle changes in gene expression was detected. Surprisingly, a handful of genes involved in the 
FGF signalling pathway were not misregulated between WT and Fgfr2cC342Y/+ when the data 
was run against an FGF entity list (Figure 60). In addition, WT5 appears to display a higher 
expression level to all other samples.    
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Figure 59: PCA plot and sequence alignment to reference genome of LCM captured samples.  
(A) PCA plot for the sequenced LCM captured coronal sutures; (B) Alignment plot of samples processed for RNAseq. Note the 3’ bias observed across the majority 
of samples, and the uniform alignment of ‘UCLGNS1172-WT5’.    
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Figure 60: In silico control of LCM, sequenced data was run against a FGF entity list. 
A majority of genes involved in the FGF signalling pathway were not misregulated. Note the 
increased expression of FGF genes in WT5. 
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7.2.3-GSEA reveals multiple molecular signatures in the embryonic suture 
 
GSEA was used to examine the enrichment profile in the embryonic suture of 
Fgfr2cC342Y/+ (Figure 61). GSEA reveals significant enrichment of genes associated with cell 
cycle, apoptosis (Enrichment score (ES): 0.27; FDR: 0.041; p=0.01) and epithelial-
mesenchymal transition (EMT) (ES: 0.36; FDR: <0.001; p=0.001) in Fgfr2cC342Y/+ (Figure 61 
A). The enhanced enrichment for cell cycle genes were characterized by E2F target genes (ES: 
0.39; FDR: 0.001; p< 0.001), Myc target genes (ES: 0.34; FDR: 0.001; p<0.001) and genes 
associated with G2M checkpoint (ES: 0.28; FDR; 0.001; p<0.001) Figure 61 A). Gene sets 
associated with growth factors signalling had attenuated enrichment in the Fgfr2cC342Y/+, such as 
the RAS-MAPK-consisting of KRas signalling (UP: ES: -0.33; FDR: 0.045; p<0.001; DOWN: 
ES: -0.31; FDR: 0.094; p=0.013) and PI3K-AKT-mTOR signalling (ES: -0.34; FDR: 0.068; 
p=0.013) (Figure 61 B). Gene sets associated with myogenesis (ES:-0.30; FDR: 0.107; p=0.011) 
and Notch signalling (ES: -0.47; FDR: 0.039; p=0.01) were also less enriched in Fgfr2cC342Y/+ 
(Figure 61 B). A summary of the ranked genes from GSEA can be found in Appendix 11. 
Altogether, GSEA reveals molecular signatures in the embryonic suture are associated with 
abnormal cellular activity and multiple signalling misregulations.  
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Figure 61: Enriched genes of Fgfr2cC342Y/+.  
(A) Indicates upregulated gene sets in Fgfr2cC342Y/+ concerning cell cycle, apoptosis and EMT; (B) Indicates downregulated gene sets in Fgfr2cC342Y/+ concerning 
RAS-MAPK/PI3K-AKT pathways, myogenesis and Notch signalling. 
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7.2.4-Shortlisting candidate genes for expression validation 
 
24,421 genes were annotated throughout the screening process. Figure 62 A highlights 
the pipeline for shortlisting the candidates. A total of 86 genes were found to be upregulated and 
325 genes downregulated more than 10-fold in mutant sutures. A further filter was to narrow the 
candidates, where the raw read counts must be consistent between biological replicates, and a 
PubMed query was performed to check its relevance to craniofacial development. Ultimately, 
this is to circumvent issues concerning the lack of expression uniformity between biological 
replicates as given by the PCA and alignment plots (Figure 59). The final shortlist consisted of 
27 genes upregulated and 36 genes downregulated (Figure 62 B). Table 21 illustrates the 
average fold change for these genes.   
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Figure 62: Pipeline for expression validation and heatmap of highly differentially 
expressed genes.  
(A) Pipeline for expression validation; (B) Heatmaps illustrating genes that were differentially 
expressed by 10 folds, with consistent read counts between the biological replicates and 
genotypes; Genes processed for expression validation are marked in orange.   
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Gene 
Symbol FC ([c342y] vs [wt]) 
 
Gene Symbol 
FC ([c342y] vs 
[wt]) 
Apol9b 28.819536 
 
Rsad2 -297.74582 
Ccdc67 26.348238 
 
Nlrc4 -100.08107 
Tsx 25.640665 
 
Srgn -94.57781 
Ch25h 25.620537 
 
Lrp11 -81.78447 
Col9a1 21.75568 
 
Lypd2 -78.46616 
Gm10344 21.652868 
 
Dsg1a -76.11076 
Slc2a6 19.816038 
 
Slc6a20a -75.41735 
Fam131c 16.886911 
 
Pcyt1b -58.077717 
Gm5887 16.78892 
 
Slc25a31 -57.71174 
Alpk1 15.403195 
 
Nalcn -56.257942 
Plek2 14.918185 
 
A830093I24Rik -49.138927 
Ptgs2 14.885597 
 
Myoz2 -39.87751 
Padi4 14.739341 
 
C030034I22Rik -38.263905 
AI661453 13.470319 
 
Lmo3 -36.095715 
Pxmp2 13.159639 
 
Rgs8 -35.990154 
AU02109
2 12.681593 
 
Ebf2 -32.45098 
Rrh 12.209546 
 
Csrp3 -29.051847 
P2ry14 11.915451 
 
Map3k9 -26.50333 
Gsto2 11.736259 
 
Ablim3 -26.32135 
Henmt1 11.732923 
 
Pdgfb -26.2745 
Hsd17b1 11.566258 
 
March3 -26.141647 
Map3k6 11.303426 
 
Slc22a6 -25.984463 
Pgbd5 11.258239 
 
8030474K03Rik -25.643427 
Serpine3 11.111681 
 
Galnt9 -23.297153 
Abcb1a 11.089977 
 
Gm15440 -22.447887 
Papln 10.616017 
 
Acsl6 -21.136223 
Lct 10.216149 
 
Sh3gl3 -20.021713 
   
Psapl1 -19.139965 
   
Rnf43 -17.816904 
   
Vtn -17.70016 
   
1700112E06Rik -17.530369 
   
Myog -17.513828 
   
Arhgef33 -16.64122 
   
Stfa2 -15.1528015 
   
Dsp -13.22994 
   
Mgst1 -12.257614 
 
Table 21: Final shortlist of genes with at least 10 folds differential expression in 
Fgfr2cC342Y/+.  
Genes highlighted in green were processed for expression validation. The heatmap of these 
genes are represented in Figure 55B (Orange). Table on the left illustrates upregulated genes 
and downregulated on the right. FC: Fold change.
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7.2.5-RT-qPCR expression validation of candidate genes 
 
Expression validation was performed between at E12.5 controls/WT and Fgfr2cC342Y/+ 
wholemount embryos due to the extensive experimental pipeline of LCM. R26RFgfr2cV5/+; 
βactinCRE/+ was also included in the analysis for comparative purposes. Table 22 illustrates the 
genes validated in this study. 
 
 
 
 
Gene Ensembl ID Function Expression 
Papln 
ENSG00000100767 
 
Papilin: extracellular glycoprotein UP 
Map3k6 
ENSG00000142733 
 
Protein kinase related to RAS-MAPK 
signalling 
UP 
Col9a1 
ENSG00000112280 
 
Collagen9a1: chondrocyte marker UP 
Pcyt1b 
ENSG00000102230 
 
Choline-phosphate cytidylyltransferase 
B: 
Enzyme in metabolic pathway 
DOWN 
Pdgfb (Pdgfβ) 
ENSG00000100311 
 
Platelet derived growth factor beta: 
cell survival and proliferation 
DOWN 
Rsad2 
ENSG00000134321 
 
Viperin: anti-viral protein DOWN 
Table 22: Genes processed for expression validation 
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7.2.6-Preliminary results of RNAseq expression validation 
7.2.6.1-The upregulated genes 
RT-qPCR was performed for Papln, Map3k6 and Col9a1 (Figure 63). Papln displayed 
a strong difference between the mean ranks to at least a pair of genotypes as indicated by 
Kruskal Wallis test (p=0.031; Control: n=6; Fgfr2cC342Y/+: n=3; R26RFgfr2cV5/+; βactinCRE/+: n=2) 
(Figure 63 B). Dunn’s post-hoc with Bonferroni correction was subsequently executed between 
the groups, and identified significant upregulation of transcript in Fgfr2cC342Y/+ to that of 
R26RFgfr2cV5/+; βactinCRE/+ (Fold change: 347, p=0.040) (Figure 63 B). No significant difference 
between mean ranks was identified in the subsequent groups. Col9a1 displayed differences 
between the mean ranks to at least a pair of genotypes as indicated by Kruskal Wallis test 
(p=0.037; Control: n=6; Fgfr2cC342Y/+: n=3; R26RFgfr2cV5/+; βactinCRE/+: n=2) (Figure 63A). 
Further analysis using Dunn’s post-hoc with Bonferroni correction identified significant 
upregulation of transcript between the control groups and Fgfr2cC342Y/+ (Fold change: 34.4; 
p=0.032), no other differences were seen across genotypes. Statistical analysis was not 
performed for Map3k6 over a lack of biological replicates in Fgfr2cC342Y/+ and R26RFgfr2cV5/+; 
βactinCRE/ (n=1 for both genotypes). However, Fgfr2cC342Y/+ have increased levels of transcripts 
compared to controls and R26RFgfr2cV5/+; βactinCRE/+ (Figure 63 E). 
7.2.6.2-The downregulated genes 
In contrast to the output of RNAseq, the downregulated genes analysed (Pcyt1b, Pdgfb) 
did not show evidence for decreased gene expression in both Fgfr2cC342Y/+ and R26RFgfr2cV5/+; 
βactinCRE/+. All of the genes analysed had augmented transcript expression (Figure 63 C and D). 
Pcyt1b display a strong trend of transcript increase between the groups, albeit close to reaching 
statistical significance (Kruskal Wallis: p=0.055; Control: n=5; Fgfr2cC342Y/+: n=3; 
R26RFgfr2cV5/+; βactinCRE/+: n=2) (Figure 63 C). Similarly, Pdgfb did not display any expression 
differences between the mean ranks to at least a pair of genotypes as indicated by Kruskal 
Wallis test (p=0.055; Control: n=6; Fgfr2cC342Y/+: n=3; R26RFgfr2cV5/+; βactinCRE/+: n=2), despite 
a strong trend for transcript upregulation (Figure 63 D). Rsad2 was not followed up owing to 
high standard deviations yielded between biological replicates in the RT-qPCR plate.  
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Figure 63: Expression validation of candidate genes at E12.5 embryos.  
(A) Col9a1, (B) Papln, (C) Pcyt1b, (D) Pdgfβ, Map3k6. Statistics: Kruskal Wallis with Dunn’s 
posthoc. Statistical analysis was not performed for Map3k6 due to lack of biological replicates 
in mutant groups. Rsad2 was not followed up for expression validation due to high standard 
deviation from RT-qPCR raw data (data not shown).    
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7.3-Discussion 
 
Abnormal osteogenesis is characteristic to bone diseases inclusive of craniosynostosis. 
This experiment is the first to attempt expression profiling of the embryonic Fgfr2cC342Y/+ 
coronal suture using samples acquired by LCM. Novel genes were identified to contribute 
towards the development of syndromic craniosynostosis previously unrelated to FGFR2c 
signalling. This mini discussion will give a brief overview of the candidate genes in addition to 
the experimental limitations occurred throughout this experiment.   
7.3.1-Molecular events occurring in the embryonic suture 
 
GSEA provides a snapshot of the molecular events occurring in the embryonic suture. 
The enrichment for genes associated with cellular activity in Fgfr2cC342Y/+ is in line and expected 
with previous studies (Holmes and Basilico, 2012, Holmes et al., 2009, Wang et al., 2012, 
Eswarakumar et al., 2004). Specifically, Fgfr2cC342Y/+ has an enriched signature associated with 
G2M checkpoint of the cell cycle, and target genes associated with the E2F and cMyc factors 
implicative of a dynamic suture. E2F and cMyc are downstream of RAS-MAPK and PI3K-AKT 
signalling and therefore, regulation of genes downstream of these transcription factors imply 
misregulation of these cascades (Sears and Nevins, 2002). Genes enriched for apoptosis were 
also upregulated in Fgfr2cC342Y/+.  Cellular apoptosis plays an essential role in bone resorption 
and is detected in the embryonic suture at E16-E17 (Rice et al., 1999). Programmed cell death 
allows effective calvarial remodeling to occur, and is strongly upregulated in osteoblasts within 
the osteogenic front and in the mesenchyme of the coronal suture (Rice et al., 1999). As the 
tissue extracted from LCM contains both the osteogenic front and the mesenchyme, it would 
have detected the apoptotic signature in Fgfr2cC342Y/+. The conversion of cells from an epithelial 
to mesenchymal status requires a series of changes from cell-cell adhesion, polarity to migratory 
properties (Thiery et al., 2009). The enrichment of genes associated with EMT suggests cells in 
the suture mesenchyme were undergoing reprogramming and differentiation events. This is also 
linked to a large cohort of genes associated with the extracellular matrix (Appendix 11). 
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Interestingly, genes enriched for the PI3K-AKT pathway were downregulated in the 
Fgfr2cC342Y/+. It should be noted GSEA does not account for the overall activity of the signalling 
pathway but rather, giving an insight into the pathways that were potentially affected. 
Therefore, the enrichment of KRas gene sets point towards aberrations to both the RAS-MAPK 
and PI3K-AKT cascades. Indeed, both pathways are linked towards craniosynostosis 
development (Eswarakumar et al., 2004, Pfaff et al., 2016, He and Soriano, 2017). Genes 
enriched for myogenesis were also downregulated in the Fgfr2cC342Y/+, which could relate 
specifically to the suture mesenchyme: The mesenchyme is hypothesized to be a stem cell niche 
and is able to contribute to bone regeneration post-injury (Zhao et al., 2015). MSCs are 
multipotent and are sufficient to give rise to a plethora of daughter cells (Uccelli et al., 2008). 
The downregulated signature of myogenic genes could suggest FGFR2c signalling suppresses 
the myogenic programme in MSCs, and potentially promoting gene expression of the 
osteogenic lineage. Finally, genes associated with Notch signalling were also downregulated in 
Fgfr2cC342Y/+, implicating FGFR2c is upstream of Notch signalling. This relationship can be 
referenced in somitogenesis, where FGF signalling synchronizes Notch cyclic genes through 
activated ERK (Dequeant and Pourquie, 2008). In particular to two of the Notch genes, Notch3 
and Jag1 possess high enrichment scores and were strongly downregulated (Appendix 11; 
Notch genes). This is an interesting observation as LOF to Jag1 is related to human Alagille 
syndrome and moreover, Jag1 is a binding partner to Notch3 (Yen et al., 2010, Gridley, 2010). 
LOF to Jag1, however, is insufficient to drive craniosynostosis on its own, but it is able to 
exacerbate coronal synostosis phenotypes such as Twist1+/- (Yen et al., 2010). Therefore, the 
downregulation of vital Notch genes suggests a synergistic relationship between FGFR2c 
signalling and suture patency. 
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7.3.2-Validation of selected differentially expressed genes identified by 
RNAseq 
Upregulated genes: 
7.3.2.1-Papln (Papilin) 
Papln is an extracellular matrix glycoprotein originally identified in the Drosophila 
embryo associated with the basement membrane (Kramerova et al., 2000). The Drosophilia 
homologue Papln is highly conserved, with a non-catalytic N-terminal sequence resembling A 
Disintegrin And Metalloproteinase (ADAM) metalloproteinases. Papilin is able to inhibit 
ADAM activity on a non-competitive basis thanks to a conserved sequence in the N-terminal 
domain (Kramerova et al., 2000). Enzymes lacking this this sequence did not show any 
reduction of catalytic activity by Papilin. Due to its ability to modulate ADAMs, Papilin aids 
extracellular matrix remodelling during organogenesis. It has been reported that Papilin 
knockdown perturbs cell movements critical for organogenesis in both Drosophila and 
nematodes (Kramerova et al., 2000, Kawano et al., 2009). There is evidence for Papln involved 
in craniofacial development despite the link with FGFR2 signalling is not yet established: For 
example, Papln was identified to be involved in molar tooth development through a microarray 
screen, and is specifically expressed in ameloblasts, cells responsible for enamel deposition 
(Pemberton et al., 2007). However, the most interesting finding related to Papln is their 
association with A Disintegrin And Metalloproteinase with Thrombospondin Type 1 motifs 
(ADAMTS1) (Kramerova et al., 2000). ADAMTS1 is heavily involved in osteogenesis, and 
sequence alignments reveal the N-terminal domain in Papilin is specific for ADAMTS1 
homolog in the mouse (Kramerova et al., 2000, Nakamura et al., 2005, Lu et al., 2009, Lind et 
al., 2005, Hu et al., 2012, Rehn et al., 2007, Sone et al., 2005). Overexpression of ADAMTS1 in 
vivo results in a loss of long bone density in the adult mice, strongly linking the role of 
metalloproteinases to bone homeostasis (Hu et al., 2012). ADAMTS1 display a peculiar pattern 
of expression, notably in bone nodules and growth plates of the long bones, in addition to dental 
pulp cells in tooth development (Lind et al., 2005, Sone et al., 2005). ADAMTS1 is secreted 
from osteoblasts, and promotes proteolytic processing of collagen precursors (pro-collagen type 
1), versican and other matrix proteins (Lind et al., 2005, Sandy et al., 2001, Rehn et al., 2007). 
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The resultant products are subsequently accumulated to form the extracellular matrix 
composition (Rehn et al., 2007). Furthermore, ADAMTS1 is capable to alter cellular 
morphology which in turns alter the capacity for osteoblasts to migrate (Rehn et al., 2007). This 
finding is particularly relevant in cases for bone metastasis and invasive tumours, and 
knockdown of ADAMTS1 is sufficient to ameliorate these phenotypes (Lu et al., 2009). The 
extracellular matrix is also able to control cellular differentiation in vitro (Xiao et al., 1998). In 
particular, osteoblasts express integrins and collagen 1, which acts as the prime substrate to 
drive osteoblast gene expression (Xiao et al., 1998, Gronthos et al., 1997). Altogether, the 
results suggest the upregulation of Papln by Fgfr2C342Y/+ negatively regulates the activity of 
ADAMTS1 in the ECM, to reduce bone resorption in membrous bones resulting in premature 
suture closure.       
7.3.2.2-Map3k6  
 
Map3k6 (aka Apoptosis Signalling Regulating Kinase 2-‘ASK2’) is an intermediate of 
the RAS-MAPK pathway that modulates signal transduction. It functions directly upstream of 
ERK and shares similar homology with its counterpart Map3k5 (Apoptosis Signalling 
Regulating Kinase 1-‘ASK1’) (Wang et al., 1998). Both isoforms form functional dimers and 
play differing roles in controlling signal transduction: Both Map3k5 and Map3k6 promote the 
activation of tumour suppressor p38 but in the case of Map3k6, it requires Map3k5 to form a 
functional heterodimer. Map3k5 stabilises Map3k6 and prevents it from being processed for 
degradation (Takeda et al., 2007). Regulating the balance to form functional dimers therefore 
implies these candidates play multiple roles in regulating cellular proliferation and cell death. 
Despite their presence in the RAS-MAPK pathway, the link with FGFR2 signalling is not yet 
shown. However, the expression of Map3k6 coincides with the location of FGFR2 signalling in 
the skin epithelium (Petiot et al., 2003, Iriyama et al., 2009) (See Figure 49 ISH). Targeted 
knockout of Map3k6 in vivo (Ask2-/-) increases susceptibility to papillomas due to its inability to 
facilitate cell death, in addition to losing protection against oxidative stress and carcinogens 
(Iriyama et al., 2009). The idea of FGFR2 promoting both proliferation and apoptosis is not 
new, and osteoblasts harbouring GOF mutations can undergo cell death (Mansukhani et al., 
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2000, Rice et al., 1999). Therefore, the identification of Map3k6 could suggest a novel 
molecular switch responsible for controlling cellular activity, switching between both 
proliferation and apoptotic fates. Altogether, the increased expression of Map3k6 in the 
Fgfr2cC342Y/+ points towards cell death as a mediator for suture abolishment in Fgfr2cC342Y/+.  
7.3.2.3-Col9a1 
 
Chondrocytes express a multitude of markers throughout their maturation process. For 
instance, immature chondrocytes express type 2 and type 9 collagens, whilst mature 
chondrocytes express type 10 collagen in addition to those described in their infancy (Gomez-
Picos and Eames, 2015). Collagen 9 is heterotypic, and comprises of multiple polypeptide 
chains in α1, α2 and α3. The α1 unit is particularly important, as it is required for the formation 
of all the isoforms of collagen 9 (Hagg et al., 1997). Specifically, Col9a1 is important for the 
correct arrangement of the bone architecture during endochondral ossification, and is expressed 
prominently in hypertrophic zones of the growth plate (Dreier et al., 2008). The inability to 
correctly pattern the extracellular matrix by Col9a1 has pronounced effects on chondrocyte 
proliferation. As a whole, the cellular consequence is disarrayed bone cytoarchitecture and loss 
of bone density. Ultimately, this results in the truncation of long bones (Dreier et al., 2008). On 
the cellular level, chondrocytes express a multitude of integrin receptors, which are specific for 
collagen chains (Kapyla et al., 2004). Not only were these interactions important to stabilize the 
extracellular matrix, it may well play roles in controlling the chondrocyte maturation program 
(Kapyla et al., 2004, Chen et al., 2005). Therefore, the molecular interaction between 
polypeptides could govern the overall process of chondrocyte differentiation, and disruption to 
the extracellular matrix would lead to a hypoplastic phenotype. Other phenotypes associated 
with Col9a1 also display differences to cytoarchitecture, including those within the tectorial 
membrane of the cochlea, and multiple epiphyseal dysplasia (Asamura et al., 2005, Czarny-
Ratajczak et al., 2001). In addition, Col9a1 is essential for normal fracture healing, where the 
absence of Col9a1 delays bone mineralization and healing (Opolka et al., 2007). It is well 
established that FGFR2 signalling is involved in chondrogenesis and drives Sox9 expression 
(Sarkar et al., 2001). Col9a1 is downstream of Sox9, linking it with FGFR2 signalling. 
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Immature chondrocytes, such as those expressing Col2a1, invades the suture mesenchyme 
under pathogenic conditions (He and Soriano, 2017). Altogether, the upregulation of Col9a1 in 
Fgfr2cC342Y/+ suggests increased chondrogenesis and mineralization in the coronal suture.  
Downregulated genes: 
7.3.2.4-Pcyt1b 
 
Pcyt1b encodes for the enzyme CTP: phosphocholine cytidydyltransferase (CCT) 
responsible for the synthesis of phosphatidylcholine, responsible for the formation of membrane 
phospholipids. There are two isoforms to CCT, in CCTα and CCTβ, where the latter is a 
product of Pcty1b expression. CCTα is widely abundant, whilst Pcyt1b is mainly expressed in 
the brain and gonads (Karim et al., 2003). Deficiencies in phosphatidylcholine affects cellular 
activity in vitro whilst reinstatement of CCT is sufficient to restore proliferation (Karim et al., 
2003). Therefore, correct formation of the plasma membrane has subsequent effect on cellular 
responses and in turn driving resultant phenotypes. For example, Pcyt1α+/- displays liver 
hypoplasia due to fewer hepatocytes, whilst Pcyt1b-/- had disrupted gonadal morphology 
(Jackowski et al., 2004, Wang et al., 2005a). Specifically, these Pcyt1b-/- animals had a larger 
lumen, reduced germinal layers owing to the degeneration of seminiferous tubes and spermatoza 
(Jackowski et al., 2004). FGFR2 is an established player in sex determination, providing a link 
between Pcty1b and FGF signalling (Bagheri-Fam et al., 2017, Bagheri-Fam et al., 2015). More 
strikingly, CCTβ and FGFR2 are both expressed testes within the seminiferous tubes 
(Jackowski et al., 2004, Lai et al., 2016). CCTβ is likely connected to altering the sensitivity of 
growth factor signalling, with specific reference to the RAS-MAPK pathway (Carter et al., 
2008, Weber et al., 2003). For example, increasing exposure of Nerve Growth Factor (NGF) 
corresponds to the expression of Pcyt1b and phosphatidylcholine concentration, implying 
increased synthesis of phospho-membrane, whilst ERK inhibition can reverse this biochemical 
event (Carter et al., 2008). The molecular mechanisms dictating signalling dynamics were 
furthered characterised in the Drosophila homologue dCCT1, where it governs the turnover of 
receptors on the cell surface (Weber et al., 2003). Knockout of dCCT1 results in increased 
membrane retention and cytoplasmic localisation of Epidermal Growth Factor Receptor 
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(EGFR). The alterations to the number of receptors on the cell surface ultimately led to 
disrupted cellular architecture in the eye, and terminal differentiation defects (Weber et al., 
2003). Maintaining the sensitivity of signalling on the cell surface is pivotal for conveying the 
correct signalling interpretation for normal cellular proliferation and differentiation 
(Miaczynska, 2013). There has been a report of non-syndromic craniosynostosis related to the 
loss of PCYT1B in humans, with the deletion of Xp22.11 on the X chromosome (van 
Kogelenberg et al., 2011). The significance of cell membrane integrity appears to have 
substantial outcomes in monitoring signalling dyamics. Furthermore, receptors carrying the 
Crouzon mutation is known to have altered trafficking dynamics. In the case for FGFR2-C278F, 
there is an increased localisation of the receptor in the cell cytoplasm due to deficiencies in 
trafficking to the cell surface (Hatch et al., 2006). Overall, this implies Fgfr2cC342Y/+ is likely to 
have affected receptor trafficking owing to disrupted cell membrane integrity through the 
indirect control of Pcty1b. 
7.3.2.5-Pdgfb 
 
Platelet derived growth factor (PDGF) signalling is prominent in embryogensis, where 
it is associated with cellular proliferation, survival, migration and formation of the extracellular 
matrix (Hoch and Soriano, 2003). Similar to FGFRs, Platelet derived growth factor receptors 
(PDGFR) are tyrosine receptor kinases binding to secreted PDGF ligands. Functional PDGFRs 
exist in three dimers αα (PDGFRα), αβ(PDGFRαβ) and ββ (PDGFRβ), for which the pairing 
allows differential pathways activation and ligand specificity. Similar to FGFRs, the isoforms 
are differentially expressed in specific tissue to promote paracrine signalling, with PDGFRα 
broadly expressed in the mesenchyme. There are four isoforms of PDGFs identified: PDGFA, 
PDGFB, PDGFC and PDGFD. All functional PDGFs are secreted homodimers, with only 
PDGFA and PDGFB able to form heteodimers together. These ligands have different affinities 
for PDGFRs, with PDGFB dimers possessing affinities to all three isoforms of PDGFRs (Hoch 
and Soriano, 2003).  
PDGFRs are critical for skeletogenesis (Soriano, 1994, Soriano, 1997, Tallquist and 
Soriano, 2003). Pdgfrα-/- embryos display multiple midline defects along the axial skeleton 
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likely due to somite mis-specification, and a facial cleft (Soriano, 1994, Tallquist et al., 2003). 
The facial cleft is due to deficiencies in NCCs populating the frontal nasal prominence, thanks 
to altered chemotaxis and limited proliferation capabilities (He and Soriano, 2013). In contrast, 
conditional deletion of Pdgfrβ in the NCC lineage is less severe, resulting in widening of the 
nasal septum and delayed palatal closure (Fantauzzo and Soriano, 2016). This redundancy may 
stem from the compensatory effect of the α isoform (Fantauzzo and Soriano, 2016). Both 
isoforms also genetically interact, as Pdgfrβ-/- in a Pdgfrα-/-  background yielded extended facial 
clefting spectrum to the α isoform (Fantauzzo and Soriano, 2016).  
Despite phenotypic spectrum yielded between both isoforms, the phenotypic 
consequence is largely related to the ligand specificities of the PDGF binding domains: 
Swapping out the catalytic domain of a PDGFR and replaced that from the other isoform (i.e α 
to β or β to α) resulted in largely redundant phenotypes (Klinghoffer et al., 2001). This suggests 
the signal transduction of PDGFRs is largely conserved, and the phenotypic consequence is 
minor to that of ligand specificity. It has been recently demonstrated from the same group the 
involvement of PDGF signalling in craniosynostosis (He and Soriano, 2017). Here, ectopic 
PDGFRα signalling led to expansion of the calvarial cartilage, and invasion of chondrocytes 
into the suture mesenchyme, which eventually trans-differentiated into osteoblasts (He et al., 
2017). PDGFA is the ligand responsible for chondrocyte specification, where increasing 
exposure of mesenchymal cells to PDGFA promotes cartilage formation (Tallquist and Soriano, 
2003). This is likely to be channelled through the PI3K-AKT pathway, a primary effector of 
PDGFRα (Klinghoffer et al., 2002, Fantauzzo and Soriano, 2014, He and Soriano, 2017). Taken 
together, PDGFRα signalling appears to be the dominant isoform in skeletogenesis and 
craniofacial development.  
In spite of this, Pdgfb-/- displays strong phenotypic similarities to Pdgfrβ-/-, suggesting 
the ‘B’ homodimer is a major binding partner to PDGFRβ (Soriano, 1994, Leveen et al., 1994). 
Major characteristics of signalling misregulation by the β isoform includes glomerular 
patterning defects and haemorrhage. One common phenotype of overactive PDGFR signalling 
is fibrosis reported in multiple organs, implying its role in inflammation and responses to injury 
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(Czochra et al., 2006, Hoyle et al., 1999, Gallini et al., 2016, Olson and Soriano, 2009). 
However, excessive PDGF can also stimulate proliferation in certain cell types, such as glial 
progenitors residing in the central nervous system (Noble et al., 1988). Overexpression of Pdgfb 
in astrocytes induces dedifferentiation into neural progenitors in gliomas (Dai et al., 2001). 
Similar responses were reported in osteogenesis, as MSC proliferation was less in Pdgfrβ-/- , but 
more importantly driving osteoblast differentiation (Tokunaga et al., 2008). In fact, the 
differentiation and mineralisation of osteoblast were in part, owed to the synergistic effects of 
BMPs and FGFs (Chaudhary et al., 2004). Application of PDGFB in vitro inhibits osteoblast 
differentiation, with a downregulation of osteogenic genes such as Runx2, Osterix and 
osteocalcin (Tokunaga et al., 2008). Cell therapies have been devised to take advantage of the 
tripartite effects of PDGFRβ, BMPs and FGFs (Chen et al., 2015b). Chen et al., 2015 
demonstrated that it is possible to pre-amplify hematopoetic stem cell (HSC) population in vitro 
through the ectopic induction of Pdgfb, prior to delivery into an irradiated (bone marrow 
deficient) host animal. Here, the authors observed a substantial increase in bone density, and 
discussed the clinical benefits for treatment of bone diseases such as osteomalacia (Chen et al., 
2015b). The downregulation of Pdgfb in Fgfr2cC342Y/+ fits in line with the previous studies, 
implying ectopic differentiation activity in the suture mesenchyme, and that PDGF signalling 
acts downstream of FGFR2 to promote suture closure.  
7.3.2.6-Rsad2 
 
Radical SAM domain containing 2 (Rsad2) encodes the protein viperin. Viperin was 
first discovered in cells in response to human cytomegalovirus (HCMV) infection. Rsad2 is 
downstream of interferon (IFN) signalling, and is responsive to IFNα, IFNβ and IFNγ (Chin and 
Cresswell, 2001). Upon expression of Rsad2, viperin is translocated to the endoplasmic 
reticulum, to the Golgi apparatus and finally to the cytoplasmic vacuoles-a cellular phenotype in 
response to cytotoxic factors (Chin and Cresswell, 2001). Rsad2 displayed the greatest 
downregulation in Fgfr2cC342Y/+, and was therefore chosen for expression validation. Despite the 
role of Rsad2 in response to virus, several studies also report Rsad2 to be downregulated in 
autoimmune bone diseases such as rheumatoid arthritis (He et al., 2016, Raterman et al., 2012). 
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This prompts the role of Rsad2 in bone remodelling to cytokines and inflammation. Despite the 
link of Rsad2 to FGFR2c signalling being elusive, the role of cytokines modulating the 
extracellular milieu is well described especially in the field of neurodegeneration (Blank and 
Prinz, 2017). IFN signalling is a major effector pathway for immune responses, and is also 
responsible for central nervous system homeostasis. IFNs are upregulated in astrocytes in 
response to neurotoxicity and is critical for microglial activation. This unique anti-inflammatory 
response allows microglia to secrete a series of cytokines, such as interleukins, to offer 
protection against neurotoxicity and degeneration. Due to their anti-inflammatory and survival 
properties, IFNβ has been clinically trialled to reduce relapse in multiple sclerosis patients 
(Chofflon, 2000). IFNs also play multiple roles in osteogenesis. For instance, IFNγ is a positive 
regulator for osteoblast differentiation and attenuates osteoclast activity (Croes et al., 2016, 
Duque et al., 2009, Takayanagi et al., 2000). Additionally, conditional knockout of IFNγ 
receptor (IFNγR-/-) led to substantial deterioration of bone architecture (Takayanagi et al., 2000). 
Conversely, IFNβ augments osteoclast activity and is linked to bone resorption (Seeliger et al., 
2015). The significance of IFN signalling is therefore to promote bone homeostasis and 
remodelling of the cytoarchitecture, and signalling misregulation has led to progressive bone 
diseases such as osteoporosis (Seeliger et al., 2015).   
Osteoporosis has been linked to Stat1 misexpression, a target of IFN signalling and the 
P13K-AKT pathway, where Stat1 attenuates osteoblast differentiation and promotes 
osteoclastogenesis (Seeliger et al., 2015, Kim et al., 2003b). Specifically, Stat1 physically 
inhibits Runx2 to prevent expression of osteogenic genes such as osteocalcin. IFNγ is upstream 
of Stat1, and is able to relieve the Stat1-Runx2 interaction to promote osteogenesis, which 
explains increased bone mass in Stat1-/- despite having accentuated osteoclast activity (Kim et 
al., 2003b). As Rsad2/viperin is a downstream target of IFN signalling, along with RNAseq 
dataset pointing towards its expression is regulated by FGFR2c, it provides a novel link 
between osteogenesis and inflammatory signalling. One speculation into the mode of action by 
viperin in osteoblast differentiation could involve the cytoskeleton (Seo et al., 2011). Despite 
reports of Rsad2 expression in reponse to virus, it also promotes viral transmission between 
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cells (Chin and Cresswell, 2001, Seo et al., 2011). HMCVs have been hypothesised to 
specifically target Rsad2 expression because of viperin’s ability to disrupt adenosine 
triphosphate (ATP) synthesis in the mitochondria, which subsequently have adverse effects on 
actin stability (Seo et al., 2011). Osteoblast differentiation is dependent on the cytoskeleton, 
whereby stabilised actin filaments (F-actin) is required for MSCs differentiating to an 
osteogenic lineage (Chen et al., 2015a). Therefore, the downregulation of Rsad2 by FGFR2c 
leads to the stability of the cytoskeleton, augmenting osteoblast differentiation.      
7.3.3-Justifications of using LCM to screen the embryonic suture 
 
The downstream targets of FGFR2c responsible for regulating suture patency remain 
relatively uncharacterized, and screening the embryonic sutures of Fgfr2cC342Y/+ directly 
provides a useful method to identify these genes. The current transcriptomic approach involves 
screening human patients with syndromic craniosynostosis, where they are categorized and 
profiled based on their phenotype (Reardon et al., 1994, Muenke et al., 1994, Twigg et al., 
2015, Twigg et al., 2004, Coussens et al., 2007). This ‘shotgun’ approach does not offer 
sufficient resolution to uncover molecular signatures inside the suture, and moreover, does not 
draw links between FGFR2c signalling and its targets. Furthermore, the expression of calvarial 
osteoblasts is different within in vivo and in vitro conditions, which makes micro-profiling 
analysis difficult (Zhao et al., 2015, Coussens et al., 2008). Indeed, one of the greatest 
challenges is to maintain stable gene expression when osteoblasts are translocated to an in vitro 
environment prior to profiling. This is related to osteoblasts reverting to a primitive state by de-
differentiating into pre-osteoblasts in culture upon removal of the ECM (Owen et al., 1990, 
Coussens et al., 2008). An interesting study performed by Coussens et al (2008) appears to 
address these issues by comparing microarray profiles of human cranial sutures directly 
obtained from surgery and those cultured under in vitro conditions. By comparing the changes 
in expression profiles, it is possible to identify the changes in gene expression responsible for 
osteoblast differentiation. Despite playing a minor role in craniofacial development, one of the 
most intriguing observations was the ectopic upregulation of FGFR3 more than a 100 fold 
(Coussens et al., 2008, Deng et al., 1996). As FGFR3 is a negative regulator of bone formation, 
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a speculation for this upregulation could be an attempt for osteoblasts to trigger negative 
feedback in response to ectopic osteoblast differentiation (Deng et al., 1996).  
However, despite experimental success in humans, extracting samples accurately from 
mouse embryonic sutures poses a greater challenge. This challenge was addressed using LCM 
to access the sutures of Fgfr2cC342Y/+ and profiling it. In particular to the LCM, the sutures are 
almost inaccessible during embryonic development due to its size. A previous microarray screen 
attempted in the lab involved isolating the coronal suture by cutting around the vicinity of the 
suture, and led to the identification of genes expressed in the periosteum (e.g. Dlk). Adopting 
FACS sorting is not possible due to the lack of markers available to the coronal suture along 
with the difficulty of obtaining sufficient cells to start a primary culture. Altogether, LCM was 
identified as a potential method to overcome these challenges, and to provide a solution for 
screening specificity.  
7.3.4-Experimental limitations 
Multiple challenges have risen throughout the LCM based gene expression analysis 
pipeline that has potentially compromised the quality of the experiment. Firstly the samples, 
since the genetic background of the mice were not uniform prior to the screening process. For 
example, the mice were generated on a mixed CD1 background to that of an inbred strain i.e. 
C57BL/6, and were also not sex matched. The latter was a decision based on the lack of 
phenotypic differences between males and females. Moreover, this was necessary to conform to 
efforts to minimize intra-litter variability by choosing littermates.  
A very important technical challenge for this experiment was attempting to preserve 
RNA integrity. Due to the nature of extracting RNA from stained tissue sections, the RNA 
quality was below the average generally used for sequencing, as indicated by Tapestation 
analysis in Figure 58 B. Furthermore, due to low levels of starting material, it was necessary to 
amplify RNA prior to cDNA library synthesis which resulted in amplification of non-specific 
signals in the process. The consequence as such, can be seen in Figure 59 in both the PCA plot 
and genome alignment of the samples. Specifically, the scattered data points along the PC1 and 
PC2 axis gave variabilities to expression analysis (Figure 59 A). This was particularly notable 
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in the WT group where unique expression profiles were detected between samples, which 
would have skewed the overall analysis of the dataset. Furthermore, there was a strong 3’ 
representation in the genome given by the alignment scores in Figure 59 B, implicating RNA 
degradation. Altogether, these factors may have skewed the overall analysis. Future experiments 
would aim to preserve RNA integrity by minimizing tissue processing. For instance, RNA 
quality could be improved if the samples were not processed for histology prior to LCM. 
However, histological staining was deemed critical to visualize the limits of the suture and 
therefore allow precise extraction of the desired tissue. This would be particularly important for 
an experiment profiling specific regions inside the suture such as the osteogenic front. This also 
implies the potentials for variability due to differential isolation from a heterogenous group of 
cells, including those that do not correspond to expressing Fgfr2c. Fgfr2 expression is abundant 
in the osteogenic front, but this LCM experiment also incorporated a substantial amount of the 
mesenchyme (Johnson et al., 2000). This could further explain the lack of differential 
expression when the RNAseq dataset was run against the FGF signalling entity list. Owing to 
multiple factors giving rise to these variabilities, subsequent analysis was not determined using 
the ‘p-value’ approach, but on the overall fold change instead. To justify the analysis further, 
read counts must be consistent across the three biological replicates within their respective 
genotype. This approach has yielded success in the selection of candidate genes for expression 
validation, for which the results corresponds to trends reported in the previous literature.    
Expression validation was attempted using different methods including RNA extracted 
from whole E12.5 embryos. This was partly due to the extensive pipeline required for LCM and 
the overall cost of the experiment. E12.5 was chosen due to the simplicity of processing the 
sample for RNA extraction and at a suitable stage of craniofacial morphogenesis (Deckelbaum 
et al., 2012). Performing expression validation at E12.5 wholemount should be proceeded with 
caution due to inconsistencies in spatial-temporal resolution of gene expression. A potential 
solution could involve RNA isolation from more precisely dissected the head mesenchyme 
tissues.  
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RT-qPCR analysis using the delta-delta CT method identified differences for the 
reference gene (Rn18) between litters (data not shown). Specifically, Fgfr2cC342Y/+ possessed 
high Ct (Cycle threshold) values in the raw data, which ultimately led to the perception of 
ectopic expression of genes in question when the ratios were calculated. This false positive 
(‘Type 1 error’) can be perceived when non-parametric Kruskal Wallis test with Dunn’s posthoc 
was performed on the analysis. Reference genes expression should not change regardless of the 
experimental condition and similar results were obtained when GAPDH was used against the 
same samples (data not shown). Therefore, the high Ct values were not due to the low input of 
cDNA, but endogenous expression levels between the litters. Expression validation should be 
processed within the same litter in the future and cDNA concentration checked within the 
desired benchmark across all samples.  
As an alternative for RT-qPCR expression validation, the following methods could be 
explored. Firstly, one could attempt to cut around the vicinity of the suture at E16.5 to obtain a 
defined region at the correct stage. Additionally, a microneedle made from capillary tube could 
be inserted into the coronal suture to scrape off the mesenchyme and osteogenic fronts. Here, 
the extracted RNA quantity is expected to be low, and would need to be amplified if necessary 
prior to cDNA synthesis. Finally, RT-qPCR would give the inference on the quantity of 
expression; qualitative approaches would involve designing ISH probes or performing IHC on 
the genes in question.      
7.3.5-Future Directions 
 
7.3.5.1-Functional analysis 
The immediate future requires addressing the pit-falls occurred during expression 
validation and to optimize the methods for quantitative and qualitative assays. In the medium 
term, experiments will need to confirm the candidates’ relationship with FGFR2c signalling. 
This could be performed in vivo, ex-vivo or in vitro. The general scope revolves around the 
manipulation of the FGFR2c signalling pathway and examining candidate gene expression 
output. This could be simply achieved in vivo by performing IHC or ISH directly on the 
Fgfr2cC342Y/+. Ex vivo or in utero experiments can also help achieve this aim, such as applying 
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FGFR2 inhibitor bead implants directly onto the embryonic suture of Fgfr2cC342Y/+ and 
observing the candidate’s response. In the long term, gene expression will need to be confirmed 
in the human calvaria, which could be carried out on samples procured via the Human 
Developmental Biology Resource (http://www.hdbr.org/). The ultimate aim of this research is to 
better understand the molecular events in play with a view to developing rational non-invasive 
compounds that can be used to minimize recurrent surgeries. Manipulating the RAS-MAPK 
cascade is a possibility but may prove to be highly risky owing to its potency (Shukla et al., 
2007). Should a candidate gene possess significant potential as an effector of FGFR2c in 
relation to the development of syndromic craniosynostosis, therapeutic compounds would aim 
to target these candidates directly to either potentiate or attenuate their expression. Novel 
compounds can be tested in vitro prior to the translation onto Fgfr2cC342Y/+ to assess the impact 
on suture morphogenesis. In particular, the mouse model will provide a platform for pre-clinical 
evaluation of the best routes of administration, safety and effectiveness of compound post 
surgery.      
7.3.5.2-Transcriptomic experiments  
‘FaceBase’ is a consortium available for craniofacial researchers 
(http://www.facebase.org). Their aim is to ‘generate data in support of advancing research into 
craniofacial development and malformation’ (www.facebase.org/about). FaceBase has a wide 
range of curated RNAseq datasets available online for craniofacial development. More 
importantly, several groups have contributed to this development by generating transcriptomic 
atlases of calvarial sutures, also acquired from LCM, during the time of the current study. So 
far, FaceBase has curated databases for the transcriptomic atlas of coronal sutures in 
Fgfr2S252W/+ (Apert) and Twist1+/- at multiple embryonic stages. Therefore, it would be useful to 
cross-reference this data with that of Fgfr2cC342Y/+ from this study. In particular, the data from 
Fgfr2S252W/+ might be expected to be similar to that of Fgfr2cC342Y/+ due to the mutations 
affecting Fgfr2. The aim of cross-referencing databases allows genes common to 
craniosynostosis to be identified, and therefore improving the chance of relevant broader acting 
novel therapeutic targets. As craniosynostosis is a progressive pathology, the expression profile 
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is expected to be dynamic and changes temporally. Further screens should involve comparing 
gene expression profile at multiple stages for the onset of suture morphogenesis to that of just 
prior to suture closure. Genes involved in craniosynostosis should be persistent throughout all 
the temporal times points analysed. Finally, a spatial transcriptomic atlas could also be explored 
through profiling landmarks within the coronal suture, such as the osteogenic front, 
mesenchyme and periosteum. 
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General Discussion 
And 
Concluding Remarks 
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8.1-Overall summary and scope of research in the wider community 
This doctoral research set out to investigate some of the molecular events contributing 
to syndromic craniosynostosis. Currently, the cellular and biochemical pathways regulated by 
FGFR2c during craniofacial development still remain elusive. Therefore, this lab created a 
conditional mouse model that overexpresses FGFR2c in order to evaluate the effect of altered 
expression on craniofacial development. This study first characterised the differential 
sensitivities to Fgfr2c misregulation in both NCC and mesoderm lineages. Specifically, Fgfr2c 
overexpression results in hypoplasia of the NCC derived cranial bones, suggesting NCC 
derivatives are affected by increased Fgfr2c signalling. Furthermore, Fgfr2c overexpression 
does not result in craniosynostosis. This may be secondary to ostegenic hypoplasia and/or works 
in concert with the attenuation of osteoblast activity in the osteogenic front. On a molecular 
level, it is known that lineage specific osteoblasts have differential expression profiles and 
altered expression Fgfr2c is likely to contribute to the spatio-temporal dynamics of the 
signalling response, potentially explaining the phenotypic consequences (Quarto et al., 2009, 
Quarto et al., 2010). However, tissue sensitivities towards FGFR2c signalling have not been 
reported in vivo, and questions remain as to the significance of the differences observed between 
the frontal and parietal osteoblasts along with their roles in bone development and suture 
patency. One hypothesis is that the frontal bone may be more dynamic to bone remodelling in 
order to accommodate the features of the skull (Moazen et al., 2015). From a clinical 
perspective, the osteogenic differences between both lineages have implications regarding the 
efficiency of bone regeneration and for selecting the correct osteoblasts for potential 
transplantation therapy (Doro et al., 2017). Differential sensitivities of the cranial mesenchyme 
demonstrated here, confirm differences in the specific embryonic lineages, particularly in 
response to FGF ligands during early development as recently reported for FGF8 (Schmidt et 
al., 2018).  
One of the most striking features of Fgfr2c overexpression compared to the 
Fgfr2cC342Y/+ mutant is the lack of craniosynostosis. To investigate this further, this study 
examined readouts of the FGF signalling pathway in the coronal suture. A key finding from this 
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experiment was the demonstration of pERK upregulation in both R26RFgfr2cV5/+; βactinCRE/+ and 
Fgfr2cC342Y/+. These similarities were unexpected due to the contrasting phenotypes of these 
sutures and the biochemical nature of receptor activation verses overexpression. Although 
pERK is upregulated in both Fgfr2cC342Y/+ and R26RFgfr2cV5/+; βactinCRE/+, only Fgfr2cC342Y/+ 
sutures show increased levels of ALP. This indicated that augmentation of RAS-MAPK 
signalling in the suture alone was not sufficient to derive a coronal synostosis phenotype. This 
was further supported by amelioration of the coronal synostosis phenotype when the Fgfr2c 
overexpression allele was introduced onto the Fgfr2cC342Y/+ background. This has pronounced 
implications for our understanding of the FGFR2c signalling paradox, where the complete 
removal or activation of FGFR2c signalling both leads to craniosynostosis (Eswarakumar et al., 
2004, Eswarakumar et al., 2002). Ultimately, elucidating the paradox should involve 
understanding the differences between cascade activation and the events immediately occurring 
after receptor activation, such as receptor turnover in the presence of GOF mutations. 
Furthermore, little is known about the downstream consequences of individual signalling 
cascades in an in vivo context. Targeted disruption of downstream mediators should help to 
address the roles of individual cascades in craniofacial development. As such, this study offers 
experimental insights suggesting that it is possible to use cancer mouse models to understand 
consequences of growth factor signalling in craniofacial development. Extracellular modulators 
of FGF ligands (e.g. HSPGs) and negative feedback mechanisms (e.g. SPRY and DUSP6) are 
also crucial to FGF signalling dynamics (Ornitz and Itoh, 2015). These are currently limited in 
our present understanding of craniofacial development, but in vivo evidence already implied 
Dusp6 LOF is sufficient to drive craniosynostosis (Li et al., 2007). Furthermore, overexpression 
of Spry2 in vitro preludes the expression of various osteoblast markers, which suggests low 
FGF signalling is required for cellular differentiation (Yang et al., 2006). This study confirmed 
the expression of Spry2 and Spry4 in the cranial bones, and therefore, understanding the 
relationship between FGF signalling and feedback regulators will give insights into the 
regulatory loops involved in maintaining suture patency.  
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Another interesting finding was the emerging role of cartilage in craniosynostosis, since 
Fgfr2cC342Y/+mice were shown to display excessive cartilage formation.  Membranous bones 
were originally thought to form without a cartilage template (Ornitz and Marie, 2015, Akiyama 
et al., 2002). However, several studies have touched upon excessive cartilage in pathological 
conditions (Wang et al., 2005b, Peskett et al., 2017, Behr et al., 2011a, He and Soriano, 2017). 
Their roles are not well characterised, but similarities can be drawn between suture closure and 
fracture healing in endochondral bones, as chondrocytes have been witnessed to invade the 
damaged mesenchyme to repair the bone (He and Soriano, 2017, He et al., 2017). Therefore, 
lessons may be learnt from fracture healing to benefit the clinical craniofacial community.  
Little is known about the downstream genes that may be misregulated as a consequence 
of Fgfr2c GOF mutation. This study therefore used the Crouzon mouse with its craniosynostosis 
phenotype as a model in which to monitor altered gene expression in developing sutures using 
RNAseq. LCM was adopted to specifically sample the embryonic coronal suture with high 
resolution. The long-term goal was to identify and test potential candidate genes that could in 
the future be targeted for therapy. This study succeeded in piloting the LCM technique and thus 
to generate an expression profile of the coronal suture mesenchyme. The experiment was 
similar to that performed elsewhere for a different mutant mouse, Fgfr2S252W/+ (Brinkley et al., 
2016). It will therefore, be important in the near future to cross-reference the Fgfr2cC342Y/+ and 
Fgfr2S252W/+ data in order to identify common genes affected by FGFR2 signalling.   
Several other issues remain to be addressed beyond the scope of this PhD and in the general 
craniofacial community: 
1) This project investigated the embryonic events leading towards craniosynostosis but 
did not look into the postnatal stages. This next stage may be especially relevant, since the 
craniosynostosis phenotype is progressive from late gestation and fully penetrant postnatally. 
Postnatal experiments with the aim of delaying or halting craniosynostosis development would 
be particularly relevant from a clinical perspective, and this would involve the testing of novel 
therapeutic compounds and surgical applications. Examples could include testing of RNA 
interference compounds or pharmacological agents that manipulate the FGFR2 signalling 
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pathway to prevent craniosynostosis in Fgfr2cC342Y/+. Other means could also include 
investigating the optimal methods of administration. Performing these experiments in vivo helps 
to monitor for such unforeseen events as unexpected side effects that might develop over the 
longer term, in addition to any off target consequences. A comprehensive understanding of 
FGFR2 signalling is vital to developing non-invasive therapies. As an example, 
pharmacological interventions may not be ideal for inhibiting FGFR2-C342Y as the receptor 
activation is ligand independent, and efforts should aim to target intermediates or downstream 
target genes that contribute to craniosynostosis. Furthermore, biomechanical modelling of the 
calvarial bones will also be necessary to test novel surgical techniques to improve craniofacial 
corrections in the long term. It is therefore an important goal to translate these findings from the 
bench to clinical benefit, with the aim of reducing the need for recurrent surgery in patients with 
syndromic craniosynostosis.  
2) An outstanding question remains as to the molecular events responsible for 
craniosynostosis in Fgfr2c-/-, and whether they are similar to that of Fgfr2cC342Y/+. In the short 
term, future work could involve performing the same experiments in this study on the Fgfr2c-/-, 
and compare the data to that of Fgfr2cC342Y/+ to determine how they differ in vivo. Other 
experiments might also aim to understand how therapeutic compounds behave in Fgfr2c-/- to 
that of Fgfr2cC342Y/+, considering both manifest the same phenotype. In addition, transcriptomic 
profiling of Fgfr2c-/- could also facilitate the understanding of identifying common and/or 
contrasting molecular signatures, which are currently unavailable in the literature. Uncovering 
the molecular signatures between both these models will be crucial to generate a blueprint of 
FGF signalling misregulation. The outcome of this data will provide insights into novel 
regulatory networks and interactions required for normal FGF biology. 
3) Despite the fact that Wnt1CRE/+ and Mesp1CRE/+ are widely used in studies of 
craniofacial development including calvarial bone formation (Jiang et al., 2002), these  do not 
specifically target the suture mesenchyme. Craniosynostosis in Saethre-Chotzen syndrome, for 
example (Twist1+/-), stems from the mesenchyme and suture abolishment is thought to be 
mechanistically distinct to that related to FGFR2 misregulation (Behr et al., 2011b, Zhao et al., 
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2015). Therefore, obtaining suture specific CRE lines will be useful to study the mesenchyme 
without interference of the calvarial bones. To this end, En1CRE/+ and Gli1CRE/+ are CREs 
currently available that according to the literature specifically target the suture mesenchyme 
(Deckelbaum et al., 2012, Deckelbaum et al., 2005, Zhao et al., 2015). Albeit not tested, CRE 
lines reflective of mesenchymal markers such as Prx1CRE/+ may also be explored (Logan et al., 
2002). Furthermore, adopting inducible CRE lines would circumvent any postnatal lethality 
caused by secondary phenotypic features like cleft palate and allow for the analysis of postnatal 
progression of craniosynostosis. 
  4) Perhaps one of the foremost challenges posed is the localisation of the FGFR2 
isoforms in vivo. The difficulty lies as a consequence of the high sequence homology of the 
splice variants, and understanding its spatial expression provides inference as to where to target 
the isoforms locally in vivo. Visualizing the individual splice-forms could be attempted using 
the following approaches: 
i) Antibodies specific for FGFR2 isoforms: There are few companies that 
produce isoform specific antibodies against FGFR2 and most studies using isoform 
specific antibodies to date, have focused on protein assays (i.e. enzyme-linked 
immunosorbent assay; ELISA) or immunoblots (Nonogaki et al., 2016). Stringent 
controls must be first examined in vitro to establish their validity. This may be achieved 
using immuoblots following cellular transfection of plasmids carrying the Fgfr2 splice 
form. For instance, a positive band is to be expected only in respective cellular 
transfection corresponding to the antibody of interest. Next, these antibodies would be 
assayed by IHC to determine the precise protein expression. Lineage specific controls 
are vital for this step. The developing limb bud serves as an excellent control as both 
isoforms are expected to be in the primordia (Li et al., 2007).    
ii) ISH on Fgfr2b-/- and Fgfr2c-/-: Whilst previous studies have attempted to 
perform ISH on the splice variants, the resolution has not been sufficient to derive 
conclusive data (Orr-Urtreger et al., 1993, Rice et al., 2000). Further inspection of the 
different splice variants using ISH could be performed on isoform-specific knockouts. 
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The overall design of the probe should cover Fgfr2 and common to both isoforms. The 
aim is to locate expression patterns unique to respective isoform specific knockouts. For 
example, if ISH is performed in the Fgfr2c-/- developing limb bud, positive 
hybridization should only be expected in the epithelium but not the mesenchyme, and 
vice versa for Fgfr2b-/-. By comparing the expression patterns unique to Fgfr2b-/- and 
Fgfr2c-/-, the domains expressing respective isoforms can be pinpointed with accuracy 
and mapped in detail.  
iii) Lineage tracing of FGFR2 isoforms driven under an endogenous promoter: 
The use of reporter lines allow cellular behaviour to be monitored in vivo and has 
revolutionised the field of developmental biology and our understanding of both 
embryogenesis and organogenesis. However, there is a lack of in vivo evidence for 
lineage tracing of FGFR2 isoforms to date. The difficulty of generating a reporter line 
for this gene is likely due to the nature of splicing mechanism of the isoforms, making it 
difficult to design a targeting construct. Generating a viable construct must therefore 
bypass any disruption to biological function and splicing mechanism. A potential 
approach to transgenesis could be attempted through generation of a fusion construct 
(Figure 64 A and B): Here, reporters (e.g. GFP) are flanked by a nucleus tag-Histone 
H2B and a 2A peptide sequence (Figure 65 A). The 2A peptide sequence was originally 
identified in foot and mouth virus with an aim to generate the mature viral protein 
(Ryan et al., 1991). Upon gene expression, the 2A peptide cleaves the reporter protein 
from the protein of interest and generates two independent products (Figure 65 B). As 
the reporter protein has a histone 2B tag, it is targeted for the nucleus upon proteolytic 
processing (Figure 65 B). This method offers significant advantages in lineage tracing, 
as it corresponds to the direct readout of the endogenous promoter i.e. Fgfr2. 
Furthermore, the 2A peptide is small (approx. 25bp), which helps to minimize 
biological interference (Ryan et al., 1991).  
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Figure 64: Potential approach to generate endogenous reporter mice for Fgfr2b (A) and 
Fgfr2c (B) lineage tracing.  
Exon 8 or 9 is substituted with a targeting construct containing the H2B-GFP-2A construct 
downstream of the exon of interest. HSV-TK/DTA: Human simplex virus-thymidine 
kinase/Detheria toxin; IIIb: exon 8 specific for Fgfr2b; IIIc: exon 9 specific for Fgfr2c; Neo: 
Neomycin selection cassette. 
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Figure 65: Expression of the H2B-eGFP-2A construct.  
(A) Mature mRNA of the Fgfr2b or Fgfr2c reporter mice with H2B-GFP-H2B construct; (B) 
Upon transgene expression, the 2A peptide separates the reporter protein from the mature 
receptor (bottom; with only D3 loop illustrated). As the reporter protein is tagged with histone 
2B, it is bounded for the nucleus upon proteolytic processing. TM: Transmembrane domain.  
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8.2-Concluding remarks 
This study has demonstrated that FGFR2c overexpression yields craniofacial hypoplasia 
without a craniosynostosis phenotype. The most striking observation is the phenotypic variation 
between R26RFgfr2cV5/+; actinCRE/+ and Fgfr2cC342Y/+ despite similarities in signalling dynamics. 
This implies that receptor overexpression and GOF mutations are mechanistically different, and 
require a different downstream interpretation to the WT. This is well characterised in vitro with 
preferential signal transduction, and the results in this thesis relate these findings to an in vivo 
context. Maintaining the correct balance between proliferation and differentiation is crucial for 
osteogenesis and suture patency, and this study has further contributed to the elucidation of the 
FGFR2c signalling paradox. Furthermore, this study opened up a new horizon towards the role 
of cartilage in syndromic craniosynostosis that is not associated with Crouzon syndrome, and 
identified genes that were not previously linked to FGFR2 related syndromic craniosynostosis 
using LCM. In conclusion, elucidating the complexity of FGFR2c signalling will improve the 
understanding of normal craniofacial development and its related pathologies, while providing a 
framework for the innovation of novel therapeutic strategies. 
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Appendix 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RNA extraction for tissue/cells Duration 
Homogenize in 1ml Trizol Variable 
Incubation at RT 5 mins 
Add 0.2ml Chloroform 3 mins 
Centrifuge 12,000rpm 4oC 15 mins 
Isolate aqueous phase and transfer to new tube * N/A 
Add 0.5ml isopropanol ** 10 mins 
Centrifuge 12,000rpm to pellet RNA 10 mins 
Discard supernatant  N/A 
Wash in 1ml 70% EtOH and vortex N/A 
Centrifuge 7,500rpm to pellet RNA 5 mins 
Discard supernatant  N/A 
Air dry at RT  10-20 mins 
Resuspend RNA 20-100ul H2O 
*: Do not remove more than 500ul 
 **: Precipitate overnight at -20oC if low yield 
 
Appendix 1: Trizol extraction 
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Appendix 2  
Cell lysis buffer RIPA Buffer 
50mM Tris Base  150mM NaCl 
150mM NaCl 1% Triton X-100  
1% Triton X-100 
0.5% sodium 
deoxycholate  
1mM sodium orthovanadate 0.1% SDS  
25mM sodium fluoride 50mM Tris-pH 8.0 
1mM protease inhibitor 
cocktail (MINI) 
1mM protease inhibitor 
cocktail (MINI) 
 
Buffers Reagent Weight/Volume 
4x running gel buffer  
1.5M Tris-Base pH8.8 90.86g 
HCl Adjust 
H2O 500ml 
10x running buffer 
Tris-Base 30.2g 
Glycine 144g 
10% SDS 100ml 
H2O Top up to 1000ml 
10x TBS 
NaCl 80g 
KCl 2g 
1M Tris HCl pH 7.5 250ml 
H2O Top up to 1000ml 
0.1% TBST 
10x TBS 100ml 
Tween-20 1ml 
H2O 900ml 
 
Appendix 2: Immunoblots
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Appendix 3 
 
 
 
 
E18.5 wholemount bone and cartilage stain 
 Protocol Duration 
 Dehydrate in 75% EtOH overnight, 4oC 
 0.01% Alcian Blue working solution overnight, RT 
 Wash in 75% EtOH overnight, RT 
 Clear in 1% KOH Until translucent 
 0.01% alizarin red working solution overnight 
 Wash in 1% KOH overnight 
 20% Glycerol-KOH overnight 
 80% Glycerol-H2O overnight and storage 
 
   
   Reagent Stock Ratio 
Alcian blue working solution 
Alcian blue 0.01% 
Acetic acid 20% 
75% EtOH 80% 
Alizarin red working solution 
Alizarin red 0.01% 
KOH 1% 
Appendix 3: Wholemount bone and cartilage stain 
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Appendix 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent Stock Volume/Weight 
NTMT 
100mM NaCl (5M stock) 1ml 
100mM Tris Base pH9.5 (1M stock) 5ml 
50mM MgCl2 (2M stock) 1.25ml 
1% Tween 0.5ml 
H2O Top up to 50ml 
NBT/BCIP-NTMT 
solution 
4-nitroblue tetrazolium chloride 
(NBT): 4.5ul/ml 22.5ul 
5-bromo-4-chloro-3-indoyl-
phosphate (BCIP): 3.5ul/ml 17.5ul 
NTMT Top up to 5ml 
1% Nuclear Fast 
Red 
Nuclear fast red 5g 
H2O 500ml 
ALP assay (frozen sections) 
Protocol Duration 
Thaw frozen sections Variable 
Fix in 4% PFA 8mins 
Wash in 1x TBS 2x 5mins 
Permeabilise in 0.1% TBST 5mins 
Wash in NTMT 2x 5mins 
Develop in NBT/BCIP-NTMT Variable 
Wash in 1xTBS 5mins 
Counterstain in 1% nuclear fast red 5mins 
Wash in H2O 5mins 
Mount in Mowiol    
Appendix 4: ALP assay 
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Appendix 5
Linearisation Volume 
  
In vitro 
Transcription Volume 
 pDNA 10ug linearised pDNA 1ug 
Enzyme buffer 20ul DIG labelling mix 2ul 
Restriction Enzyme 3ul Transcription buffer 2ul 
BSA 2ul RNAse inhibitor 0.5ul 
    RNA polymerase 2ul 
H2O Up to 200ul H2O (Sigma) Up to 20ul 
Appendix 5: Plasmid linearization and in vitro transcription 
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Appendix 6 
 
 
 
 
Reagent Stock Volume/Weight Notes 
DEPC-H2O 
Diethylpyrocarbonate 
(DEPC) 1ml 
Autoclave H2O 1000ml 
DEPC-PBS 
10x PBS (autoclaved) 10ml 
  DEPC-H2O 990ml 
5M NaCl 
NaCl 146.1g 
Autoclave H2O 500ml 
2M MgCl2 
MgCl2.6H2O 203.3g 
Autoclave H2O 500ml 
20x SSC pH4.5 
NaCl 87.7g 
Autoclave 
Sodium Citrate Tribasic 
Dihydrate  44.1g 
Adjust to pH4.5 with HCl Variable 
H2O Top up to 500ml 
10% SDS 
Sodium dodecyl sulphate 50g 
  H2O 500ml 
1M Tris Base 
pH9.5 
Tris Base  121.14g 
Autoclave 
adjust to pH9.5 with HCl Variable 
H2O 
Top up to 
1000ml 
1M Tris HCl 
pH9.5 
Tris HCl  157.6g 
Autoclave 
adjust to pH7.5 with HCl Variable 
H2O 
Top up to 
1000ml 
10x TBS 
NaCl 80g 
Autoclave 
KCl 2g 
1M Tris HCl pH 7.5 250ml 
H2O 
Top up to 
1000ml 
DEPC-MeOH 
MeOH 
make 25%, 
50%, 75% 
  DEPC- H2O Up to 500ml 
MeOH 100% MeOH 500ml   
Appendix 6: WMISH 
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Stocks Reagents Volume/Weight Notes 
0.1% PTW 
Tween-20 1ml 
  DEPC-PBS 1000ml 
4% 
Paraformaldehyde 
(PFA) 
PFA powder 20g 
Dissolve in 
65oC water 
bath DEPC-PBS 500ml 
Hybridisation Mix  
50% Formamide 25ml 
Store in -20oC 
5x SSC pH4.5 (20x stock) 12.5ml 
50ug/ml yeast tRNA (10mg/ml 
stock) 250ul 
1% SDS (10% stock) 5ml 
50ug/ml heparin (25mg/ml 
stock) 100ul 
DEPC-H2O Top up to 50ml 
Solution 1 
50% Formamide 25ml 
  
5x SSC (20% stock) 12.5ml 
1% SDS (10% Stock) 5ml 
DEPC-H2O Top up to 50ml 
Solution 2 
50% Formamide 25ml 
  
2x SSC 5ml 
1% SDS 5ml 
DEPC-H2O Top up to 50ml 
1% TBST 
TBS (10x stock) 50ml 
  
Tween-20 5ml 
DEPC-H2O Top up to 500ml 
NTMT 
100mM NaCl (5M stock) 1ml 
  
100mM Tris Base pH9.5 (1M 
stock) 5ml 
50mM MgCl2 (2M stock) 1.25ml 
1% Tween 0.5ml 
H2O Top up to 50ml 
Developing 
solution 
4-nitroblue tetrazolium chloride 
(NBT): 4.5ul/ml 22.5ul 
  
5-bromo-4-chloro-3-indoyl-
phosphate (BCIP): 3.5ul/ml 17.5ul 
NTMT Top up to 5ml 
Proteinase K 
solution 
Proteinase K  10ug/ml  
  0.1% PTW 10ml 
Post fix 
0.2% Glutaraldehyde (20% 
stock) 80ul 
  4% PFA  10ml 
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Wholemount ISH Protocol Duration 
Embryo preparation  
Fix in 4% PFA Overnight 
Wash in PTW 2x 5 mins 
25% MeOH until embryos sink  
50% MeOH until embryos sink  
75% MeOH until embryos sink  
Proceed or store in -20oC indefinitely 
Hybridisation 
6% H2O2-MeOH 1 hour 
75% MeOH until embryos sink  
50% MeOH until embryos sink  
25% MeOH until embryos sink  
0.1% PTW 3x 5mins 
Incubate in Proteinase K solution 20 mins 
0.1% PTW 2x rinse 
Post fix  20mins 
0.1% PTW 3x 5mins 
1ml hybridisation mix at 70oC 2 hours 
Proceed or store in -20oC indefinitely   
Add ISH probe to 1ug/ml of hybridisation mix  Overnight, 65/70oC 
Post-hybridisation wash and antibody 
Remove hybridisation mix (probes can be reused 5x) N/A 
Wash in solution 1 in hybridisation temperature  Rinse 
Wash in solution 1 in hybridisation temperature  1 hour 
Wash in solution 2 in hybridisation temperature  1 hour 
0.1% TBST 3x 5mins 
Block in 10% sheep serum-TBST 1 hour 
Anti-DIG antibody (1:2000) in 1% sheep serum-TBST 4oC, overnight 
Post antibody wash and development 
1% TBST 5x 10mins  
NTMT 2x 10mins 
Substrate reaction (NBT-BCIP in NTMT) Until developed  
NTMT 3x 5mins 
PBT 3x 5mins 
Fix in 4% PFA For storage 
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Appendix 7  
 
 
 Reagent Stock Volume/Weight Notes 
DEPC-H2O 
Diethylpyrocarbonate 
(DEPC) 1ml 
Autoclave H2O 1000ml 
DEPC-PBS 
10x PBS (autoclaved) 10ml 
  DEPC-H2O 990ml 
5M NaCl 
NaCl 146.1g 
Autoclave H2O 500ml 
2M MgCl2 
MgCl2.6H2O 203.3g 
Autoclave H2O 500ml 
20x SSC pH 7.0 
NaCl 87.7g 
Autoclave 
Sodium Citrate Tribasic 
Dihydrate  44.1g 
adjust to pH 7.0 with HCl Variable 
H2O Top up to 500ml 
1M Tris Base 
pH9.5 
Tris Base  121.14g 
Autoclave 
adjust to pH9.5 with HCl Variable 
H2O Top up to 1000ml 
1M Tris HCl 
pH7.5 
Tris HCl  157.6g 
Autoclave 
adjust to pH7.5 with HCl Variable 
H2O Top up to 1000ml 
1M Tris Base 
pH8.5 
Tris Base  121.14g 
Autoclave 
adjust to pH8.5 with HCl Variable 
H2O Top up to 1000ml 
10% Polyvinyl 
alcohol 
PVA powder 50g 
65oC water 
bath H2O 500ml 
Graded DEPC-
EtOH 
EtOH 25%, 50%, 70% 
  
DEPC- H2O Up to 500 ml 
EtOH 100% EtOH 500ml 
Appendix 7: Section ISH 
 251 
Reagent Stock Volume/Weight/Conc. Notes 
Hybridisation solution 
Formamide 25ml 
Store in -20oC 
5M NaCl 3ml 
1M Tris-Base pH 8.5 1ml 
0.5M EDTA pH 8.0 0.5ml 
1ml Denhart's solution  1ml Denhart's solution 
Dextran sulphate 5g 
DEPC- H2O Top up to 50ml 
Working 
hybridisation mix 
Hybridisation solution 120ul/slide   
Rnase inhibitor  1ul/ml   
Yeast tRNA 0.5mg/ml   
Formamide wash 
Formamide 350ml 
Warm to 65oC 
20x SSC 70ml 
2x SSC 
20x SSC 100ml 
H2O 900ml 
0.2x SSC 
20x SSC 10ml 
H2O 990ml 
20ug/ml Proteinase K 
solution 
10mg/ml Proteinase K 800ul   
DEPC-PBS 400ml   
Buffer 1 
1M Tris-HCl pH 7.6  100ml   
5M NaCl 30ml   
H2O 870ml   
Blocking solution  
HISS 10%   
Buffer 1 Up to 500ml   
Antibody solution 
Anti-DIG antibody 1.2000   
 HISS 1%   
Buffer 1 Vol. depends on slides    
2x Buffer 2 
1M Tris-Base pH9.5 200ml   
5M NaCl 40ml   
2M MgCl2 50ml   
H2O 710ml   
Buffer 2 
2x Buffer 2 500ml   
H2O 500ml   
Developing solution 
2x Buffer 2 7.5ml   
10% PVA 7.5ml   
NBT 67.5ul   
BCIP 52.5ul   
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Section ISH Protocol Duration Notes 
Pre-hybridisation    
Histoclear 2x 10 mins Paraffin start 
100% EtOH 2x 2mins   
75% EtOH 2 mins   
50% EtOH 2 mins   
25% EtOH 2 mins   
PBS 2 mins Cryo start 
Fix in 4% PFA 20 mins   
PBS  2x 2mins   
Proteinase K solution 8 mins   
4% PFA 5 mins   
PBS 2 mins   
Triethanolamine solution 
10 mins  On stirrer drizzle 1ml acetic anhydride 
PBS 2x 2 mins   
25% EtOH 2 mins   
50% EtOH 2 mins   
75% EtOH 2 mins   
100% EtOH 2x 2 mins   
Air dry slides on bench Until dry   
Hybridisation    
Hybridisation at 300ng probe and 120ul hybridisation solution per slide. Coverslip slides and 
lay flat. Transfer into humidified chamber with a wet tissue soaked in 1:1 ratio of formamide 
and 2x SSC 
Hybridise overnight at 65oC   
Post hybridisation washes (in 65oC water bath) 
Warm up SSC and formamide 
solution beforehand  
2x SSC 20mins Allows coverslip to fall off 
Formamide solution  2x 20 mins   
2x SSC 2x 20mins   
0.2x SSC 2x 20mins Allow to cool after last wash 
Antibody detection   
Buffer 1 2 mins   
Blocking solution  1 hour   
Antibody solution  Overnight, 4oC 500ul/slide in humidified chamber.  
Post-antibody washes and development   
Buffer 1 3x 5 mins   
Buffer 2  2x 5 mins   
Developing solution  
Until 
developed 
500ul/slide in humidified chamber.  
Incubate 4oC for overnight 
Running tap water 10 mins   
PBS 2 mins   
Mount in mowiol -   
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Appendix 8
Stock Reagent Volume/Weight Notes 
Blocking Buffer 
(BB): 
0.1% Tx-100 250ul 
  
0.15% Glycine 375mg 
2mg/ml BSA 500mg 
PBS 250ml 
0.1% PBST 
Triton X-100 1ml 
  PBS 1000ml 
0.1% Sudan black 
 Sudan black 50mg 
Quench background. 
Filter and wrap in foil 70% EtOH 50ml 
Blocking solution 
BB 
Volume is slide dependent 10% HISS 
Antibody solution  
BB 
Volume and antibody concentration are 
slide dependent. HISS may vary depending 
on background. 10%/1% HISS 
Primary 
antibody 
Antigen retrieval 
solution, sodium 
citrate pH6.5 
Sodium citrate   
2.94g 
  
HCl Adjust to pH6.5 
0.05% Tween-
20 500ul 
H2O 
Top up to 
1000ml 
HISS: Heat Inactivated Sheep Serum  
  BSA: Bovine Serum Albumin 
  
Appendix 8: Frozen section IHC 
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Cryosection IHC 
Protocol Duration 
Day 1 Thaw sections in humidified chamber Variable 
  Fix in 4% PFA 10mins 
  PBS 5mins 
  (Optional) Antigen retrieval  110oC, 2mins 
  0.1% PBST 3x 5mins 
  Block: BB and 10% HISS  1 hour 
  Primaries in BB, 10% or 1% HISS Overnight 
Day 2 0.1% PBST 3x 5mins 
  Secondaries in 10% HISS 1 hour 
  0.1% PBST 3x 5mins 
  1.500 Streptavidin 555 amplification 
1 hour   in BB and 1% HISS 
  (Optional) Sudan Black    
  0.1% Sudan Black-70% EtOH  5mins 
  0.02% PBST 3x 5mins 
  PBS 5mins 
  DAPI (1.10,000) in PBS 2mins 
  PBS 2x 5mins 
  Mount in Mowiol/Hydromount  N/A 
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Appendix 9 
 
  Paraffin IHC Protocol Duration 
Day 1 Dewax: Histolear 2x 10mins 
  100% EtOH 5mins 
  70% EtOH 5mins 
  50% EtOH 5mins 
  25% EtOH 5mins 
  Running Tap water 5mins 
  Antigen Retrieval (appropriate buffer) 110oC, 2mins 
  0.1% PBST 3x 5mins 
  Block: BB and 10% HISS  1 hour 
  Primaries in BB and 10% or 1% HISS Overnight 
Day 2 0.1% PBST 3x 5mins 
  Appropriate secondaries in 10% HISS 1 hour 
  *0.1% PBST 3x 5mins 
  
(Optional) 1.500 Streptavidin 555 amplification in BB 
and 1% HISS 1 hour 
  (Optional) 0.1% Sudan Black  5mins 
  0.02% PBST 3x 5mins 
  *PBS 5mins 
  DAPI (1:10,000) in PBS 2mins 
  PBS 2x 5mins 
  Mount in Mowiol/Hydromount  N/A 
*Proceed to PBS washes if amplification is not required. 
Working reagents can be found in Appendix.8 
 
Appendix 9: Paraffin sections IHC 
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Appendix 10 
 
Appendix 10: Protocol for generating prenatal calvarial osteoblast cultures. 
 
Adapted from Daniel Doro Pereira (Dept. of Craniofacial Development & Stem Cell Biology, 
King’s College London). 
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Appendix 11 
GENE SYMBOL 
E2F Myc_targets_V1 
G2M 
Checkpoint EMT Apoptosis 
PLK1 RPS2 PLK1 COL6A2 RHOT2 
TUBG1 FBL AURKB ACTA2 TIMP1 
AURKB POLD2 BIRC5 MATN2 APP 
BIRC5 CCT2 TPX2 TIMP1 TNFRSF12A 
CCP110 RPL18 PLK4 ELN BGN 
PLK4 PSMB3 UPF1 FERMT2 CCND2 
CCNE1 RPS3 CDK1 PDLIM4 TSPO 
POLD2 NAP1L1 BCL3 TNFRSF12A CREBBP 
CDK1 SNRPG PML MGP BTG2 
BUB1B RPS10 UBE2C BGN RARA 
DNMT1 NHP2 EFNA5 GEM TAP1 
ING3 PSMA7 ATF5 FMOD EBP 
NCAPD2 SRM KPNA2 LOXL1 LMNA 
CDCA8 RPL14 SMC1A LGALS1 ROCK1 
NAP1L1 KPNA2 SNRPD1 COL5A1 IFNGR1 
MLH1 CAD RAD54L ANPEP BCL2L2 
RNASEH2A RPS5 H2AFX PMEPA1 TIMP3 
KPNA2 SNRPD1 RAD23B VIM SMAD7 
CSE1L SET CHEK1 GPC1 TGFB2 
SMC1A NME1 KIF23 COL6A3 PPP3R1 
RRM2 SNRPA PRIM2 ITGB5 CD44 
RPA1 RAD23B BARD1 MYL9 TIMP2 
H2AFX NPM1 CDC27 COL12A1 IRF1 
CDCA3 GNB2L1 CDKN1B COL7A1 CDKN1B 
MTHFD2 RFC4 TOP2A COL4A2 TOP2A 
NME1 RPL6 SMC4 LRP1 CASP6 
CBX5 HSP90AB1 CDC25A FLNA TNF 
DEK PTGES3 CCND1 MAGEE1 CCND1 
CHEK1 DEK GINS2 PLOD3 SOD1 
PRIM2 LDHA NUSAP1 COL16A1 IGF2R 
BARD1 CANX UBE2S MEST PSEN1 
UBE2T PSMD7 CUL5 FBLN1 DAP 
MCM7 RPL22 INCENP SNAI2 IER3 
NAA38 CCT5 KIF22 COL4A1   
PSIP1 XPOT MKI67 EMP3   
DCTPP1 MCM7 HSPA8 POSTN   
CDKN1B SF3B3 E2F1 ITGA5   
TOP2A UBE2L3 SYNCRIP TIMP3   
CENPM SNRPD2 H2AFV COL8A2   
SMC4 EIF2S2 PAFAH1B1 COL5A2   
CDC25A ABCE1 E2F4 CD44   
LIG1 PSMD3 CCNB2 TNC   
UBE2S LSM7 SETD8 PLOD1   
KIF22 PGK1 PRC1 MCM7   
MKI67 SYNCRIP MCM6 COL3A1   
SPC24 EIF1AX HMGA1 LRRC15   
SYNCRIP MCM4 RASAL2 TPM4   
MCM4 HSPE1 CDC25B LAMC1   
DCK EEF1B2 KIF15 TGFBI   
ASF1B PHB FBXO5 LOXL2   
    HMMR PFN2   
    HIF1A THY1   
    TNPO2 THBS2   
    CDC20 SERPINE1   
    UCK2 IGFBP2   
    NUP50 TPM2   
    XPO1 
 
  
    HUS1 
 
  
    PRMT5 
 
  
    CKS2 
 
  
    ESPL1 
 
  
    NUMA1 
 
  
    
    PURA     
Appendix 11: Enriched gene sets in Fgfr2cC342Y/+
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GENE SYMBOL 
KRas signalling UP KRas signalling DOWN PI3K-AKT mTOR Myogenesis Notch signalling 
LCP1 RSAD2 TRIB3 ACTC1 NOTCH3 
DOCK2 ACTC1 UBE2N ACTN2 JAG1 
SLMO2 CKM ADCY2 APOD CUL1 
HDAC9 CCDC132 MAPKAP1 CKM ARRB1 
APOD RYR1 TIAM1 RYR1 LFNG 
CBX8 TFAP2B MYD88 MYLPF WNT2 
SATB1 ADCK3 MAPK8 TNNI2 DTX2 
CROT KRT1 MKNK1 ATP6AP1 DLL1 
CSF2RA SEPP1 PPP1CA PFKM TCF7L2 
MMP9 SGK1 ACTR3 MYL1 FZD5 
GLRX LFNG RPS6KA1 CLU   
TNFRSF1B YPEL1 MAPK10 TNNT3   
F13A1 SLC16A7 MAP2K6 GPX3   
ANGPTL4 MSH5 GSK3B APLNR   
SPP1 STAG3 SLA TNNI1   
LY96 COL2A1 CXCR4 GABARAPL2   
LAPTM5 THNSL2 TRAF2 SOD3   
PLVAP FAM46C PRKCB ACTA1   
ITGA2 SPHK2 RIT1 CKB   
BPGM MTHFR IL2RG LDB3   
TFPI FGGY ITPR2 ITGA7   
PRDM1 LYPD3 RALB DMD   
PRKG2 ZFP112 TBK1 MYH3   
G0S2 YBX2 RPTOR SYNGR2   
BTC RGS11 GNA14 CSRP3   
CFH CHST2 SFN TNNC2   
TMEM176B CYP39A1 AKT1 MYH8   
ALDH1A2 EGF VAV3 CKMT2   
CXCR4 GPRC5C RIPK1 RB1   
GUCY1A3 SOX10 EIF4E LAMA2   
ITGB2 SLC38A3 TNFRSF1A PYGM   
MAP7 ITIH3   RIT1   
IL2RG SNCB   SLN   
RABGAP1L SHOX2   ADCY9   
GPNMB SNN   DMPK   
AKAP12 RYR2   NAV2   
ID2 PTGFR   PPP1R3C   
CFB KCNMB1   IGFBP7   
AVL9 OXT   DTNA   
TSPAN1 NRIP2   EIF4A2   
FLT4 ATP6V1B1   SH2B1   
FUCA1 CAPN9   COX7A1   
CFHR2 KLK7   SPEG   
WNT7A NOS1   COX6A2   
MYCN TNNI3   MYOG   
PECAM1     BAG1   
      TNNC1   
      FST   
      MYLK   
      CAMK2B   
      SPHK1   
      MEF2A   
Appendix 11: Enriched genes for Fgfr2cC342Y/+ 
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